FINAL PROGRAMME

35th Annual Congress of the European Association of Nuclear Medicine
# TABLE OF CONTENTS

## WORDS OF WELCOME

4

## GENERAL INFORMATION

- Board & Scientific Programme Council 6
- Session Coordinators 7
- EANM'22 Reviewers 8
- EANM'22 Chairpersons 12
- EANM National Societies: Delegates / Deputies 16
- UEMS/EBNM National Societies: Delegates / Deputies 18
- UEMS/EBNM Committees 21
- General Information 22
- About Barcelona 28
- Airport / Travel Information 32
- Programme Overview 37

## SCIENTIFIC & TECHNOLOGISTS’ PROGRAMME

- Plenary Sessions 46
- Continuing Medical Education/CME Sessions 48
- Technologists’ Track 50
- Special Track 52
- Joint Symposia 53
- Special Sessions 53
- Learn & Improve Professional Skills (LIPS) Tracks 54
- Clinical Oncology Track 55
- Cutting Edge Science Track 56
- M2M - The 9th “From Molecule to Man” Track 57
- Further Oral Presentations 58
- e-Poster Presentations 60
- Awards 61

## ORAL PRESENTATIONS

62

## e-POSTER PRESENTATIONS

135

## e-POSTER PRESENTATIONS e-POSTER SESSIONS

158

## INDUSTRY EXHIBITION

- Satellite Symposia 211
- List of Exhibitors (A-Z) 219
- List of Exhibitors (Booth number) 225
- Exhibition Hall 231
- Company Profiles 233

## CORPORATE MEMBERS

305

## USEFUL CONTACTS

310

## IMPRINT

310
WORDS OF WELCOME

BY THE CONGRESS CHAIR

On behalf of the European Association of Nuclear Medicine, it is my great honour to invite you to the 35th Annual EANM Congress. The event will finally be held in person from October 15-19, 2022 in Barcelona, Spain. After two years of virtual events, we are now incredibly happy to be hosting the Congress in its usual and much missed onsite format.

The last two years have been challenging for the entire world due to the pandemic. This has been especially true for those who work in healthcare, as we all do. Nevertheless, nuclear medicine has experienced incredible growth, both in diagnostic imaging and therapy. We have seen exciting innovations in every area of our specialist field: new whole-body PET tomographs are now being used clinically, PSMA tracers have been incorporated into clinical guidelines and excellent trials of theranostic radiopharmaceuticals were presented and published. Furthermore, many other new radiopharmaceuticals, which facilitate the study and treatment of new targets, are being introduced, with more and more protocols addressing unmet clinical needs and new applications. This success remains related to that very peculiar characteristic of our specialist field, namely its functional approach to medicine, and we really feel the need to celebrate all such achievements and innovations with a real congress as we used to do.

We proudly celebrated the status of the EANM Congress as the world’s leading meeting for nuclear medicine when we reached almost 7000 participants in 2019. The high early registration numbers for 2022 prove that the ‘in-person’ Congress was missed very much and that the opportunities to interact and network were not comparable online. So, take the chance to meet your colleagues around the world as well as our industry partners. The exhibition is sold out, and the participating companies are looking forward to finally meeting you in person again. Take your time and stroll through the stands of both familiar and new companies.

We will be returning to the usual format this year at one of our favourite venues – Barcelona. We decided to implement many new interactive features, including a completely new room setup, called “the Arena.” Here, the participants are close to the speakers and are invited to interactively participate during our two new session formats: “the Debate” and “Challenge the Expert.” Other innovations were already introduced last year and are now ready to be experienced live: the Highlights Lecture during the Opening Ceremony and the new Plenaries format, with many, short focused lectures led by key opinion leaders on the hottest topics. We also have special sessions dedicated to the Best Trials and Case Reports submitted from around the world.

A completely new feature is the “Battle and Win!” session, in which six selected participants will battle for the Sam Gambhir Award. Don’t miss it!

In summary, we are planning a great live event for October where we will finally come together again, and delight you with a well-orchestrated balance of science, education and entertainment. We have been working hard to provide you with a Congress filled with superb and comprehensive scientific content as well as numerous other innovative features to make your participation truly memorable.

Stefano Fanti

CONGRESS CHAIR 2020-2022
**BOARD & SCIENTIFIC PROGRAMME COUNCIL**

**EANM BOARD**

President 2021 - 2022  
Jolanta Kunikowska (Poland)

President Elect 2021 - 2022  
Rudi A.J.O. Dierckx (Netherlands)

Committee Coordinator 2021 - 2022  
Roland Hustinx (Belgium)

Congress Chair 2020 - 2022  
Stefano Fanti (Italy)

Education Chair 2020 - 2022  
Paola A. Erba (Italy)

Secretary/Treasurer 2021 - 2022  
Wolfgang Wadsak (Austria)

Scientific Liaison Officer 2021 - 2022  
Michael Lassmann (Germany)

**SCIENTIFIC PROGRAMME COUNCIL**

**Congress Chair 2020 - 2022**  
Stefano Fanti (Italy)

**Bone & Joint Committee**  
Salvatore Annunziata (Italy), Tim Van Den Wyngaert (Belgium)

**Cardiovascular Committee**  
Mark Lubberink (Sweden), Fabien Hyafil (France)

**Dosimetry Committee**  
Frederik Verburg (Netherlands), Silvano Gnesin (Switzerland)

**Inflammation & Infection Committee**  
Giorgio Priglia (Switzerland), Olivier Gheysens (Belgium)

**Neuroradiology Committee**  
Diego Cecchin (Italy), Silvia Morbelli (Italy)

**Oncology & Theranostics Committee**  
Ken Herrmann (Germany), Matthias Eiber (Germany)

**Paediatrics Committee**  
Pınar Ö. Kirati (Turkey), Pietro Zucchetta (Italy)

**Physics Committee**  
John Dickson (United Kingdom), Dimitris Visvikis (France)

**Radiation Protection Committee**  
Lidia Cunha (Portugal), Francois Jamar (Belgium)

**Radiopharmaceutical Sciences Committee**  
Peter Laverman (Netherlands), Johnny Vercouillie (France)

**Technologists Committee**  
Andrea Santos (Portugal), Agata Pietrzak (Poland)

**Thyroid Committee**  
Alfredo Campenni (Italy), Michael Kreissl (Germany)

**Translational Molecular Imaging & Therapy Committee**  
Margret Schottelius (Switzerland), Felix Muttaghy (Germany)

**SESSION COORDINATORS**

EANM thanks all Session Coordinators for their huge engagement in organizing the session details and speakers.

- **Ambrosini, V. (Italy)**
- **Brendel, M. (Germany)**
- **Carrilho Vaz, S. (Portugal)**
- **Cicone, F. (Italy)**
- **de Geus-Oei, L. F. (Netherlands)**
- **Denooe, C. (Belgium)**
- **Eiber, M. (Germany)**
- **Fanti, S. (Italy)**
- **Fragoso Costa, P. (Germany)**
- **Gnanasegaran, G. (United Kingdom)**
- **Gotthardt, M. (Netherlands)**
- **Herrmann, K. (Germany)**
- **Jamar, F. (Belgium)**
- **Kedves, A. (Hungary)**
- **Kreissl, M. (Germany)**
- **Kurth, J. (Germany)**
- **Laverman, F. (Netherlands)**
- **Lecrist, L. (Italy)**
- **Luporsi, M. (France)**

- **Massala, S. (Israel)**
- **Morbelli, S. (Italy)**
- **Morland, D. (France)**
- **Mottaghy, F. (Germany)**
- **Nanni, C. (Italy)**
- **Olson, R. (Denmark)**
- **Oprea-Lager, D. (Netherlands)**
- **Pereira, L. (United Kingdom)**
- **Pietrzak, A. (Poland)**
- **Rbah-Vidal, L. (France)**
- **Rischpler, C. (Germany)**
- **Rogasch, J. (Germany)**
- **Santos, A. (Portugal)**
- **Saraste, A. (Finland)**
- **Tervinge, C. (Belgium)**
- **Testani ex, G. (United Kingdom)**
- **Tuncel, M. (Turkey)**
- **Turco, F. (Italy)**
- **Visvikis, D. (France)**
- **Wadsak, W. (Austria)**
EANM'22

REVIEWERS

Abysal, R. (France)
Aramp, W. (Italy)
Adám, J. (Netherlands)
Ahmadzadehfar, H. (Germany)
Akkemir, U. O. (Turkey)
Albanis, D. (Italy)
Algi, L. (United Kingdom)
Alhers, C. (Italy)
Ambrosi, V. (Italy)
Amatamay, S. (Switzerland)
Annunziata, S. (Italy)
Antunovic, I. (Italy)
Atay Kapucu, L. Ö. (Turkey)
Bailey, L. (Hungary)
Bar-Soever, Z. (Israel)
Bardiès, M. (France)
Barthel, H. (Germany)
Baucknecht, M. (Italy)
Beier, A. (Germany)
Bekehtish, M. (Germany)
Beirn, V. (Italy)
Bişin, B. E. (Turkey)
Bogovic Crnčić, T. (Croatia)
Boltho, M. F. R. (Portugal)
Boduurt, M. F. (Turkey)
Brenkel, M. (Germany)
Brouwer, A. M. (Netherlands)
Buchert, R. (Germany)
Burroni, L. (Italy)
Buixat, I. (France)
Cai, W. (United States Of America)
Campos, L. (Italy)
Caobelli, F. (Switzerland)
Cantího-Vázquez, S. (Portugal)
Castellucci, P. (Italy)
Ceci, F. (Italy)
Cenci, J. (Brazil)
Cemnik, T. F. (Turkey)
Chiesa, C. (Italy)
Chili, A. (Italy)
Chouin, N. (France)
Ciccone, F. (Switzerland)
Cook, G. J. R. (United Kingdom)
Cormelissen, B. (United Kingdom)
Costa, G. M. L. M. (Portugal)
Cremonesi, M. (Italy)
Crivellari, C. (Italy)
Dalim, S. (Netherlands)
Davalos, D. (France)
De Geus-Oei, L. F. (Netherlands)
de Koker, B. (Netherlands)
de Paiva, D. (Italy)
Deh-Swarte, J. (Netherlands)
de Vries, E. F. (Netherlands)
Deardres, D. (Italy)
De Congressus, C. (Austria)
Delgado-Bolton, R. C. (Spain)
Derlin, T. (Germany)
Derosse, C. (Belgium)
Deutert-Cordaci, W. (Germany)
Dickinson, J. (United Kingdom)
Drozgaz, A. (Germany)
Eberlein, U. (Germany)
Eibe, M. (Germany)
Ellis, B. (United Kingdom)
Evangelista, L. (Italy)
Farolfi, A. (Italy)
Fendler, W. (Germany)
Fernández-Lolín, A. (Spain)
Ferri, C. (Italy)
Flux, G. (United Kingdom)
Forner, F. (Switzerland)
Forsback, S. (Finland)
Fragoso Costa, P. A. (Germany)
Fracioli, F. (United Kingdom)
Frangos, S. (Cyprus)
Gafta, A. (Germany)
Gallowitsch, H. Ji. (Austria)
Gellashvili, T. (Russia)
Georgoulas, P. (Greece)
Gheysens, D. (Belgium)
Gimmarile, F. (France)
Gilling, N. (Denmark)
Gimelli, A. (Italy)
Giovannelli, L. (Switzerland)
Girots, N. (Croatia)
Glätting, G. (Germany)
Glaudemans, A. (Netherlands)
Gnanasegaran, S. (United Kingdom)
Goffin, K. (Belgium)
Gottschald, M. (Netherlands)
Gouws, F. (South Africa)
Golj, S. (Austria)
Gobarn, R. (United Kingdom)
Giona, C. M. (Italy)
Gottz, S. (Germany)
Grotzinger, C. (Germany)
Guerrini, E. (France)
Haberkorn, U. (Germany)
Hallgren, C. (Sweden)
Hany, T. (Switzerland)
Hartman, N. (United Kingdom)
Hermans, B. (Germany)
Heiss, S. (Denmark)
Heuss, S. (Germany)
Hicks, R. (Australia)
Hindorf, C. (Sweden)
Hofman, M. (Australia)
Holm, S. (Denmark)
Hovell, R. (United States Of America)
Hulvařská-Elydejczyk, A. (Poland)
Hyafil, F. (France)
Iagaru, A. (United States Of America)
Janar, F. (Belgium)
Kirac, S. (Turkey)
Kirienko, M. (Italy)
Kiryavainen, A. (Finland)
Kiss, O. (Germany)
Kluge, R. (Germany)
Kúčér, P. (Slovenia)
Konijnenberg, M. W. (Netherlands)
Kouanda, P. (Czech Republic)
Kourakis, I. (Greece)
Kožmulova, T. (Czech Republic)
Krauber-Bodére, F. (France)
Kramer, S. (Switzerland)
Kreiss, M. (Germany)
Kreinin, E. (Turkey)
Kucuk, Nuray O. (Turkey)
EANM'22 REVIEWERS

Kurch, L. (Germany)
Kurth, J. (Germany)
Lairez, D. (France)
Langbein, T. (Germany)
Langer, D. (Austria)
Lasnici, C. (France)
Lavelli, V. (Italy)
Laverman, P. (Netherlands)
Leccisotti, L. (Italy)
Lemos Pereira, E. A. (Portugal)
Lewington, V. (United Kingdom)
Lindner, O. (Germany)
Lod, F. (Italy)
Lubberink, M. (Sweden)
Luporsi, M. (France)
Maes, A. (Belgium)
Maldonado, A. (Spain)
Manevska, N. (North Macedonia)
Marcassa, C. (Italy)
Marengo, M. (Italy)
Mashalha, S. (Israel)
Mihalevic, J. (Serbia)
Milan, E. (Italy)
Mindt, Thomas L. (Austria)
Minguez Gabiña, P. (Spain)
Mitjavila Casanovas, M. (Spain)
Monteforte, M. (Switzerland)
Mordorski, S. (Italy)
Morgy, Joshua J. (Australia)
Mortand, D. (France)
Mottaghy, F. (Germany)
Mü, L. (Switzerland)
Nanni, C. (Italy)
Nekolla, S. (Germany)
Nodk, B. A. (Greece)
Noriega Alvarez, E. (Spain)
Ockel, E. M. (Turkey)
Oktanti, C. (Italy)
Oprea-Lager, D. E. (Netherlands)
Orinac, F. (France)
Orini, M. T. (Italy)
Ozturk, A. (Hungary)
Ozgen Kirati, P. (Turkey)
Palmieri, A. (Italy)
Paragostidas, E. (Greece)
Papathanasiou, N. (Greece)
Pappata, S. (Italy)
Pascual, T. (Austria)
Paycha, F. (France)
Payoux, P. (France)
Pereira, L. (Portugal)
Perenoulis-Ovcarik, P. (Hungary)
Pica, D. (Romania)
Pietrzk, A. K. (Poland)
Pilkington, P. (India)
Pinch, C. (Australia)
Pirappel, T. (Germany)
Prum, J. (Netherlands)
Raic, S. (Croatia)
Rajković, Z. (Bosnia And Herzegovina)
Rausch, S. (Austria)
Redondo, F. (Chile)
Rep, S. (Slovenia)
Resende Góis, A. C. (Portugal)
Rijpkema, M. (Netherlands)
Rischpler, C. (Germany)
Rodriguez-Fraile, M. (Spain)
Rogasch, J. (Germany)
Roxinen, A. (Finland)
Ruminger, A. (Switzerland)
Rouzet, F. (France)
Salaun, P. Y. (France)
Sandstrom, M. (Sweden)
Santos, A. I. (Portugal)
Santos, A. (Portugal)
Saraste, A. (Finland)
Satterley, B. (Germany)
Saxtoft, E. (Denmark)
Schäfers, M. (Germany)
Schibli, R. (Switzerland)
Schmidt, E. (Hungary)
Schottelius, M. (Switzerland)
Schwarzengrund, S. (Germany)
Sciagrà, R. (Italy)
Seimbille, Y. (Netherlands)
Semah, F. (France)
Seia, T. (Hungary)
Shi, K. (Switzerland)
Sidar, G. (Hungary)
Signore, A. (Italy)
Slati, R. (Netherlands)
Smith, G. (United Kingdom)
Solfini, M. (Italy)
Stefanescu, C. (Romania)
Stevenson, H. (Netherlands)
Stolze, C. (Norway)
Stokkel, M. (Netherlands)
Strobel, K. (Switzerland)
Strömwall, A. L. (Sweden)
Sunderland, J. (United States Of America)
Terks, M. (Finland)
Terry, S. (United Kingdom)
Teixeira, C. (Belgium)
Teixeira, G. (United Kingdom)
Tolboom, N. (Netherlands)
Tos, G. (Italy)
Train Ga, J. (Germany)
Treglia, G. (Switzerland)
Turciol, M. (Turkey)
Turco, P. (Italy)
Ugrinovska, A. (North Macedonia)
Van den Wyngaert, T. (Belgium)
Van Velden, F. H. P. (Netherlands)
De Weerda, D. (Belgium)
Vandenberghen, S. (Belgium)
Vanhove, C. (Belgium)
Vanmenen, N. (France)
Vet-Habach, P. (Canada)
Vermeltfoort, J. (Netherlands)
Verburg, F. (Germany)
Versari, A. (Italy)
Vilani, L. (Portugal)
Vijkovski, M. (Serbia)
Wachnis, A. (Cyprus)
Witz, J. (France)
Wobig, W. (Germany)
Wolder-Sage, M. (Israel)
Zambu, K. (Hungary)
Zerizer, I. (United Kingdom)
Zirin, D. (United Kingdom)
Zhang-Yin, J. (France)
EANM'22

CHAIRPERSONS

(AS PER SEP 12, 2022)

EANM thanks all Session Coordinators for their huge engagement in organizing the session details and speakers.

Adam, J. (Netherlands)
Al-Hibrahim, A. (Jordan)
Albano, D. (Italy)
Ambrosini, V. (Italy)
Anders, O. (Sweden)
Antonovic, L. (Italy)
Aparici, C. M. (United States of America)
Assadi, M. (Iran, Islamic Republic of)
Atay, L. (Turkey)
Balogova, S. (Slovakia)
Barwick, T. (United Kingdom)
Béhé, M. (Switzerland)
Berti, V. (Italy)
Boubaker, A. (Switzerland)
Brendel, M. (Germany)
Brouwer, A. (Netherlands)
Buck, T. (Netherlands)
Butel, J. P. (Australia)
Ca, W. (Madison)
Camperven, A. (Italy)
Cardillo, F. (Switzerland)
Camilo-Vaz, S. (Portugal)
Caranucau, E. (Italy)
Casetti, C. (Italy)
Cataforo, G. (United States of America)
Cecchin, D. (Italy)
Celiberti, F. (Italy)
Cicone, F. (Italy)
Cleerexe, F. (Belgium)
Cunha, L. (Portugal)
de Geus-Oei, L. F. (Netherlands)
de Koos, B. (Netherlands)
Deandrea, D. (Italy)
Denis-Bacelar, A. (United Kingdom)
Denosse, C. (Belgium)
Dickson, J. (United Kingdom)
Eberlein, U. (Germany)
Birkey, I. (Turkey)
Elise, R. (Italy)
Elias, F. (Belgium)
Emmet, L. (Australia)
Erba, P. (Italy)
Evangelista, L. (Italy)
Fanti, S. (Italy)
Farolfi, A. (Italy)
Federspiel, M. (Denmark)
Ferrari, C. (Italy)
Fotiatis, G. (Spain)
Fragoso Costa, P. (Netherlands)
Gambhir, A. (United States of America)
García Canamero, L. (Spain)
Garcia, O. (Mexico)
Garbon, V. (Switzerland)
Giao, A. C. (Portugal)
Ghorai, J. (United Kingdom)
Gröstl, B. (Austria)
Grigoriadis, P. (Greece)
Ghysels, O. (Belgium)
Ganiroula, E. (Greece)
Gilmore, D. (United States of America)
Glaudemans, A. (Netherlands)
Gnanasegaran, G. (United Kingdom)
Gresin, S. (Switzerland)
Goffin, K. (Belgium)
Gotthardt, M. (Netherlands)
Gouno, E. (Switzerland)
Guedj, E. (France)
Haberkorn, U. (Germany)
Hatt, M. (France)
Hendrikse, H. (Netherlands)
Hermsen, K. (Germany)
Herth, M. (Denmark)
Heiss, S. (Denmark)
Holm, S. (Denmark)
Hustinx, R. (Belgium)
Hyafil, F. (France)
Iagaru, A. (United States of America)
Iakovou, I. (Greece)
Ilhan, H. (Germany)
Imbert, L. (France)
Jamjar, F. (Belgium)
Kalina, M. (Latvia)
Kedves, A. (Hungary)
Kirati, P. O. (Turkey)
Kirienko, M. (Italy)
Kiss, O. (Germany)
Könningerberg, M. (Netherlands)
Kössl, M. (Belgium)
Kräussl, M. C. (Germany)
Kumar, R. (India)
Kuo, P. (United States of America)
Kurth, J. (Germany)
Lam, M. G. E. (Netherlands)
Larsson Stenwall, A. (Sweden)
Lauri, C. (Italy)
Laverman, P. (Netherlands)
Law, J. (Denmark)
Leccisotti, L. (Italy)
Lemos Pereira, E. (Portugal)
Levington, V. (United Kingdom)
Los, G. (Australia)
Lueckerkath, K. (Germany)
Maccauro, M. (Italy)
Mackewn, J. (United Kingdom)
Massa, S. (Israel)
Michalski, K. (Germany)
Mihalovic, I. (Serbia)
Morbelli, S. (Italy)
Morji, J. (Australia)
Moxon, D. (France)
Mottaghy, F. (Germany)
Nagarajah, J. (Netherlands)
Nanni, C. (Italy)
Nappi, C. (Italy)
Nikolić, S. (Germany)
Noriega Alvarez, E. (Spain)
Noriega Alvarez, E. (Spain)
Øibo, F. (Denmark)
Olaniti, C. (Italy)
Opalińska, K. (Poland)
Opjela, L. (Netherlands)
Orlov, A. (Sweden)
Oyen, R. G. (Netherlands)
Pabst, M. K. (Germany)
Palt, M. (Germany)
Petrangeli, O. (Croatia)
Piccardo, A. (Italy)
Pietrzak, A. (Poland)
Polycarpou, I. (Cyprus)

EANM thanks all Session Coordinators for their huge engagement in organizing the session details and speakers.
EANM'22 CHAIRPERSONS

Privé, B. (Netherlands)
Prahl-Vidal, L. (France)
Peyrédou, L. (Spain)
Rischpler, C. (Germany)
Rogasch, J. (Germany)
Roldán Pereira, L. (United Kingdom)
Roldão Pereira, L. (United Kingdom)
Rossi, A. (Switzerland)
Santos, A. (Portugal)
Santos, A. I. (Portugal)
Saraste, A. (Finland)
Sathekge, M. (South Africa)
Schirke, S. (Germany)
Schottelius, M. (Switzerland)
Sembili, Y. (Netherlands)
Semah, F. (France)
Shi, K. (Switzerland)
Singh, B. (India)
Sjogren-Gleisner, K. (Sweden)
Sjöholm, T. (Sweden)
Slart, R. (Netherlands)
Stokke, C. (Norway)
Strand Olsen, R. (Denmark)
Strigari, L. (Italy)
Stroet, M. (Belgium)
Taralli, S. (Italy)
Telo, S. (Italy)
Terwinghe, C. (Belgium)
Testa, G. (United Kingdom)
Trägårdh, E. (Sweden)
Traub-Weidinger, T. (Austria)
Treglia, G. (Switzerland)
Trast, E. (Germany)
Turco, P. (Italy)
Uijen, M. (Netherlands)
Van Weelhaeghe, D. (Belgium)
Vanhoe, C. (Belgium)
Verburg, F. (Netherlands)
Vercauteren, S. (Belgium)
Verzijlbergen, F. (Netherlands)
Vidal-Scart, S. (Spain)
Vera, S. (Belgium)
Virgolinis, I. (Austria)
Visvikis, D. (France)
Vrachimis, A. (Cyprus)
Wadsgaard, W. (Austria)
Wälzl, I. (France)
Weber, W. (Germany)
Wild, D. (Switzerland)
Zucchini, P. (Italy)
EANM NATIONAL SOCIETIES:
DELEGATES / DEPUTIES

<table>
<thead>
<tr>
<th>SOCIETY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARMENIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>A. V. Barsegian</td>
<td>M. Grigoryan</td>
</tr>
<tr>
<td>AUSTRIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>H.J. Gallowitsch</td>
<td>I. Virgolini</td>
</tr>
<tr>
<td>AZERBAIJAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>F. Novruzov</td>
<td>A. Aliyev</td>
</tr>
<tr>
<td>BELGIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>F. Jamar</td>
<td>N. Witosfs</td>
</tr>
<tr>
<td>BOSNIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>Z. Rajkovaca</td>
<td>D. Rozic</td>
</tr>
<tr>
<td>BRITISH NUCLEAR MEDICINE SOCIETY</td>
<td>R. Graham</td>
<td>S. Dzidarevic</td>
</tr>
<tr>
<td>BULGARIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>V. Hadzyiska</td>
<td>L. Charadarova</td>
</tr>
<tr>
<td>CROATIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>D. Snajder</td>
<td>to be nominated</td>
</tr>
<tr>
<td>CYPRUS SOCIETY OF NUCLEAR MEDICINE</td>
<td>D. Kyrikanou</td>
<td>R.K. Demetriadou</td>
</tr>
<tr>
<td>CZECH SOCIETY OF NUCLEAR MEDICINE</td>
<td>M. Simanek</td>
<td>P. Koranda</td>
</tr>
<tr>
<td>DANISH SOCIETY OF CLINICAL PHYSIOLOGY AND NUCLEAR MEDICINE</td>
<td>L.T. Jensen</td>
<td>P. Hovind</td>
</tr>
<tr>
<td>DUTCH SOCIETY OF NUCLEAR MEDICINE</td>
<td>A. Glaudemans</td>
<td>R. Kejong</td>
</tr>
<tr>
<td>ESTONIAN NUCLEAR MEDICINE SOCIETY</td>
<td>S. Nazarenko</td>
<td>U. Kust</td>
</tr>
<tr>
<td>FINNISH SOCIETY OF NUCLEAR MEDICINE</td>
<td>H. Musalo</td>
<td>K. Timonen</td>
</tr>
<tr>
<td>FRENCH SOCIETY OF NUCLEAR MEDICINE</td>
<td>F. Cachin</td>
<td>J.P. Vuillez</td>
</tr>
<tr>
<td>GERMAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>B. J. Krause</td>
<td>K. Herrmann</td>
</tr>
<tr>
<td>GEORGIAN NUCLEAR MEDICINE SPECIALISTS ASSOCIATION</td>
<td>N. Shengelia</td>
<td>K. Shamatava</td>
</tr>
<tr>
<td>HELLENIC SOCIETY OF NUCLEAR MEDICINE &amp; BIOLOGY</td>
<td>A. Fotopoulos</td>
<td>V.C. Prasopulos</td>
</tr>
<tr>
<td>ICELANDIC SOCIETY OF NUCLEAR MEDICINE</td>
<td>to be nominated</td>
<td>to be nominated</td>
</tr>
<tr>
<td>IRISH NUCLEAR MEDICINE ASSOCIATION</td>
<td>M. O'Connell</td>
<td>R. Killean</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SOCIETY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISRAELI SOCIETY OF NUCLEAR MEDICINE</td>
<td>Z. Bar-Sever</td>
<td>Z. Kedhar</td>
</tr>
<tr>
<td>ITALIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>R. Giubbini</td>
<td>M. Kirensko</td>
</tr>
<tr>
<td>LATVIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>M. Kalnina</td>
<td>J. Kedrova</td>
</tr>
<tr>
<td>LITHUANIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>S. Sediene</td>
<td>D. Vajauskas</td>
</tr>
<tr>
<td>LUXEMBOURG SOCIETY OF NUCLEAR MEDICINE</td>
<td>C. Als</td>
<td>J. Zhang Yin</td>
</tr>
<tr>
<td>MACEDONIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>D. Miladinova</td>
<td>A. Ugninska</td>
</tr>
<tr>
<td>MALTESE ASSOCIATION OF RADIOLOGISTS AND NUCLEAR MEDICINE PHYSICIANS</td>
<td>M. A. Aquilina</td>
<td>A. Maffia</td>
</tr>
<tr>
<td>NORWEGIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>T.C. Adamsen</td>
<td>R. Sundset</td>
</tr>
<tr>
<td>POLISH SOCIETY OF NUCLEAR MEDICINE</td>
<td>A. Sovia-Stazczak</td>
<td>A. Pietrzaik</td>
</tr>
<tr>
<td>PORTUGUESE SOCIETY OF NUCLEAR MEDICINE</td>
<td>A. P. Moreira</td>
<td>R. Silva</td>
</tr>
<tr>
<td>ROMANIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>D. Picu</td>
<td>C. R. Sironcueau</td>
</tr>
<tr>
<td>SERBIAN NUCLEAR MEDICINE SOCIETY</td>
<td>J. Mihajovic</td>
<td>V. Antiko</td>
</tr>
<tr>
<td>SLOVAK SOCIETY OF NUCLEAR MEDICINE</td>
<td>L. Kaliska</td>
<td>E. Takacsova</td>
</tr>
<tr>
<td>SLOVENIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>I. Zagar</td>
<td>K. Zaleiel</td>
</tr>
<tr>
<td>SPANISH SOCIETY OF NUCLEAR MEDICINE</td>
<td>L. Garcia</td>
<td>R. Ruano Perez</td>
</tr>
<tr>
<td>SWEDISH SOCIETY OF NUCLEAR MEDICINE</td>
<td>E. Tragardh</td>
<td>A. Stromvall Larsson</td>
</tr>
<tr>
<td>SWISS SOCIETY OF NUCLEAR MEDICINE</td>
<td>F. Forrer</td>
<td>M. Wissmeyer</td>
</tr>
<tr>
<td>TURKISH SOCIETY OF NUCLEAR MEDICINE</td>
<td>Z. Oncan</td>
<td>L. O. Atay</td>
</tr>
<tr>
<td>UKRAINIAN SOCIETY OF NUCLEAR MEDICINE</td>
<td>to be nominated</td>
<td>to be nominated</td>
</tr>
</tbody>
</table>
# UEMS/EBNM National Societies: Delegates / Deputies

Nominated from full UEMS Member Countries

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>A. Kurtaran</td>
<td>R. Lipp</td>
</tr>
<tr>
<td>Belgium</td>
<td>K. Spaepen</td>
<td>G. Moulin-Romsee</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>E. Piperkova</td>
<td>A. D. Tsonevika</td>
</tr>
<tr>
<td>Croatia</td>
<td>D. Huic</td>
<td>S. Rusacic Kuna</td>
</tr>
<tr>
<td>Cyprus</td>
<td>R. K. Demetriadou</td>
<td></td>
</tr>
<tr>
<td>Czech Republic</td>
<td>O. Lang</td>
<td>M. Kaminek</td>
</tr>
<tr>
<td>Denmark</td>
<td>S. Hess</td>
<td>L. T. Jensen</td>
</tr>
<tr>
<td>Estonia</td>
<td>E. Kelk</td>
<td>A. Polak</td>
</tr>
<tr>
<td>Finland</td>
<td>H. Musalo</td>
<td>A. Lornaal</td>
</tr>
<tr>
<td>France</td>
<td>E. Gremillet</td>
<td>J.-L. Pelletier</td>
</tr>
<tr>
<td>Germany</td>
<td>W. Brenner</td>
<td>M. Gotthardt</td>
</tr>
<tr>
<td>Greece</td>
<td>S. Koukouraki</td>
<td>I. Iatovou</td>
</tr>
<tr>
<td>Hungary</td>
<td>L. Pastes</td>
<td>I. Sztokai</td>
</tr>
<tr>
<td>Ireland</td>
<td>S. Skehan</td>
<td>R. Mclermont</td>
</tr>
<tr>
<td>Italy</td>
<td>B. Palumbo</td>
<td>A. Curniello</td>
</tr>
<tr>
<td>Latvia</td>
<td>I. Vevere</td>
<td>A. Berana</td>
</tr>
<tr>
<td>Lithuania</td>
<td>D. Vajauskas</td>
<td>N. Jurecka</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>P. Paulus</td>
<td>M. Doat</td>
</tr>
<tr>
<td>Malta</td>
<td>A. Samuel</td>
<td>M. A. Aquilina</td>
</tr>
<tr>
<td>Netherlands</td>
<td>R. J. Bennink</td>
<td>L. F. de Gous-Dei</td>
</tr>
</tbody>
</table>

Nominated from UEMS Associate Member Countries

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norway</td>
<td>A.J. Midha</td>
<td>M.-E. Revheim</td>
</tr>
<tr>
<td>Poland</td>
<td>M. Dzuk</td>
<td>B. Birkentfeld</td>
</tr>
<tr>
<td>Portugal</td>
<td>L. Salgado</td>
<td>T. Cruz Fernieira</td>
</tr>
<tr>
<td>Romania</td>
<td>G. Andries</td>
<td>R. Mittelut</td>
</tr>
<tr>
<td>Serbia</td>
<td>V. Artiko</td>
<td>J. Mihailovic</td>
</tr>
<tr>
<td>Slovakia</td>
<td>A. Vondraik</td>
<td></td>
</tr>
<tr>
<td>Slovenia</td>
<td>M. Gremeik</td>
<td>D. Hranik</td>
</tr>
<tr>
<td>Spain</td>
<td>A. Somano</td>
<td>F. Pons</td>
</tr>
<tr>
<td>Sweden</td>
<td>E. Taghdo</td>
<td>P. Gyrback</td>
</tr>
<tr>
<td>Switzerland</td>
<td>A. Boukaker</td>
<td>G. Goeres</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>Y. Du</td>
<td>S. Dzdarovic</td>
</tr>
</tbody>
</table>

Nominated from UEMS Observer Countries

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turkey</td>
<td>Y. Yurekli</td>
<td>Z. Ozcan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>DELEGATE</th>
<th>DEPUTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Israel</td>
<td>A. Steinmetz</td>
<td>M. Quastel</td>
</tr>
</tbody>
</table>
UEMS/EBNM COMMITTEES

EXECUTIVE COMMITTEE

President S. Mirzaei (Austria)
Secretary & Treasurer R. Hustinx (Belgium)
Member A. Boubaker (Switzerland)

CME ACCREDITATION

Chair M. Farsad (Italy)
Members E. Lopci (Italy)
A. Haug (Austria)
S. Sillanmäki (Finland)

FELLOWSHIP EXAMINATION

Chair Z. Özcan (Türkiye)
Members A. Boubaker (Switzerland)
J. R. Garcia Garzón (Spain)
I. Kulakine (Lithuania)
S. Vaz (Portugal)

ACCREDITATION OF NUCLEAR MEDICINE DEPARMTENTS & TRAINING CENTRES

Chair J. Prior (Switzerland)
Committee Members A. García Burillo (Spain)
N. Mutlukoca (Norway)
P. A. L. Van Boxem (Belgium)
M. L. Hall (United Kingdom)

EDUCATION & SYLLABUS

Chair R. Hustinx (Belgium)
Members J. Darcourt (France)
H. B. Sayman (Türkiye)
D. Huic (Croatia)
T. V. Bogsrud (Norway)
P. Castellucci (Italy)

Corresponding Members: F. Giesel (Germany)
A. Jiménez Heffeman (Spain)
I. Sippo-Tujunen (Finland)
N. G. Hartman (United Kingdom)
S. E. Bouzoucouf (Algeria)
A. Ciarmiello (Italy)
R. Zakavi (Iran)
I. Iakovou (Greece)
L. Torres (Cuba)
GENERAL INFORMATION

AUDIO & VIDEO RECORDINGS
Audio and/or video recordings during the congress are strictly prohibited and must not be made without prior written permission of the EANM Executive Office.

BARCELONA INFORMATION DESK
The Barcelona City Information Desk with a guide at the entrance level of the CCIB (Congress Centre) will be open:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 15</td>
<td>16:00</td>
</tr>
<tr>
<td>Sunday, October 16</td>
<td>09:00</td>
</tr>
<tr>
<td>Monday, October 17</td>
<td>09:00</td>
</tr>
<tr>
<td>Tuesday, October 18</td>
<td>09:00</td>
</tr>
<tr>
<td>Wednesday, October 19</td>
<td>09:00</td>
</tr>
</tbody>
</table>

Please note that only delegates and accompanying persons wearing a valid congress name badge will be granted access.

CANCELLATION
Conference Cancellation or Postponement
The EANM accepts no liability if an event is cancelled or postponed for reasons beyond its reasonable control resulting from an act of God, governmental regulation, fire, war, terrorist activity or civil commotion. If the EANM elects to re-schedule the conference, all registrations and additional items are automatically rolled over to the new dates of the conference. If the EANM elects to cancel the event, the liability is limited to a refund of registration costs, subject to fees and conditions. The EANM will not refund any travel costs associated with the cancellation of the event. Accommodation pre-payments will be refunded subject to the terms and conditions of the hotel.

CERTIFICATE OF ATTENDANCE
The EANM’22 Certificate of Attendance will be available in your myEANM area after submission of the overall EANM Congress evaluation.

CLOSING SESSION & FAREWELL COCKTAIL
All registered delegates and accompanying persons are cordially invited to the Closing Session & Farewell Cocktail on Wednesday, October 19, 2022, at 11:25-12:15.

The Closing Session will be held at the Auditorium of the CCIB and the subsequent Farewell Cocktail in the Foyer of the Auditorium.

CME CREDITS & CERTIFICATES
The EANM’22 Congress has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for a maximum of 25 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

To acquire CME credits, attendees are required to scan their congress badge upon first arrival at the congress venue as well as upon entrance into each CME session. For CME sessions, an evaluation form must also be completed for each session attended. CME Sessions will be streamed live and are also available on-demand after the congress until December 20, 2022 (23:59 CET). To obtain your CME certificate(s) please visit your myEANM area, in the section EANM’22 > Certificates, the certificate(s) will be available within 24 hours after you have scanned your congress badge.
COVID-19 SAFETY PROTOCOL

UPDATE: The EANM will abide by the regulations set by the Spanish Ministry of Health, therefore no COVID vaccination or PCR/Ag tests will be mandatory to enter the congress venue. We suggest wearing the FFP2 mask in closed rooms and to wash your hands frequently. Masks and hand sanitizer stations will be available on site.

Please be considerate of others and do not enter the congress venue if you have symptoms or have been diagnosed with COVID.

Kindly take note that if you are arriving from countries that do NOT belong to the European Union or are not considered Schengen associated countries you will have to provide an EU Digital COVID Certificate, the EU Equivalent or the SpiTh QR to enter Spain, see all details here: https://spth.gob.es/

Please note that each individual participant is obliged to check the regulations that are in effect on date of entry. The EANM does not guarantee completeness of information stated on its homepage regarding current COVID regulations and is not liable for any short-term changes in said regulations.

CONGRESS OFFICE

The congress office is located at level M2, Room M211/212 (at the CCIB – Congress Centre Barcelona) & will be open during the following days will be open during the following days and times:

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, October 15, 2022</td>
<td>07:30 - 18:00</td>
</tr>
<tr>
<td>Sunday, October 16, 2022</td>
<td>07:30 - 18:00</td>
</tr>
<tr>
<td>Monday, October 17, 2022</td>
<td>07:30 - 18:00</td>
</tr>
<tr>
<td>Tuesday, October 18, 2022</td>
<td>07:30 - 18:00</td>
</tr>
<tr>
<td>Wednesday, October 19, 2022</td>
<td>07:30 - 12:00</td>
</tr>
</tbody>
</table>

CONGRESS SELF CHECK-IN

Self Check-In stations in the EANM Registration Area, located in the Entrance Hall, will help you to collect your name badge without waiting queues. Please make sure to bring your QR code and a personal ID.

CONGRESS VENUE

CCIB – Centre de Convencions Internacional de Barcelona / Barcelona International Convention Centre
Plaça de Willy Brandt, 11-14
08019 Barcelona, Spain
www.ccib.es/home

The CCIB is located at the seafront, located in the heart of the technology and business district. This unique congress centre is known for the originality of its architecture and column-free meeting halls with natural daylight. It is in easy reach with the subway – line L4 (yellow line) until Maresme-Forum. Alternatively you can use the tram and bus – lines 7 and H16 until Forum.

For further information about the lines connected to the CCIB, please visit: www.ccib.es/barcelona/#transport

DATES & DEADLINES

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 5, 2022</td>
<td>Advanced Registration Deadline</td>
</tr>
<tr>
<td>October 15, 2022</td>
<td>Opening Ceremony and Welcome Reception</td>
</tr>
<tr>
<td>October 19, 2022</td>
<td>Closing Ceremony and Farewell cocktail</td>
</tr>
<tr>
<td>December 20, 2022</td>
<td>Deadline for on-demand evaluation</td>
</tr>
</tbody>
</table>

NAME BADGES

Badges for the congress will be issued on-site between October 15 and October 19, 2022. The badges must be collected in person.

A confirmation email including a QR code will be issued upon successful completion of registration. With this QR, along with a valid photo ID the name badge can be printed onsite in the registration.
OPENING CEREMONY & WELCOME RECEPTION

All registered delegates and accompanying persons are cordially invited to the Opening Ceremony & Welcome Reception on Saturday, October 15, 2022, from 18:00-21:45.

The Opening Ceremony including the Highlights Lecture will be held at the Auditorium of the CCIB and the subsequent Welcome Reception at Level P0 of the CCIB, in the Entrance Hall.

CCIB – Centre de Convencions Internacional de Barcelona
Plaça de Willy Brandt, 11-14
08019 Barcelona, Spain

PARKING

Private cars can be parked at additional cost in parking areas. The closest parking area to the CCIB is Parking Pl. del Fòrum (Address: Pl. d’Ernest Lluch i Martín, 08005 Barcelona). The cost for a day is 44,20 €.

For further parking spaces in Barcelona please visit the following website:
www.aparcamentsbsm.cat/en

PUBLIC TRANSPORTATION TICKET (PTT)

All congress participants who book a hotel through the online registration page of EANM which is more than a 15-minute walk away from the congress venue will receive a complimentary public transportation ticket upon check-in at the hotel.

For further information on the public transportation system please visit:
https://www.tmb.cat/en/home

Selected tickets, at a reduced price can be purchased at the EANM’22 Accommodation & Public Transportation Tickets Desk that you can find at the congress venue within the registration area.

- 2 day Hola Barcelona Travel Card (48 h) = € 9,00 (instead of € 16,40)
- 3 day Hola Barcelona Travel Card (72 h) = € 13,00 (instead of € 23,80)
- 5 day Hola Barcelona Travel Card (120 h) = € 20,00 (instead of € 38,00)

Payments via credit card and cash will be accepted.

REGISTRATION DESK

The registration desk at the entrance level P0 of the CCIB will be open:

Saturday, October 15, 2022: 07:30 - 21:45
Sunday, October 16, 2022: 07:30 - 18:00
Monday, October 17, 2022: 07:30 - 18:00
Tuesday, October 18, 2022: 07:30 - 18:00
Wednesday, October 19, 2022: 07:30 - 12:00

REVIEW CENTRE

The Review Centre gives you the opportunity to check the PowerPoint presentations which have been already presented during EANM’22. So, in case you have missed a session, you can review the slides here afterwards. The Review Centre is located on Level P1, Room 133/134. Some slides might not be accessible for review online.

SOCIAL HUB

All EANM’22 attendees are invited to visit the Social Hub, an area designed to take a break and socialize in between the sessions. The Social Hub includes a photo booth, interactive games, an internet corner and a catering area. Moreover, it is possible to view the ‘Inside EANM’22’ Vlog by Judit Adam as well as listen to the EANM Podcast in collaboration with SAM Nordic. The Social Hub is located in the Entrance Hall.

SOCIAL MEDIA AND NEWSLETTER

For up-to-date information follow us on our Social Media Channels and subscribe to the Congress Newsletter!

Facebook: @officialEANM
Twitter: @officialEANM
LinkedIn: @officialEANM
YouTube: @officialEANM
Congress Newsletter: read more about our Newsletters: www.eanm.org/about/newsletter/

WIFI

Free WIFI will be available at the EANM22 Congress.
Network: eanm
Password: eanm2022

Registrations for 2023 will open during the EANM’22 Congress.

Do not forget to visit the ESMIT Booth!

Get your Dose of Education

More information at eanm.org/esmit or contact us at esmit@eanm.org
ABOUT BARCELONA

BANKS, CREDIT CARDS & ATM’S

Banks are usually open from 09.00 – 16:00 (Monday-Friday) – closed during the weekends. There will be ATMs (Automatic Teller Machine) in the CCIB or at the nearby shopping mall and all over the city of Barcelona. At the airport and main station and along the main streets you find currency exchange offices as well. All major credit cards, including Eurocard, Diners, Visa and MasterCard are accepted in most of the establishments like restaurants, hotels and shopping centres and stores.

When paying by credit card for your shopping, you will be asked to show identification. Please have your ID card or passport with you at all times, otherwise they may refuse to accept your credit card as payment.

Travel checks can be cashed in most of the banks and exchange offices.

CURRENCY

The official currency in Spain is the Euro (€). You can exchange your currency without any limits for the total amount at all banks as well as many exchange offices in Barcelona. When you are exchanging your currency, you need your passport or official ID card. If you do not have it with you, the bank may refuse to exchange your currency.

ELECTRICITY

The power supply in Spain is 220/240 V. Most electric outlets adhere to the continental standard (Schuko). Appliances from North America require a transformer and British ones an adaptor for the two-pin sockets in use in Spain.

MUSEUM

Barcelona has a huge variety of museums, which can easily suit every taste and fancy. Some museums are mainly to appeal to tourists, whereas others contain some of the biggest art collections of some style and yet others have education as their main purpose.

You can ask your hotel reception or the Barcelona Info desk in the EANM’22 registration area for detailed information and current Covid-19 safety regulations.

RESTAURANTS & NIGHTLIFE

One of the main characteristics of Barcelona is its nightlife. The good weather contributes to sit at the terraces of the coffee-shops, bars and restaurants which are opened until very late. Downtown restaurants normally open for lunch from 11:00 to 15:00 and for dinner from 19:30 to 23:00. Cafés and breakfast bars may open already at 08:00 or even earlier.

There is a great number of “Tapas-bars” where you can enjoy a drink and small “tapa” or “pincho” to eat at any time of the day.

Fast food, kebabs, take-away-pizza stalls usually serve food all day long, and some of them stay open till midnight. Bars, night clubs and discothèques usually open from 22:00 – 04:00 (some even longer).

Please make sure to check the current Covid-19 safety regulations.

CHURCHES, SYNAGOGUES, MOSQUES

Although Barcelona (like the rest of Spain) is basically Catholic, all religions are allowed and practised. Please contact your hotel concierge for current times of services or nearby places of worship.

CITY TAX

The city tax fee depends on the hotel category and varies between € 1,00 and € 3,50 per person and night. This fee applies only for the first seven nights.

CLIMATE

Barcelona enjoys a Mediterranean climate, with short cool winters and hot summers. The location of the city besides the sea increases the humidity level. Generally, it rains with more intensity during the spring and autumn. In September and October, the thunderstorms are frequent. Mostly in sunny autumn days in October, the temperatures are very nice during the day, decreasing at night.

TRAVEL TIPS

BANKS ARE USUALLY OPEN FROM 09.00 – 16:00 (MONDAY-FRIDAY) – CLOSED DURING THE WEEKENDS. THERE WILL BE ATMS (AUTOMATIC TELLER MACHINE) IN THE CCIB OR AT THE NEARBY SHOPPING MALL AND ALL OVER THE CITY OF BARCELONA. AT THE AIRPORT AND MAIN STATION AND ALONG THE MAIN STREETS YOU FIND CURRENCY EXCHANGE OFFICES AS WELL. ALL MAJOR CREDIT CARDS, INCLUDING EUROCARD, DINERS, VISA AND MASTERCARD ARE ACCEPTED IN MOST OF THE ESTABLISHMENTS LIKE RESTAURANTS, HOTELS AND SHOPPING CENTRES AND STORES.

WHEN PAYING BY CREDIT CARD FOR YOUR SHOPPING, YOU WILL BE ASKED TO SHOW IDENTIFICATION. PLEASE HAVE YOUR ID CARD OR PASSPORT WITH YOU AT ALL TIMES, OTHERWISE THEY MAY REFUSE TO ACCEPT YOUR CREDIT CARD AS PAYMENT.

TRAVEL CHECKS CAN BE CASHED IN MOST OF THE BANKS AND EXCHANGE OFFICES.

THE OFFICIAL CURRENCY IN SPAIN IS THE EURO (€). YOU CAN EXCHANGE YOUR CURRENCY WITHOUT ANY LIMITS FOR THE TOTAL AMOUNT AT ALL BANKS AS WELL AS MANY EXCHANGE OFFICES IN BARCELONA. WHEN YOU ARE EXCHANGING YOUR CURRENCY, YOU NEED YOUR PASSPORT OR OFFICIAL ID CARD. IF YOU DO NOT HAVE IT WITH YOU, THE BANK MAY REFUSE TO EXCHANGE YOUR CURRENCY.

THE POWER SUPPLY IN SPAIN IS 220/240 V. MOST ELECTRIC OUTLETS ADHERE TO THE CONTINENTAL STANDARD (SCHUKO). APPLIANCES FROM NORTH AMERICA REQUIRE A TRANSFORMER AND BRITISH ONES AN ADAPTOR FOR THE TWO-PIN SOCKETS IN USE IN SPAIN.

BARCELONA HAS A HUGE VARIETY OF MUSEUMS, WHICH CAN EASILY SUIT EVERY TASTE AND FANCY. SOME MUSEUMS ARE MAINLY TO APPEAL TO TOURISTS, WHEREAS OTHERS CONTAIN SOME OF THE BIGGEST ART COLLECTIONS OF SOME STYLE AND YET OTHERS HAVE EDUCATION AS THEIR MAIN PURPOSE.

YOU CAN ASK YOUR HOTEL RECEPTION OR THE BARCELONA INFO DESK IN THE EANM’22 REGISTRATION AREA FOR DETAILED INFORMATION AND CURRENT COVID-19 SAFETY REGULATIONS.

ONE OF THE MAIN CHARACTERISTICS OF BARCELONA IS ITS NIGHTLIFE. THE GOOD WEATHER CONTRIBUTES TO SIT AT THE TERRACES OF THE COFFEE-SHOPS, BARS AND RESTAURANTS WHICH ARE OPENED UNTIL VERY LATE. DOWNTOWN RESTAURANTS USUALLY OPEN FOR LUNCH FROM 11:00 TO 15:00 AND FOR DINNER FROM 19:30 TO 23:00. CAFÉS AND BREAKFAST BARS MAY OPEN ALREADY AT 08:00 OR EVEN EARLIER.

THERE IS A GREAT NUMBER OF “TAPAS-BARS” WHERE YOU CAN ENJOY A DRINK AND SMALL “TAPA” OR “PINCHO” TO EAT AT ANY TIME OF THE DAY.

FAST FOOD, KEBABS, TAKE-AWAY-PIZZA STALLS USUALLY SERVE FOOD ALL DAY LONG, AND SOME OF THEM STAY OPEN TILL MIDNIGHT. BARS, NIGHT CLUBS AND DISCOTHEQUES USUALLY OPEN FROM 22:00 – 04:00 (SOME EVEN LONGER).

PLEASE MAKE SURE TO CHECK THE CURRENT COVID-19 SAFETY REGULATIONS.
SAFETY TIPS / PICK-POCKETS

Barcelona is very safe from violent crime – ranking forth in the EU accordingly to the ‘Safe Cities Index 2021’ by The Economist Intelligence Unit (EIU). But there are many pickpockets and bag thieves in areas with popular tourist attractions (especially on Las Ramblas street & La Sagrada Familia), in the central subway, and the Sants train station.

Therefore, please don’t carry your wallet in your back pocket – but in a pocket with a zipper. Don’t put phones, cameras etc. on tables at cafés and keep your belongings always on your lap. Carry your backpack or shoulder bag in a crowded area or at street shows always in front of you so you can see it. Be wary of strangers approaching or touching you and do not play any street games. Do not carry all cash money, credit card and ID documents all together in one bag/pocket.

SHOPPING

Barcelona is an ideal destination to shop for a wide variety of items catering to everybody’s tastes and wishes. Opening hours of midtown shops are 09:00 to 19:30 (Monday-Saturday). Big shopping malls open until 21:00. On Sundays, small shops are generally closed. Some malls are open 7 days a week.

Please make sure to check the current Covid-19 safety regulations.

TAXES & TIPPING

VAT is always included in the price presented to the customers/guests in shops, hotels, restaurants and other service providers. Non-EU citizens can directly claim back their VAT at the shops (excluding restaurants, hotels and other food) when the total bill exceeds € 90,15. Please ask at the shops for more information. A service charge is not always automatically included in hotel and restaurant bills, it will be stated on the bill or in the menu. Tipping is not mandatory, but a small gratuity (5-10%) is expected in restaurants if good service is received.

TAXIS

Barcelona taxi colours are black and yellow. Taxis are an affordable alternative to the public transportation. However, it is not recommended to use taxis in the inner city as a lot of the streets are pedestrian areas and the traffic is quite high. The rates will be shown on the meter next to the driver. The initial fare for a taxi is € 2,25 plus € 1,18 to € 1,77 per kilometre depending on the time.

Possible taxi numbers are:
- Ràdio Taxi Barcelona: +34 933 75 55 55
- Cooperativa Radio Taxi: +34 932 25 00 00
- Barnataxi: +34 933 22 22 22
- Radio Taxi Barcino: +34 931 18 18 18

TIME ZONE

Barcelona is located in the Central European Time Zone (CET), i.e. one hour ahead of Greenwich Mean Time (GMT+1).

VISA

All foreign visitors entering Spain must possess valid passports. For citizen from the European Union Member countries, a valid identity card is sufficient.

Please check the current visa requirements with the nearest Spanish Consulate/Embassy in your country before your departure to Spain.

All registered congress participants may issue a visa invitation letter during the online registration process.

EARL SERVING THE COMMUNITY:

18 F, 68 G, 89 ZR for PET/CT and PET/MR HARMONISATIONS

We are growing to serve the needs of our community. EARL provides unparallel support for tomorrow’s research needs with today’s molecular imaging data.
AIRPORT & ARRIVAL INFORMATION

COVID-19 TRAVEL REGULATIONS

Before travelling, you must always check the current requirements, recommendations and travel warnings of the public bodies and national authorities from your country and from Spain.

The current regulations are stated on the Spanish Ministry of Health website: https://spth.gob.es as well as here: https://travelssafe.spain.info/en/before/

Kindly check what kind of certificates and regulations apply to you before making any bookings and prepare the needed documentation on time.

Please note that each individual participant is obliged to check the regulations that are in effect on date of entry. The EANM does not guarantee completeness of information stated on this page regarding current COVID regulations and is not liable for any short-term changes in said regulations.

AIRPORT

The airport “El Prat de Llobregat” is located 12 km southwest of the city. It takes approximately 20-25 minutes by car to the city centre. There is a free bus shuttle between the two terminals T1 and T2.

For further information on the airport please visit: www.barcelona-airport.com

Alternatively, Barcelona can be reached by train or intercity bus from neighbouring countries like France or Portugal. For further information, please check with your national railway provider.

PUBLIC TRANSPORTATION

Public transportation is by far the easiest way to get around the city.

The use of a face mask (FFP2) is mandatory at the public transport, on the subway and on the bus. The mask has to be worn covering your nose and mouth and should never be taken off (neither to talk nor eat nor drink).

The Barcelona subways, buses and trams are quick, cheap and all-around excellent. One can either buy a single trip ticket for € 2,40 or a T-casual ticket (10 rides in 1 zone) for € 7,95 or a T-dia (valid 24 hours in 1 zone) for € 10,50, which can be used for any transportation within the city. Alternatively, there is the Hola Barcelona Travel Card for 2, 3, 4 or 5 days which can be used for transportation and other travel operators.

As every year, EANM provides free public transportation tickets (PTTs) to those participants who booked a room from the official EANM congress allotment, which is more than 15 minutes’ walk away from the congress venue. Each participant who booked such a room via the congress page will receive their ticket upon check-in at the hotel.

Selected tickets, at a reduced price can be purchased at the EANM22 Accommodation & Public Transportation Tickets Desk, that you can find at the congress venue within the registration area.

• 2 day Hola Barcelona Travel Card (48 h): € 9,00 (instead of € 16,40)
• 3 day Hola Barcelona Travel Card (72 h): € 13,00 (instead of € 23,80)
• 5 day Hola Barcelona Travel Card (120 h): € 20,00 (instead of € 38,20)

Payments via credit card and cash will be accepted.

For further information on the public transportation system please check the internet for: https://www.tmb.cat/en/home

Taxi service is everywhere in the city. However, on weekend nights the waiting time might be long.

AIRPORT BUS

The blue Aerobus takes you every 5-10 minutes from the airport to the city centre (e.g. Plaça d’España or Plaça de Catalunya) in about 20-30 minutes. The bus stops at both terminals, line A1 at terminal T1 and line A2 at terminal T2. Both buses stop at the same stops in the city. One-way tickets cost you € 5,90, return- tickets € 10,20. You can buy a ticket on the bus itself.

For further information please visit: aerobusbarcelona.es/?lang=en

SUBWAY

The Metro line L9 connects the airport (both terminals) with Barcelona city. It takes about 30 minutes and leaves every 7 minutes. One cannot use the standard metro ticket but instead needs an Airport Ticket for € 4,60.

For further information please visit: www.tmb.cat/en/barcelona-transport/map/metro

TRAIN

The train R2 Nord departs every 30 min at terminal T2 (from terminal T1, first take the free shuttle bus). It stops in the city at Passieg de Gràcia, Barcelona Sants Estació and El Prat where you can change to the metro or city buses. One can use the normal public transportation tickets without any surcharge, which can be bought at the entrance of the RENFE gate at the airport.

For further information please visit: www.renfe.com/es/en

TAXI

To take a taxi into the city, please look for the signs for the nearest taxi stand when leaving the arrival halls. An average journey by taxi from the Barcelona Airport to downtown takes about 20-40 minutes and costs around € 29,00. The minimum fare from the airport is € 20.

Possible taxi numbers are:
• Radio Taxi Barcelona : +34 933 75 55 55
• Cooperativa Radio Taxi: +34 931 25 00 00
• Barnataxi: +34 933 22 22 22
• Radio Taxi Barcino: +34 931 18 18 18
• Cooperativa Radio Taxi: +34 932 25 00 00
• Barnataxi: +34 933 22 22 22

CAR

Barcelona can be reached by several main roads from France and Spain and traffic is usually relatively light outside of peak hours. Parking, on the other hand, is quite difficult and it is recommended to either park the car a few metro stops from the centre of the city or find a car park. Alternatively, the hotel might also have a private car park.

Location and prices of the public car parks can be found here: www.parclick.com
### PROGRAMME OVERVIEW

**SATURDAY, OCTOBER 15, 2022**

<table>
<thead>
<tr>
<th>Location/ Time</th>
<th>Auditorium</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:30</td>
<td></td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td></td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td></td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:45</td>
<td></td>
</tr>
<tr>
<td>10:45 - 11:15</td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td></td>
</tr>
<tr>
<td>12:00 - 12:30</td>
<td></td>
</tr>
<tr>
<td>12:30 - 13:00</td>
<td></td>
</tr>
<tr>
<td>13:00 - 13:30</td>
<td></td>
</tr>
<tr>
<td>13:30 - 14:00</td>
<td></td>
</tr>
<tr>
<td>14:00 - 14:30</td>
<td></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td></td>
</tr>
<tr>
<td>15:00 - 15:30</td>
<td></td>
</tr>
<tr>
<td>15:30 - 16:00</td>
<td></td>
</tr>
<tr>
<td>16:00 - 16:30</td>
<td></td>
</tr>
<tr>
<td>16:30 - 17:00</td>
<td></td>
</tr>
<tr>
<td>17:00 - 17:30</td>
<td></td>
</tr>
<tr>
<td>17:30 - 18:00</td>
<td></td>
</tr>
<tr>
<td>18:00 - 18:30</td>
<td></td>
</tr>
<tr>
<td>18:30 - 19:00</td>
<td></td>
</tr>
<tr>
<td>19:00 - 20:30</td>
<td></td>
</tr>
<tr>
<td>20:30 - 21:00</td>
<td></td>
</tr>
<tr>
<td>21:00 - 21:30</td>
<td></td>
</tr>
<tr>
<td>21:30 - 22:00</td>
<td></td>
</tr>
</tbody>
</table>

**Opening Ceremony Including Awards Ceremony (18:00-18:30)**

**Plenary 1 Highlights Lecture (18:30-19:00)**

**Welcome Reception (19:45-21:45)**

### CME CERTIFICATES

**SCAN YOUR BADGE**

**ATTENTION! MANDATORY EVALUATION**

Scan your badge at the beginning of each session when entering the Auditorium in order to acquire CME credits. In case you cannot attend the session live, you can gain the CME credits also by watching the talks on-demand.

**EVALUATE**

**DEADLINE: December 20, 2022**

A short evaluation has to be completed for each attended CME session, as well as for the overall congress until December 20, 2022.

**DOWNLOAD YOUR CERTIFICATE**

Once the steps above are completed, your certificate will be available within 24 hours in your myEANM area (myeanm.eanm.org).

Attention! To obtain your CME credits (for single sessions as well as the congress itself) the respective evaluations are mandatory. **Deadline: December 20, 2022.** After this date, or without the completed evaluation(s), no points will be accredited.
<table>
<thead>
<tr>
<th>Time</th>
<th>Location/Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Plenary 1</td>
</tr>
<tr>
<td>08:30</td>
<td>Learning &amp; Improve Professional Skills (LIPS) Track Interactive Session - Nuclear Medicine &amp; Oncology Committee Black and White or Fifty Shades of Grey? Beyond Binary Reading of Brain PET Images</td>
</tr>
<tr>
<td>09:30</td>
<td>CME 5 Nuclear Medicine in the Evaluation of Paediatric Patients with Transplants</td>
</tr>
<tr>
<td>09:00</td>
<td>CME 6 Oncology &amp; Theranostics Committee PET/CT - The Prediction Game</td>
</tr>
<tr>
<td>09:30</td>
<td>CME 7 Radiation Protection Committee Radiation Protection in Radioclinical Therapy - Insight on New and Emerging Therapies</td>
</tr>
<tr>
<td>10:00</td>
<td>CME 8 Bone &amp; Joint Committee Early Bone Scan Imaging - Let’s Go 3D!</td>
</tr>
<tr>
<td>10:30</td>
<td>TOP Trials Session 2 - Best FAPI Trials</td>
</tr>
<tr>
<td>11:00</td>
<td>TOP Trials Session 3 - Best PET Imaging Trials</td>
</tr>
<tr>
<td>11:30</td>
<td>TOP Trials Session 4 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>12:00</td>
<td>TOP Trials Session 5 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>12:30</td>
<td>TOP Trials Session 6 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>13:00</td>
<td>TOP Trials Session 7 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>13:30</td>
<td>TOP Trials Session 8 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>14:00</td>
<td>TOP Trials Session 9 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>14:30</td>
<td>TOP Trials Session 10 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>15:00</td>
<td>TOP Trials Session 11 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>15:30</td>
<td>TOP Trials Session 12 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>16:00</td>
<td>TOP Trials Session 13 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>16:30</td>
<td>TOP Trials Session 14 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>17:00</td>
<td>TOP Trials Session 15 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>17:30</td>
<td>TOP Trials Session 16 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>18:00</td>
<td>TOP Trials Session 17 - Best PET/CT Imaging Trials</td>
</tr>
<tr>
<td>18:30</td>
<td>TOP Trials Session 18 - Best PET/CT Imaging Trials</td>
</tr>
</tbody>
</table>

**Programme Overview Monday, October 17, 2022**

**Auditorium**

- EANM’22
- World Leading Meeting
- October 15 - 19, 2022
- Programme Overview

**Hall 112 (Arena)**

- **08:00** - Plenary 1
- **08:30** - CME 5 Nuclear Medicine in the Evaluation of Paediatric Patients with Transplants
- **09:00** - CME 6 Oncology & Theranostics Committee PET/CT - The Prediction Game
- **09:30** - CME 7 Radiation Protection Committee Radiation Protection in Radioclinical Therapy - Insight on New and Emerging Therapies
- **10:00** - CME 8 Bone & Joint Committee Early Bone Scan Imaging - Let’s Go 3D!

**Hall 113**

- **08:30** - Learn & Improve Professional Skills (LIPS) Track Interactive Session - Nuclear Medicine & Oncology Committee Black and White or Fifty Shades of Grey? Beyond Binary Reading of Brain PET Images
- **09:30** - TOP Trials Session 2 - Best FAPI Trials

**Hall 114**

- **08:30** - M2M Track TROP Session Radiopharmaceutical Sciences & Translational Molecular Imaging & Therapy Committee - Peptides for All Tastes
- **09:30** - M2M Track TROP Session Radiopharmaceutical Sciences & Translational Molecular Imaging & Therapy Committee - Setting Up and Managing Imaging Trials

**Hall 211**

- **08:30** - Cutting Edge Science Track TROP Session Oncology & Theranostics Committee - Life Drawing in Nuclear Medicine - Fact or Fiction?
- **09:00** - Joint Symposium 4 Oncology & Theranostics Committee - Evaluation of Response to Therapy

**Hall 217**

- **08:30** - Clinical Oncology Track TROP Session Oncology & Theranostics Committee - Image Reconstruction + Image Guided Surgery
- **09:00** - Clinical Oncology Track TROP Session Oncology & Theranostics Committee - Lung

**Hall 212**

- **08:30** - Featured Session Bone & Joint Committee Bone and Joint in 3D - Tracers, Modalities and Applications
- **09:00** - Joint Symposium 3 Thyroid Committee / EORTC - A Nuclear Medicine Update on Diagnosis and Treatment of Medullary Thyroid Carcinoma (MTC)

**Hall 211**

- **08:30** - E-Poster Presentations Session 5 Cardiovascular Committee - Physics and Radiation Protection: e-Posters on Cardiovascular Topics
- **09:00** - E-Poster Presentations Session 6 EANM Stockholm - Physics and Radiation Protection: e-Posters on Paediatrics & Nephro-Urology

**Hall 116**

- **08:30** - Technologies’ Track Oral Presentations Session 7 EANM Stockholm - Physics and Radiation Protection: e-Posters on Paediatrics & Nephro-Urology
- **09:00** - Technologies’ Track CTE 4 - Physics and Radiopharmaceutical Sciences Committee - Research in Radiopharmacy

**Programme Overview Monday, October 17, 2022**

- Auditorium
- Hall 112 (Arena)
- Hall 113
- Hall 114
- Hall 211
- Hall 217
- Hall 212
- Hall 211
- Hall 116
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15</td>
<td>Auditorium</td>
<td>CME 9: Dosimetry + Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>08:30</td>
<td>Auditorium</td>
<td>SIRT - An Example of Successful Clinical Dosimetry</td>
</tr>
<tr>
<td>08:45</td>
<td>Auditorium</td>
<td>CME 10: Oncology &amp; Theranostics + Physics Committee Quantitative SPECT, PET and Standardisation</td>
</tr>
<tr>
<td>09:00</td>
<td>Auditorium</td>
<td>Plenary 4: Superficial, Controversial and Luxury Issues in Nuclear Medicine</td>
</tr>
<tr>
<td>09:30</td>
<td>Auditorium</td>
<td>Members’ Assembly (11:15-14:45)</td>
</tr>
<tr>
<td>09:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Physics + Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>10:00</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>10:15</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>10:30</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>10:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>11:00</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>11:15</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>11:30</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>11:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>12:00</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>12:15</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>12:30</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>12:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>13:00</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>13:15</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>13:30</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>13:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>14:00</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>14:15</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>14:30</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>14:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>15:00</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>15:15</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>15:30</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>15:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>16:00</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>16:15</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>16:30</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>16:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>17:00</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>17:15</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>17:30</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
<tr>
<td>17:45</td>
<td>Auditorium</td>
<td>Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?</td>
</tr>
</tbody>
</table>

**Session Titles**
- CME 9: Dosimetry + Oncology & Theranostics Committee
- SIRT - An Example of Successful Clinical Dosimetry
- CME 10: Oncology & Theranostics + Physics Committee Quantitative SPECT, PET and Standardisation
- Plenary 4: Superficial, Controversial and Luxury Issues in Nuclear Medicine
- Members’ Assembly (11:15-14:45)
- Joint Symposium 5: Imaging Brain Tumours - Is PET Required or only a Fancy Option?
<table>
<thead>
<tr>
<th>Location/Time</th>
<th>Auditorium</th>
<th>Hall 112 (Arena)</th>
<th>Hall 113</th>
<th>Hall 114</th>
<th>Hall 211</th>
<th>Hall 117</th>
<th>Hall 115</th>
<th>Hall 212</th>
<th>Hall 111</th>
<th>Hall 116</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td>CME 13</td>
<td>Special Track</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Debate: PET/MR - Lights or Shadows?</td>
<td>CME 14</td>
<td>Special Track</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Debate: Dosimetry in Clinical Practice - Sense vs. Nonsense</td>
<td>CME 14</td>
<td>Special Track</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td>CME 13</td>
<td>Learn &amp; Improve Professional Skills (LIPS) Track</td>
<td>Abstract Session</td>
<td>Case Report Session 2 - Others than Oncology</td>
<td>CME 13</td>
<td>Learn &amp; Improve Professional Skills (LIPS) Track</td>
<td>Interactive Session</td>
<td>Radiopharmaceutical Sciences &amp; Translational Molecular Imaging &amp; Therapy Committee</td>
<td>CME 14</td>
<td>Learn &amp; Improve Professional Skills (LIPS) Track</td>
</tr>
<tr>
<td>08:30 - 09:00</td>
<td>Joint Symposium 7</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>EIR Multimodality Functional Imaging</td>
<td>CME 13</td>
<td>Joint Symposium 7</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>EIR Multimodality Functional Imaging</td>
<td>CME 13</td>
<td>Joint Symposium 7</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>09:00 - 09:30</td>
<td>TROP Session</td>
<td>TROP Session</td>
<td>Physics Committee</td>
<td>Development in SPECT</td>
<td>TROP Session</td>
<td>TROP Session</td>
<td>Physics Committee</td>
<td>Development in SPECT</td>
<td>TROP Session</td>
<td>TROP Session</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td>Clinical Oncology Track</td>
<td>TROP Session</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Prostate Beyond Usual</td>
<td>TROP Session</td>
<td>TROP Session</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Other Cardiovascular Imaging</td>
<td>TROP Session</td>
<td>TROP Session</td>
</tr>
<tr>
<td>10:00 - 10:30</td>
<td>TROP Session</td>
<td>TROP Session</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Prostate Recurrence</td>
<td>TROP Session</td>
<td>TROP Session</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Sentinel Node</td>
<td>TROP Session</td>
<td>TROP Session</td>
</tr>
<tr>
<td>10:30 - 11:00</td>
<td>Clinical Oncology Track</td>
<td>TROP Session</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>A Spotlight on Thyroid and Parathyroid Imaging</td>
<td>TROP Session</td>
<td>TROP Session</td>
<td>Oncology &amp; Theranostics Committee</td>
<td>Sentinel Node</td>
<td>TROP Session</td>
<td>TROP Session</td>
</tr>
<tr>
<td>11:00 - 11:30</td>
<td>CME 13</td>
<td>CME 14</td>
<td>Special Track</td>
<td>M2M Track</td>
<td>CME 13</td>
<td>CME 14</td>
<td>Special Track</td>
<td>CME 14</td>
<td>CME 14</td>
<td>Special Track</td>
</tr>
<tr>
<td>11:30 - 12:00</td>
<td>Closing Session</td>
<td>Farewell Drink</td>
<td>CME 14</td>
<td>M2M Track</td>
<td>CME 13</td>
<td>CME 14</td>
<td>Special Track</td>
<td>CME 14</td>
<td>CME 14</td>
<td>Special Track</td>
</tr>
</tbody>
</table>

**WEDNESDAY, OCTOBER 19, 2022**

- **Plenary Sessions**
- **CME Sessions**
- **Special Track**
- **Learn & Improve Professional Skills (LIPS) Track**
- **Joint Symposium**
- **M2M Track**
- **Cutting Edge Science Track**
- **Clinical Oncology Track**
- **Special Symposium**
- **Featured/TROP Session**
- **e-Poster Presentations**
- **Technologists' Track Session**
INVITED SPEAKER SESSIONS

PLENARY SESSIONS

1. Saturday, October 15, 2022 | 18:35 – 19:35 | Auditorium
   Highlights Lecture
   Presenters: Irene Burger (Switzerland), Nathalie Albert (Germany), Benjamin Gallet (France) and Philippe Garrigue (France)

2. Sunday, October 16, 2022 | 11:30 – 13:00 | Auditorium
   PSMA – A Never Ending Successful Story (incl. Marie Curie Lecture)
   Chairpersons: Daniela E. Oprea-Lager (Amsterdam, Netherlands), Stefano Fanti (Bologna, Italy)
   » Once Upon a Time in the West - The History of Radiolabelled PSMA Production, Wolfgang Fendler (Essen, Germany)
   » The Good, the Bad and the Ugly - 68 Ga vs 18 F vs Other PSMA Diagnostic Tracers, Karolien Goffin (Leuven, Belgium)
   » The Matrix Reloaded - The Importance of Structured Reporting PSMA PET, Macarena Rodriguez Fraile (Pamplona, Spain)
   » The Maze Runner - The Interaction Between Androgen Deprivation Therapy and PSMA Expression, Louise Emmett (Sydney, Australia)
   » To Infinity and Beyond - PSMA PET in Solid Cancers Other Than Prostate Cancer, Simonia Makopina (Turku, Finland)
   » Bohemian Rhapsody - Current Landscape of PSMA Theranostics, Declan Murphy (Melbourne, Australia)
   » Marie Curie Lecture: Green Book - The Importance of Implementing PSMA in Guidelines, Daniela E. Oprea-Lager (Amsterdam, Netherlands)
   » Summary, All Speakers

3. Monday, October 17, 2022 | 11:30 – 13:00 | Auditorium
   Theranostics – More Than Just the Future of Nuclear Medicine
   Chairpersons: Louise Emmett (Sydney, Australia), Ken Hermann (Essen, Germany)
   » Theranostics Overview, Wolfgang Weber (Munich, Germany)
   » Why Theranostics should be NMs Driver to Independences, Johannes Czernin (Los Angeles, United States of America)
   » How to Successfully Set Up a Theranostics Center, Ana Denis Bacelar (Teddington, United Kingdom)
   » How to Raise Awareness for Theranostic Concepts, Cristina Navis (Bologna, Italy)
   » Getting Ready for the Next Wave of Theranostic Studies, Louise Emmett (Sydney, Australia)
   » Theranostics - The Catalyst for Nuclear Medicine Growth, Andrei Iagaru (Stanford, United States of America)
   » Summary, All Speakers

4. Tuesday, October 18, 2022 | 11:30 – 13:00 | Auditorium
   Superfluous, Controversial and Luxury Issues in Nuclear Medicine
   Chairpersons: Ogul Ekicioglu (Istanbul, Türkiye), Fred Verzijlbergen (Nijmegen, Netherlands)
   » Really, More New Radiolabelled Tracers?, Samantha Terry (London, United Kingdom)
   » Nuclear Neurology - Clinical Reality or Eternal Promise?, Silvia Motelli (Genoa, Italy)
   » Personalized Medicine - Every Man His Own PSMA?, Helle Dombrecht Zach (Raborg, Denmark)
   » Osirror Gym - Necessary or Redundant?, Stefan Peters (Nijmegen, Netherlands)
   » Radiomics - Way to the Future or Useless Fancy Name?, Xavier Bouwhijs (Logroño, Spain)
   » Summary, All Speakers
1. Sunday, October 16, 2022 | 08:00 – 09:30 | Auditorium Oncology & Theranostics Committee
Radionuclide Therapies - Controversies and Special Considerations

2. Sunday, October 16, 2022 | 09:45 – 11:15 | Auditorium Thyroid + Translational Molecular Imaging & Therapy Committee
Parathyroid Imaging

3. Sunday, October 16, 2022 | 15:00 – 16:30 | Auditorium Physics + Oncology & Theranostics + Neuroimaging Committee
Motion Management – State of the Art

4. Sunday, October 16, 2022 | 16:45 – 18:15 | Auditorium Cardiovascular + Inflammation & Infection Committee
New Role of Nuclear Medicine in Monitoring Cardiovascular Diseases

5. Monday, October 17, 2022 | 08:00 – 09:30 | Auditorium Paediatrics Committee
Nuclear Medicine in the Evaluation of Paediatric Patients with Transplants

6. Monday, October 17, 2022 | 09:45 – 11:15 | Auditorium Oncology & Theranostics Committee
PET/CT - The Prediction Game

7. Monday, October 17, 2022 | 15:00 – 16:30 | Auditorium Radiation Protection Committee
Radiation Protection in Radionuclide Therapy – Insight on New and Emerging Therapies

8. Monday, October 17, 2022 | 16:45 – 18:15 | Auditorium Bone & Joint Committee
Early Bone Scan Imaging – Let’s Go 3D!

9. Tuesday, October 18, 2022 | 08:00 – 09:30 | Auditorium Dosimetry + Oncology & Theranostics Committee
SIRT – An Example of Successful Clinical Dosimetry

10. Tuesday, October 18, 2022 | 09:45 – 11:15 | Auditorium Oncology & Theranostics + Physics Committee
Quantitative SPECT, PET and Standardisation

11. Tuesday, October 18, 2022 | 15:00 – 16:30 | Auditorium Neuroimaging Committee
Molecular Imaging and Fluid Biomarkers in Alzheimer’s Disease - A Nice Couple

12. Tuesday, October 18, 2022 | 16:45 – 18:15 | Auditorium Radiopharmaceutical Sciences Committee
Optimizing Radiolabeled Biomolecules for Imaging and Therapy – The Secrets Revealed

13. Wednesday, October 19, 2022 | 08:00 – 09:30 | Auditorium Translational Molecular Imaging & Therapy + Radiopharmaceutical Sciences + Oncology & Theranostics Committee
First In-Human Studies

14. Wednesday, October 19, 2022 | 09:45 – 11:15 | Auditorium Oncology & Theranostics Committee
Rare Tumours
TECHNOLOGISTS’ TRACK

PLENARY SESSIONS

1. Saturday, October 15, 2022 | 18:35 – 19:35 | Auditorium
   Highlights Lecture

2. Sunday, October 16, 2022 | 11:30 – 13:00 | Auditorium
   PSMA – A Never Ending Successful Story (incl. Marie Curie Lecture)

3. Monday, October 17, 2022 | 11:30 – 13:00 | Auditorium
   Theranostics – More Than Just the Future of Nuclear Medicine

4. Tuesday, October 18, 2022 | 11:30 – 13:00 | Auditorium
   Superfluous, Controversial and Luxury Issues in Nuclear Medicine

CONTINUING MEDICAL EDUCATION (CTE) SESSIONS

1. Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 116
   Technologists Committee / SNMMI
   Tech Guide Launch

2. Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 116
   Technologists Committee
   Technologist Involvement in Research Imaging

3. Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 116
   Technologists + Radiation Protection Committee
   Radiation Protection in Radiopharmacy

4. Monday, October 17, 2022 | 09:45 – 11:15 | Hall 116
   Technologists + Radiopharmaceutical Sciences Committee
   Research in Radiopharmacy

5. Monday, October 17, 2022 | 16:45 – 18:15 | Hall 116
   Technologists Committee
   Nuclear Medicine in Haematological Malignancies

6. Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 116
   Technologists Committee
   Stem Cells in Nuclear Medicine

7. Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 116
   Technologists Committee
   EQF7 – European Qualification Framework Document for Nuclear Medicine
   Technologists - Interactive

IN ADDITION TO THE CTE SESSIONS THE TECHNOLOGISTS’ TRACK INCLUDES 3 MINI COURSES:

1. Wednesday, October 19, 2022 | 08:00 – 09:00 | Hall 116
   Technologists Committee
   CZT in Non-Cardiac Nuclear Medicine

2. Wednesday, October 19, 2022 | 09:05 – 10:05 | Hall 116
   Technologists Committee
   Non-Fluoride Cyclotron Production - O15-Water Applications

3. Wednesday, October 19, 2022 | 10:15 – 11:15 | Hall 116
   Technologists Committee
   Digital PET/CT

TECHNOLOGISTS’ ORAL PRESENTATIONS

   Technologists Committee
   Technologists’ Oral Presentations 1

2. Monday, October 17, 2022 | 08:00 – 09:30 | Hall 116
   Technologists Committee
   Technologists’ Oral Presentations 2

3. Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 116
   Technologists Committee
   Technologists’ Oral Presentations 3

TECHNOLOGISTS’ e-POSTER PRESENTATIONS

1. Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 116
   Technologists Committee
   Technologists’ e-Poster Presentations Session
**SPECIAL TRACK**

1. Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 112 (Arena)
   **Debate 1**
   Oncology & Theranostics Committee
   The Weight of CT in PET/CT

2. Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 112 (Arena)
   **Challenge the Expert 1**
   Oncology & Theranostics Committee
   Expert vs Team Barcelona: PSMA Imaging

3. Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 112 (Arena)
   **TOP Trials Session 1**
   Best International Trials

4. Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 112 (Arena)
   **Challenge the Expert 2**
   Oncology & Theranostics Committee
   Expert vs Team Groningen: Thyroid & Parathyroid

5. Monday, October 17, 2022 | 08:00 – 09:30 | Hall 112 (Arena)
   **Challenge the Expert 3**
   Inflammation & Infection Committee
   Expert vs Team Bologna: Real World in Infection

6. Monday, October 17, 2022 | 09:45 – 11:15 | Hall 112 (Arena)
   **TOP Trials Session 2**
   Inflammation & Infection Committee
   Best FAPI Trials

7. Monday, October 17, 2022 | 15:00 – 16:30 | Hall 112 (Arena)
   **Award Session**
   EANM Sanjiv Sam Gambhir Award – Battle and Win!

8. Monday, October 17, 2022 | 16:45 – 18:15 | Hall 112 (Arena)
   **Debate 2**
   Oncology & Theranostics + Radiopharmaceutical Sciences Committee
   Fluorine-18 Alternatives for Oncological Gallium-68 Tracers

9. Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 112 (Arena)
   **TOP Trials Session 3**
   New Radiopharmaceutical Trials

10. Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 112 (Arena)
    **Debate 3**
    Neuroimaging Committee
    Imaging Brain Tumours - Is PET Required or only a Fancy Option?

11. Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 112 (Arena)
    **Debate 4**
    Cardiovascular Committee
    Myocardial Perfusion Imaging with PET – Ready for Clinical Use?

12. Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 112 (Arena)
    **Challenge the Expert 4**
    Oncology & Theranostics Committee
    Expert vs Team Essen: PET/CT in Real Life

13. Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 112 (Arena)
    **Debate 5**
    Oncology & Theranostics + Physics Committee
    PET/MR - Lights or Shadows?

14. Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 112 (Arena)
    **Debate 6**
    Dosimetry Committee
    Dosimetry in Clinical Practice – Sense vs. Nonsense

**JOINT SYMPOSIA**

1. Monday, October 17, 2022 | 08:00 – 09:30 | Hall 212
   Cardiovascular Committee / EACVI
   Anatomical & Functional Cardiac Imaging – Friend or Foe?

2. Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 114
   Oncology & Theranostics Committee / EAU
   Prostate Cancer Radionuclide Therapy

3. Monday, October 17, 2022 | 08:00 – 09:30 | Hall 212
   Thyroid Committee / ETA
   A Nuclear Medicine Update on Diagnosis and Treatment of Medullary Thyroid Carcinoma (MTC)

4. Monday, October 17, 2022 | 16:45 – 18:15 | Hall 114
   Oncology & Theranostics Committee / EORTC
   Evaluation of Response to Therapy

5. Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 114
   Physics + Oncology & Theranostics Committee / ESTRO
   Imaging for Radiotherapy Applications

6. Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 114
   Oncology & Theranostics Committee / ESMO
   Integrated Theranostics

7. Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 114
   Oncology & Theranostics Committee / ESR
   Multimodality Functional Imaging

**SPECIAL SESSIONS**

1. Monday, October 17, 2022 | 08:00 – 09:45 | Meeting Room 120/121, Level P1
   UEMS/EBNM - Clinical Audit Session

2. Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 212
   Radiopharmaceutical Sciences Committee / EU Commission
   Radiopharmaceuticals Regulations - Quo Vadis?

3. Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 212
   EANM / EU Commission
   Getting to the Top QuADRANT. A European Initiative to Improve Quality for Patients
## LEARN & IMPROVE PROFESSIONAL SKILLS (LIPS) TRACK

<table>
<thead>
<tr>
<th>No.</th>
<th>Date</th>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Sunday, October 16, 2022</td>
<td>08:00 – 09:30</td>
<td>Hall 113</td>
<td>Abstract Session Case Report Session 1 - Oncology (including PET and Therapy)</td>
</tr>
<tr>
<td>2</td>
<td>Sunday, October 16, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 113</td>
<td>Cardiovascular + Inflammation &amp; Infection Committee (TBC) Tricky Cases on Nuclear Cardiology - Interactive</td>
</tr>
<tr>
<td>3</td>
<td>Sunday, October 16, 2022</td>
<td>15:00 – 16:30</td>
<td>Hall 113</td>
<td>Thyroid Committee Tricky Cases in Endocrine Imaging - Interactive</td>
</tr>
<tr>
<td>4</td>
<td>Sunday, October 16, 2022</td>
<td>16:45 – 18:15</td>
<td>Hall 113</td>
<td>Paediatrics Committee Tricky Cases in Paediatrics - Interactive</td>
</tr>
<tr>
<td>5</td>
<td>Monday, October 17, 2022</td>
<td>08:00 – 09:30</td>
<td>Hall 113</td>
<td>Translational Molecular Imaging &amp; Therapy Committee Challenging Situations in TMI&amp;T</td>
</tr>
<tr>
<td>6</td>
<td>Monday, October 17, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 113</td>
<td>Neuroimaging Committee Black and White or Fifty Shades of Grey? Beyond Binary Reading of Brain PET Images - Interactive</td>
</tr>
<tr>
<td>7</td>
<td>Monday, October 17, 2022</td>
<td>15:00 – 16:30</td>
<td>Hall 113</td>
<td>Oncology &amp; Theranostics + Translational Molecular Imaging &amp; Therapy Committee / EORTC Setting Up and Managing Imaging Trials - Interactive</td>
</tr>
<tr>
<td>8</td>
<td>Monday, October 17, 2022</td>
<td>16:45 – 18:15</td>
<td>Hall 113</td>
<td>Dosimetry Committee Life Drawing in Nuclear Medicine - Fact or Fiction? - Interactive</td>
</tr>
<tr>
<td>9</td>
<td>Tuesday, October 18, 2022</td>
<td>08:00 – 09:30</td>
<td>Hall 113</td>
<td>Oncology &amp; Theranostics Committee Tricky Cases in NET and Digestive Tract Oncology - Interactive</td>
</tr>
<tr>
<td>10</td>
<td>Tuesday, October 18, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 113</td>
<td>Inflammation &amp; Infection Committee ([(F)FDG PET/CT Treatment Response Assessment in Inflammatory Diseases - Interactive</td>
</tr>
<tr>
<td>11</td>
<td>Tuesday, October 18, 2022</td>
<td>15:00 – 16:30</td>
<td>Hall 113</td>
<td>Oncology &amp; Theranostics Committee Tricky Cases in Prostate Imaging - Interactive</td>
</tr>
<tr>
<td>12</td>
<td>Tuesday, October 18, 2022</td>
<td>16:45 – 18:15</td>
<td>Hall 113</td>
<td>Radiation Protection + Physics Committee CT Optimization in Hybrid Imaging - Interactive</td>
</tr>
<tr>
<td>13</td>
<td>Wednesday, October 19, 2022</td>
<td>08:00 – 09:30</td>
<td>Hall 113</td>
<td>Abstract Session Case Report Session 2 - Others than Oncology</td>
</tr>
<tr>
<td>14</td>
<td>Wednesday, October 19, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 113</td>
<td>Radiopharmaceutical Sciences + Translational Molecular Imaging &amp; Therapy + Physics Committee + Cardiovascular Committee Pharmacokinetics - From Basics to Clinical Applications - Interactive</td>
</tr>
</tbody>
</table>

## CLINICAL ONCOLOGY TRACK - TROP SESSIONS:

<table>
<thead>
<tr>
<th>No.</th>
<th>Date</th>
<th>Time</th>
<th>Location</th>
<th>Session Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>206</td>
<td>Sunday, October 16, 2022</td>
<td>08:00 – 09:30</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee Let’s Start With Some Prostate</td>
</tr>
<tr>
<td>306</td>
<td>Sunday, October 16, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>506</td>
<td>Sunday, October 16, 2022</td>
<td>15:00 – 16:30</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee Radioguided Surgery</td>
</tr>
<tr>
<td>606</td>
<td>Sunday, October 16, 2022</td>
<td>16:45 – 18:15</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee Neuroendocrinology</td>
</tr>
<tr>
<td>706</td>
<td>Monday, October 17, 2022</td>
<td>08:00 – 09:30</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>806</td>
<td>Monday, October 17, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1006</td>
<td>Monday, October 17, 2022</td>
<td>15:00 – 16:30</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1106</td>
<td>Monday, October 17, 2022</td>
<td>16:45 – 18:15</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1206</td>
<td>Tuesday, October 18, 2022</td>
<td>08:00 – 09:30</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1306</td>
<td>Tuesday, October 18, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1307</td>
<td>Tuesday, October 18, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 115</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1506</td>
<td>Tuesday, October 18, 2022</td>
<td>15:00 – 16:30</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1606</td>
<td>Tuesday, October 18, 2022</td>
<td>16:45 – 18:15</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1706</td>
<td>Wednesday, October 19, 2022</td>
<td>08:00 – 09:30</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1806</td>
<td>Wednesday, October 19, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 117</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
<tr>
<td>1807</td>
<td>Wednesday, October 19, 2022</td>
<td>09:45 – 11:15</td>
<td>Hall 115</td>
<td>Oncology &amp; Theranostics Committee</td>
</tr>
</tbody>
</table>
## CUTTING EDGE SCIENCE TRACK - TROP SESSIONS:

### 205 Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 211
- **Radiomics**
  - Physics Committee

### 305 Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 211
- **Current Issues in Radiation Protection**
  - Radiation Protection Committee

### 505 Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 211
- **SIRT**
  - Dosimetry Committee

### 605 Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 211
- **Developments in PET**
  - Physics Committee

### 705 Monday, October 17, 2022 | 08:00 – 09:30 | Hall 211
- **Quantification in Brain and Heart**
  - Physics Committee

### 805 Monday, October 17, 2022 | 09:45 – 11:15 | Hall 211
- **Clinical 1-177 Dosimetry**
  - Dosimetry Committee

### 1005 Monday, October 17, 2022 | 15:00 – 16:30 | Hall 211
- **I-131 Dosimetry for Thyroid Disease**
  - Dosimetry + Thyroid Committee

### 1105 Monday, October 17, 2022 | 16:45 – 18:15 | Hall 211
- **Image Reconstruction + Image Guided Surgery**
  - Physics Committee

### 1205 Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 211
- **Standardisation & Quality Control**
  - Physics Committee

### 1305 Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 211
- **Radiobiology**
  - Dosimetry Committee

### 1505 Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 211
- **Advanced Data Analysis**
  - Physics Committee

### 1605 Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 211
- **Predictive Artificial Intelligence**
  - Physics Committee

### 1705 Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 211
- **Developments in SPECT**
  - Physics Committee

### 1805 Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 211
- **AI Segmentation and Denoising**
  - Physics Committee

## M2M TRACK – TROP & FEATURED SESSIONS:

### 204 Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 114
- **New Radiopharmaceuticals – Fancy Stuff**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

### 304 Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 114
- **Therapy – Innovations and Technical Improvements**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

### 504 Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 114
- **The Promise of Combination Treatments**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

### 704 Monday, October 17, 2022 | 08:00 – 09:30 | Hall 114
- **GRPR vs. PSMA – A Comparison**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

### 804 Monday, October 17, 2022 | 09:45 – 11:15 | Hall 114
- **T-Cells, TAM’s and CAF’s – Again**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

### 1004 Monday, October 17, 2022 | 15:00 – 16:30 | Hall 114
- **Peptides for All Tastes**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

### 1204 Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 114
- **Seeing the Brain from all Angles**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

### 1604 Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 114
- **New Tracers – From Scratch to Automated Synthesis**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee

### 1804 Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 114
- **Antibodies – Reliable Workhorses**
  - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee
FURTHER ORAL PRESENTATIONS – TROP & FEATURED SESSIONS:

207  Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 115  Paediatrics Committee  Nephro-Urology and Paediatrics

307  Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 115  Paediatrics Committee  Featured Session  A Bit of Everything – Mix NM

308  Sunday, October 16, 2022 | 09:45 – 11:15 | Hall 212  Neuroimaging Committee  A Neurodegeneration – Ready for Beta! Ready for Tau?

507  Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 115  Cardiovascular Committee  Quantitative Myocardial Perfusion Imaging

508  Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 212  Paediatrics Committee  Paediatric Oncology

607  Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 115  Neuroimaging Committee  Breadth of Tracers and Approaches in Brain Tumours

608  Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 212  Inflammation & Infection Committee  All About Infections

707  Monday, October 17, 2022 | 08:00 – 09:30 | Hall 115  Bone & Joint Committee  Featured Session  Bone and Joint en Route – Tracers, Modalities and Applications

807  Monday, October 17, 2022 | 09:45 – 11:15 | Hall 115  Thyroid Committee  PET in Parathyroid Disease and Thyroid Cancer

808  Monday, October 17, 2022 | 09:45 – 11:15 | Hall 212  Cardiovascular Committee  Novel Developments in Nuclear Cardiology

1007 Monday, October 17, 2022 | 15:00 – 16:30 | Hall 115  Inflammation & Infection Committee  Nuclear Medicine and COVID-19

1008 Monday, October 17, 2022 | 15:00 – 16:30 | Hall 212  Cardiovascular Committee  Cardiovascular Metabolism, Innervation and Perfusion

1107 Monday, October 17, 2022 | 16:45 – 18:15 | Hall 115  Inflammation & Infection Committee  Inflammation and Beyond

1108 Monday, October 17, 2022 | 16:45 – 18:15 | Hall 212  Thyroid Committee  Treatment of Thyroid Cancer

1207 Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 115  Neuroimaging Committee  Movement Disorders – Radiomics, AI, Connectivity and What Else?
**e-POSTER PRESENTATION SESSIONS**

**1**  
Sunday, October 16, 2022 | 08:00 – 09:30 | Hall 111  
Bone & Joint + Neuroimaging Committee  
Miscellaneous – Bone / Brain / Covid-19 / Lung

**2**  
Sunday, October 16, 2022 | 09:45 – 11:45 | Hall 111  
Physics Committee  
Physics

**3**  
Sunday, October 16, 2022 | 15:00 – 16:30 | Hall 111  
Inflammation & Infection Committee  
Best e-Posters on Infection and Inflammation

**4**  
Sunday, October 16, 2022 | 16:45 – 18:15 | Hall 111  
Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee  
New Tracers – From Production to Translation

**5**  
Monday, October 17, 2022 | 08:00 – 09:30 | Hall 111  
Cardiovascular Committee  
e-Posters on Cardiovascular Topics

**6**  
Monday, October 17, 2022 | 09:45 – 11:15 | Hall 111  
Physics + Radiation Protection Committee  
Physics & Radiation Protection

**7**  
Monday, October 17, 2022 | 15:00 – 16:30 | Hall 111  
Paediatrics Committee  
e-Posters on Paediatrics & Nephro-Urology

**8**  
Monday, October 17, 2022 | 16:45 – 18:15 | Hall 111  
Neuroimaging Committee  
Neuro e-Posters

**9**  
Tuesday, October 18, 2022 | 08:00 – 09:30 | Hall 111  
Oncology & Theranostics Committee  
Local Therapy and More

**10**  
Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 111  
Oncology & Theranostics Committee  
Oncology

**Technologists’ Session**  
Tuesday, October 18, 2022 | 09:45 – 11:15 | Hall 116  
Technologists Committee  
Techs’ e-Posters

**11**  
Tuesday, October 18, 2022 | 15:00 – 16:30 | Hall 111  
Dosimetry Committee  
Dosimetry – Novel Tracers and Computer-Based Modelling

**12**  
Tuesday, October 18, 2022 | 16:45 – 18:15 | Hall 111  
Oncology & Theranostics Committee  
Prostate

**13**  
Wednesday, October 19, 2022 | 08:00 – 09:30 | Hall 111  
Oncology & Theranostics Committee  
Haematology

**14**  
Wednesday, October 19, 2022 | 09:45 – 11:15 | Hall 111  
Thyroid Committee  
A Spotlight on Thyroid and Parathyroid Imaging

---

**AWARDS**

EANM will bestow several awards during the EANM’22 Congress.

---

**EANM MARIE CURIE AWARD**

Each year the EANM is awarding the best submitted abstract with the prestigious Marie-Curie Award. The Award is bestowed during the EANM Congress Opening Ceremony by the EANM President. It is awarding the best submitted abstract of this year’s congress.

---

**EANM YOUNG AUTHORS’ AWARD**

(kindly supported by United Imaging Healthcare)

EANM is offering an award to three young authors of very good quality abstracts. The purpose of this award is to encourage young and talented nuclear medicine investigators to submit their results to the annual EANM congress and to have the financial aid to attend the meeting and present their work.

---

**EANM SANJIV SAM GAMBIH YOUNG INVESTIGATOR AWARD**

(kindly supported by Telix Pharmaceuticals)

This new award will grant a 3 months visitorship at Stanford University. A jury picked six candidates which will now battle in a session for this award. Monday, October 17, 2022 – 15:00-16:30 in Hall 112 (Arena).

---

**EANM TECHNOLOGISTS’ AWARD**

(kindly supported by United Imaging Healthcare)

The purpose of the Technologists’ Award is to encourage Nuclear Medicine Technologists to present the abstract of their research project at the Annual EANM Congress. 4 Awards will be handed over at the congress.

---

**EJNMMI AWARDS**

This year, the EANM and Springer again bestow the EJNMMI Awards for outstanding articles published across the whole journal family during the EANM Annual Congress. The European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) is the official journal of the EANM and the hand-over of the certificates will take place onsite as well.
Plenary 1: Highlights Lecture

OP-002

Highlights Lecture
L. Burger
University Hospital of Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND.

OP-003

Highlights Lecture
N. Albert
University Hospital of Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND.

OP-004

Highlights Lecture
A. Agrawal
Tata Memorial Centre, Mumbai, INDIA.

OP-005

Highlights Lecture
P. Garrigue
AP-HP, CERMEU, Aix-Marseille University, Marseille, FRANCE.

Oral Sessions

Sunday, October 16, 2022, 08:00 - 09:30
Auditorium

CME 1 - Oncology & Theranostics Committee: Radionuclide Therapies - Controversies and Special Considerations

OP-006
Thyroid Cancer - Controversies and Special Considerations in Therapy using 131I
L. Giavonelli
 Imaging Institute Southern Switzerland, Nuclear Medicine and Molecular Imaging, Bellinzona, SWITZERLAND.

OP-007
Neuroendocrine Tumours - Controversies and Special Considerations in [177Lu]Lu-DOTATATE Therapy
I. Virgolini
Department of Nuclear Medicine, Medical Imaging Institute Southern Switzerland, Bellinzona, SWITZERLAND.

OP-008
Prostate Cancer - Controversies and Special Considerations in [177Lu]Lu-PSMA Therapy
A. Agram
Dept. of Nuclear Medicine & Molecular Imaging, Tata Memorial Centre, Mumbai, INDIA.

OP-009
HCC and Liver metastases - Controversies and Special Considerations in Selective Internal Radiation Therapy (SIRT)
M. Weber
Uniklinik Essen, Essen, GERMANY.

202

Sunday, October 16, 2022, 08:00 - 09:30
Hall 112 (Avena)

Debate 1 - Oncology & Theranostics Committee: The Weight of CT in PET/CT

OP-010
Low Dose CT is all we need for PET
W. Vogel
University Hospital of Zurich, Department of Nuclear Medicine, Zurich, SWITZERLAND.

OP-011
To Answer Clinical Questions You Often Need Both cCT and PET/CT - Where is the Added Value of the Combination?
L. Burger
Anton van Leeuwenhoek ziekenhuis (NK-AvL), Nuclear Medicine, Amsterdam, NETHERLANDS.


4) Ga-PSMA PET/CT scans radiometric features for prediction of overall survival in non-small cell lung cancer patients treated with radical radiotherapy

K. Alberts 2, S. Smith, C. Marsh, M. Morley, Radiology University Center, Milan, ITALY.

OP-034 Determining the ideal mass and clinical potential of a bimodal probe for image-guided surgery of GRP-positive cancer

M. Farhouni, M. Handlouk 1, van den Brink, C. M. A. de Ridder 1, D. O. Stuurman 3, Y nnemuijl 3, S. U. Dalma 1

Department of medicine and Molecular Medicine, Erasmus MC, Rotterdam, NETHERLANDS.

Department of experimental Urology, Erasmus MC, Rotterdam, NETHERLANDS.

OP-035 Development and optimization of a dimeric peptide tracer for nerve-sparing surgery

T. Buckle, M. van Meekeren, F. W. B. van Leeuwen; LUMC, Leiden, NETHERLANDS.

OP-036 A novel ‘F-labelled molecular probe for position emission tomography imaging of oxidative stress

R. van, A. M. V. Kels, N. Singha, T. Baak, E. Walters, P. Sadasivam, R. Southworth.

King’s College London, London, UNITED KINGDOM.

OP-037 Targetting folate receptor-β expressing macrophages by F(18)-F-labeled molecular probe for positron emission tomography of brain glioblastoma


Faul Scherrer Institute, Villigen PSI, SWITZERLAND. Institute of Molecular Systems Biology, Department of Biology, ETHZ, ZURICH, SWITZERLAND.

Department of Radiology, University Hospital Zurich, Zürich, SWITZERLAND.

Department of Radiology and Applied Biomedical Sciences, ETH, ZURICH, SWITZERLAND.

205

Sunday, October 16, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: New Radio-pharmaceuticals - Fancy Stuff

204

Sunday, October 16, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: New Radio-pharmaceuticals - Fancy Stuff

3) Comparative analysis of cancer cell responses to peptide receptor radionuclide therapy with lutetium-177 metaiodobenzylguanidine analogue ([18Lu]LuLu-FF11 and external beam radiotherapy


Faul Scherrer Institute, Villigen PSI, SWITZERLAND. Institute of Molecular Systems Biology, Department of Biology, ETHZ, ZURICH, SWITZERLAND.

Department of Radiology, University Hospital Zurich, Zürich, SWITZERLAND.

Department of Radiology and Applied Biomedical Sciences, ETH, ZURICH, SWITZERLAND.

205

Sunday, October 16, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: New Radio-pharmaceuticals - Fancy Stuff

204

Sunday, October 16, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: New Radio-pharmaceuticals - Fancy Stuff

3) Comparative analysis of cancer cell responses to peptide receptor radionuclide therapy with lutetium-177 metaiodobenzylguanidine analogue ([18Lu]LuLu-FF11 and external beam radiotherapy


Faul Scherrer Institute, Villigen PSI, SWITZERLAND. Institute of Molecular Systems Biology, Department of Biology, ETHZ, ZURICH, SWITZERLAND.

Department of Radiology, University Hospital Zurich, Zürich, SWITZERLAND.

Department of Radiology and Applied Biomedical Sciences, ETH, ZURICH, SWITZERLAND.

205

Sunday, October 16, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: New Radio-pharmaceuticals - Fancy Stuff

204
Can Diagnostic Features Derived from [18F]PET Imaging of Glioma Patients Be Pooled When Different Reconstruction Settings or Segmentation Methods Are Used?

A. Zounek, A. Holgen, A. Bollenbacher, J. Braitenberg, G. Böning, L. Kaiser

Department of Nuclear Medicine, University Hospital LMU Munich, GERMANY.

Quality Assurance of PET-based Diagnostic Features in the Prospective Randomised Multicentre PEPPA-trial

V. Zhang, H. Li, T. Ekdahl, G. Gao, G. Gao, P. Gao, F. Reiter, W. Zeng, K. Lin, W. Li, H. Li, Y. Zhang

University of Ural, Department of Nuclear Medicine, YEKAB, CHINA.

University of Ural, Department of Nuclear Medicine, YEKAB, CHINA.

ORAL SESSIONS

Reconstruction Settings or Segmentation Methods Are

University, Department of Urology, Ankara, TÜRKIYE.

Medicina, Universidade de Coimbra, Coimbra, PORTUGAL.

P. Bartenstein, N. L. Albert, S. Ziegler, L. Kaiser; A. Holzgreve, A. Bollenbacher, J. Brosch-Lenz, G. Böning, A. Zounek

Reconstruction Settings or Segmentation Methods Are

Istituto Clinico Humanitas, Department of Nuclear Medicine, Milan, ITALY.

Istituto Clinico Humanitas, Department of Nuclear Medicine, Milan, ITALY.

Istituto Clinico Humanitas, Department of Nuclear Medicine, Milan, ITALY.

Istituto Clinico Humanitas, Department of Clinical Pathology and Cytology, Milano, S. Frediano.

Waldenborg Centre for Molecular Medicine, Lund University, Lund SWEEDEN.

Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEEDEN.

Department of Translational Medicine, Lund University, Lund, SWEEDEN.

Department of Urology, Skåne University Hospital, Malmö, SWEEDEN.

Department of Clinical Pathology and Cytology, Skåne University Hospital, Malmö, SWEEDEN.

Ga-PSMA-11 PET for quantitative and qualitative response assessment in newly diagnosed prostate cancer patients following Androgen Deprivation Therapy

A. Mohite, A. Agarwala, V. Murthy, M. Praste, M. Prathna, N. Pandurand, S. Shah, A. Pratun, S. Choudhury, V. Rangarajan; Tata Memorial Hospital, Mumbai, INDIA.

18F-Choline PET/CT and conventional imaging vs. conventional imaging alone in patients with intermediate and high prostate cancer before curative intent therapy (IOV-PR-CH-1-2021): a prospective, open, randomized, multicenter study


Waldenborg Centre for Molecular Medicine, Lund University, Lund SWEEDEN.

Clinical Physiology and Nuclear Medicine, Skåne University Hospital, Malmö, SWEEDEN.

Department of Urology, Skåne University Hospital, Malmö, SWEEDEN.

Department of Urology, Skåne University Hospital, Malmö, SWEEDEN.

Department of Pathology, Rozzano, ITALY.

Department of Nuclear Medicine, Humanitas, Department of Pathology, Rozzano, ITALY.

Studie der University der Città della Salute e della Scienza di Torino, Turin, ITALY.

University of Coimbra, Coimbra, PORTUGAL.

ORAL SESSIONS

Clinical Oncology Track - TROP Session: Let's Start With Some Prostate

Sunday, October 16, 2022, 08:00 - 09:30

Hall 117

P055 Additional value of semiquantitative parameters in clinical staging of primary prostate cancer with 68Ga-PSMA PET/CT: preliminary results of a single-centre cohort study

J. Jandrig1,2, M. Redolfi, G. Lughezoana1, N. Bittf, G. Guzzaniga1, P. Cioa1, M. Lazzeri, B. Hunte, A. Sastri, K. Kreuz, V. Farsad1, P. Colombatto1, M. Cerr1, M. Sali1, A. Chel1

Halmiandes University Pire Emanuele - Milano, ITALY.

IRCCS Istituto Clinica Humanitas, Department of Nuclear Medicine, Rho, ITALY.

IRCCS Istituto Clinica Humanitas, Department of Nuclear Medicine, Rho, ITALY.

IRCCS Istituto Clinica Humanitas, Department of Nuclear Medicine, Rho, ITALY.

Hall 115

Sunday, October 16, 2022, 08:00 - 09:30

Paediatrics Committee - TROP Session: Nephro-Urology and Paediatrics

P006 PROMISE-criteria inspired quantitative response in PSMA PET to androgen deprivation in patients with treatment naïve advanced prostate cancer

A. Anand, N. Nickolai, D. Sumerdak, G. Benne, N. Kamar, S. Smith1, A. Rentsch1

VA Greater Los Angeles Healthcare System, Los Angeles, CA, UNITED STATES OF AMERICA.

ERNI Diagnostics, Lund SWEEDEN.

UCL, Los Angeles, CA, UNITED STATES OF AMERICA.

P066 Determination of Normal Gastric Emptying Values in Pediatric Age Groups

A. B. Niklas, B. O. S. Knutls, H. Karlsson, Department of Nuclear Medicine, Umeå, SWEDEN.

P067 Interest of whole-body SPECT-CT imaging in the management of patients with neuroblastoma

B. Smidt, L. Guillon, M. Stojczynski, P. Fayoux, University Hospital of Toulouse Purpan, Toulouse, FRANCE.

P068 Can FDG PET-CT Predict Chemobrain in Pediatric Lymphoma Patients?

G. Kays1, B. Volkan Salancı, P. Ozen, H. Kalgo, Hacettepe University Medical School, Department of Nuclear Medicine, Ankara, TURKIYE.

P069 Comparison of 18F-DOPA and other single-membrane Filtration Rate Determination (EANM Guidelines) with Non-radioactive Methods in Adolescents

P. Korandj, H. Hoogland, R. Linsord, L. Serenilav1, L. Quinn, M. Kamil,1

1Dept of Nuclear Medicine, Univ. Hospital and Palacký University, Olomouc, CZECH REPUBLIC; 2Dept of Paediatrics, Univ. Hospital and Palacký University, Olomouc, CZECH REPUBLIC; 3Dept of Clinical Biochemistry, Univ. Hospital and Palacký University, Olomouc, CZECH REPUBLIC.

P070 What Have We Learned from Clinical Studies in the Past 10 Years?

D. Neglia

Fontanilac Toscana G. Monastario, Cardiovascular and Imaging Departments, Pisa, ITALY.

P071 What is the Current Best Strategy for Imaging CAD in Clinical Practice?

C. Nappi

University of Naples Federico II, Department of Advanced Biomedical Sciences, Naples, ITALY.

P072 Functional Imaging First - For Which Patients?

C. Nappi

University of Naples Federico II, Department of Advanced Biomedical Sciences, Naples, ITALY.

P073 What is the Current Best Strategy for Imaging CAD Patients?

C. Rischpler

University Hospital ESM, Department of Nuclear Medicine, Lünen, GERMANY.
CTE 1 - Technologists Committee / SNMMI: Tech Guide Launch

OP-074 The Role of a Nuclear Medicine Technologist in Radionuclide Therapy Management
D. Gilmore
School of Medical Imaging and Therapeutics, Boston, UNITED STATES OF AMERICA.

OP-075 Pre- and Post-Therapy Imaging
C. Wendorf
University of California San Diego Health, San Diego, UNITED STATES OF AMERICA.

OP-076 Hospitalisation During Radionuclide Therapy Assessment
L. Pereira
Maastricht and Tunbridge Wells NHS Trust, Nuclear Medicine, Royal Tunbridge Wells, UNITED KINGDOM.

Auditorium

Sunday, October 16, 2022, 09:45 - 11:15

CME 2 - Thyroid + Translational Molecular Imaging & Therapy Committee: Parathyroid Imaging

OP-077 The EANM Practice Guideline for Parathyroid Imaging
P. Petronovitch Ovchinnik
Department of oncology and Nuclear medicine, University Hospital Center “Centre hospitalier”, Zagreb, CROATIA.

OP-078 ([18F]Fluorocholine PET-CT Imaging of Parathyroid Adenoma
E. Guire
Department of nuclear medicine, Centre François Baclesse, Caen, FRANCE.

OP-079 Parathyroid Ultrasonography - Tips and Tricks
M. Gotthardt
Department of nuclear medicine, UMC, Nijmegen, NETHERLANDS.

OP-080 Minimal Invasive Parathyroid Surgery - What the Surgeon Wants to Know
T. van Ginhoven
Department of surgery, ErasmusMC, Rotterdam, NETHERLANDS.
Clinical Oncology Track - TROP Session: Genetic and Colorlorectal

Prognostic Value of 68Ga-FAPI PET/CT compared with 18F-FDG PET/CT in Esophageal Squamous Cell Carcinoma L. Zhao, P. Song, S. Chen, H. Qin, Q. Lin; The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, CHINA.

Comparison of 68Ga-FAPI-46 Uptake 20 and 60 Minutes Post Injection in Healthy Tissues and Pathologic Lesions in 15 Patients After Resection of Pancreatic Ductal Adenocarcinoma L. van Genknijtth, J. Hoppner*, U. Hager*, F. E. Gerth*, A. van Genknijtth, U. Haberen**, M. Röhrich; *Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, GERMANY, **Department of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, GERMANY, ***Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, GERMANY.

The Role of 68Ga-DOTA-FAPI-PET/CT on Altering Stage in Patients with Non-FDG-avid Lesions G. Beydagi; N. Alan Scielico, E. Demir,*, K. Alcay*, B. Ovent,*, S. Leem, F. Sent, O. Saimmet, B. Caner,*, T. Taskk, M. Cizm, M. Kahasky*; *Yeditepe University, Department of Nuclear Medicine, Istanbul, TURKEY, **Federal University of Medicine and Pharmacy, Department of Medical Oncology, ISTANBUL, **Memorial Hospital, Department of Medical Oncology, Istanbul, TURKEY, ***Yeditepe University, Faculty of Medicine, Istanbul, TURKEY, ****Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, TURKEY, *****Istanbul University-Cerrahpaşa Department of Nuclear Medicine, Istanbul, TURKEY.

Comparison of 68Ga-FAPI-PET/CT and F18-FDG PET/CT for the Evaluation of Gastric Adenocarcinoma: Preliminary Results E. Beyhan; O. Erol Feniccioglu, R. Sahin, G. Alpin, T. Aksoy, E. Arslan, N. Engil, T. Geyik; University of Health Sciences, Istanbul Training and Research Hospital, Department of Nuclear Medicine, Istanbul, TURKEY.

Biodistribution of 111In-labelled platelets: feasibility of examination on 360° CZT digital SPECT/CT P. Gueret, E. Cassol, P. Blanc, M. Alonso, P. Payoux, A. Salabert; *Sorbonne Universités, INSERM, U1326, 20, Rue de la Concorde, 75009 Paris, FRANCE.

Clinical validation of 99mTc-MDP and 111In-labelled ibalum with cyclotron-produced 99mTc as a potential alternative to generator-produced isotope E. Creoteau, A. Huet-Denault, R. Coulet, C. Poulet, J. Rouesseau, E. Lavallet. E. Turet, E. Rousseau, B. Guiton; *Sherbrooke Molecular Imaging Center (CMIS), Sherbrooke University Hospital Research Center (CRCHUS), Sherbrooke, QC, CANADA, **Department of Nuclear Medicine and Radiology, Faculty of Medicine and Health Sciences, Sherbrooke, QC, CANADA.

FDG Gallibladder Uptake: Observation from a Total-Body PET/CT Scanner A. Celeborg, M. Y. Holidayer, E. A. Tsiamountzid, B. A. Spencer, M. Chen, J. D. Albano, B. C. Cassire, F. Bertranou, F. Donald, S. A. Reynolds, R. D. Badawy, S. Y. Landet; **SASK, Pediatric Nuclear Medicine, University of Western Carolina, Brescia, ITALY, **University of California Davis, CA, UNITED STATES OF AMERICA, ***Klinikum der Hochschule, Germany, ****Rome, ITALY, ***Sangre Grande Hospital, Eastern Regional Health Authority, Sanger Grande, TRINIDAD AND TOBAGO.


Collaborative Findings in Early And Late (68Ga)Ga-FAPi-PET/CT Scans Among Oncological Patients E. Fortunati; G. Luzza,*, T. Celli**, C. Manni,*, P. Castelluccio, A. Fontani, L. Zanoni, L. Malossi, M. Lodi, V. Cabatott,*, F. Amstori,*, P. Soia,*, M. Ferrar*, N. Tatsos,*, G. Galizia,*, B. Mandrell, P. Candoli,*, G. Perrone,*, L. Cabot*, M. Tagliull*, A. Perrone,*, M. Testi**, P. De Jacob,*, T. Celli**; *Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, **National Cancer Institute, Department of Oncology, University of Modena and Reggio Emilia, Modena, ITALY, **University of Modena and Reggio Emilia, Modena, ITALY, **Division of Oncologic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, PET Radiopharmacy Unit, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, **Division of Thoracic Surgery, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, **Pententorio Aulunomy, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, **Brest Surgery, Department of Oncology and Hematological Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, **Division of Oncologic Gynecology, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY, **Department of Medical and Surgical Sciences (DIMES)-Centro di Studio e Ricerca delle Neoplasie Gastroenterologiche (CENEG), University of Bologna, Bologna, ITALY.

Analysis of liver and pancreatic enzymes and “Ga-FAPi-46” uptake of hepatic and pancreatic parenchyma after 20 and 60 minutes in patients after resection of pancreatic ductal adenocarcinoma J. Hoppner, L. Trimbosch, L. Sperling, T. Calitzky, U. Heger, U. Haberen, M. Röhrich, Universitätsklinikum Heidelberg, Heidelberg, GERMANY.
OP-128 Visual assessment of \("^{18}\)F-florbetapir PET across the Alzheimer's disease continuum and in dementia with Lewy Bodies
1Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, NETHERLANDS; 2Katholiek Universitair Medisch Centrum, Heerlen, NETHERLANDS; 3Department of Radiology & Nuclear Medicine, University of Amsterdam, Amsterdam, NETHERLANDS; 4Alzheimer Centre Amsterdam, Department of Neurology, Amsterdam University Medical Centers, Amsterdam, NETHERLANDS.

OP-131 Prognostic Value of ATN Profiles in a Memory Clinic Cohort
D. Peretti, F. Rohlw, S. Forcynak, S. Stampacchia, M. Schiffer, G. Frisoni, V. Garibotto
University of Geneva, Geneva, SWITZERLAND.

OP-135 The use of amyloid-PET in memory clinic patients: AMYPAD Diagnostic and Patient Management Study
University of Geneva, Geneva, SWITZERLAND; 2University of Amsterdam, Amsterdam, NETHERLANDS; 3Department of Radiology & Nuclear Medicine, University of Amsterdam, Amsterdam, NETHERLANDS; 4National Clinical Research Center for Aging and Medicine, Neuroscience Centre, University of Stockholm, Stockholm, SWEDEN; 5University College London, London, UNITED KINGDOM; 6Lausanne University Hospital, Lausanne, SWITZERLAND; 7Life Molecular Imaging, Berlin, GERMANY; 8G.E Healthcare, Amsterdam, UNITED KINGDOM.

OP-136 The centroid scale applied to \(^{18}\)F-florbetaben and \(^{18}\)F-flutemetamol PET renders comparable estimates of amyloid burden in memory clinic patients
On behalf of the AMYPAD consortium; 14Barcelona Brain Research Centre, Barcelona, SPAIN; 15GE Healthcare, Amsterdam, UNITED KINGDOM; 16Amsterdam University Medical Center, Amsterdam, NETHERLANDS; 17Department of Radiology & Nuclear Medicine, University of Stockholm, Stockholm, SWEDEN; 18Laboratory of Neuroimaging and Innovative Molecular Tracers (LNMIT), Geneva University Neuroscience Center and Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND; 19Life Molecular Imaging, Berlin, GERMANY.

OP-142 The Good, the Bad and the Ugly - 68Ga vs 18F vs Other PSMA Diagnostic Tracers
K. Goffin1
University Hospital Leuven and KU Leuven, Department of Nuclear Medicine, Leuven, BELGIUM.

OP-144 The Maze Runner - The Interaction Between Androgen Deprivation Therapy and PSA Expression
J. Emmett
St. Vincent's Hospital Sydney, University of New South Wales, Kensington, NSW, Department of Theranostics and Nuclear Medicine, Sydney, AUSTRALIA.

OP-163 Regional amyloid load contributes to stage-dependent tau spreading
M. Hoenig1
1Department of Nuclear Medicine, Innsbruck University, Innsbruck, AUSTRIA; 2Department of Neuropathology, Innsbruck University Hospital, Innsbruck, AUSTRIA; 3Austrian Academy of Sciences, Medical University Innsbruck, Innsbruck, AUSTRIA.

OP-164 Bohemian Rhapsody - Current Landscape of PSMA Theranostics
D. Murphy
The Peter MacCallum Cancer Centre, Department of Radiology, University of Melbourne, Melbourne, AUSTRALIA.

OP-171 Introduction by Chairpersons

Plenary 2 (incl. Marie Curie Lecture): PSMA - A Never Ending Successful Story

OP-139 PET-MRI in Research - Phantom Scanning and Healthy Volunteers
S. Kinella
King’s College London & Guy’s and St Thomas’ PET Centre School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM.

OP-140 Once Upon a Time in the West - The History of Radiolabelled PSMA Production
W. Fendler
University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-141 On the Road to Infinity: PSMA Imaging, Theranostics and Clinical Applications
L. Emmett
University College London, Institute of Nuclear Medicine, London, UNITED KINGDOM.

OP-145 To Infinity and Beyond - PSMA PET in Solid Cancers Other Than Prostate Cancer
S. Malaspina
University of Turku and Turku University Hospital, Turku PET Centre, Turku, FINLAND.

OP-146 Regional Amyloid load contributes to stage-dependent tau spreading
M. Hoenig1
1Department of Nuclear Medicine, Innsbruck University, Innsbruck, AUSTRIA; 2Department of Neuropathology, Innsbruck University Hospital, Innsbruck, AUSTRIA; 3Austrian Academy of Sciences, Medical University Innsbruck, Innsbruck, AUSTRIA.

OP-152 Session Summary by Chairpersons

OP-153 The EARL Harmonisation of PET/CT Systems - Why, How, When and Next Steps
R. Boellaard
Amsterdam UMC, Radiology and Nuclear Medicine, AMSTERDAM, NETHERLANDS.

OP-149 A Decade of Motion Management Developments in NM Imaging
J. Oprea-Lager
Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-157 The Matrix Reloaded - The Importance of Structured Reporting PET/CT
M. Rodriguez Fraile
Clinica Universidad de Navarra, Department of Nuclear Medicine, Pamplona, SPAIN.

OP-150 Motion Management in NM Imaging for Oncology Applications
R. Bucher
Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY.

OP-154 Bohemian Rhapsody - Current Landscape of PSMA Theranostics
D. Murphy
The Peter MacCallum Cancer Centre, Department of Radiology, University of Melbourne, Melbourne, AUSTRALIA.

OP-151 Respiratory Motion Management for Cardiac PET/CT and PET/MRI Imaging
R.C. Siekkinen
Turku PET Center, Turku, FINLAND.

OP-153 The Matrix Reloaded - The Importance of Structured Reporting PET/CT
M. Rodriguez Fraile
Clinica Universidad de Navarra, Department of Nuclear Medicine, Pamplona, SPAIN.

OP-146 Bohemian Rhapsody - Current Landscape of PSMA Theranostics
D. Murphy
The Peter MacCallum Cancer Centre, Department of Radiology, University of Melbourne, Melbourne, AUSTRALIA.

OP-147 Marie Curie Lecture: Green Book - The Importance of Implementing PSMA in Guidelines
D. Oprea-Lager
Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, NETHERLANDS.

OP-148 Session Summary by Chairpersons

OCTOBER 15-19, 2022
WORLD LEADING MEETING  |  FINAL PROGRAMME
ORAL SESSIONS | FINAL PROGRAMME
WORLD LEADING MEETING  EANM’22
OCTOBER 15-19, 2022

EANM’22  WORLD LEADING MEETING
Results from the PYTHON trial: A Prospective Study

On “FDG PET/CT imaging in First Biochemical Recurrence - Prostate Cancer After Primary Therapy With Curative Intention

Olivier Namur, site Godinne, Yvoir, BELGIUM,
Institut Curie, Paris, FRANCE,
and PET/Biomedical Cyclotron Unit, Erasme Hospital, Université Libre de Bruxelles, Brussels, BELGIUM

An International study of inter-site variability in the \( ^{111}\)Tc MAA multi-compartment dynamic cardiac radioimobilization: analyses from the TARGET phantom study

G. Keane, H. de Jong, P. Van Rooy, M. Lam; UMCU, Utrecht, NETHERLANDS

Radioimmunotherapy for HCC Patients with Personalized \( ^{131}I\) Yttrium-90 Dosimetry for Curative Intent (RAPY90D): an interim analysis

S. Kappadath, S. Henry, A. Mohahes; LT MD Anderson Cancer Center, Houston, TX, UNITED STATES OF AMERICA

Evaluation of \( ^{177}Lu\)PSMA SCPECT quantification as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LUPIN)

L. Emmett; [Author Group]

Safety and Effectiveness of \( ^{177}Lu\)-PSMA-617 Versus Cabazitaxel in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Radium-223 (223Ra): The RALU Study

K. Rohrbach; K. L. Leung, M. Ebert, C. Faustner, V. Ptaszek, W. B. Kendall, P. Rassig, E. Hoxha, K. Dittmann, R. A. Bundsch, K. M. Pabst, M. Kretzschmar, S. Mirlohi, D. Hartung; Department of Nuclear Medicine, University of Münster Medical Center, Münster, GERMANY; Department of Nuclear Medicine, University Hospital Bonn, Bonn, GERMANY; Department of Radiology, University Hospital Tübingen, Tübingen, GERMANY; Department of Nuclear Medicine, Technical University of Munich, Munich, GERMANY; Department of Nuclear Medicine and Molecular Imaging, University Hospital Düsseldorf, Düsseldorf, GERMANY; Department of Nuclear Medicine, University of Ulm, Ulm, GERMANY; Department of Nuclear Medicine, German Cancer Consortium (DKTK) University Hospital Essen, Essen, GERMANY; Bayer Healthcare, Pharmaceuticals, Whippany, NJ, UNITED STATES OF AMERICA; Bayer Consumer Care, Germany; [Author Group]; Sir Charles Gairdner Hospital, Perth, WESTERN AUSTRALIA, Australia

LIPS Session 3 - Thyroid Committee: Tricky Cases in Endocrine Imaging Interactive Session

OP-156

\[ {\text{PSA and FDG PET as Predictive and Prognostic Biomarkers in Men with Metastatic, Castration-Resistant Prostate Cancer (mCRPC): an Analysis of the Randomised, Phase 2 Trial \( ^{177}Lu\)-PSMA-617 Versus Cabazitaxel (TheraP, ANZUP 1603) }} \]

J. Buteau; A. Martin, E. Ixart; S. Sandhu; A. M

Joshua J. R. Francis; A. Y. Zhang; A. M. Scarp; S. Lee; A. Azad; M. McKinnon; A. R. Stacke; S. Williams; J. D. Davis; M. S. Hoffman; Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA

OP-157

Health-related quality of life (HRQoL), pain and outcomes in the phase 3 VISION study of \( ^{177}Lu\)-PSMA-617 in patients with metastatic castration-resistant prostate cancer

K. Hermann; B. J. Kieler; K. Rahbari; K. N. Chel; M. J. Morin; G. Sorte; T. Tagawa; A. T. Kindz; V. Vogelciq; J. Calais; M. Nagyrag; X. X. Wei; V. Kohsik; J. Besargues; B. Chang; M. DeSarac; R. A. Messmann; J. de Bonet; K. Fisz

Radionuclide Cancer Centre, Vancouver, BC, CANADA; [Author Group]; Sir Charles Gairdner Hospital, Perth, WESTERN AUSTRALIA, Australia

OP-158

Modulating the Epigenetic Machinery for Increased SSTR Expression in Small-Cell Lung Cancer Cells

M. J. Kloe; J. van der Laarse, J. van der Molen; P.M van Kriekert, M. de Jong; S. U. Dalim; Erasmus MC, Rotterdam, NETHERLANDS

OP-159

5-phase enrichment by hydroxyurea treatment enhances the [\( ^{186}Re\)-DOTA-TATE] uptake in vitro

J. Cheng; L. Livieratos, S. Terry; Kings' College London, London, UNITED KINGDOM

OP-160

Ultrasoundographic Correlates of Scintigraphy in Endocrine Imaging

S. Irgan

Göteborg Hospital, Department of Nuclear Medicine, Linköping, SWEDEN

Tricky Cases and Pitfalls in Parathyroid Imaging

D. Deandrea; Nuclear Medicine Division, Department of Medical Sciences, University of Turin, AOU Città della salute e dellaalsa, Turin, ITALY

Potential Combination Therapy with \( ^{188}Re\)-DOTA-MSA Anti-Carcinoidoma, 4-Dimethylamino-2,6-Di-N-Acetyl- \( ^{188}Re\)-DOTA-MSA against Endothelial Cell and Neutrophil Chemotaxis

S. Kleinendorst; T. Mohajer Shojai; F. A. Martínez; M. F. Pabst; V. Koshkin; J. Calais

Uppsala University, Uppsala, SWEDEN

Combination Therapy with \( ^{188}Re\)-DOTA-MSA Anti-Carcinoidoma, 4-Dimethylamino-2,6-Di-N-Acetyl- \( ^{188}Re\)-DOTA-MSA against Endothelial Cell and Neutrophil Chemotaxis

S. Kleinendorst; T. Mohajer Shojai; F. A. Martínez; M. F. Pabst; V. Koshkin; J. Calais

Uppsala University, Uppsala, SWEDEN
How does the Internal Bremsstrahlung contribute to the

Cutting Edge Science Track - TROP Session:

Sunday, October 16, 2022, 15:00 - 16:30

Hall 117

Sunday, October 16, 2022, 15:00 - 16:30

Hall 117
EANM'22 WORLD LEADING MEETING
OCTOBER 15 - 19, 2022

FINAL PROGRAMME | ORAL SESSIONS

ORAL SESSIONS | FINAL PROGRAMME

508

Sunday, October 16, 2022, 15:00 - 16:30
Hall 212

Paediatrics Committee - TROP Session: Paediatric Oncology

OP-201

Application Value of PET/MR Radiomics Features in Predicting the COG Risk Stratification of Neuroblastoma

J. Liang
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA

OP-202

"Cu62 PET/CT in high-grade infiltrative paediatric glioma: a diagnostic and dosimetric study"

I.R.O. Ospedale Galliera, Genoa, ITALY; IRCCS Bambino Gesù Children's Hospital, Rome, ITALY; IRCCS Istituto Giannina Gaslini, Genoa, ITALY; M.O.R. Sant'Anastassio Ruffinilli, Genoa, ITALY; University of Turin, Turin, ITALY

OP-203

Are Interim TLG and MTV Better Predictors of Treatment Response Than Deauville Score for Pediatric Non-Hodgkin Lymphoma Patients?

G. Kaya, B. Volkan Sabancı, B. Aydar, P. Özen Kkräfte, Hacettepe University Medical School, Department of Nuclear Medicine, Ankara, TURKEY, Hacettepe University Medical School, Department of Paediatric Oncology, Ankara, TURKEY

OP-204

Can Semiquantitative 18FDG PET/CT Parameters Predict Outcome in Paediatric Patients with Ewing Sarcoma?

B. Soydas Turan, B. Volkan Sabancı, G. B. Aydar, E. Emre Sunal, M. Özen Kkräfte, Hacettepe University Medical School, Department of Nuclear Medicine, Ankara, TURKEY, Hacettepe University Medical School, Department of Paediatric Oncology, Ankara, TURKEY

OP-205

18F-FDG PET / MR imaging features and staging value of neuroblastoma

Y. Xu, J. Wang, J. Jiang, F. Li, Hangzhou Universal Imaging Diagnostic Center, Hangzhou, CHINA; Children's Hospital of Soochow University, Suzhou, CHINA

OP-206

PET/CCT with "C-methionine for the evaluation of low-grade brain tumours in paediatric and young adult patients

O. Alonso*, A. Damián, E. Lochovsky, L. Gutierrez, C. Bermand, A. Quaglisi, P. Diante, R. Ferdinandi, Urgasim Center of Molecular Imaging (CUIMI), Montevideo, URUGUAY; Nuclear Medicine and Molecular Imaging Centre, Clinical Hospital, University of Uruguay, Montevideo, URUGUAY

OP-207

FDG PET/CT based scoring system in neuroblastoma: Comparison with existing NMBd based scoring system and evaluation of new cut-off values as a prognostic tool

A. Prakash, S. Shahid, M. Mathammb, N. C. Panandera, A. Agirbas, D. D. Panam, V. Rangarajan, Tata Memorial Hospital, Mumbai, INDIA; Jawaharlal Nehru National Institute, HNB, Mumbai, INDIA

OP-208

The value of "F-FDG PET / MR whole body imaging in children with multisystem Langerhans histiocytosis"

F. Wang, J. Wang, Y. Xu
Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA; Children's Hospital of Soochow University, Suzhou, CHINA

OP-209

Characterization of the use of 2(18F) FDG PET-CT in initial staging and final treatment of pediatric patients with Histiocytic Disorders

M. Acyle Hernandez, P. Palma Rossa, R. Mora Ramirez, Universidad Autónoma de Bucaramanga, Bucaramanga, COLOMBIA; Instituto Nacional de Pediatría, Ciudad de México, MEXICO

510

Sunday, October 16, 2022, 15:00 - 16:30
Hall 116

CTE 3 - Technologists + Radiation Protection Committee: Radiation Protection in Radionuclide Therapy

OP-210

Radiation Protection for the Public Environment after Radionuclide Therapy Procedure and Social Impact for the Patient

L. Cunha, Isolar-Azores, Azores, PORTUGAL

OP-211

Regular and Emergency Patient Care - Radionuclide Therapy Routine vs Accidents

F. Jamar, Cliniques universitaires St-Luc, Nuclear Medicine Department, Brussels, BELGIUM

OP-212

Doses on Extremities During the Manipulation of INT Radiopharmaceuticals

P. Covens, Vrije Universiteit Brussel, in vivo Cellular and Molecular Imaging Lab, Brussels, BELGIUM

OP-213

Cardiac Sarcoïdosis

L. Lecissiotti, Institute of Nuclear Medicine, Siena Cuneo, Catholic University, Rome, ITALY

OP-214

Vasculitis

G. Ghysenys, Cliniques Universitaires Saint-Luc et Institute of Clinical and Experimental Research (IRIC), Department of Nuclear Medicine, Université Catholique de Louvain (UCLouvain), Brussels, BELGIUM

OP-215

Amyloidosis

J. Sørensen, Aarhus University Hospital, Department of Nuclear Medicine and PET Centre, Aarhus, DENMARK

OP-216

Coronary Artery Disease

C. Nappi, Department of Advanced Biomedical Sciences, University Federico II, Naples, ITALY

OP-217

PET-Paramovit Ovarickec* vs A. Brouwers and W. Noordzij, H. Schouw, A. Monyp Gonalez, J. Vistern, W. Zandee, Department of oncology and Nuclear medicine, University Hospital Center 'Sestre milosrdnice', Zagreb, CROATIA

OP-218

LIPS Session 4 - Paediatrics Committee: Tricky Cases in Paediatrics Interactive Session

OP-225

Interactive Session

Cases in Paediatrics

P. Petranović Ovčariček vs A. Brouwers and W. Noordzij, H. Schouw, A. Monyp Gonalez, J. Vistern, W. Zandee, Department of oncology and Nuclear medicine, University Hospital Center 'Sestre milosrdnice', Zagreb, CROATIA

77
OP-226 Discussion

OP-227 Paediatric Gastroenterology
M. Vojvodic
University Clinical Center Niš, Center of Nuclear Medicine, Niš, SRBIA.

OP-228 Discussion

OP-229 Paediatric Nephro-Urology
J. Rogasch
Chonte Universitätsmedizin Berlin, Department of Nuclear Medicine, Berlin, GERMANY.

OP-230 Discussion

604

Sunday, October 16, 2022, 16:45 - 18:15
Hall 211

Cutting Edge Science Track - TROP Session: Developments in PET

OP-235 Long axial field of view PET enables ultra-low-dose PET/CT
M. Krüger, J. Honert e e, E. Renexs, F. Lüttep Andersen, I. Nejgaard, P. M. Fischer e, C. Constantinou University Hospital, Radiology, Copenhagen, DENMARK; Copenhagen University, Department of Clinical Medicine, Copenhagen, DENMARK.

OP-236 Clinical impact of ultra-high sensitivity mode in comparison to the currently available high sensitivity mode in long axial FOV PET scanner
C. Mingels, M. Windt e, H. Sart e, P. Buers e, K. Zempkes e, M. Vasic e, A. Aftart-Dramen e, K. Shi e, J. Albert e, A. Röninger e, Department of Nuclear Medicine, University Hospital, Berlin, Berne, SWITZERLAND, Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.

OP-237 Clinical Performance Comparison of a Long versus a Short Axial Field of View PET/CT
M. Raya e, J. V. van Snick, P. Boelaert e, A. Gaulme e, C. Toumpan, J. van Slui e, University Medical Center Groningen, Groningen, NETHERLANDS; Amsterdam University Medical Center, Amsterdam, NETHERLANDS.

OP-238 Image quality and detectability assessment of a new Digital-BGO PET/CT in comparison to TOF technology
Q. Maingeon e, J. S. Tervel e, S. Broulez e, F. Borteron, C. Meziad e, K. Laser e, M. Levy e, C. Ossart e, Institut Claudius Regaud - IUCT Oncopole, Toulouse, FRANCE, Institut Gustave Roussy, Villejuif, FRANCE, IEGHC, HealthCare, Paris, ISRAEL.

OP-239 Deep Learning Based Missing Information Recovery in Partial Ring Total Body PET Scanner
H. Kroutil e, P. Szekeres et, P. Gudram et, J. Stoff e, M. Ay e, Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF; Hurayia Medical Center, Tunis, TUNISIA, Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Institute of Molecular and Nuclear Imaging, Geneva University Hospital, Geneva, SWITZERLAND.

OP-240 Validation of a Dedicated Brain PET Scanner for the Assessment of Neurodegenerative Disorders
P. Nespal Torres e, P. Barsanaru e, A. Delgado-Cano e, A. Cano e, G. González-Pastor e, C. Márquez-Ballester e, J. A. Martínez-Gua e, J. J. Camar d e-Gallegos e, M. N. Cabrera-Mariano e, Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IISCS), Hospital Clínico San Carlos, Universidad Complutense, Madrid, SPAIN, University Hospital La Fe, Valencia, SPAIN, University Hospital Estudiantes, Moncloa, Madrid, SPAIN, University Hospital La Fe, Valencia, SPAIN.

General Equipment for Medical Imaging S.A., Madrid, SPAIN, Department of Neurology, Instituto de Investigación Sanitaria San Carlos (IISCS), Hospital Clínico San Carlos, Madrid, SPAIN.

OP-241 Development of a PET System Capable of Imaging Organs-on-Chips
C. Clement e, G. Birnbaumer e, M. Peschina e, F. Pagano e, M. Krishnadass-Jaki e, S. Ziegler e, A. Röninger e, A. Julliay, K. Shi e, University Hospital, Berne, SWITZERLAND, University of Milano-Bicocca, Milan, ITALY, IAKU, Munich, GERMANY.

OP-242 Practice of domain knowledge in trustworthy deep learning using PET imaging
S. Xue e, H. Gao e, H. Sart e, C. Mingels e, K. Zempkes e, P. Genois e, R. Szirmai e, A. Röninger e, B. C. P. Shi e, University of Bern, Berne, SWITZERLAND, Shanghai Jiao Tong University School of Medicine, Shanghai, CHINA, Advanced Clinical Imaging Technology, Siemens Healthcare AG, Lausanne, SWITZERLAND.

P. Sheikhzadeh e, H. Rezzab e, M. Ay e, Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

OP-244 Impact of interim PET staging with SSTR-anales after two cycles of C-MD-M INDuction in NET patients: a multicenter analysis
H. Bhan e, H. Bauer e, A. Tadisci e, C. Pföhl e, L. Trefil, J. Breyen e, V. Wenter e, P. Bartenstein e, A. Bueck e, R. Winnen e, C. Lapait e, H. Windolf e, P. Hartmamp e, Department of Nuclear Medicine, LMU Munich, Munich, GERMANY, Department of Radiology and Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, AUSTRIA, Department of Nuclear Medicine, Johannes Kepler University, Linz, AUSTRIA, Department of Nuclear Medicine, University Hospital LMU Munich, Munich, GERMANY, Department of Imaging and Nuclear Medicine, Medical University Innsbruck, Innsbruck, AUSTRIA, Department of Radiology and Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, AUSTRIA, Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, AUSTRIA.

OP-245 Changes in Tumor-Blood Ratio as a prognostic marker for progression-free survival and overall survival in neuroendocrine tumor patients undergoing PRRT
M. Weber e, G. Petersen e, R. Steffen e, B. M. Schlachetzki e, W. P. Fendler e, C. Raschke e, H. Lautenbe e, K. Hemmert e, A. Sundin e, University Hospital Essen, Essen, GERMANY, Department of Surgical Sciences, Uppsala University, Uppsala, SWEDEN.

OP-246 Novel 9mTc-labeled somatostatin receptor antagonists in the diagnostic algorithm of neuroendocrine neoplasms - study design of clinical part of a multicentre, phase 3 TEANT study
A. Hubalewsky-Dydekcy e, C. O'Conroller e, R. Mikolajczak e, P. Kowale e, L. Laza e, M. Opalińska e, A. Studer e, P. Gaurc e, C. Rangger e, M. Tremlisch-Mulder e, U. Simoncic e, I. Vogt e, M. Toary e, M. Kratzy e, K. Skowroniewicz e, B. Glowac e, A. Sadowska-Stachura e, J. Janota e, A. Sawicka e, 79
**Satellite Session:** Analysis of Mutations in Cancer 12:30 – 14:00 Room 3

- **Title:** Analysis of Mutations in Cancer 12:30 – 14:00 Room 3
  - Speaker: Dr. Jane Smith
  - Abstract: This session will cover recent advances in the analysis of mutations in cancer, including the latest tools and techniques for detecting and characterizing mutations.

**Poster Session:** Poster Presentations 14:00 – 17:00 Room 4

- **Poster Session:** Poster Presentations 14:00 – 17:00 Room 4
  - A variety of posters will be presented, covering a wide range of topics in radiology and oncology.

**Panel Discussion:** Future Directions in Radiology and Oncology 17:00 – 18:00 Room 5

- **Panel Discussion:** Future Directions in Radiology and Oncology 17:00 – 18:00 Room 5
  - Panelists: Dr. John Doe, Dr. Jane Smith, and Dr. Mike Brown
  - Discussion: This panel will focus on the future directions in radiology and oncology, including emerging technologies and trends in the field.

**Networking Event:** Reception and Social Event 18:00 – 20:00 Room 6

- **Networking Event:** Reception and Social Event 18:00 – 20:00 Room 6
  - A networking event will be held to encourage interactions between attendees and facilitate knowledge exchange.

**Further Information:**

- **Program Logistics:** For more information on the conference program, please visit the EANM website or contact the conference organizer.
- **Registration:** Attendees are encouraged to register early to secure their participation and to take advantage of early bird rates.
- **Accommodation:** Information on local accommodations and travel arrangements will be provided.

**Contact Information:**

- **E-mail:** info@eanm22.org
- **Phone:** +1 (123) 456-7890

**Important Notes:**

- **Cancellations:** Registrations can be cancelled up to 7 days prior to the event for a full refund.
- **Substitutions:** Substitutions can be made at any time without penalty.
- **Refunds:** Refunds will only be issued for event cancellations made before the cancellation deadline.

**Safety Precautions:**

- **Mask Mandate:** Attendees are required to wear masks at all times during the conference.
- **Health Protocols:** Health protocols will be in place to ensure a safe and healthy environment for all attendees.

**Acknowledgments:**

- **Sponsors:** Thank you to our sponsors for making this event possible.
- **Volunteers:** Special thanks to our dedicated volunteers for their hard work and commitment.

**Contact:**

- **EANM:** info@eanm.org
- **Conference Organizer:** info@eanmconference.org

**Follow Us:**

- **EANM on Twitter:** @EANM
- **EANM on Facebook:** Facebook.com/EANM
- **EANM on LinkedIn:** LinkedIn.com/EANM

**Website:**
EANM.org

**Location:**

- **Venue:** The conference will be held at the International Conference Center, located at 123 Main Street, City, Country.

**Travel Information:**

- **Flights:** Flights can be booked through a variety of airlines, with frequent service into the local airport.
- **Hotels:** A range of hotels will be available, offering comfortable accommodations at various price points.

**Local Attractions:**

- **Sights:** Explore the local sights and attractions, including museums, parks, and historical landmarks.
- **Cuisine:** Experience the local cuisine, offering a variety of dishes to suit all palates.

**Press Information:**

- **Media:** Media inquiries should be directed to the press contact provided.
- **Photos:** High-resolution photos of the conference and attendees will be available for media use.

**Legal Information:**

- **Disclaimer:** The information provided is subject to change and is intended for informational purposes only.
- **Copyright:** All rights reserved. Reproduction in whole or in part in any form or medium without express written permission is prohibited.
Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, SOUTH AFRICA; Department of Medical Microbiology, University of Pretoria, Pretoria, SOUTH AFRICA; Nuclear Medicine Research Infrastructure (Nukeri), Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA.

OP-277 Optimization And Acquisition Of The 18-F choline PET/CT Protocol In The Detection Of Parathyroid Adenomas. M. Mercado Moreno1, I. J. Montes de Jesus2, F. M. Ortega-Sánchez3, M. S. Costa Dias4, A. Benitez Segura2, E. Linares Tell1, J. Vinher Consegor1, M. Cortés Romero1, M. A. Berger1, D. H. van der Walt2.

OP-278 (Re)thinking patient education and preparation in Nuclear Medicine and Radiology Departments: perspectives from Technologists and recent graduates. P. Costa1, M. S. Rufi1, A. Salgado1, M. Anelli2, S. Myöhänen1, H. Gröhn2, A. Keinänen3.

Hall 114

Monday, October 17, 2022, 08:00 - 09:30

Challenger the Expert 3 - Inflammation & Infection: Expert vs Team Bologna: Real World in Infection


Hall 113

Monday, October 17, 2022, 08:00 - 09:30

LPS Session 5 - Translational Molecular Imaging & Therapy Committee: Challenging Situations in TM&I

OP-290 Technology vs Clinical Needs - What Drives Translational Research? T. Buckle1. Leiden University Medical Center, Interventional Molecular Imaging laboratory, Department of Radiology, Leiden, NETHERLANDS.

OP-291 Regulatory Hurdles and Directions Along the Translational Pipeline. P. Kolen1. University Medical Center Ljubljana, Department of Nuclear Medicine, Ljubljana, SLOVENIA.

OP-292 Ownership of Clinical Studies - What is the Role of Nuclear Medicine? W. Fendler1. University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.

OP-293 Building a Business Case T. Wendler1. Klinikum rechts der Isar (Technische Universität München), Department of Radiology, Munich, GERMANY.

Monday, October 17, 2022, 08:00 - 09:30

OP-294 Discussion

- Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, SOUTH AFRICA; Department of Medical Microbiology, University of Pretoria, Pretoria, SOUTH AFRICA; Nuclear Medicine Research Infrastructure (Nukeri), Steve Biko Academic Hospital, Pretoria, SOUTH AFRICA.
- Department of Radiology, University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY.
- University of British Columbia, Vancouver, BC, CANADA.
- University Medical Center Ljubljana, Department of Nuclear Medicine, Ljubljana, SLOVENIA.
- Rigshospitalet Copenhagen University Hospital, Department of Nuclear Medicine, Copenhagen, DENMARK.
EANM'22  WORLD LEADING MEETING
OCTOBER 15-19, 2022

FRANCE, Université de Lorraine, Department of Nuclear Medicine - Nanoparticle Imaging Platform - DCAC, Nancy, FRANCE, Department of Radiology, University Hospital of Nancy, CHRU Nancy, Department of Nuclear Medicine, CHU Nancy, Nancy, FRANCE.

OP-307

Semi-quantification in nuclear cardiology: Automated analysis vs. expert reading - Correlations with the angiographic score


OP-308

We can simplify semiquantitative analysis in 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTcDPD) scintigraphy performed in patients with transitional related cardiac amyloidosis (aCARD)?


OP-309

Machine Learning Model To Predict Dysfunction Of Mild Cognitive Impairment By Using Radiomic And Amyloid Brain PET

G. Giovaccini, F. Gavranovic, S. Pastreno, O. Ferrando, A. Mironini, A. Tantaglione, A. Cuzzarreda, T. Atsara hospital, La Spezia, Italy.

Clinical Oncology Track - TROP Session: Oncology Miscellaneous

OP-310

Effects of implementing the Point Spread Function to detect the IDH mutation in newly diagnosed gliomas: a Dynamic 18F-FDOPA PET/CT study


OP-311

18FDG PET/CT Radiomics in Infective Endocarditis


Humanitas University, Pene Emmanuelle, Milan, ITALY, Regional Center of Nuclear Medicine, Humanitas Research Park, Rozzano, Milan, ITALY, University of Trieste, Trieste, ITALY, University of Padova, Padova, ITALY, University of Bologna, Bologna, Italy.

OP-312

Automated AI-assisted diagnosis of active atherosclerotic lesions with PET/CT imaging


University of Leeds, Leeds, UNITED KINGDOM, Leeds Teaching Hospitals NHS Trust, Leeds, UNITED KINGDOM, University of Cambridge, Cambridge, UNITED KINGDOM.

Hall 121

Monday, October 17, 2022, 08:00 - 09:30

Clinical Oncology Track - TROP Session: Oncology Miscellaneous

OP-313

Diagnostic Performance of Whole-Body "F"-FDG PET/IMR in M Staging: A Systematic Review and Meta-Analysis


"Joint Department of Medical Imaging, University Health Network, Toronto, ON, CANADA, Sunnybrook Health Sciences Center, Toronto, ON, CANADA.

OP-314


"Peking Union Medical College Hospital, Beijing, CHINA, urinary Normal University, Beijing, CHINA, University of Pennsylvania, Pennsylvania, PA, UNITED STATES OF AMERICA.

OP-315

[(68)Ga]PSMA-PET/CT Performance in Neoplasms Different From Prostate Cancer: Preliminary Results From a Prospective Single-center Study


"National Institute of Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, Nuclear Medicine, IRCCS, Azeda Universitaria di Bologna, Bologna, ITALY.

Hall 117

Monday, October 17, 2022, 08:00 - 09:30

Clinical Oncology Track - TROP Session: Oncology Miscellaneous

OP-316

Application Value of PET/IMR radiomics features and metabolic parameter in predicting lung adenocarcinoma and squamous cell carcinoma

J. Liang, Hangzhou Universal Medical Imaging Diagnostic Center, Hangzhou, CHINA.

OP-317

Optimizing targeting in RB-2 and FDG uptake in thoracic lesions


Manchester University, Manchester, UNITED KINGDOM.

OP-318

PET/IMR of hypoxia in ER+ breast cancer: Correlations with immunohistochemistry


University of Cambridge, Cambridge, UNITED KINGDOM.

OP-319

Evaluation of Histopathological HER-2 Relationship with Imaging Features in Breast Cancer


University of Genova, IRCCS Ospedale Policlinico San Matteo, Novara, ITALY, Azienda Ospedaliero Universitaria di Pavia, Pavia, ITALY, Humanitas Istituto Clinico Catanese, AORN Ospedali dei Colli, Rome, ITALY, University of Pennsylvania, Pennsylvania, PA, UNITED STATES OF AMERICA.

OP-320

PET/IMR of hypoxia in BRCA1-2 breast cancer: Results from a prospective study


Manchester University, Manchester, UNITED KINGDOM.

OP-321

With 18-F FDG PET/CT SUVmax Values in Gastric Cancers Evaluation of Histopathological HER-2 Relationship

N. Taleyl, B. Cappiello.

Ankara City Hospital Nuclear Medicine Department, Ankara, TURKEY.

Hall 707

Monday, October 17, 2022, 20:00 - 21:30

Bone & Joint Committee - Session Featured: Bone and Joint in Route - Trazers, Modalities and Applications

OP-322

Bone and Joint in Route

S. Fondazione PoliChirurologica Universitaria, A. Gaetani, RCMC, Rome, ITALY, Fondazione PoliChirurologica Universitaria, A. Gaetani, RCMC, Rome, ITALY, Fondazione PoliChirurologica Universitaria, A. Gaetani, RCMC, Rome, ITALY, Fondazione PoliChirurologica Universitaria, A. Gaetani, RCMC, Rome, ITALY.
Monday, October 17, 2022, 08:00 - 09:30

Hall 212

Joint Symposium 3 - Thyroid Committee / ETA: A Nuclear Medicine Update on Diagnosis and Treatment of Medullary Thyroid Carcinoma (MTC)

OP-331 Update on Systematic Treatment of MTC R. Els¨et Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, ITALY

OP-332 State of the Art Nuclear Medicine Imaging of MTC M. Luster Department of Nuclear Medicine, University Hospital Marburg, Marburg, GERMANY

OP-333 Radiogand Therapy in MTC G. Nicolas Division of Nuclear Medicine, University Hospital Basel, Basel, SWITZERLAND

Monday, October 17, 2022, 08:00 - 09:30

Hall 116

Technologists’ Oral Presentations 2: Diagnosis and Therapy

OP-335 Absolute quantification of thyroid uptake and volume using SPECT-CT in pre and post low dose iodine-131 therapy in patients with Grave’s disease K. Kaur, M. Kaur, M. Mittal Post-graduate institute of medical education and research, Chandigarh, INDIA

OP-336 Assessment of Pretreatment Diffusion Parameters in Low- and Intermediate-Risk Prostate Cancer Patients Treated with Stereotoxic Ablative Radiotherapy A. Kvedra1,2, K. Kissad1, C. Gl¨aad1, A. Lannert3, A. Kavcic3, F. Loun2

1Institute of Neuroradiology, University of Pécs, Pécs, HUNGARY
2Department of Medical Imaging, Faculty of Health Sciences, University of Pécs, Pécs, HUNGARY
3Department of Nuclear Medicine, University of Debrecen, Debrecen, HUNGARY

OP-337 A Tale of Serendipity from Misadministration M. Vyas1,2, M. Hesselman, A. Rawlings, J. Puget, R. Joseph,1,2 Institute of Oncological Sciences, Auckland, NEW ZEALAND

OP-338 Using a novel long-axis-of-view (LAFOV) PET/CT system for dual tracer scanning with 68GaGaPSMA-11 and 18F-FDG PET/CT for PSMA therapy assessment A. Scheps,1 G. Tempeze,1 M. Visconte,1 A. Rimmer,1 A. Milhorat,2,3,4,5,6,7,8 J. Alberts,1,2 B. Lambert1,2,3,5,6,2,3,4,5,6,7,8

Monday, October 17, 2022, 09:45 - 11:15

Auditorium

CME 6 - Oncology & Theranostics Committee: PET/CT – The Prediction Game

OP-344 FDG in Haematology B. M. Fischer Department of Clinical Physiology and Nuclear Medicine Rijshospitalet, University of Copenhagen, Copenhagen, DENMARK

OP-345 FDG in Solid Tumours M. Bauckheult UZ Gasthuisberg, Vrije Universiteit Brussel, Brussels, BELGIUM, LUOULI-ENDO

OP-346 Non-FDG in Oncology S. Balogová Department of Nuclear Medicine of Medical Faculty of Comenius University Bratislava and St Elisabeth Oncologial Institute, Bratislava, SLOVAKIA

Monday, October 17, 2022, 09:45 - 11:15

Hall 112 (Arenas)

TOP Trials Session 2: Best FAPI Trials

OP-346a Introduction into FAPI U. Haberkorn University Hospital Heidelberg, Department of Nuclear Medicine, Heidelberg, GERMANY

OP-347 Head-to-head comparison of new FAPI binders designed to enhance tumor residence for Targeted Radionuclide Therapy L. Millul,1 L. Koestep, R. H. Gronow,1 K. Sparrer, R. Mansa,2,3 F. Mansa,4 University Hospital Basel, Basel, SWITZERLAND, Tel Aviv University, Tel Aviv, ISRAEL

Monday, October 17, 2022, 09:45 - 11:15

Monday, October 17, 2022, 09:45 - 11:15
OP-349

(68)Ga-FAP-FAPI-66 PET/CT In Staging Lung Cancer Patients: A Preliminary Study


"Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; I.R.C.C.S., Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; "PET Radonpharmacy Unit, IRCSS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; "Division of Thoracic Surgery, IRCSS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; "Innentreti Pulmology Unit, IRCSS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"

OP-350

Assessing the performance of Ga-68-Fibrilas expressing protein inhibitor-04 (FAPI) in the diagnosis of the hepatobiliary malignancies (HBM): A prospective pilot study

V. Rajaraman, A. Jetha, D. Halaniak, B. Pottakkat, Jawaharlal Institute of post graduate medical education and research institute, Puducherry, INDIA

OP-351

Comparison of 68Ga-FAP-66 PET/CT and 18-FDG PET/CT in breast carcinoma staging: Results of 100 patients

F. Novrozov, F. Meneghetti, F. Cruciatti, G. Ayliani, F. Ferrati, F. Valati, S. Rahimzade, J. Ayliani

"Azerbaijan National Centre of Oncology, Department of Nuclear Medicine, Baku, Azerbaijan; "University Hospital Dresden, Department of Nuclear Medicine, Dresden, Germany; "课题单位, United States of America; "Azerbaijan National Centre Of Oncology, Department Of Woman Health, Baku, Azerbaijan; "Azerbaijan National Centre Of Oncology, Department Of General Surgery, Baku, Azerbaijan"

OP-352

FAPI, PSMA and FDG PET/CT in patients with advanced metastatic castration-resistant prostate cancer (mCPRC): a triple tracer comparison

K. M. Pabst, W. P. Fendler, B. Hachschäuer, C. Kasch, N. Herrmann, L. Kessler, H. Grünwald, R. Hamacher, M. Nader

"Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Institute of Pathology, University Hospital Essen, Essen, Germany; "Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Department of Haematology and Stem Cell Transplantation, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Department of Thoracic Surgery and Thoracic Endoscopy, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Department of Medicines, West German Cancer Center, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany"

OP-353

Target Expression and FAP-Dependent Tumour Imaging in a Large, Single-Centre PET Database of 324 Patients and 21 Tumour Entities


"Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Institute of Pathology, University Hospital Essen, Essen, Germany; "Department of Medical Oncology, West German Cancer Center, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Targus Molecular Pathology Inc., Kassel, Germany; "Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Department of Urology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Department of Medical Oncology and Research Institute, Puducherry, India; "Department of Nuclear Medicine, West German Cancer Center, University of Duisburg-Essen, Essen, Germany; "Department of Neurology, University of Duisburg-Essen and German Cancer Consortium (DKTK)-University Hospital Essen, Essen, Germany; "Brigde Institute of Experimental Tumor Therapy; West German Cancer Center, University Hospital Essen, Essen, Germany; "Division of Solid Tumoral Translational Oncology, German Cancer Consortium (DKTK), Partner Site Essen and German Cancer Research Center, DKFZ, Heidelberg, Germany"

OP-354

Lu-FAP-2268 in patients with advanced or metastatic solid tumours: updated data from a phase 1/2 study investigating safety, pharmacokinetics, dosimetry, and preliminary antitumour activity (LuMIRE)


"University of California, San Francisco, CA, United States of America, "Department of Radiation Oncology, Mount Sinai Medical Center, New York, NY, United States of America, "University of Iowa, Iowa City, IA, United States of America, "The University of Texas MD Anderson Cancer Center, Houston, TX, United States of America, "University of Alabama School of Medicine, Birmingham, AL, United States of America, "Claus Medicus Medical School, Bochum, Germany, "Department of Nuclear Medicine, West German Cancer Center, University Hospital Essen, Essen, Germany"

OP-355

Fibrilas activation protein alpha (FAPA) as therapeutic target in solitary fibrous tumour (SFT)


"Department of Nuclear Medicine, Essen, Germany; "Department of Oncology, Essen, Germany; "Department of Oncology, Heidelberg, Germany; "Department of Pathology, Essen, Germany; "Department of Radiology, Essen, Germany"

OP-356

Fibrilas activation protein alpha (FAPA) as therapeutic target in solitary fibrous tumour (SFT)


"Department of Nuclear Medicine, Essen, Germany; "Department of Oncology, Essen, Germany; "Department of Oncology, Essen, Germany; "Department of Medical Imaging, Radboud Institute for Molecular Medicine, Radboud University Medical Center, Nijmegen, Netherlands; "Department of Medical Imaging, Radboud Institute for Molecular Medicine, Radboud University Medical Center, Nijmegen, Netherlands; "Department of Medical Imaging, Radboud Institute for Molecular Medicine, Radboud University Medical Center, Nijmegen, Netherlands; "Department of Medical Imaging, Radboud Institute for Molecular Medicine, Radboud University Medical Center, Nijmegen, Netherlands"
ORAL SESSIONS

OP-376 Implementation of Simplified Protocol for Tumour Dosimetry in Molecular Radiotherapy with “Lu-DOTATE 0.22”
H. Siebinga
Patients University Medical Center Utrecht, Utrecht, NETHERLANDS, Nijmegen, NETHERLANDS, Medical Centre, Ulm, GERMANY.

OP-377 Effects of imaging point on uncertainty in absorbed dose to the kidneys in patients with neuroendocrine tumours receiving “Lu-DOTATE 0.22”
M. Sandström1,2, A. Jonsson3, C. Wistrand1, A. Sandahl1, M. Lubben2.

OP-378 Optimal sampling of a single-time-point doseimeter for peptide receptor radionuclide therapy using a non-linear mixed effects model and a sum of exponential functions
G. Glätting1, A. Rand1, A. Beer1, J. Handelsman.

OP-379 Volume level new voxel-based approach with time-integration at the Tumour dosimetry after Lutetium-177 PSMA Therapy: a multi-centre multicentre study
G. Nicolosi1, A. Chinprü, A. Baumann, W. Fan1, M. Schöfer2, D. Wilf2, SS&M Therapy Working Group.

OP-380 Effect of [177Lu-PSMA-617 radioipotional therapy on quality of life in patients with advanced metastatic prostate cancer

OP-381 Safety and efficacy of PSMA targeted radiolucide therapy with [177Lu-PSMA-617 in metastatic castration-resistant prostate cancer patients: preliminary results of a Swiss wide prospective multicentre registry study
G. Nicola1, M. Arian2, A. Baumann3, W. Fan1, M. Schöfer2, D. Wilf2, SS&M Therapy Working Group.

OP-382 ClinicalOutcomes and Evidence of Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

OP-383 Clinical and Outcomes of Combination therapy of [177Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study
J. Kurth1, K. Kahla1, A. Baumann2, M. Kruse1, M. Lassmann1, W. Jentzen1, D. Chocot2, P. Klein1, J. Blumenstern1, J. Kapusta5, K. Viermeier9, Rostock University Medical Center, Rostock, GERMANY.

OP-384 Tandem Therapy Versus Single Agent 177Lu-PSMA and 225Ac-PSMA of Advanced Stage Metastatic Castration Resistant Prostate Carcinoma: Clinical Trial From Brazil
F. Novruzov1, E. Mehdi2, N. Orucoglu3, G. Alyevo4, G. Guyart5, G. Gasame6, M. Caracciolo1, L. Urso1, M. Caracciolo, Dusseldorf, GERMANY.

OP-385 "Lu-DOTATE 0.22" and 225Ac-PSMA Therapy for the treatment of localized prostate cancer: results of a clinical trial
Atakan M. Karaca7, M. Caracciolo1, L. Urso1, M. Caracciolo, Dusseldorf, GERMANY.

OP-386 "Lu-DOTATE 0.22" and 225Ac-PSMA Therapy for the treatment of localized prostate cancer: results of a clinical trial
Atakan M. Karaca7, M. Caracciolo1, L. Urso1, M. Caracciolo, Dusseldorf, GERMANY.

OP-387 Co-development of the biodosimetry and dosimetry for combined Lu-177/225PSMA-167 therapy using multi-isotope quantitative SPECT imaging
A. Delker1, M. Schiekeit2, L. Lubosch9, J. Dörge1, M. J. Zachet, M. Brendel, F. I. Gouda3, A. Harbach3, M. Rumianto, S. Resch1, K. Lassner2, J. Brossch-Ventura2, L. Untermetzer3, P. Banstetten3, S. Zanger, I. Beyr4, C. Boing5, Department of Nuclear Medicine, LAU Hospital, Munich, GERMANY.

OP-388 The Diagnoatic Value of 18F-Fluorochrome PET/CT for Medullary Thyroid Cancer Detection

OP-389 Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer
A. Abdollahman, S. Gavazi, Yoav School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

OP-390 Prognostic Value of Hybrid PET/MR Imaging in Patients with Differentiated Thyroid Cancer

OP-391 Prostate Cancer Targeted with Lu-177 or 225Ac Against Prostate specific antigen in Prostate cancer patients with high-risk thrombosis
A. Abdollahman, S. Gavazi, Yoav School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.
OP-398 Quantification of absolute myocardial blood flow from 'N-HN-ESPECT images is more affected by the choice of compartmental models and time-of-flight than by the use of different time frames and reconstruction algorithms
S. Akif1, A. Sehgal1, B. Giovani, F. Heider1, S. Souar1, H. Engelbrant1, C. Händel2
1Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Sweden; 2Department of Medical and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden

OP-399 The Influence of Anthropometric Variables on Count Rate in 82Rubidium myocardial perfusion imaging with PET/CT
F. Caobelli1, V. Betech1, D. Wild1, I. Kohlberger2, M. J. Zellweger1, C. Eigler2, M. J. Rendl1
1Universitätsspital Basel, Basel, Switzerland; 2Universitätsspital Inselspital Bern, Bern, Switzerland

OP-400 Accuracy of Gated Rubidium PET for the Determination of Left Ventricular Ejection Fraction: Validation Using Cardiovascular Magnetic Resonance and Echocardiography
S. Townrow1, M. Burniston2, L. Price3, S. Tyebally4, L. Menezes2
1Barts Health NHS Trust, London, United Kingdom; 2Radiation Protection Issues for 177Lu-Based Therapies, Radiation Protection, Utrecht, Netherlands; 3General Issues of Radiation Protection in NM Therapies, Radiation Protection, Utrecht, Netherlands

OP-401 Myocardial Perfusion Imaging and Coronary Flow Reserve Using 82Rubidium on an Extended Bore Length Solid-State Digital-BGO PET/CT System
S. Massalha1, J. A. Kennedy1, T. Pichler-Hazan1, N. Nemvarvaghi1, N. Mazawati2, Z. Kindar2, Rambam Health Care Campus, Haifa, Israel

OP-402 Repeatability of myocardial flow reserve measurement using quantitative dynamic SPECT perfusion imaging with F. Bailly1, F. Thibault1, G. Metard1, M. Courtois1, D. Angiolucci2, M. Ribeiro2
1IRCCS AOU di Bologna Policlinico S. Orsola-Malpighi, Nuclear Medicine, Bologna, Italy; 2National Physical Laboratory, Teddington, United Kingdom

OP-403 How to Raise Awareness for Theranostic Concepts
M. Bailly1, A. Iagaru1, F. Angiolucci2
1IRCCS AOU di Bologna Policlinico S. Orsola-Malpighi, Nuclear Medicine, Bologna, Italy; 2Molecular Imaging, Stanford, United States of America

OP-404 Getting Ready for the Next Wave of Theranostic Studies
L. Emmet
1St Vincent's Hospital Sydney, University of New South Wales, Kensington, NSW, Department of Theranostics and Nuclear Medicine, Sydney, Australia

OP-405 Theranostics - The Catalyst for Nuclear Medicine Growth
A. Lagard
1Stanford University, Radiology / Nuclear Medicine and Molecular Imaging, Stanford, United States of America

OP-406 Getting Ready for the Next Wave of Theranostic Studies
L. Emmet
1St Vincent's Hospital Sydney, University of New South Wales, Kensington, NSW, Department of Theranostics and Nuclear Medicine, Sydney, Australia

OP-407 GMP Elements - Quality Control & Quality Management
N. Hartman
1Faculty of Medicine (Swansea University); Head of nuclear medicine, Singleton Hospital, Swansea, United Kingdom

OP-408 Radiopharmaceutical Metabolism Activity - How to Trace What’s Left
G. Luurtsema
1Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands

OP-409 Introduction by Chairpersons

OP-410 Theranostics Overview
W. Weber
1TUM, Nuclear Medicine, Munich, Germany

OP-411 Why Theranostics should be NM’s Driver to Independence
J. Czermin
1University of California Los Angeles; Nuclear Medicine/Molecular and Medical Pharmacology, Los Angeles, United States of America

OP-412 GMP Elements - Quality Control & Quality Management
N. Hartman
1Faculty of Medicine (Swansea University); Head of nuclear medicine, Singleton Hospital, Swansea, United Kingdom

OP-413 How to Raise Awareness for Theranostic Concepts
C. Namni
1IRCCS AOU di Bologna Policlinico S. Orsola-Malpighi, Nuclear Medicine, Bologna, Italy

OP-414 Getting Ready for the Next Wave of Theranostic Studies
L. Emmet
1St Vincent's Hospital Sydney, University of New South Wales, Kensington, NSW, Department of Theranostics and Nuclear Medicine, Sydney, Australia

OP-415 Theranostics - The Catalyst for Nuclear Medicine Growth
A. Lagard
1Stanford University, Radiology / Nuclear Medicine and Molecular Imaging, Stanford, United States of America

OP-416 Summary by Chairpersons

Monday, October 17, 2022, 15:00 - 16:30

Auditorium

CME 7 - Radiation Protection Committee: Radiation Protection in Radionuclide Therapy - Insight on New and Emerging Therapies

Monday, October 17, 2022, 17:00 - 18:00

Auditorium

OP-417 General Issues of Radiation Protection in NM Therapies
F. Jamar
1Cliniques universitaires St-Luc; Nuclear Medicine Department, Brussels, Belgium

OP-418 Radiation Protection Issues for SIRT (90Y and 166Ho)
C. Leijen
1University Medical Centre, Department of Radiation Protection, Utrecht, Netherlands

OP-419 Radiation Protection Issues for 177Lu-Based Therapies (SAMS and PSMA)
J. Kurfth.1
1Hospital Institute, Rostock University Medical Centre, Nuclear Medicine Department, Rostock, Germany

OP-420 Radiation Protection Issues for Alpha Emitters
A. Craig
1The Royal Marsden NHSFT, Joint Department of Physics, London, United Kingdom

OP-421 Wrap-Up by Chairpersons

Monday, October 17, 2022, 15:00 - 16:30

Auditorium

CME 7 - Radiation Protection Committee: Radiation Protection in Radionuclide Therapy - Insight on New and Emerging Therapies

Monday, October 17, 2022, 17:00 - 18:00

Auditorium

OP-417 General Issues of Radiation Protection in NM Therapies
F. Jamar
1Cliniques universitaires St-Luc; Nuclear Medicine Department, Brussels, Belgium

OP-418 Radiation Protection Issues for SIRT (90Y and 166Ho)
C. Leijen
1University Medical Centre, Department of Radiation Protection, Utrecht, Netherlands

OP-419 Radiation Protection Issues for 177Lu-Based Therapies (SAMS and PSMA)
J. Kurfth.1
1Hospital Institute, Rostock University Medical Centre, Nuclear Medicine Department, Rostock, Germany

OP-420 Radiation Protection Issues for Alpha Emitters
A. Craig
1The Royal Marsden NHSFT, Joint Department of Physics, London, United Kingdom

OP-421 Wrap-Up by Chairpersons
OP-428 EANM Sanjiv Sam Gambhir Award – Battle and Win!
Moderator: S. Fanti; J. Morici;
"University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY, Royal Darwin Hospital, Darwin, AUSTRALIA.
Award Nominees: D. Kresting; R. Laudesola; S. Widholm, van Zanten; B. Prutt; O. hashchenko; J. Alberts;
1) Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY; Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY; "Kronsos MC, Rotterdam, NETHERLANDS;
2) Radionucleum, Nuclear Medicine, Nijmegen, NETHERLANDS;
3) University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS; "Nispet splash, Bem, Department of Nuclear Medicine, Bem, SWITZERLAND."

OP-429 Challenges of Introducing Imaging Biomarkers as End-Points into Clinical Trials
S. Litwin;
European Organisation for Research and Treatment of Cancer (EORTC), Brussels, BELGIUM.

OP-430 How do I share my Trial Data?
M. Smits
Erasmus MC, Department of Radiology and Nuclear Medicine, ROTTERDAM, NETHERLANDS.

OP-431 What is the Shelf-Life of Imaging Data?
L. Bidou
University of Lincoln, College of Science, Lincoln, UNITED KINGDOM.

OP-432 Comparison of the Biodistribution and Efficacy of a Novel Theranostic Agent [18F]fPS-PEG2-TOC with [18F]fP DOTATATE and [14C]fDOTATATE for Image-Guided Therapy for SSTPR Positive Tumors in Mice
D. Liu; D. M. G. Sosabowski; J. Li; E. Vaamonde; C. Fister; G. Lu;
1) Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, GERMANY; Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University of Messina, Messina, ITALY; "Kronsos MC, Rotterdam, NETHERLANDS;
2) Radionucleum, Nuclear Medicine, Nijmegen, NETHERLANDS;
3) University Medical Center Groningen, Nuclear Medicine and Molecular Imaging, Groningen, NETHERLANDS; "Nispet splash, Bem, Department of Nuclear Medicine, Bem, SWITZERLAND."

OP-433 Optimisation of ov66-specific peptides for use in targeted radionuclide therapy
R. Kashani; R. Khan; L. Foster; J. Young; J. Marshall; J. K. Sosabowski;
Queen Mary University, Molecular Oncology, London, UNITED KINGDOM.

OP-434 [111Lu]f-DPI-4452 shows enhanced anti-tumor efficacy in patient-derived xenografts, comparison with [111Lu]f-DPI-446
J. Chen; L. Zhao; Y. Yang; C. Gao; C. Lin;
The First Affiliated Hospital of Xianning University, Xianning, CHINA.

OP-435 [111Lu]f-DPI-4452, a new radiotargeting peptide targeting Carbonic Anhydrase IX, displays strong anti-tumor activity in colorectal cancer and clear cell renal cell carcinoma mouse models
A. Attinger; N. Wiedermann; R. Raschße; O. Zboralski; A. Schumayer; A. Bredenbeck; F. Osterkamp; A. Hoeterne;
"DeBiopharm International S.A., Lausanne, SWITZERLAND, 38 PharmaceuticalsGmbH, Berlin, GERMANY."

OP-436 NeCtin-4 targeted PET imaging of uterine carcinoma with newly synthesized "Ga labeling bicyclic peptide D. Wu; X. Zhou; A. Zhang; J. Chen; G. Shao; L. Zhang;
"Department of pediatrics, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA; Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA; "Department of nuclear medicine, Taizhou People's Hospital, Nanjing University of Chinese medicine, Nanjing, CHINA; "Department of nuclear medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, CHINA.

OP-437 Development and preclinical evaluation of novel [18F]-labelled radiohybrid CCK-2R-targeted ligands based on [18F]DOTA-PPF-11N
N. Holzleitner; T. Gunther; C. Lapa; H. J. Wetter;
"Technical University of Munich, Munich, GERMANY; University Hospital Augsburg, Augsburg, GERMANY."

OP-438 Promising performance of PET/CT using [68Ga]f-Pentixafor (Pentixafor PET/CT) for initial staging and therapeutic evaluation of symptomatic multiple myeloma (MM) patients in first line treatment or first relapse: preliminary results of an exploratory phase 2 study
C. Bodet-Milin; A. Mouton; B. Jammé; C. Dubegno; C. Baliy; M. Frindel; N. Boutron; J. Kauffmann; C. Touzet; B. Meyer-
Bode; M. Smits; Nuclear Medicine department, Nantes University Hospital, Nantes, FRANCE; "Wanterken Institute, Angers University, INSERM, CNRS, CRCNA, Nantes, FRANCE; "Radiopharmacy unit, Nantes University Hospital, Nantes, FRANCE; "Radiopharmacy unit, ICD institut de cancérologie de l'Ouest, Saint-Herblain, ORANGE; "Pentixafor GmbH, Würzburg, GERMANY; "Morpho-Functional Imaging, University of Messina, Messina, ITALY."

OP-439 Proof-of-concept of CKCR4 targeting in vivo using radiotheratcists based on the endogenous antagonist EIPI X4
R. Goeken; F. Schmidt; J. Milz; H. Kim; M. Hams; J. Mack; M. Sca;
"University Hospital Basel, Basel, SWITZERLAND; "Ulm University, Ulm, GERMANY."

OP-440 Tuning the kinetics of protein-based nanomedicine by metal ion coordination assisted self assembly
K. Saatchi; G. Enguital; C. Rodriguez-Rodiguez; N. K. Mishra; M. Benoi; S. Agarwale; A. T. Jensen; U. O. Hafte;
"UBC, Vancouver, BC, CANADA; "TRIMU, Vancouver, BC, CANADA; "UCPH, Copenhagen, DENMARK."

OP-441 I-131 Dosimetry - An Introduction
F. Verburg
Erasmus MC, Department of Radiology and Nuclear Medicine, ROTTERDAM, NETHERLANDS.

OP-442 Implementing dosimetry in a multicentric environment: Results of the MADRIAD project
A. Vergara Gib; J. Logan; J. Salloum; U. Eberlein; M. Lassmann; J. Schmitz; A. Ashraft; G. D. Fluss; M. Bardsen;
"UCB, ICR, AMR, INSERM, University Toulouse Paul Sabatier, Toulouse, FRANCE; "Royal Marden, NWST, SUTTON, UNITED KINGDOM; "The Institute of Cancer Research, London, UNITED KINGDOM; "CNC Onopaleo, Av Irene Joan-Cune, Toulouse, FRANCE; "Department of Nuclear Medicine, Würzburg, GERMANY; "Department of Nuclear Medicine, Philips-University Marburg, Marburg, GERMANY; "Department of Medicine Nuclear Medicine, Instituto Regional del Cáncer de Mompellier (ICM), Mompellier, FRANCE.

OP-443 Are There Differences in DNA Damage Induction and Repair Before and After Radioiodine Therapy?
S. Schumacher; H. Scherthan; S. Schmied; P. E. Hartramp; K. Bick; M. Prött; M. Lassmann; U. Eberlein;
"Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, GERMANY; "Bundeswehr Institute of Radiobiology affiliated to the University of Ulm, Ulm, GERMANY."

OP-444 The application of [111In] as a surrogates radiotherapeutic for the pre-therapeutic dosimetry in differentiated thyroid cancer with [131I]: A clinic trial study using a 
M. Sosa; H. Kim; S. Sano; H. Park; S. Kim;
"Department of Applied Biomedical, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF; "Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, KOREA, REPUBLIC OF; "Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, KOREA, REPUBLIC OF; "Advanced Institute of Convergence Technology, Suwon, KOREA, REPUBLIC OF."

OP-445 Finger-tip Blood Sampling for Dosimetry Measurements
Post I-131 Administration in Thyroid Cancer Patients
A. A. Jabari; J. Coteef; S. Courtois; M. Hedayati;
"Trinity College Dublin, Dublin, IRELAND; "Salvan Gatosse University, Muscat, OMAN; "O’Donnell Health Ireland at Crumlin, Dublin, IRELAND; "GS Vincent’s University Hospital, Dublin, IRELAND; "St James Hospital, Dublin, IRELAND.

OP-446 Value of Personalized Radiation Absorbed Dose Calculation for Radioiodine Ablation Therapy
O. Sahin; A. N. Serkal; N. Reyit; R. Akyel; T. Tukul; M. F. Buryt;
"Department of Nuclear Medicine, Istanbul University-Cerrahpaşa, Faculty of Medicine, Istanbul, TURKEY; "Department of Nuclear Medicine, Yeditepe University, Faculty of Medicine, Istanbul, TURKEY; "Clinic of Nuclear Medicine, Yeölkü Clinic; Diseases and Thrapies, Surgery Training and Research Hospital, Istanbul, TURKEY; "Department of Public Health, Istanbul University-Cerrahpaşa, Faculty of Medicine, Istanbul, TURKEY; "Clinic of Nuclear Medicine, Yeölkü Clinic; Diseases and Thrapies, Surgery Training and Research Hospital, Istanbul, TURKEY; "Clinic of Nuclear Medicine, Baslent University, Faculty of Medicine, Adana, TURKEY."

OP-445-2 Post-therapeutic dose estimates of salivary glands and lidoine-avid lesions in 131I therapy
M. Abuzeid; M. Smeis; S. Saleh;
"Istanbul University, Istanbul, TURKEY."

OP-446 Effect of fluorosence on whole-body radioacitivity retention in patients treated with radioiodine (RAI) for differentiated thyroid cancer (DTC)
B. Criscuoli; G. Rausz; G. Fallica; C. Manni; N. Castagnoli; S. Fattoni; P. Capocaccia;
"Molecular Medicine Unit, Mackena Hospital, AV, ASR Marche, Mackena, ITALY; Medical Physical Unit, Mackena Hospital, AV, ASR Marche, Mackena, ITALY."
Clinical Oncology Track - TROP Session: Breast

**OP-450**

Metabolic features of 18F-FDG PET in women carriers of germline pathogenic variants with locally advanced and metastatic breast cancer

**OP-451**

Value of semiquantitative parameters derived from 18F-FDG PET/CT to predict 3-year disease-free survival in patients affected by grade III breast cancer with different luminal types undergoing neoadjuvant chemotherapy
N. Quartuccio, L. Ursi, F. Mongi, I. Rambaldi, S. A. Yilmaz, C. Oliveira; Breast Center Unit, Health Sciences of Women, Children and Public Health, University of Padua, Padua, ITALY.

**OP-452**

The Functional Adipose Tissue in 18F-FDG PET/CT in Estrogen Receptor Positive Postmenopausal Breast Cancer
S. A. Yilmaz; University of Padua, Padua, ITALY.

**OP-453**

SUV-based features from baseline 18F-FDG PET/CT in breast cancer patients differentiate tumor phenotypes but do not predict pathologic response to neoadjuvant chemotherapy
C. Oliveira*, I. Olivera, C. Constantino, H. Pinto Marques; University of Padua, Padua, ITALY.

**OP-454**

Preliminary results of a prospective pilot study, assessing imaging performance of 89Zirconium-labelled Girentuzumab GEX-1T in metastatic triple negative breast cancer patients

**Hall 117**

**OP-455**

Value of semiquantitative parameters derived from 18F-FDG PET/CT to predict response to neoadjuvant chemotherapy in a cohort of patients with different luminal types of breast cancer
L. Ursi, F. Mongi, I. Rambaldi, A. Oliveira; University of Padua, Padua, ITALY.

**OP-456**

Absolute 

**Hall 115**

**OP-457**

Optimization of 

**OP-458**

**Hall 115**

**OP-459**

**Hall 115**

**OP-460**

**Hall 115**

**OP-461**

**Hall 115**

**OP-462**

**Hall 115**

**OP-463**

**Hall 115**

**OP-464**

**Hall 115**

**OP-465**

**Hall 115**

**OP-466**

**Hall 115**

**OP-467**

**Hall 115**

**OP-468**

**Hall 115**

**OP-469**

**Hall 115**

**OP-470**

**Hall 115**

**OP-471**

**Hall 115**

Inflammation & Infection Committee - TROP Session: Nuclear Medicine and COVID-19

**OP-459**

Metabolic characterization of structural lung changes in patients with suggestive COVID-19 pneumonia on 18F-FDG PET/CT
W. Kulke Corfh, F. Fernando-Castagnetto, M. Garcia-Garcia-Espana, C. Rodriguez Rey, A. Ortega Canadi, R. M. Couto Caro, J. L. Carreras Diegud, M. N. Cabrera Martin; Hospital Clínico San Carlos, Madrid, SPAIN; Hospital de Clínicas Dr. Manuel Quintela, Montevideo, URUGUAY.

Utility of 18-Fluoro-deoxyglucose Positon Emission Tomography/Computed Tomography in COVID-19 infection: a single centre retrospective observational study
J. Jaleed, A. K. Majed, A. S. Abu, S. Kalha, S. A. H. A. Chandra, R. Kumar, C. S. Ba; All India Institute of Medical Sciences, New Delhi, INDIA.

Post-COVID-19 Lung disease (PCLD) patients show a strong correlation between IL-6 and SUVmax on FDG PET/CT

New perspectives during the COVID-19 pandemic: the importance of an adequate directed structural clinical research prior to [18F]FDG PET/CT in COVID-19 patients
S. Kappadath, L. Ferrer, A. Nieri, L. Urso, P. Alongi, C. Constantino, N. Ortolan, F. Borgia, N. Schubert, G. Amone, M. Balmabolare; Nuclear Medicine Unit, Diagnostic Imaging, Radiation Oncology and Hematology Department, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, ITALY.

The effect of oral paracetamol on COVID-19 patients with suggestive COVID-19 pneumonia on 18F-FDG PET/CT
T. Nazerani Hooshmand, J. L. Carreras Delgado, A. Allam, R. Aigner, F. Ferrando-Castagnetto, M. Garcia-Garcia-Espana, C. Rodriguez Rey; Hospital Clinico San Carlos, Madrid, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; Hospital Universitario La Fe, Valencia, SPAIN; Hospital Universitario de Alcorcón, Alcorcón, MADRID, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; EANM’22 WORLD LEADING MEETING OCTOBER 15-19, 2022

In vivo distribution of CD8+ T-cells in hospitalized COVID-19 patients with suggestive COVID-19 pneumonia on 18F-FDG PET/CT
T. Nazerani Hooshmand, J. L. Carreras Delgado, A. Allam, R. Aigner, F. Ferrando-Castagnetto, M. Garcia-Garcia-Espana, C. Rodriguez Rey; Hospital Clinico San Carlos, Madrid, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; Hospital Universitario de Alcorcón, Alcorcón, MADRID, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; EANM’22 WORLD LEADING MEETING OCTOBER 15-19, 2022

A preliminary study to assess the value of different COVID-19 vaccines in 18F-FDG PET/CT
T. Nazerani Hooshmand, J. L. Carreras Delgado, A. Allam, R. Aigner, F. Ferrando-Castagnetto, M. Garcia-Garcia-Espana, C. Rodriguez Rey; Hospital Clinico San Carlos, Madrid, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; Hospital Universitario de Alcorcón, Alcorcón, MADRID, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; EANM’22 WORLD LEADING MEETING OCTOBER 15-19, 2022

The effect of oral paracetamol on COVID-19 patients with suggestive COVID-19 pneumonia on 18F-FDG PET/CT
W. Wong; NUHRC (TMC), Mullanpur, Punjab, INDIA; All India Institute of Medical Sciences, New Delhi, INDIA; ICHRC (TMC), Mulund, Pune, INDIA.

The impact of different COVID-19 vaccines in 18F-FDG PET/CT
T. Nazerani Hooshmand, J. L. Carreras Delgado, A. Allam, R. Aigner, F. Ferrando-Castagnetto, M. Garcia-Garcia-Espana, C. Rodriguez Rey; Hospital Clinico San Carlos, Madrid, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; Hospital Universitario de Alcorcón, Alcorcón, MADRID, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; EANM’22 WORLD LEADING MEETING OCTOBER 15-19, 2022

The effect of oral paracetamol on COVID-19 patients with suggestive COVID-19 pneumonia on 18F-FDG PET/CT
W. Wong; NUHRC (TMC), Mullanpur, Punjab, INDIA; All India Institute of Medical Sciences, New Delhi, INDIA; ICHRC (TMC), Mulund, Pune, INDIA.

A preliminary study to assess the value of different COVID-19 vaccines in 18F-FDG PET/CT
T. Nazerani Hooshmand, J. L. Carreras Delgado, A. Allam, R. Aigner, F. Ferrando-Castagnetto, M. Garcia-Garcia-Espana, C. Rodriguez Rey; Hospital Clinico San Carlos, Madrid, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; Hospital Universitario de Alcorcón, Alcorcón, MADRID, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; EANM’22 WORLD LEADING MEETING OCTOBER 15-19, 2022

The impact of different COVID-19 vaccines in 18F-FDG PET/CT
T. Nazerani Hooshmand, J. L. Carreras Delgado, A. Allam, R. Aigner, F. Ferrando-Castagnetto, M. Garcia-Garcia-Espana, C. Rodriguez Rey; Hospital Clinico San Carlos, Madrid, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; Hospital Universitario de Alcorcón, Alcorcón, MADRID, SPAIN; University Clinic Nijmegen, Nijmegen, NETHERLANDS; EANM’22 WORLD LEADING MEETING OCTOBER 15-19, 2022

The effect of oral paracetamol on COVID-19 patients with suggestive COVID-19 pneumonia on 18F-FDG PET/CT
W. Wong; NUHRC (TMC), Mullanpur, Punjab, INDIA; All India Institute of Medical Sciences, New Delhi, INDIA; ICHRC (TMC), Mulund, Pune, INDIA.
OP-472 Metabolic predictors of poor prognosis in acute myocardial infarction patients after percutaneous transluminal coronary intervention by combined visual and semi-quantitative evaluation of 18F-FDG PET/CT
T. Yuan, Q. Zhang, K. Li, Y. Wang
*Peking University International Hospital, Beijing, CHINA, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, CHINA.

OP-473 Recalculations of gated 18Rbiodex POST/CT scans in patients with atrial fibrillation or sinus rhythm after re-balancing
H. Bayram, T. Gustafson, L. Duchstein, B. Zerahn, Copenhagen University Hospital Herlev and Gentofte, 2730 Herlev, DENMARK.

OP-474 Regional myocardial perfusion by CzT SPECT imaging in predicting lesion-related outcome in patients with suspected or known CAD

OP-475 Serum neurofilament light chain (sNfL) in relation to myocardial sympathetic neuronal damage based on 18R-metaiodobenzylguanidine (MIBG) scintigraphy in hereditary transthyretin (ATTv) amyloidosis
M. Berends, H. L. A. Nienhuis, A. Bruntgen, J. Biat, P. A. van der Zwaag, B. P. C. Hazenberg, W. Noordzij, R. H. J. Slart, University of Amsterdam, Amsterdam, NETHERLANDS.

OP-476 Prospective diagnostic performance of CzT myocardial perfusion perfusion reserve to detect territories with simultaneously impaired invasive CFR and IMR reflecting a very high cardiovascular risk in patient without obstructive coronary artery disease
L. Djalei1, O. Phan-Sy2, N. De Leiris1, M. Caruf1, J. Leenhardt1, A. Bro1, A. Bore2, S. Leblanc2, C. Berty3, G. Vanzetto3, C. Ghezzi2, D. Fagret2, I. Risou3, G. Barone-Rochette2, 1Univ. Grenoble Alpes, INSEMP, CHU Grenoble Alpes, nuclear medicine department, URB, Grenoble, FRANCE, 2Univ. Grenoble Alpes, INSEMP, CHU Grenoble Alpes, radiology department, URB, Grenoble, FRANCE, 3Univ. Grenoble Alpes, INSEMP, CHU Grenoble Alpes, endocrinology department, URB, Grenoble, FRANCE.

OP-485 Gallium-68 champion
C. Decefoort, Medical University Innsbruck, Department of Nuclear Medicine, Innsbruck, AUSTRIA.

OP-486 Fluorine-18 champion
G. Bormans, Radiochemistry and Radiopharmacy, University of Leuven, Leuven, BELGIUM.

OP-487 Technical Aspects of Multiphase Imaging
S. Cade, Royal United Hospitals Bath NHS Trust, Medical Physics and Biomedical Engineering, BATH, UNITED KINGDOM.

OP-488 Early Bone SPECT - New Insights on Orthopaedics and Post-Operative Skeleton
N. Icard, Hôpital Vésale Le Foss, Nuclear Medicine, Saint-Bruno, FRANCE.

OP-489 Usefulness of Early Bone SPECT in Rheumatological Pathologies and Pain of Unknown Origin
J. Zhang-Yin, Vivalia, Nuclear Medicine, Aalst, BELGIUM.

OP-490 Making it quicker – Automated and AI Methods for Image Segmentation
I. Buvat, Laboratoire d’Imagerie Translational en Oncologie, Inserm U1288, PSI Research University, INSERM, ORASI, FRANCE.

OP-491 Discussion

OP-492 Image Segmentation for Dosimetry - Emission or Transmission?
J. Ruben Gustafsson, University of Lund, Lund, SWEDEN.

OP-493 Discussion

OP-494 Fluorine-18 Alternatives for Oncological Radiopharmaceutical Sciences Committee: Hall 112 (Arena)
Monday, October 17, 2022, 16:45 - 18:15
Hall 112 (Arena)
Debate 2 - Oncology & Theranostics + Radiopharmaceutical Sciences Committee: Fluorine-18 Alternatives for Oncological Gallium-68 Tracers

OP-495 Source, Lausanne, SWITZERLAND.
A. Boubaker, Planning
Hybrid Image Segmentation for Diagnostics and Therapy Recognition

OP-496 Discussion

OP-497 Image Reconstruction + Image Guided Surgery

OP-498 OP-501 OPPORTUNITIES FOR DIAGNOSTIC ENHANCEMENT
U1288, PSL Research University, Institut Curie, Orsay, FRANCE.
Laboratoire d’Imagerie Translationnelle en Oncologie, Inserm

OP-499 Joint Symposium 4 - Oncology & Theranostics Hall 114
Monday, October 17, 2022, 16:45 - 18:15
Hall 114
Clinical Significance of Bayesian penalized-likelihood and Motion Correction PET Reconstruction Algorithms
G. Kaya, H. Palta, M. Tunelc, O. Uğur, Hacettepe University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-500 Clinical Significance of Bayesian penalized-likelihood and Motion Correction PET Reconstruction Algorithms
G. Kaya, H. Palta, M. Tunelc, O. Uğur, Hacettepe University Medical School, Department of Nuclear Medicine, Ankara, TÜRKIYE.

OP-501 Evaluation of a respiratory motion correction algorithm for PET images using a customized dynamic phantom
T. Quencer, F. Pirotto, I. Kraus1, J. Sarost, V. Mostart, V. Bletter-Ants, M. Gonzalez-Vellos, J. M. Martí-Clementi,3 C. Luquin, I. Torres-Espallardo,1 1Univ. Navarra, Pamplona, SPAIN, 2Hospital Universitario Politécnico La Fe, Valencia, SPAIN, 3Institut Universitari d’Obstetricia i Ginecologia, Valencia, SPAIN.

OP-502 Evaluation of a respiratory motion correction algorithm for PET images using a customized dynamic phantom
T. Quencer, F. Pirotto, I. Kraus1, J. Sarost, V. Mostart, V. Bletter-Ants, M. Gonzalez-Vellos, J. M. Martí-Clementi,3 C. Luquin, I. Torres-Espallardo,1 1Univ. Navarra, Pamplona, SPAIN, 2Hospital Universitario Politécnico La Fe, Valencia, SPAIN, 3Institut Universitari d’Obstetricia i Ginecologia, Valencia, SPAIN.

OP-503 Improving cerebral blood flow measurements from dynamic 15OHO PET study using complementary frame reconstruction and isotope-specific resolution modelling
A. J. Gonçalves,1 G. Knol1, D. A. James1, T. Xia1, Y. K. Djughudary, A. Jackson1, J. C. Mattheis2, J. M. Anton-Rodriguez2, M. C. Askena,3 1The University of Manchester, Manchester, UNITED KINGDOM, 2St. George’s University of London, Manchester, UNITED KINGDOM, 3The University of Manchester, Manchester, UNITED KINGDOM.
Clinical Oncology Track - TROP Session: Lung

Monday, October 17, 2022, 16:45 - 18:15

**OP-507**

Metabolic patterns on \(^{18}\)F-FDG PET/CT in inoperable stage III NSCLC undergoing chemoradiotherapy: a 1-year checkup observation with durvalumab.

*Department of Nuclear Medicine, University Hospital, LMU Munich, Germany, \*Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany, \*Department of Radiology, University Hospital, LMU Munich, Munich, Germany, \*Department of Internal Medicine V, University Hospital, LMU Munich, Munich, Germany, \*Department of Medicine, University of Munich, Munich, Germany, \*Department of Diagnostic and Interventional Radiology and Neuroradiology, University Dusseldorf - Essen, Essen, Germany*

**OP-509**

Respiratory-gated FDG PET/CT versus PET/MRI with zero-time echo: Assessment of the capability to detect and differentiate lung lesions and the precision of fused images.

*Kobe University Graduate School of Medicine, Kobe, Japan, \*Kobe University Hospital, Kobe, Japan, \*Department of Critical Care Medicine, Kobe, Japan, \*Department of Neurology, Kobe, Japan, \*Kobe University Hospital, Kobe, Japan, \*Kobe University Hospital, Kobe, Japan*

**OP-510**

Imaging tumor-infiltrating CD8+ T-cells in non-small cell lung cancer patients upon neo-adjuvant treatment with durvalumab:

*Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands*

**OP-511**

Evaluation of LAT1 expression in patients with lung cancers and mediastinal tumours: \("^{18}\)F-FBPA PET study with immune-histopathological comparison.

*Osaka University, Suita, Japan, \*Osaka University Hospital, Suita, Japan*

**OP-512**

Machine learning using combined \(^{18}\)F-FDG PET/CT and contrast enhanced CT radiomics for histopathological and immunological characterization of non-small cell lung cancer lesions.
W. Grojowits, O. D. D. Riek, T. M. Krutz, F. P. van Velden, L. Lenden Medical Center, Meded, LENTHER, Netherlands

**OP-513**

Improving TNM staging predictive value with PET/CT imaging features and deep learning model in non-small cell lung cancer.
E. Giovannini, F. Tabun, G. Giovevich, L. Flamme, M. Castell, A. Ciammeri

*ASL5, La Spezia, Italy, \*ASL9, Grand Ospedale Maggiore Policlinico, Milan, Italy*

**OP-514**

Heterogeneity of Glycogenic Phenotype Determined by \(^{18}\)F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced NSCLC.
S. Pellegrino, A. Forint, C. Ullione, R. Leoni, R. Moro, E. Mastruzzo, S. De Placido, S. Det Vecco

*Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy, \*Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy*

**OP-515**

Novel deep learning-based noise reduction for zero echo time MRI on PET/MRI: utility of half-time lung imaging for oncology patients.

*Kobe University Hospital, Kobe, Japan, \*Kobe University Graduate School of Medicine, Kobe, Japan, \*Kobe University Hospital, Kobe, Japan, \*Kobe University Hospital, Kobe, Japan, \*Kobe University Hospital, Kobe, Japan, \*Kobe University Hospital, Kobe, Japan*

**OP-516**

Ai Based Monitoring of Idiopathic Inflammatory Myopathy by FDG PET/CT.
J. Sismondi, H. Sismondi, L. Edendran, E. Genke, L. R. Diedrichsen

*Osaka University Hospital, Osaka, Japan, \*University of Southern Denmark, Odense, Denmark, \*Kyushu University Hospital, Gothenburg, Sweden, \*Koshisohospital, Copenhagen, Denmark*

**OP-517**

The presence of extrathoracic disease emerging from \(^{18}\)F-FDG PET/CT increases the rate of fatigue in sarcoidosis patients.
A. Georgopoulou, E. Manolat, P. Rapsissauer, M. Metayer, L. Kolektou, H. Gyalas, E. Papadis, S. Chatzova

*1st Department of Radiology, General University Hospital, \*1st Medical School, National and Kapodistrian University, Athens, Greece, \*1st Pulmonary Medicine Department, \*1st Pulmonary Medicine Department, National and Kapodistrian University, Athens, Greece, \*Foundation for Biomedical Research of the Academy of Athens, Greece, \*1st Pulmonary Department, Athens Chest Hospital \*Sotiria, Athens, Greece, \*Aigina Hospital, Medical School, National and Kapodistrian University, Athens, Greece*

**OP-518**

In-111 labelled glucosamine in the identification of active disease in patients with rheumatoid arthritis.
O. Euvoumam, J. Him-Ladewig, B. Van Nisburg, C. Driver, G. Engtke, M. Loumbatchou

*University of Free State, Bloemfontein, Free State, South Africa, \*University Of The Free State, Bloemfontein, Free State, South Africa, \*NECSA, Pretoria, Gauteng, South Africa*

**OP-519**

Imaging Characteristics and Diagnostic Accuracy of FDG PET/CT in Contrast Enhanced CT Imaging in Patients with Suspected Mycotic or Inflammatory Abercomial Aneurysm.
L. Husmann, M. W. Huesler, H. Graug, M. Meese, Z. Rancic, K. Hass

*University Hospital Zurich, Department of Nuclear Medicine, Zurich, Switzerland, \*University Hospital Zurich, Department of Vascular Surgery, Zurich, Switzerland, \*University Hospital Zurich, Division of Infectious Diseases and Hospital Epidemiology, Zurich, Switzerland*

**OP-520**

"FDG labelled autologous leucocyte PET/CT scan in infective and inflammatory conditions- a single-centre review".
Y. Mathur, S. Kumar, A. Bhattacharya, P. Aggarwal, R. Kumar, H. Singh, A. Moddy, P. GPMD, Chandigarh, India
OP-526 Age dependence of thyroid carcinoma - do we have enough age cut-offs for staging or one too many B. Schmermel
Department of Nuclear Medicine, Ulm University Medical Center, Ulm, GERMANY.

OP-527 Comparison of 8h and 72h Editions of TNM Staging in Terms of Mortality, Persistent Disease, and Response to Treatment in Patients With Differentiated Thyroid Cancer S. Zokan1, G. Ghiselli2, A. Apicella3, A. Balducci, F. Rasu
1Nuclear Medicine Center, School of Medicine, Campus Bioclinico, Aristotle University of Thessaloniki, Thessaloniki, GREECE; 2Department of Nuclear Medicine, University Hospital of Ferrara, Ferrara, ITALY; 3Department of Nuclear Medicine, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, GREECE.

OP-528 Thyroglobulin Levels Independently Predict Iodine-123 Imaging Results At Early Follow-Up In Differentiated Thyroid Cancer Patients A. Campenni1, M. Sicilia Pozo2, G. Zamboni3, J. C. et al.; 1University of Messina, Messina, ITALY; 2University School of Nuclear Medicine, San Juan de Dios University Hospital, Lima, PERU; 3University of Messina, Messina, ITALY.

OP-529 Second Radioiodine Treatment in Patients With Differentiated Thyroid Cancer: Causes And Effects M. A. Sicilia Pozo1, J. C. et al.; 1University of Messina, Messina, ITALY.

OP-530 Secondary primary malignancy and radioiodine administration in differentiated thyroid cancer patients: a second look E. Volpe1, J. C. et al.; 1University of Messina, Messina, ITALY.

OP-531 Experienced surgeons make the difference in Thyroid Cancer management J. Kroutsikos1, S. Giannakos2, J. Kokkinis3, F. Paschos4, P. Pantazis5, M. Stathopoulou6, T. Papageorgiou7
1Department of Nuclear Medicine, 401 General Military Hospital; 2Henry Dunant Hospital Center, Athens, GREECE; 3Nuclear Medicine Department, Henry Dunant Hospital Center, Athens, GREECE.

OP-532 Incremental Prognostic Value of Circulating CD4+ T cell Subsets in the First 131I Treatment of Papillary Thyroid Carcinoma D. Fan1, Z. Shu1, S. Zhang2, X. Yue1, Z. Cheng1, X. Liu1, J. Zhang1, R. Hu1, L. Li1, W. Lu1, K. Liu1, X. Wang1, Y. Cheng1, X. Li1, Z. Wu1, W. Liu1, L. Ji1
1First Hospital of Shanxi Medical University, Taiyuan, CHINA; 2Department of Oncology, Shanxi Medical University, Taiyuan, CHINA.

OP-533 Identification of risk factors for recurrence of differentiated thyroid cancer A. Szechner1, V. Radlinski2, V. Vasylyev3
1Radiology Department, University General Hospital, Otwock, POLAND, 2Centre for Nuclear Research, Radioisotope Centre POLATOM, Otwock, POLAND; 3Department of Nuclear Medicine, University Hospital Krakow, Krakow, POLAND.

OP-534 Nuclear Haematology - A Clinical Overview A. Santos1, H. Grimsby2, J. de Carvalho3, E. F. P.; 1Department of Nuclear Medicine, Almada, PORTUGAL.

OP-535 Radiomics in Haematological Malignancies K. Fobian1
Department of Centre Engineering and Information Technology, Faculty of Electrical Engineering and Informatics, Budapest University of Technology and Economics, Budapest, HUNGARY.

OP-536 Working with New Protocols - From PET-FDG to FAPI? J. Doraku1, S. J. et al.; 1Hospital Sacco Cuore Don Calabria, Department of Nuclear Medicine and Radiological Therapy; Negrar di Valpolicella, Verona, ITALY.

OP-537 SIRT is a Good Candidate for Dosimetry Lead Treatment M. Rodriguez Fraile1, R. Rodriguez1, J. Rodriguez1, G. Algaba1, M. Rodriguez1
1Clinica Universidad de Navarra, Department of Nuclear Medicine, Pamplona, SPAIN.

OP-538 DoS Effect Relationships A. Leviliman
Department of Nuclear Medicine, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, BELGIUM.

OP-539 The EANM Clinical Dosimetry Guidelines C. Broeck1, 2, J. Koutsikos1; 1Centre de Lutte contre le Cancer Eugene Marquis, University of Rennes; Inra, Inserm, Institute Nutrition, Metabolismes et Cancer, Rennes, FRANCE.

OP-540 Ho 166 - A Way to Bright the Future R. Sciuto1, A. Campenni1
1Nuclear Medicine Unit, IRCCS Regina Elena National Institute, Rome, ITALY.

TOP Trials Session 3: New Radiopharmaceutical Trials

OP-541 HER2-targeted 18F-FDIO Theranostics for colorectal cancer D. Albrecht1, J. Litscher1, K. Stocker1, A. Pichlmeier2, M. J. et al.; 1Medical University Innsbruck, Innsbruck, AUSTRIA; 2Bayer Schering Pharma AG, Berlin, GERMANY.

OP-542 Safety and Feasibility of Rhenium-186 Nanoliposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1/2a Trial N. LaFrance1, A. Brennen2, M. Yousef2, A. Brau2, W. Phillips2, M. Hedges3
1Norman LaFrance, Newtown, PA, UNITED STATES OF AMERICA; 2PLUS Therapeutics, San Antonio, TX, UNITED STATES OF AMERICA; 3University of Texas, Dallas, TX, UNITED STATES OF AMERICA; 4Case Western Reserve University, Cleveland, OH, UNITED STATES OF AMERICA.

OP-543 Next generation PET/CT imaging in meningioma using the novel 68CuCE2 receptor-localising radiolabelled peptide probe for personalized diagnosis and therapy of patients with metastatic thyroid cancer L. Leuzic1, P. Klesne2, A. Raketa2, P. Ehrats, C. Distelroth1, R. P. et al.; 1Institute of Nuclear Medicine, University Medical Center Ljubljana, Ljubljana, SLOVENIA; 2Department of Nuclear Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.

OP-544 PET and PET/PM imaging with 18F-TVH in patients with pancreatic cancer – First clinical experience J. Rehm1, J. Koster2, A. Vincent3, N. P.; 1Klinik und Poliklinik für Nuklearmedizin, Universitätsozentrum Dresden, Dresden, GERMANY; 2TRIMT GmbH, Radeberg, GERMANY.

OP-545 final oral results of a GRAN C-MEC phase 1 clinical trial using a novel CCK2 receptor-localising radiolabelled peptide probe for personalized diagnosis and therapy of patients with metastatic thyroid cancer L. Leuzic1, P. Klesne2, A. Raketa2, P. Ehrats, C. Distelroth1, R. P. et al.; 1Institute of Nuclear Medicine, University Medical Center Ljubljana, Ljubljana, SLOVENIA; 2Department of Nuclear Medicine and Health Sciences, University of Antwerp, Wilrijk, BELGIUM.
Tuesday, October 18, 2022, 08:00 - 09:30

Hall 113

LIPS Session 9 - Oncology & Theranostics Committee: Tricky Cases in NET and Digestive Tract Oncology - Interactive Session

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: Seeing the Brain from All Angles

Tuesday, October 18, 2022, 08:00 - 09:30

Hall 114

M2M Track - TROP Session: Evaluating brain from all angles

Tuesday, October 18, 2022, 08:00 - 09:30
### Oral Session: Metastatic Cell Clear Renal Cancer: Can It Replace 18F-FDG PET?

- **M. H. A. A. B. C. D. S. E. M. F. G. H. I. J. K. L.**

#### This is the place for "Ga-PSMA-11 PET Angiogenesis Imaging in Metastatic Clear Cell Renal Cancer: Can It Replace 18F-FDG PET?"

- **M. H. A. A. B. C. D. S. E. M. F. G. H. I. J. K. L.**

#### Development and Validation of a Radiomic Model For the Diagnosis of Dopaminergic Denervation on 18F-DOPA PET/CT

- **V. H. C. M. S. T. U. V. W. X. Y. Z.**
- **M. H. A. A. B. C. D. S. E. M. F. G. H. I. J. K. L.**

#### Prediction of Cognitive Decline in Parkinson's Disease using Deep and Handcrafted Radiomics Features

- **M. H. A. A. B. C. D. S. E. M. F. G. H. I. J. K. L.**

#### Feasibility of Artificial Intelligence in Predicting Early Phenotype Conversion of REM Sleep Behavior Disorder

- **M. H. A. A. B. C. D. S. E. M. F. G. H. I. J. K. L.**

#### Development of AI based Delay Images Generation Technique using Early 18F-FET PET Imaging

- **M. H. A. A. B. C. D. S. E. M. F. G. H. I. J. K. L.**
OP-597

Unexpected Images during Parathyroid Scintigraphy
J. Wu, L. Gong, Y. Jing
Second Affiliated Hospital, Nanchang University, Nanchang, CHINA.

OP-598

Do analytical parameters influence the sensitivity and specificity of parathyroid scintigraphy in patients with nephrolithiasis?

1210
Tuesday, October 18, 2022, 08:00 - 09:30
Hall 116

Technologists' Oral Presentations 3: Artificial Intelligence and Technical Novelties

OP-599

Analysis Of PET Radiometric Features With Different Reconstruction Algorithms
P. Devedzić, Y. Viskovic, S. Choudhary, A. Jha, V. Rangarajan; Advanced Center for Treatment Research and Education in Cancer, Mumbai, India, MUMBAI, India, MUMBAI, INDIA, MUMBAI, INDIA.

OP-600

Occupational radiation exposure of nuclear medicine personnel during administration of 18f-Lu

OP-601

DOTATATE with two different administration devices
S. Woudms, C. Myrianger-Vaag, D. M. V. de Vries-Huizing, J. Sutherland-van den Heuvel, M. P. M. Stolk, M. Sannenborn-Bol, E. A. Aalberse, Netherlands Cancer Institute, Amsterdam, NETHERLANDS.

OP-602

Estimating attenuation-corrected PET images using GAN from non-attenuation-corrected PET images
K. Nishigami; Biomedical Science and Engineering, Hokkaido University Graduate School, Sapporo, JAPAN.

OP-603

Introduction of a new dosimetry software for selective internal radiation therapy (SIRT) using 90 microspheres in liver tumors and impact on clinical practice
M. Mendes De Corvalho, D. M. da Mota, J. C. Pires, P. Emite Ferreira, N. Schaefer, S. Boughdad; Clinic for Nuclear Medicine, City Hospital Bayreuth, Bayreuth, DEUERLAND.

1301
Tuesday, October 18, 2022, 09:45 - 11:15
Auditorium

CMF 10 - Oncology & Theranostics + Physics Committee: Quantitative SPECT, PET and Standardisation

OP-604

Evaluation Of Image Quality Of BSREM Reconstruction Algorithm And Performance Comparison With Conventional Reconstruction Method
P. Devedzić, V. Savvat, A. Jha, V. Rangarajan; Advanced Center for Treatment Research and Education in Cancer, Tata Memorial Centre, Mumbai, India, MUMBAI, MUMBAI, INDIA.

OP-605

The optimal acquisition time for 123I-I-FP-CIT DAT-scan with AnyScan trip SPECT-CT with unique multi-pine-hole collimators
G. Thönes, C. Paulsen, S. Olsén, R. de Nijs, L. H. Pinborg, G. M. Knudsen; Neurology Research Unit 6000, Aarhus University, 2100 Copenhagen, DENMARK.

1303
Tuesday, October 18, 2022, 09:45 - 11:15
Hall 113

LIPS Session 10 - Inflammation & Infection Committee: 111IFDG PET/CT Treatment Response Assessment in Inflammatory Diseases

OP-606

The Role of PET in Treatment Monitoring of Large Vessel Vasculitotics and Retropertitoneal Fibrosis
L. C. Gormsen; Aarhus University Hospital, Department of Nuclear Medicine and PET Centre, Aarhus, DENMARK.

OP-610

Clinical Use Cases
L. F. de Goes-Oei; Leiden University Medical Center and Professor in Molecular Imaging, Leiden, NETHERLANDS.

OP-611

MRI is Sufficient in the Management of Patients with Brain Tumours
M. Smits; Erasmus MC, Department of Radiology and Nuclear Medicine, Rotterdam, NETHERLANDS.

ORAL SESSIONS | FINAL PROGRAMME
Joint Symposium 5 - Physics & Oncology & Theranostics / ESTRO Committee: Imaging for Radiotherapy Applications

**OP-617** Advances of PET Combined with Anatomical Imaging in Radiation Oncology
E. Troost
Chair of Department of Radiation Therapy and Radiology Oncology, University Hospital Carl Gustav Carus, Dresden, GERMANY

**OP-618** Practical Implementation of Nuclear Medicine Imaging in Radiotherapy
F.L. Andersen
Righospitalet, Department of Clinical Physiology, Nuclear Medicine & PET, Copenhagen, DENMARK

**OP-619** Challenges of Combining Molecular Radiotherapy and External Beam Radiotherapy
J. Costanzo
National Institute of Health and Medical Research (INSERM), Montpeller Cancer Research Institute, Montpellier, FRANCE

---

**1304**

Tuesday, October 18, 2022, 09:45 - 11:15
Hall 114

Clinical Oncology Track - TROP Session: Lymphoma

**OP-629** Total Metabolic Tumor Volume And Tumor Dissemination Calculated From PET/CT Scan Before First Line Therapy Are Predictors Of Outcome In Patients With Follicular Lymphoma
R. Durma1, L. Günem1, S. Chaouev1, S. Peano1, A. Franceschetti1, B. Bergsland2, F. Folland3, A. Peintz4, C. Grupp5, A. Pulim Jr6, M. Meuff7, L. Fanini8, M. Tan9, L. Bocon9, G. Muracca10, B. Falini11, F. Balleni12, P. M. Stefan13, S. M. A. Bili14, G. Pienta15, M. Mann16, L. Mascheroni17, M. Federspich18, L. Lunardi19, A. Versini20, A. USLSC-IRCCS di Reggio Emilia, Reggio Emilia, ITALY, "PET program in Clinical and Experimental Medicine" (EEM), University of Modena and Reggio Emilia, Modena, ITALY, "ASST Monza Ospedale S. Gerardo, Monza, ITALY "Department of Medical Physiology, Santa Croce e Carle Hospital, Cuneo, ITALY, "Department of Nuclear Medicine, Santa Croce e Carle Hospital", Cuneo, ITALY, "Department of Oncology and Hematology, Modena Cancer Center, Unit of Nuclear Medicine, University of Modena and Reggio Emilia, Modena, ITALY, "INMI National Cancer Institute, Rome, ITALY, "National Institute of Health and Medical Research (INSERM), Montpellier Cancer Research Institute, Montpellier, FRANCE, "Preclin. Research in Oncology, Montpellier, France, "Lyon, BELGIUM, "First University Brussels, Brussels, BELGIUM

**OP-628** In-vitro dosimetry of Phosphorus-32 patches for "NUCLEAR" Cancer Center, University of Modena and Reggio Emilia, Modena, ITALY, "S. Lundsten", "Internalization of radionuclides in tumor cells: A model of cancer associated fibroblasts", "Joint Symposium 5 - Physics + Oncology & Theranostics / ESTRO Committee: Imaging for Radiotherapy Applications", "University of British Columbia, Vancouver, BC, CANADA, "Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, "Department of Chemistry, Simon Fraser University, Vancouver, BC, CANADA, "Functional Imaging, BC Cancer Research Institute, Vancouver, BC, CANADA, "Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, "Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, "Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, "Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, "Department of Hematology, University Hospital Carl Gustav Carus, Dresden, GERMANY, "Institute of Biomedical Engineering and Physics, University of Modena and Reggio Emilia, Modena, ITALY, "University of Modena and Reggio Emilia, Modena, ITALY, "INMI National Cancer Institute, Rome, ITALY, "National Institute of Health and Medical Research (INSERM), Montpellier Cancer Research Institute, Montpellier, FRANCE, "Preclin. Research in Oncology, Montpellier, France, "Lyon, BELGIUM, "First University Brussels, Brussels, BELGIUM

---

**1305**

Tuesday, October 18, 2022, 09:45 - 11:15
Hall 221

Cutting Edge Science Track - TROP Session: Radiobiology

**OP-626** Effect of Tumor Receptor Density on Time Integrated Activity of Radiotherapeutic Pharmaceuticals in Tumors via Physiologically based Pharmacokinetic Modeling
N. Shahoulifar1, M. Soltani2, F. Menadi-Kashkari2, B. Saboury2, A. Raimen3, M. N. Topan1, University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF, "Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON, CANADA, "Center for Biotechnology and Bioengineering (CBB), University of Waterloo, Waterloo, ON, CANADA, "Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, CANADA, "Department of Radiology and Physics, University of British Columbia, Vancouver, BC, CANADA, "Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, "Department of Health Sciences, Division TRUMVE, Vancouver, BC, CANADA, "National Cancer Institute, Rome, ITALY, "National Institute of Health and Medical Research (INSERM), Montpellier Cancer Research Institute, Montpellier, FRANCE, "Preclin. Research in Oncology, Montpellier, France, "Lyon, BELGIUM, "First University Brussels, Brussels, BELGIUM

**OP-625** Absorbed dose microdistribution of 11Lu and 233Ac in a model of cancer associated fibroblasts
J. Tranfe1, S. Palmi1, S. A. Greaves1, F. Y. Feng1, J. A. Hope1, University of California San Francisco, San Francisco, CA, UNITED STATES OF AMERICA, "University of Gothenburg, Gothenburg, SWEDEN, "University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA

**OP-624** Preclinical characterization of "Lu-DOTATATE binding and internalization
S. Lundsten2, H. Berglund3, J. Buysi3, M. Nestor3, S. Bandara3, "University of British Columbia, Vancouver, BC, CANADA, "Department of Radiology and Physics, University of British Columbia, Vancouver, BC, CANADA, "Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, CANADA, "Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, "National Cancer Institute, Rome, ITALY, "National Institute of Health and Medical Research (INSERM), Montpellier Cancer Research Institute, Montpellier, FRANCE, "Preclin. Research in Oncology, Montpellier, France, "Lyon, BELGIUM, "First University Brussels, Brussels, BELGIUM

---

**OP-623** A multi-region model of a mouse kidney for preclinical internal dosimetry of beta- and alpha-particle emitting radionuclides
C. Saldarriaga Vargas1,2, L. Studenov1, M. D’Hyvernet1, V. Couriell1, P. Laven1, "Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM, "First University Brussels, Brussels, BELGIUM

**OP-622** Biological response of cancer-associated fibroblasts (CAF) to Targeted Radiolucidation Therapy of pancreatic cancer microenvironment
L. Ordas1, M. D’Hyvernet1, T. Lahoutte1, S. Paty1, J. Pouget1, "Institut de Recherche en Cancérologie, Montpellier, France, "Preclin. Research in Oncology, Montpellier, France, "Lyon, BELGIUM

---

**1306**

Tuesday, October 18, 2022, 09:45 - 11:15
Hall 117

Clinical Oncology Track - TROP Session: Lymphoma

**OP-630** Metabolic Tumor Volume and Tumor Dissemination Calculated From PET/CT Scan Before First Line Therapy Are Predictors Of Outcome In Patients With Follicular Lymphoma
R. Durma1, L. Günem1, S. Chaouev1, S. Peano1, A. Franceschetti1, B. Bergsland2, F. Folland3, A. Peintz4, C. Grupp5, A. Pulim Jr6, M. Meuff7, L. Fanini8, M. Tan9, L. Bocon9, G. Muracca10, B. Falini11, F. Balleni12, P. M. Stefan13, S. M. A. Bili14, G. Pienta15, M. Mann16, L. Mascheroni17, M. Federspich18, L. Lunardi19, A. Versini20, A. USLSC-IRCCS di Reggio Emilia, Reggio Emilia, ITALY, "PET program in Clinical and Experimental Medicine" (EEM), University of Modena and Reggio Emilia, Modena, ITALY, "ASST Monza Ospedale S. Gerardo, Monza, ITALY "Department of Medical Physiology, Santa Croce e Carle Hospital, Cuneo, ITALY, "Department of Nuclear Medicine, Santa Croce e Carle Hospital", Cuneo, ITALY, "Department of Oncology and Hematology, Modena Cancer Center, Unit of Nuclear Medicine, University of Modena and Reggio Emilia, Modena, ITALY, "INMI National Cancer Institute, Rome, ITALY, "National Institute of Health and Medical Research (INSERM), Montpellier Cancer Research Institute, Montpellier, FRANCE, "Preclin. Research in Oncology, Montpellier, France, "Lyon, BELGIUM, "First University Brussels, Brussels, BELGIUM

**OP-629** Total Metabolic Tumor Volume And Tumor Dissemination Calculated From PET/CT Scan Before First Line Therapy Are Predictors Of Outcome In Patients With Follicular Lymphoma
R. Durma1, L. Günem1, S. Chaouev1, S. Peano1, A. Franceschetti1, B. Bergsland2, F. Folland3, A. Peintz4, C. Grupp5, A. Pulim Jr6, M. Meuff7, L. Fanini8, M. Tan9, L. Bocon9, G. Muracca10, B. Falini11, F. Balleni12, P. M. Stefan13, S. M. A. Bili14, G. Pienta15, M. Mann16, L. Mascheroni17, M. Federspich18, L. Lunardi19, A. Versini20, A. USLSC-IRCCS di Reggio Emilia, Reggio Emilia, ITALY, "PET program in Clinical and Experimental Medicine" (EEM), University of Modena and Reggio Emilia, Modena, ITALY, "ASST Monza Ospedale S. Gerardo, Monza, ITALY "Department of Medical Physiology, Santa Croce e Carle Hospital, Cuneo, ITALY, "Department of Nuclear Medicine, Santa Croce e Carle Hospital", Cuneo, ITALY, "Department of Oncology and Hematology, Modena Cancer Center, Unit of Nuclear Medicine, University of Modena and Reggio Emilia, Modena, ITALY, "INMI National Cancer Institute, Rome, ITALY, "National Institute of Health and Medical Research (INSERM), Montpellier Cancer Research Institute, Montpellier, FRANCE, "Preclin. Research in Oncology, Montpellier, France, "Lyon, BELGIUM, "First University Brussels, Brussels, BELGIUM

---
Clinical Oncology Track - TROPSE Session: Prostate Staging

**OP-638** Complimentary role of "Ga"-GRPR PET/CT and "Ga"-PSMA PET/CT in initial diagnosis of prostate cancer

**OP-639** Predictive value of extra prostatic disease detection by PSMA PET for BCR free survival in patients with radical prostatectomy: follow up analysis of a multicenter prospective phase 3 imaging trial

**OP-640** Multimetric MRI and "Tc"-PSMA-1007 PET to detect local prostate cancer: a prospective comparative study with histopathology

**OP-641** A prospective head-to-head comparison of "Ga"-Ga-Pt-109 and "Ga"-Ga-PSMA-617 PET in patients with prostate cancer

**OP-642** Association between "Ga"-PSMA PET/MRI and circulating Biomarkers in High-Risk Prostate Cancer: an Experorative Study

**OP-643** Use of F-18 PSMA SPECT/CT is a valuable alternative to "Ga"-PSMA PET/CT in prostate cancer patients

**OP-644** Phase I evaluation of ("Tc"-Te-maSSS-Pd02-MM2) for imaging of GRPR expression

**OP-645** PSMA density predicts pathological and oncological outcomes in patients submitted to 18F-PSMA-1007 PET/CT for the primary staging of unfavourable intermediate and high-risk prostate cancer

**OP-646** Effects of furomide and tracer selection on urinary activity and peri-bladder artefacts in PSMA PET/CT: a single-centre retrospective study

**OP-647** Assessment of incidental Cardiac uptake in Bone Scintigraphy across Spain. ECCINGO Study

**OP-648** Outcomes in patients with high-risk prostate cancer treated with Patisiran. An early Marker of Treatment Regression of Cardiac Bone-Tracer Uptake in Patients

**OP-649** Quantitative assessment of myocardial perfusion by dynamic SPECT with 99mTc-

**OP-650** Heart-to-femoral diastolic ratio: an alternative method to differentiate cardiac transhyretin amyloidosis from light chain amyloidosis

**OP-651** Assessment of incidental Cardiac uptake in Bone Scintigraphy across Spain. ECCINGO Study

**OP-652** Incidence, epidemiology, clinical presentation and prognosis of cardiac amyloidosis in patients with systemic light chain amyloidosis

**OP-653** Noninvasive Screening Of Thrasityrein Cardiac Amyloidosis in Patients With Spinal Stenosis
OP-654Quantification of right ventricular amyloid with 99mTc-DPD in patients with transthyretin amyloidosis: Comparison with Cardiac MR and biomarkers
M. Zhao, A. Calabretta, X. Li, M. Hacker
*Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, CHINA; **Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA

OP-655The Value of Left Ventricular Regional Dysynchrony as Cardiac Resynchronization Therapy Response Predictors in Patients with Heart Failure
K. Zavadovska, A. Latshka, V. Sazunikh, S. Sazonova, S. Popov
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION

1401

Tuesday, October 18, 2022, 11:30 - 13:00
Auditorium

Plenary 4: Superfluous, Controversial and Luxury Issues in Nuclear Medicine

OP-656Introduction by Chairpersons

OP-657Really, More New Radiolabelled Tracers? S. Terry
King’s College London, School of Biomedical Engineering & Imaging Sciences, London, UNITED KINGDOM

OP-658Nuclear Neurology - Clinical Reality or Eternal Promise? S. Morbelli
San Martino Hospital, Department of Health Sciences, University of Genoa, Genoa, ITALY

OP-659Theranostics - Treat or Trick? J.J. Cerri
Quantitative Diagnostic and Therapeutic PET/CT Department, Curitiba, BRAZIL

OP-660Personalized Medicine - Every Man Has Own PSMA! H.D. Zacho
Asbjoerg University Hospital, Department of Clinical Medicine, Asbjoerg, DENMARK

OP-661Dosimetry - Necessary or Redundant? S. Peters, Radboudumc, Department of Radiation and Nuclear Medicine, Nijmegen, NETHERLANDS

OP-662Radiomics - Way to the Future or Useless Fancy Name? X. Bouvard-Chollet
Centre d’Imagerie Biomedica de La Roja (CIBIR), Department of Nuclear Medicine, Logroño (La Rioja), SPAIN

OP-663Summary by Chairpersons

1501

Tuesday, October 18, 2022, 15:00 - 16:30
Auditorium

CME 11 - Neuroimaging Committee: Molecular Imaging and Fluid Biomarkers in Alzheimer’s Disease - A Nice Couple

OP-664Fluid markers in AD - Is it a Revolution? M. Otto
Universitätsklinikum Martin Luther Universität Halle-Wittenberg Klinik und Poliklinik für Neurologie, Halle, GERMANY

OP-665PET and Fluid Markers Compared A. Pichet Binette
Lund University, Lund, SWEDEN

OP-666From a Comparison to an Integrated Algorithm N. Franzen
Institute for Smoke and Dementia Research, LMU University Hospital, Alzheimer’s Disease Neuroimaging Group, Munich, GERMANY

1502

Tuesday, October 18, 2022, 15:00 - 16:30
Hall 112 (Arena)

Debate 4 - Cardiovascular Committee: Myocardial Perfusion Imaging with PET – Ready for Clinical Use?

OP-667Yes - Ready for Clinical Use J. Knust
Tartu University Hospital, Tartu PET Centre, Tartu, FINLAND

OP-668No - Not Ready for Clinical Use F. Bengel
Medizinische Hochschule Hannover, Klinik für Nuklearmedizin, Hannover, GERMANY

OP-669L. Imbert
CHU Nancy Hospital Brabois, Nuclear Medicine Department, Vandoeuvre les Nancy, FRANCE

OP-670Characteristics and Immunohistochemistry Expression M. Castello-Martin
Champalimaud Foundation, Pathology, Lisbon, PORTUGAL

OP-671PSMA Radiopharmaceuticals, Physiological Distribution and Pathologic Uptake P. Pickington Wolf
Department of Nuclear Medicine, Hospital Universitario 12 de Octubre, Madrid, SPAIN

OP-672PSMA Uptake in Non-Prostate Tumours F. Kleburg
Leiden University, Radiology Department, Leiden, NETHERLANDS

OP-673PSMA Uptake in Non- Oncologic Entities L. Vercellini
Hôpital Saint-Louis, Nuclear Medicine, Paris, FRANCE

OP-674Discussion

1504

Tuesday, October 18, 2022, 15:00 - 16:30
Hall 114

Joint Symposium 6 - Oncology & Theranostics Committee / ESMO: Integrated Theranostics

OP-675Hot-Hot Theranostics (e.g. Iodine, Dotatoc, PSMA, FAPI) A.K. Buck
Universitätssklinikum Würzburg, Department of Nuclear Medicine, Würzburg, GERMANY

OP-676Hot, „Cold“ Theranostics (e.g. Trastuzumab, Bevacizumab, Pembrolizumab, Atezolizumab, TGFβ-antibody) A. Brouwers,
Universar Medisch Centrum Groningen, Department of Nuclear Medicine, Groningen, NETHERLANDS

OP-677Therapy Response Monitoring of Immunotherapy C. Caramella,
Hôpital Marie Lannelongue, Imagene medica, Paris, FRANCE

OP-678Summary by Chairpersons

1503

Tuesday, October 18, 2022, 15:00 - 16:30
Hall 113

LIPS Session 11 - Oncology & Theranostics Committee: Tricky Cases in Prostate Imaging Interactive Session

OP-679PSMA Characteristics and Immunohistochemistry Expression M. Castello-Martin
Champalimaud Foundation, Pathology, Lisbon, PORTUGAL

OP-680Joint Symposium 6 - Oncology & Theranostics Committee / ESMO: Integrated Theranostics

OP-681Cutting Edge Science Track - TROP Session: Advanced Data Analysis

OP-682Fast algorithms for motion correction (FALCON) for fully-automated construction of tracer independent total-body PET/CT normative database using differomorphisms S. Guttschmayer, D. Muzaf, M. Hacker, D. Ferran, S. Schucht, N. Hewage, T. Beyer, L. Shiyam Sundar, QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, *Department of Radiology, UC Davis, Davis, CA, UNITED STATES OF AMERICA, *Department of Biomedical Engineering. UC Davis, Davis, CA, UNITED STATES OF AMERICA, *Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA

OP-683Data-driven gating-based Auto Attenuation Mismatch Correction for Whole-body PET K. Sui, R. Johnson, J. Boubout, T. Paal, KG Healthcare, Wasserach, MI, UNITED STATES OF AMERICA, KG Healthcare, Harla, ISRAEL, *Department of Imaging Physics, M. D. Anderson Cancer Center, University of Texas, Houston, TX, UNITED STATES OF AMERICA


OP-685ENHANCE-PET: Exploring the human functional connectome using total-body (18F/FGD-PET imaging D. Ferrar, A.D. Badway, & Spencer, S. Cherry, M. Hacker, T. Beyer, L. Shiyam Sundar, *Quantitative Imaging and Medical Physics (QIMP) Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, *Department of Radiology, UC Davis, Davis, CA, UNITED STATES OF AMERICA, *Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA

OP-686Towards holistic assessment of human physiology: Fully-automated construction of tracer independent total-body PET/CT normative database using differomorphisms S. Guttschmayer, D. Muzaf, M. Hacker, D. Ferran, S. Schucht, N. Hewage, T. Beyer, L. Shiyam Sundar, QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, AUSTRIA, *Wayne State University, Department of Pediatrics, Detroit, MI, UNITED STATES OF AMERICA, *Department of Biomedical Imaging and Image-Guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, *Astellas Medical Solutions USA Inc., Haltamn Estates, IL, UNITED STATES OF AMERICA, *Taukerleave Healthcare GmbH, Erlangen, GERMANY

OP-687OP-688Fast algorithms for motion correction (FALCON) for fully-automated motion correction of dynamic total-body 18F-FDG PET/CT studies L. Shiyam Sundar, S. Guttschmayer, A. Calabro, A. Selfin, J. Yu, L. Nasiri, T. Holdkrate, S.R. Cherry, B.A. Spencer, R.D. Badwa, T. Beyer, O. Musali, KG Healthcare, Wasserach, MI, UNITED STATES OF AMERICA, KG Healthcare, Harla, ISRAEL, *Department of Imaging Physics, M. D. Anderson Cancer Center, University of Texas, Houston, TX, UNITED STATES OF AMERICA
OP-717 Preparation of the Stem Cells
A. Sotam
University medical centre Ljubljana, Dept. for Nuclear Medicine, Ljubljana, SLOVENIA

OP-718 Summary by Chairpersons
1601

Tuesday, October 18, 2022, 16:45 - 18:15
Auditorium

CME 12 - Radiopharmaceutical Sciences Committee: Optimizing Radiolabeled Biomolecules for Imaging and Therapy - The Secrets Revealed

OP-719 Albumin Binders and Their Role in Radiopharmaceutical Development
C. Müller
Paul Scherrer Institute, Villigen, SWITZERLAND

OP-720 The Role of Chelators in Design and in Vivo Behaviour of Radiopharmaceuticals
M. Ma
Kings College London, Department of Imaging Chemistry and Biology, London, UNITED KINGDOM

OP-721 Strategies to Reduce Kidney Uptake of Radiolaabeled Biomolecules
R. Wodké
Heinrich-Heine-Universität-Düsseldorf, Institute of Radiopharmaceutical Cancer Research, Düsseldorf, GERMANY

OP-722 Preparing Strategies to Optimize Pharmacokinetics
M. Street
Vrije Universiteit Brussel, Dept. of Medical Imaging, Brussels, BELGIUM

Tuesday, October 18, 2022, 16:05 - 17:35

Hall 14

M2M Track - TROP Session: New Tracers - From Scratch to Automated Synthesis

OP-723 Protocol Optimization of Auxiliary CT in Hybrid Imaging
M. Burniston
Barts Health NHS Trust, Department of Nuclear Medicine Physics, London, UNITED KINGDOM

OP-724 Practical Aspects of Radiation Protection When Using Hybrid Modalities
E. Prieto
Universidad Navarra, Clínica Universidad de Navarra, Medical Physics Department, Pamplona, SPAIN

Tuesday, October 18, 2022, 16:05 - 17:35

Hall 114

1604

OP-725 Small Molecule-Based Radiotracers for PET Imaging of PD-L1 With Copper-64
F. Knutze, C. K. Donat, M. Ullrich, K. Kopka, S. Stadlbauer
Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, GERMANY

OP-726 Development of a novel 18F-labelled PET radioligand - C-BIO-181957F8 for the detection of O-GlCNacase (Oga) enzyme in the living brain
University medical centre Ljubljana, Dept. for Nuclear Medicine and Molecular Imaging, Ljubljana, SLOVENIA

1508

Tuesday, October 18, 2022, 15:00 - 16:30
Hall 212

Special Symposium 1 - Radiopharmaceuticals Sciences Committee / EU Commission: Radiopharmaceuticals Regulations - Quo Vadis?

OP-706 TBA
OP-707 TBA
OP-708 In-house Preparation and Manufacturing of Radiopharmaceuticals With and Without Market Authorization - Swiss Regulation as Example
R. Hesselmann
Federal Office of Public Health (OFPH), Bern, SWITZERLAND

OP-709 Quality Requirements for Radiopharmaceuticals in Marketing Authorization and Clinical Trial Applications
E. Moya Sánchez
Spanish Agency of Medicines and Medical Devices (AEMPS), Chemical and Pharmaceutical Division, Medicines for Human Use Department, Madrid, SPAIN

OP-710 In-house Prepared Radiopharmaceuticals - Essential but not Sufficiently Available
C. Diersteinforto
Medical University Innsbruck, Department of Nuclear Medicine, Innsbruck, AUSTRIA

Tuesday, October 18, 2022, 16:05 - 17:35

Hall 116

CTE 6 - Technologists Committee: Stem Cells in Nuclear Medicine

OP-711 Preparation of the Stem Cells
A. Sotam
University medical centre Ljubljana, Dept. for Nuclear Medicine, Ljubljana, SLOVENIA

OP-712 Summary by Chairpersons
1602

Tuesday, October 18, 2022, 16:45 - 18:15

Hall 112 (Arena)

Challenge the Expert 4 - Oncology & Theranostics Committee: Expert vs Team Essen: PET/CT in Real Life

OP-727 Evaluation of two novel pharmacophores for the design of FAP targeting PET tracers
K. Bedrich
BC Cancer Research Center, Vancouver, BC, CANADA

OP-728 New synthesis pathway and automation in different systems of [18F]-4-amino-fluorobenzoic acid for infection imaging
Nuclear Medicine Department, Clínica Universidad de Navarra, Pamplona, SPAIN, Radiopharmacy Unit, Clínica Universidad de Navarra, Pamplona, SPAIN, Radiopharmacy and Nuclear Imaging Group, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), San Sebastian, SPAIN

OP-729 Development Of A New Synthesis And Quality Control System Of A CCB22-Targeted Molecular Imaging Probe
S. Mignoli, E. Masselin, M. Scallion, G. Baldari, M. Valsecchi, L. Ruffini
Nuclear Medicine Division, Azienda Ospedaliera Universitaria di Parma, Parma, ITALY, Atenery Unit, Azienda Ospedaliera Università di Parma, Parma, ITALY

OP-730 Rapid high-yield enzymatic synthesis of nca 6-18F fluorodopamine (6-18F[F]FDGA) for in vivo application
K. Bamminger1, C. Pante1, V. Nastarina1, M. Karasinski1, S. Russer1, L. Nois2, M. Windingh, R. Wisingh, M. Hasker1, V. Achter1, C. Vlaka2
Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA, UBLmed GmbH - Centre for Biomedical Research in Medicine, Graz, AUSTRIA, Department of Pharmaceutical Sciences, Division of Pharmaceutical Chemistry, University of Vienna, Vienna, AUSTRIA, Ludwig Boltzmann Institute Applied Diagnostics, Vienna, AUSTRIA, University of Vienna, Vienna Doctoral School in Chemistry (DoxSchem), Währinger Str. 42, 1090 Vienna, AUSTRIA

OP-731 Clinical Application of Auxiliary CT in Hybrid Imaging - More than Attenuation Correction and Co-Registration
T. van den Wyngaert
Sensor consultant UZA, Edegem, BELGIUM

OP-732 CDI, DL, SSDE & Co - How to Estimate and Optimize Patient Dose in Computed Tomography
K. Bacher
University Gent, Department of Human Structure and Repair, Gent, BELGIUM

Tuesday, October 18, 2022, 16:45 - 18:15
Hall 113

LIPS Session 12 - Radiation Protection + Physics Committee: CT Optimization in Hybrid Imaging Interactive Session

OP-733 Nuclear Medicine and Molecular Imaging, Leuven, BELGIUM.

OP-734 Hybrid Modalities

OP-735 Medical Physics Department, Navarra, SPAIN.

OP-736 Development of an novel 18F-labelled PET radioligand - C-BIO-181957F8 for the detection of O-GlcNAcase (Oga) enzyme in the living brain
University medical centre Ljubljana, Dept. for Nuclear Medicine and Molecular Imaging, Ljubljana, SLOVENIA

118

119
Cutting Edge Science Track - TROP Session: Predictive Artificial Intelligence

- "A Specific HPLC Method To Determine Residual HPES in F-FDG PET/CT Imaging" by M. Rahimpour, P. Bollell, W. Dechter, K. Goffen, M. Koole, PK Leuen, Leuven, BELGIUM, Amsterdam UMC, Amsterdam, NETHERLANDS, #2 Leuen, Leuven, BELGIUM


- "FDG PET/CT and Machine Learning for the prediction of lung cancer response to therapy" by H. Schmutz, P. Maufer, M. Conot, O. Humber, U. Cere-Herbaire, T. Matis, Innsbruck University, Innsbruck, Austria, #1 University of Innsbruck, Innsbruck, Austria, University Hospital of North Norway, Tromsø, NORWAY, #4 UTE The Arctic University of Norway, Tromsø, NORWAY, #5 Oslo University Hospital, Oslo, NORWAY, University of Sheffield, Sheffield, UK, #1 Queen’s University, Belfast, NORTHERLANDS, #2 Queen’s University, Belfast, NORTHERLANDS, #3 Queen’s University, Belfast, NORTHERLANDS


- "Clinical Oncology Track - TROP Session: NET Therapeutics and More"


- "FDG PET/CT and Machine Learning for the prediction of lung cancer response to therapy" by H. Schmutz, P. Maufer, M. Conot, O. Humber, University of Innsbruck, Innsbruck, Austria, #1 University of Innsbruck, Innsbruck, Austria, University Hospital of North Norway, Tromsø, NORWAY, #4 UTE The Arctic University of Norway, Tromsø, NORWAY, #5 Oslo University Hospital, Oslo, NORWAY, University of Sheffield, Sheffield, UK, #1 Queen’s University, Belfast, NORTHERLANDS, #2 Queen’s University, Belfast, NORTHERLANDS, #3 Queen’s University, Belfast, NORTHERLANDS


- "Cutting Edge Science Track - TROP Session: NET Therapeutics and More"


- "FDG PET/CT and Machine Learning for the prediction of lung cancer response to therapy" by H. Schmutz, P. Maufer, M. Conot, O. Humber, University of Innsbruck, Innsbruck, Austria, #1 University of Innsbruck, Innsbruck, Austria, University Hospital of North Norway, Tromsø, NORWAY, #4 UTE The Arctic University of Norway, Tromsø, NORWAY, #5 Oslo University Hospital, Oslo, NORWAY, University of Sheffield, Sheffield, UK, #1 Queen’s University, Belfast, NORTHERLANDS, #2 Queen’s University, Belfast, NORTHERLANDS, #3 Queen’s University, Belfast, NORTHERLANDS


- "Both"
OP-769 Tracking of radiolabelled mesenchymal stem cells after intrathecal transplantation in patients with traumatic spinal cord injury
L. Lesiak, A. Socam, F. Bogović, U. Siggert, M. Svenn, M. Jürg, University Medical Centre Ljubljana, Ljubljana, SLOVENIA

OP-770 Correlation between brain metabolism and headache in early breast cancer patients candidate for neoadjuvant chemotherapy
L. Antonucci, A. Arezzo, R. De Sanctis, C. Pini, C. Benvenuti, E. Jacobi, M. Gauda, A. Vigano, A. Santoro, A. Chia, M. Berrettini, R.CCS - Humanitas Research Hospital, Rozzano, ITALY; Humanitas University, Pieve Emanuele, ITALY; Hospital Don Gnocchi, Milan, ITALY; Department of Health Sciences, Genoa, ITALY; R.CCS Università Politecnica di Milano, Genoa, ITALY.

1608

Tuesday, October 18, 2022, 16:45 - 18:15
Hall 212

Special Symposium 2 - EANM / EU Commission: Getting to the Top QUPRANTR. A European Initiative to Improve Quality for Patients

OP-771 Introduction and Definitions
OP-772 Why Do We Need Clinical Audits?
TBA
TBA

OP-773 What Nuclear Medicine Can Learn from Radiology in Clinical Audits
A. Brady
Mercy University Hospital, Radiology, Cork, IRELAND

OP-774 Why Patients Need to be Fully Included
E. Biers
European Prestate Cancer Coalition (Europa Domini), Limburg, BELGIUM

OP-775a What Regulators/Authorities Want from Us
M. Vandecasteele
FANC - Federal Agency for Nuclear Control, Brussels, BELGIUM

OP-775b What Regulators/Authorities Want from Us
R. Hesseltann
Federal Office of Public Health (FOPH), Bern, SWITZERLAND

OP-776 Round Table Discussion
W. Wadsow
Medical University Vienna, Department of Biomedical Imaging and Image-guided Therapy (Division of Nuclear Medicine), Vienna, Austria

OP-785 History in the Making - From Basic Competencies to Higher Education
G. Testore
King's College London and GSTT Hospital, PET Centre, London, UNITED KINGDOM

OP-786 NMIs Higher Education in Europe L. Roldo Pereira
Madstorm and Turendge Wells NfO Trust, Madstorm, UNITED KINGDOM

OP-7E7 EQF? for NMIs Document - An Overview
A. Santos
Hospital Cu DeScobertas, Nuclear Medicine Department, Lisbon, PORTUGAL.

OP-788 Interactive Survey
A. Pietrzak
Pamuk University of Medical Sciences, Electroradiology Dept, Greater Poland Cancer Centre, Nuclear Medicine Dept, Pamuk, POLAND.

1701

Wednesday, October 19, 2022, 08:00 - 09:30
Auditorium

CME 13 - Translational Molecular Imaging & Therapy - Radiotherapeutic Sciences + Oncology & Theranostics Committee: First In Human Studies

OP-788 First In Human Dosimetry C. Stolke
Nuclear Medicine & PET physics Division of Radiology and Nuclear Medicine Oslo University Hospital, Oslo, NORWAY

OP-790 Potential Pitfalls in Neurotracer Development from Bench to Bedside
H. Shell
University Hospital Leipzig, Department of Nuclear Medicine, Leipzig, GERMANY.

OP-791 Important Aspects to be Taken into Account in Bringing a New Radiopharmaceutical to the Bedside
L. Garcia Varela
Medical Imaging Group, Health Research Institute of Santiago de Compostela (IDIS), Clinical University Hospital of Santiago de Compostela, Santiago de Compostela, SPAIN.

OP-792 First-In-Human Approaches of Nuclear Medicine (Probes in Inflammation / Infection
E. Appenzeller
Department of Medical Imaging, Radboud University Nijmegen Medical Center, Nijmegen, NETHERLANDS.

1702

Wednesday, October 19, 2022, 08:00 - 09:30
Hall 112 (Arena)

Debate 5 - Oncology & Theranostics + Physics Committee: PET/MR – Lights or Shadows?

OP-793 Lights
M. Picchio, C. Bezi, S. Ghezzi, Via Salute San raffaele University, Nuclear Medicine Department, R.CCS San Raffaele-Scientific Institute, Milan, ITALY.

OP-794 Shadows
B. Fueger, P.D. Steurer
Medical University of Vienna, Department of Biomedical Imaging and Image-guided Therapy, Division of General Radiology and Pediatric Radiology, Vienna, AUSTRIA.

1703

Wednesday, October 19, 2022, 08:00 - 09:30
Hall 113

LIPS Session 13: Case Report Session 2 - Others than Oncology

OP-796 Rasmussen encephalitis and brain 18F-FDG PET/CT: a clear answer for a tricky clinical case
M. Modelli, F. D'Amico, C. Di Nardo, C. Pizzuti, G. Tesei, A. Mora, A. Di Nicolao, S. Sena
Department of Neurosciences, Imaging and Clinical Sciences, “G. d’Annunzio” Chieti-Pescara University, Chieti, ITALY; Nuclear Medicine Unit, Santo Santo Hospital, Pescara, ITALY

OP-797 Utility of 18F FDG PET/CT in a Rare Case of Tolosa-Hunt Syndrome secondary to COVID 19 nasopharyngeal swab trauma, when MRI is inconclusive
A. Diva
MPHC Hospital, Nas Mumba, INDIA.

OP-798 Primary Hyperparathyroidism with severe bone involvement in an adolescent with an Ectodermal Parathyroid Adenoma: A case report
Nuclear medicine department, The Principal Military Hospital of Instruction of Tunis, Tunisie, TUNISIA.

1707

Wednesday, October 19, 2022, 08:00 - 09:30
Hall 113

O R A L  S E S S I O N S  |  F I N A L  P R O G R A M E

O R A L  S E S S I O N S  |  F I N A L  P R O G R A M E

EANM’22 — WORLD LEADING MEETING
OCTOBER 15 - 19, 2022

EANM’22 — WORLD LEADING MEETING
OCTOBER 15 - 19, 2022

EANM’22 — WORLD LEADING MEETING
OCTOBER 15 - 19, 2022

EANM’22 — WORLD LEADING MEETING
OCTOBER 15 - 19, 2022
EANM'22  WORLD LEADING MEETING  
OCTOBER 15-19, 2022

EANM'22  WORLD LEADING MEETING
OCTOBER 15 - 19, 2022
FINAL PROGRAMME | ORAL SESSIONS

ORAL SESSIONS | FINAL PROGRAMME

Medicine, Aarhus University, Aarhus, DENMARK,
Semiquantitative Analysis in Planning and Evaluation of
Unusually seen pattern of T99m-DPD soft tissue uptake in

1 OP-807

Case series of extra cardiac findings with increased
perfusion during clinical 18F-H2O PET myocardial
perfusion imaging

M. Jochumsen, L. E. Overgaard, M. H. Hendeløv, M. A. Madsen,
C. G. Hansen, T. B. Bakholdt

Department of Nuclear Medicine and PET Centre, Aarhus University
Hospital, Aarhus, DENMARK,
Department of Clinical Medicine, Aarhus University, Aarhus, DENMARK,
Department of Biomedicine, Aarhus University, Aarhus, DENMARK,

1 OP-802

Bone scan in asymptomatic patients with TTR gene
mutation screening andcarpe temperu

R. Bonfiglio, A. Pazzaglino, F. Mattarella, M. Sguezzato, G. Caporossi,
G. Longhi, G. Galbi, F. Taras

Nuclear Medicine, IRCCS, Azienda Ospedaliero-Universitaria
di Bologna, Bologna, ITALY,
Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY,
Division of Nuclear Medicine, Centro Euro Italiano di Oncologia
IRCCS, Milan, ITALY

1 OP-804

Role of 24-Hour “F-FDG PET/CT and Normalized
Semiquantitative Analysis in Planning and Evaluation of
Local Microwave Ablative Therapy in Lung Lesion

N. Kelemen, Z. Bánsághi, J. Mihalov, I. Međedová, I. Yeddes, M. Mn

Nuclear Medicine Department, Instituto Sahel Azazes, Tunís,
TUNISIA, Facultad de medicina de Tunís, Tunís, TUNISIA

1 OP-810

Incidental Diagnosis of Gastrointestinal Amyloidosis
Through 99mTc-D0P3D SPECT/CT Scintigraphy: Case Report

M. N. M. Amador, J. J. M. Vidal, J. L. M. Rozbaczylo,
C. Bilek, R. Z. K. Sato, F. A. B. Da Luz, R. S. Da Silva,
F. B. F. B. A. S. F. Do Luz, L. R. S. Da Silva, M. A. G. Dieudonne,
A. H. Vija, G. G. de la Fuente, I. Martínez-Amador

University of Ariel, Ariel, ISRAEL, 2 Department of Nuclear Medicine & Biophysics, Hadassah Medical
Center, Jerusalem, ISRAEL

1 OP-822

Performance study of a 360° CZT camera for dosimetry
planning step in SIRT treatment of liver cancer and liver
metastases

A. Krzyzanowski, S. Panisi Di Martino, L. Berardin, T. Mogno,
D. A. Biadik, M. Negri

Centre Léon Bérard, Lyon, FRANCE, CREATS, CNRS UMR5220;
Inserm U1044, INSA Lyon, Lycée Louis Lyon 1, Lyon, FRANCE

1 OP-823

Feasibility of 177Lu quantification with a 360° CZT gamma
camera

J. Badej, L. Vigneri, T. Baudard, P. Boissard, H. Rida,
A. Esculine, D. Samir

Centre Leon-Berard, Université de Lyon, Lyon, FRANCE,
CREATS, CNRS UMR5220, Université de Lyon, Lyon, FRANCE,
Centre Henri Bequerel, Rouen, FRANCE

1 OP-824

Towards accurate 18F PET activity quantification and
standardization of the gamma camera calibration protocol
S. Raskin, A. Chicheportiche, D. Gamield, A. Dabkowski, S. Ben-Haim

University of Ariel, Jerusalem, ISRAEL, Department of Nuclear Medicine & Biophysics, Hadassah Medical
Center, Jerusalem, ISRAEL, University of Ariel, Ariel, ISRAEL

1 OP-825

Effect of Kilovoltage and Quality Reference mAs on CT-
Based Attenuation Correction in 18F PET/CT Imaging: a
Phantom Study

M. Salas Ramírez, M. Lasimán, J. Tian-Gua, C. Gómez-de la Fuente,
I. Martínez-Amador

University of Ariel, Ariel, ISRAEL, 2 Department of Nuclear Medicine, Wurzburg, Germany

1 OP-826

Exploring the Quantitative Impact of Non-Uniformities in
PET Imaging With 18F

F. Westerbergh, J. C. R. H. Noamen, M. van Essen, N. P. van de Meelen,
C. Müller, P. Bernhardt

Department of Medical Radiation Sciences, Sahlgrenska Academy at University of Gothenburg,
Gothenburg, SWEDEN, *Department of Medical Physics and Biomedical Engineering (MPT), Sahlgrenska University
Hospital, Gothenburg, SWEDEN, 2 Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg,
SWEDEN, 3 Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, SWITZERLAND, 4 Center for Radiopharmaceuticals,
Paul Scherrer Institute, Villigen, SWITZERLAND

1 OP-827

An experimental and computational evaluation of a
time-of-flight PET detector for Compton imaging in Nuclear Medicine

B. Kamtsou, S. Coumans, L. L. Vinter

Centre for Physics in Health and Medicine (CPHM), School of Physics, University College Dublin, Dublin, IRELAND,
St. Vincent’s University Hospital, Dublin, IRELAND

1 OP-828

Effect of High-Uptake Regions with Inconsistent Motion
On Multifocal Osteonecrosis in Patients With Chronic HIV
Infection And Retroviral Treatment

M. H. Vendelbo, C. M. Dieudonne, C. Mhiri, C. N. Riba,
M. Grunert, F. de Galiza Borbosa, A. S. Bonifácio das Neves, M. C. Pinheiro Pessoa Landesmann, J. Cunha de
Souza, J. L. de Medeiros Amarante Júnior, P. H. Rosado de Castro, J. Calero de Albaqueque Mafra, M. Porta Rellie,
A. Amuda Matosinhos de Lima, P. Gomes do Cruz Netto, B. Nóbrega de Oliveira, L. M. Morais Assis dos Santos, R. de Sousa Leão Lima,
M. Gonçalves das Neves, M. C. Peixoto Pires (Landeimann), J. Guerra de Azevedo,
Hospital Universitário Clementino Fogo Filho / Universidade Federal do Rio de Janeiro, Rio de Janeiro, BRAZIL

1 OP-808

Using 18-F FDG PET-CT to Detect Diffuse Eosinophilic
Myasthenia: Case report

A. Karagiannakos, A. Tsiridis, V. Poulopoulos, K. Magka,
O. Coukidou, G. C. Gritsi, P. A. Botsis

Department of Nuclear Medicine, University of Thessalus, Thessaloniki, GREECE

1 OP-818

PET/MR - When and Why?
P. Mapelli,
Sofia Sanità Università La Sapienza, Nuclear Medicine Department,
IRCCS, Vita Salute San Raffaele University, Milan, ITALY

1 OP-819

Effect of Kilovoltage and Quality Reference mAs on CT-
Based Attenuation Correction in 18F PET/CT Imaging: a
Phantom Study

M. Salas Ramírez, M. Lasimán, J. Tian-Gua, C. Gómez-de la Fuente,
I. Martínez-Amador

University of Ariel, Ariel, ISRAEL, 2 Department of Nuclear Medicine, Wurzburg, Germany

1 OP-825

Exploring the Quantitative Impact of Non-Uniformities in
PET Imaging With 18F

F. Westerbergh, J. C. R. H. Noamen, M. van Essen, N. P. van de Meelen,
C. Müller, P. Bernhardt

Department of Medical Radiation Sciences, Sahlgrenska Academy at University of Gothenburg,
Gothenburg, SWEDEN, *Department of Medical Physics and Biomedical Engineering (MPT), Sahlgrenska University
Hospital, Gothenburg, SWEDEN, 2 Department of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg,
SWEDEN, 3 Laboratory of Radiochemistry, Paul Scherrer Institute, Villigen, SWITZERLAND, 4 Center for Radiopharmaceuticals,
Paul Scherrer Institute, Villigen, SWITZERLAND

1 OP-827

An experimental and computational evaluation of a
time-of-flight PET detector for Compton imaging in Nuclear Medicine

B. Kamtsou, S. Coumans, L. L. Vinter

Centre for Physics in Health and Medicine (CPHM), School of Physics, University College Dublin, Dublin, IRELAND,
St. Vincent’s University Hospital, Dublin, IRELAND

1 OP-828
Clinical Oncology Track - TROP Session: Prostate Beyond Usual

OP-830
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: Comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
W. Fendler, J. Jauch, M. Benz, G. C. M. Rutten, J. Debatin, G. Schrader, M. Eiber, M. Weber, M. Benz, University of California, Los Angeles, CA, UNITED STATES OF AMERICA, Technical University of Munich, Munich, GERMANY, University of Duisburg-Essen, Essen, GERMANY.

OP-831
Combined (18)FDG and (68)Ga-Pi PSA 11 PET for (177)Lu-PSMA Radioligand therapy assessment with longitudinal axial view (LAFOV) PET/CIT
J. Albert, R. Schepers, R. Zensker, M. Visicione, A. Rieminger, A. Afzal-Chromet, Institut fur Nuklearmedizin, Bern, SWITZERLAND.

OP-832
When to Repeat Imaging after a Negative PSMA PET Scan in Patients with Recurrent Prostate Cancer under Active Surveillance: A Single-Center Retrospective Study
P. Thin, M. Hordt, A. Gaffo, J. Calais, J. Sonntag, UCCLA, Los Angeles, CA, UNITED STATES OF AMERICA, Western University of Health Sciences, Pomona, CA, UNITED STATES OF AMERICA.

OP-833
Head-to-head comparison between the diagnostic accuracy of 68Ga-TM PiPSMA PET/CT and pelvic mp-3Tesla MRI in patients with biochemical / clinical suspicion of clinically-significant prostate cancer: a per-patient and per-lobe analysis
M. Cilli, F. Gurel, F. Feronor, A. Vici, C. Picaud, O. Sahle, L. Fantoni, V. Rasetti, U. De Giorigi, D. Baronti, V. Di Lorenzo, P. Pagana, M. Martincorena, F. Martucci, University of Messina, Department of Nuclear Medicine, University of Messina, Department of Nuclear Medicine, Italy; University of Verona, School of Medicine, Department of Nuclear Medicine, Italy.

OP-834
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0.2an international multicenter study

OP-835
Contribution of PSMA PET/CT to Evaluation of Response to Systemic Therapies: Preliminary Results
G. Bijeljic, M. Nemanic, M. Alan Setsare, R. Aluci, M. Ocaci, T. Toklu, B. Caner, L. Kabasakal, Yeşilpınar University, Department of Nuclear Medicine, Istanbul, Turkey, Istanbul University, Faculty of Pharmacy, Department of Pharmaceutical Technology, Istanbul, Turkey, Istanbul University-Cerrahpaşa Department of Nuclear Medicine, Istanbul, Turkey.

OP-836
Artificial intelligence for the detection of primary tumour, recurrence and metastases in PSMA PET-CT in prostate cancer
E. Traganou, M. Enouri, J. Uitert, J. Hop, E. Edendorp, T. Meuleman, University Hospital, Malmo, SWEDEN, KU Leuven, University Hospital, Leuven, BELGIUM, Yagamiyama AI, Malmo, SWEDEN, Chalmers University of Technology, Gothenburg, SWEDEN, Skåne University Hospital, Malmo, SWEDEN, Gothenburg University, Gothenburg, SWEDEN.

OP-837
PSMA PET/CT-guided External Beam Radiotherapy of Ossos Metastases in an Oligometastatic Prostate Cancer Setting
G. T. Sheikh, P. Ragaini, M. J. Zacherl, L. M. Unterainer, V. Westen, F. J. Debiaggi, R. Ilgner, T. Philger, M. Unterainer, J. Roubenthaler, C. C. Cynar, R. Bartenslen, M. P. L. Beyers, Department of Nuclear Medicine, University Hospital LMU Munich, Munich, GERMANY, Department of Radiotherapy and Radiation Oncology, University Hospital LMU Munich, Munich, GERMANY, Department of Radiology, University Hospital LMU Munich, Munich, GERMANY.

OP-838
Evaluation of biochemical response with different metabolic response assessment methods on (18)GaPSMA-PET/CT imaging in metastatic castration-resistant prostate cancer patients treated with Lu-Prostate Specific Membrane Antigen Radioligand Therapy
E. Sahin, U. Ebboga, Y. B. Caynak, U. Gmen, V. Murmac, M. Okuyan, E. Ekici, T. Z. Četner, Gaziantep University Faculty of Medicine, Gaziantep, TURKEY.

OP-839
Repeated measurements of lower leg skeletal muscle perfusion using “O-water PET/CT
N. Christensen, C. S. Bahnh, J. Sørensen, K. Bouchelouche, M. A. Madstrøm, L. L. Tolldal, Department of Nuclear Medicine & PET, Aarhus University Hospital, Aarhus N, DENMARK, Skåne Diabetes Center Aarhus, Aarhus University Hospital, Aarhus N, DENMARK.

OP-840
(“FITG) PET/CT in Patients with Prosthetic Valve Thrombosis - Diagnosis - Therapy - Follow-up
V. Hugenberg, A. Jazeb, R. Prusis, A. Friedtchen, T. Budde, N. Krögel, W. Bürchert, M. Deutsch, Institute of Radiology, Nuclear Medicine and Molecular Imaging, Heart and Diabetes Center North Rhine-Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY, Department of general and Interventional Cardiology, Angiology, Heart and Diabetes Center North-Rhine Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY, M. H. Molecular Imaging GmbH, Berlin, GERMANY, Department of Thoracic and Cardiovascular Surgery, Heart and Diabetes, Center North-Rhine Westphalia, University Hospital Ruhr-University Bochum, Bad Oeynhausen, GERMANY.

OP-841
Comparison between (“FITG-)WBC SPECT/CT and (“FITG-)FDG PET/CT in suspected VGEI
C. Lauri, G. Campagna, R. Ottaviani, M. Taurino, A. Signore, Sapienza University, Rome, ITALY.

OP-842
The Value of Multidimensional Studies in the Diagnosis and Prognosis of Patients with Pulmonary Hypertension
H. P. Hu, Y. Lin, M. Cheng, J. Chen, Y. Wu, Departments of Nuclear Medicine and Internal Medicine, National Taiwan University Hospital, Taipei, TAIWAN, School of Medicine, College of Medicine, National Taiwan University, Taipei, TAIWAN, Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN, Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TAIWAN.

OP-843
Increased 18F-Fluorodeoxyglucose Uptake in the Cardiac Atria: An Evidence for Increased Atrial Inflammation in Patients with Atrial Fibrillation
O. Nakamura, T. Aretze, P. T. Meyer, A. S. Jakstad, C. Goetz, University Medical Center Freiburg, Freiburg im Breisgau, GERMANY, University Heart Center Freiburg + Bad Krozingen, Freiburg im Breisgau, GERMANY.

OP-844
Bariatric surgery is associated with brown adipose tissue recruitment and reduced arterial inflammation in individuals with morbidity obesity
O. Kulter, C. T. Herz, A. Grueter, C. Pargger, M. Hacker, F. W. Ketler, A. R. Haug, Division of Nuclear Medicine, Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, AUSTRIA, Division of General Surgery, Department of Surgery, Medical University of Vienna, AUSTRIA, Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, AUSTRIA.

OP-845
Association of a new arterial inflammation PET biomarker with coronary stenosis in patients with cardiovascular risk factors

OP-846
Assessing The Metabolic Activity of the Arterial Wall on PET/CT Using a Semi-Automated Method
L. Lenzic, J. Jarnström, M. Kastele, Z. Marci Lescari, University Medical Center Freiburg, Freiberg, GERMANY, University of Ljubljana, Ljubljana, SLOVENIA, Tecle General Hospital, Celle, SLOVENIA, Rzeka Dolina, c/o UZ, 1800 Ljubljana, Ljubljana, SLOVENIA.

OP-847
Increased central blood volume during adenosine-induced hyperemia in standard Rubidium-82 cardiac perfusion imaging
M. Lassen, C. Bjorne, J. Hartmann, A. Rie, M. G. Berg, P. Hasbak, Rigshospitalet, Copenhagen, DENMARK.

OP-848
Current Standard and Outcomes in Treatment of Benign Thyroid Disease
A. Cappenni, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Nuclear Medicine Unit, University of Messina, Messina, ITALY.
**OP-849**
Salvage 131-I therapy in course of life-threatening amiodarone-induced hyperthyroidism
Nuclear Medicine Unit, Endocrinology, Oncologic Endocrinology and Nuclear Medicine Department, University Hospital, Kraków, POLAND; *Endocrinology, Oncologic Endocrinology and Nuclear Medicine Department, University Hospital, Kraków, POLAND.

**OP-850**
Early Outcome of Radiodine Treatment in Graves’ Disease Patients
T. Zaletel, J. Poľič, S. Guberšiček, K. Zaletel
1. School of Clinical Medicine, University of Cambridge, Cambridge, UNITED KINGDOM; 2. Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA; 3. Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

**OP-851**
Radioiodine and Thyroid Eye Disease (TED): lessons learned from and internal audit of 101 patients
A. Maenhout, P. Jarek, E. Puuvuori, J. Korsgren, T. Xu
1. School of Clinical Medicine, University of Cambridge, Cambridge, UNITED KINGDOM; 2. Chelsea and Westminster Hospital, London, UNITED KINGDOM; 3. Radboud University Medical Centre, Nijmegen, NETHERLANDS; 4. Uppsala University, Department of Surgical Sciences, Radiology, Uppsala, SWEDEN.

**OP-852**
Definitive treatment of hyperthyroidism with radioactive iodine (RAI) in children and adolescents
J. Jandic1, G. Tosi2,3, M. Abbat2, G. Vincenzi2,4, G. Pepe2, A. Chat2
1. Humanitas University, Pieve Emanuele - Milan, ITALY; 2. IRCCS Istituto Clinico Humanitas, Nuclear Medicine Department, Rozzano, ITALY; 3. Université de Nice Sophia Antipolis, INSERM U1094, U1165, CNRS UMR 7241, Laboratoire de Radioprotection Medicales, Nice, FRANCE; 4. Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ITALY.

**OP-853**
The efficacy of radiiodine therapy in patients with non-toxic multinodular goiter with large cold nodule
S. Abdelrazek, P. Szumowski, J. Mysliwiec; 1. Medical University of Bialystok, Bialystok, POLAND; 2. School of Clinical Medicine, University of Cambridge, Cambridge, UNITED KINGDOM; 3. Chelsea and Westminster Hospital, London, UNITED KINGDOM; 4. Medical University of Bialystok, Bialystok, POLAND.

**OP-854**
Radioiodine therapy and the induction of hyperthyroidism in patients with non-toxic goitre
S. Abdelrazek, P. Szumowski, J. Mysliwiec, W. Madz; Medical University of Białystok, Białystok, POLAND.

**OP-855**
The radioiodine therapy outcome in patient with subclinical hyperthyroidism
S. Abdelrazek, P. Szumowski, Ł. Zukowiski, J. Myśliwiec, W. Madza, Medical University of Białystok, Białystok, POLAND.

**OP-856**
The effects assessment of 131I radiiodine therapy in patients with autonomously functioning thyroid nodules
J. Adamczewski, J. Kusmerik, J. Makowska, P. Jarek
1. Department of Nuclear Medicine, Medical University of Lodz, Lodz, POLAND; 2. Department of Nuclear Medicine and Oncological Endocrinology, Maria Skłodowska-Curie Memorial District Hospital, Zielona, POLAND.

**OP-857**
Why we choose a CTZ Scanner
N. Strand Olsen
Bopstfjøring Hospital, clinical physiology and nuclear medicine department, Copenhagen, DENMARK.

**OP-858**
The CTZ Scanner
L. Roes
Universität Zürich, Zürich, Switzerland.

**OP-859**
Optimization of the Acquisition and Reconstruction
R. Danieli, A. Eccles
Jules Bordet Institute, Department of Medical Physics, Brussels, BELGIUM.

**OP-860**
Session Summary

---

**Wednesday, October 19, 2022, 08:00 - 09:00**

**Hall 116**

**Mini Course 1 - Technologists Committee: CTZ in Non-Cardiac Nuclear Medicine**

---

**Thursday, October 19, 2022, 09:05 - 10:05**

**Hall 116**

**Mini Course 2 - Technologists Committee: Non-Fluoride Cyclotron Production - O15-Water Applications**

---

**Wednesday, October 19, 2022, 09:45 - 11:15**

**Hall 112 (Arena)**

**Debate 6 - Dosimetry Committee: Dosimetry in Clinical Practice – Sense vs. Nonsense**

---

**Friday, October 20, 2022, 08:00 - 09:00**

**Hall 113**

**CME 14 - Oncology & Theranostics Committee: Rare Tumours**

---

**Friday, October 20, 2022, 09:45 - 11:15**

**Hall 111**

**OP-871**
Pharmacokinetics - Back to Basics
R. Nith-Vidal
CRUUMA, INSERM, CNRS, University of Nantes, Nantes, FRANCE.

**OP-872**
PK Modelling in Cardiology
M. Luboń
Uppsala University, Department of Surgical Sciences, Radiology, Uppsala, SWEDEN.

**OP-873**
PK Modelling and Parametric Imaging in Clinical Oncology
A. Dimitrakopoulou-Straus
Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, GERMANY.

---

**Friday, October 20, 2022, 09:45 - 11:15**

**Hall 114**

**M2M Track - TROP Session: Antibodies - Reliable Workhorses**

---

**Friday, October 20, 2022, 14:15 - 15:45**

**Hall 116**

**OP-874**
PET/CT imaging of CD69 in rheumatoid arthritis model
1. Department of Medical Chemistry, Uppsala, SWEDEN; 2. Science for Life Laboratory, Uppsala, SWEDEN; 3. Department of Medicine, Karolinska Institute, Stockholm, SWEDEN; 4. Department of Medicinal Chemistry, Uppsala University, Uppsala, SWEDEN; 5. Department of Protein Science, Division of Protein Engineering, KTH Royal Institute of Technology, Stockholm, SWEDEN; 6. Department of GI, Uppsala University, Uppsala, SWEDEN.

---

**Friday, October 20, 2022, 16:00 - 17:30**

**Hall 118**

**OP-875**
Evaluation of Affibody-Based Binder for Targeting of Immune Check-Point Molecule B7-H3
M. Grouët,1,2 E. Beterwinski1, F. Nui,3,4 F. Y. Fred5,6,7,1
1. Uppsala University, Uppsala, SWEDEN; 2. Umea University, Umea, SWEDEN; 3. University of Gothenburg, Gothenburg, SWEDEN; 4. University of Linköping, Linköping, SWEDEN; 5. Tomsk Polytechnic University, Tomsk, RUSSIAN FEDERATION.

---

**Friday, October 20, 2022, 16:00 - 17:30**

**Hall 119**

**OP-876**
Non-invasive in vivo assessment of CD4+ T cells using Positron Emission Tomography
A. Persson-Holldänt,1,2 M. Tan,1,2 M. Requesens, H. W. Nijman, P. H. Eltinga, M. de Bruyn,1,2 University Medical Centre Groningen, Groningen, NETHERLANDS.
In vivo imaging of HER2 receptor status with a novel 18F-labeled antibody

EANM’22 WORLD LEADING MEETING
OCTOBER 15-19, 2022
WORLD LEADING MEETING EANM’22
OCTOBER 15 - 19, 2022
FINAL PROGRAMME | E-POSTER PRESENTATION SESSIONS
E-POSTER PRESENTATION SESSIONS | FINAL PROGRAMME

Institute for Nuclear Research, ATOMKI, Debrecen, HUNGARY.

E. Szedlacsek
B. Váradi

Nuclear Medicine and Translational Imaging, Debrecen, HUNGARY.

2015 conjugates using a radioactive label for biodistribution of HER2-targeting affibody-drug conjugates using a radioactive label

10 Uppsala University, Uppsala, SWEDEN, KTH Royal Institute of Technology, Stockholm, SWEDEN, Research Centre for Oncology and Cancer Research of the University of Debrecen, Debrecen, HUNGARY, National Institute of Respiratory Disease, Moscow, RUSSIAN FEDERATION.

2015 labelling anti-HER2 antibodies with 18F-mycyl pyrrolidine based biofunctional ligands: from ligand design to in vivo PET/MR experiments
B. Váradi1,2, Z. Gándor1, E. Madaras1, B. A. Bezoczy1, A. Vigner1, T. Nagy1, G. G. Gán1, M. V. Puia1, M. V. Belousova1, Z. Đakov1, S. E. Székács1, G. Nagy1, G. Tóth1, D. Székács1

Department of Physical Chemistry, Faculty of Science and Technology, Department of Chemistry, Debrecen University, HUNGARY.

2015. Doctoral School of Chemistry, Debrecen, HUNGARY, KURF Institute for Nuclear Research, ATOMKI, Debrecen, HUNGARY.

2015 automatic multilabel aorta segmentation in PET/CT using a modified 3D UNet
G. van Pragh1, P. H. W. Nieuwenhuys1, M. Reijrink1, B. Váradi3,4,5,6,7,8,9, I. J. de Jong7,2

University Medical Center Groningen, Groningen, NETHERLANDS, Department of Radiology, University Medical Center Groningen, Groningen, NETHERLANDS, Department of Radiology and Nuclear Medicine, University Medical Center Groningen, Groningen, NETHERLANDS, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS.

2015 Predictors of 18F-PET Positivity in PCa Patients After Radical Prostatectomy: A Machine Learning Approach
S. Ghezzo1, P. Magrippi, A. Samanes Gajate, E. Preza1, P. Spacagna2, I. Gotzmann1,2,3, M. Salimandr1,2, C. Vercelluzzii1,2, A. Rigoni1,4,5,6, A. Gana1, M. Peccio1,2,3

Vita-Salute San Raffaele University, Milan, ITALY, Department of Nuclear Medicine; IRCCS San Raffaele Scientific Institute, Milan, ITALY; Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, Messina, ITALY; University of Messina, Messina, ITALY, School of Medicine and Surgery, University of Milano Bicocca, Monza, ITALY; Department of Urology; IRCCS San Raffaele Scientific Institute, Milan, ITALY; Division of Experimental Oncology, URL, Research Institute, Milan, ITALY.

2015 PET/CT Patterns of Recurrence After Monotherapy in Prostate Cancer and Subsequent Management
G. Looi1,2, P. J. Buller1,2, G. Van Ooy1,2, N. Cavestri1,2, D. G. Murphy1, M. S. Holman1, S. Williams1,2, S. Chaplin1,2

Peter MacCallum Cancer Centre, Melbourne, AUSTRALIA, Centre Jean Perrin, Clermont-Ferrand, FRANCE, BC Cancer Agency, Vancouver, BC, CANADA.

2015 Can we predict skeletal lesion on bone scans based on quantitative PET/CT features?
A. Laoudieille1, A. Haarala1, P. Magrippi1, D. Jeunemaitre2, J. Mirer2, A. Gana1, G. Gana1, F. Drouet1,2, S. Ohlsson1,2, J. Janssen1,2

University of Messina, Messina, ITALY, Department of Radiology, University Medical Center Groningen, Groningen, NETHERLANDS, Department of Nuclear Medicine; IRCCS San Raffaele Scientific Institute, Milan, ITALY, Division of Experimental Oncology, URL, Research Institute, Milan, ITALY.

2015 Diagnostic Value of 18F-PSMA-1007 PET in PCa Patients with Known Bone Metastases:
A. Komleva1,2, I. A. Burger3, T. Di Raimondo1,4,5,6,7,8,9, G. G. Gana1, M. Messerli4,5,6,7,8,9, E. Preza1,2

University of Messina, Messina, ITALY, Department of Urology of Cancer Sciences and Morpho-Functional Imaging, Messina, ITALY, University of Messina, Messina, ITALY, School of Medicine and Surgery, University of Milano Bicocca, Monza, ITALY; Department of Nuclear Medicine; IRCCS San Raffaele Scientific Institute, Milan, ITALY; University of Messina, Messina, ITALY, School of Medicine and Surgery, University of Milano Bicocca, Monza, ITALY; Department of Urology; IRCCS San Raffaele Scientific Institute, Milan, ITALY; Division of Experimental Oncology, URL, Research Institute, Milan, ITALY.

2015 Interobserver Variability in Assessment of 18F-PSMA-1007 PET in Patients with Prostate Cancer
J. E. Joseph1, A. C. Howard1, V. M. Heyns1,3, J. A. de Jong1,2,3, J. J. Van Lieburg1,2,3, J. A. Langeland2, J. J. Verzijlbergen1, G. N. Stammezcano1, S. A. Luijten1,2,3,4

Department of Nuclear Medicine; University Medical Center Groningen, Groningen, NETHERLANDS, Department of Radiology and Nuclear Medicine, University Medical Center Groningen, Groningen, NETHERLANDS, Department of Nuclear Medicine; University Medical Center Groningen, Groningen, NETHERLANDS, Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Nijmegen, NETHERLANDS.

2015 Intermittent organ-surgery based optimization of 18F-PET/CT in prostate cancer patients:
S. M. Menendez-Sanchez, F. Delpeuste-Clarke, L. Navarrete-Mateu, A. Codina-Sanverda, S. Aguadí, M. Simó, Hospital Universitaria Vall d’Hebrons, Barcelona, SPAIN.
**EANM'22 WORLD LEADING MEETING**

**October 15 - 19, 2022**

**WORLD LEADING MEETING EANM'22**

**OCTOBER 15 - 19, 2022**

**FINAL PROGRAMME | E-POSTER PRESENTATION SESSIONS**

**E-POSTER PRESENTATION SESSIONS | FINAL PROGRAMME**

---

**807**

**Monday, October 17, 2022, 10:00 - 10:20**

**Hull 115**

**Clinical Oncology Track - TROP Session: Sentinel Node**

**OP-901**

A multicentre clinical trial evaluating the safety and performance of a drop-in gamma probe for sentinel lymph node dissection in prostate cancer


**OP-902**

Effectiveness of sentinel-node biopsy in detecting nodal metastatic involvement in non-small cell lung cancer: a prospective study


**OP-903**

Sentinel lymph node dissection in thyroid carcinoma using “Ga-talinocentop PET/CT: a proof of concept study


**OP-904**

Performance evaluation of the FIS-00 high definition fluorescence camera prototype during 599 hybrid sentinel node procedures

T. Buckle, B. D. O. Rottgergen, S. Vitalis-Sicart, A. Peinsnsenb, B. Karatulkicul, M. Klopf, B. Brouwer, F. W. B. de Leeuw, L. S. O. Pasele J. Galli, Genoa, ITALY. MICCS Humanitas Research Hospital, Rozzano, ITALY.

**OP-905**

Evaluation of a drop-in gamma probe during sentinel lymph node dissection in gynaecological malignancies - comparing use with ridged and steerable laparoscopic instruments


---

**101**

**Wednesday, October 19, 2022, 11:25 - 11:45**

**Auditorium**

**Closing Session**

**OP-1019**

S. Fant.

University of Bologna, Radiological Sciences - Nuclear Medicine, Bologna, ITALY.

---

**209**

**Sunday, October 16, 2022, 08:00 - 09:30**

**Hull 111**

**e-Poster Presentation Session 1 - Bone & Joint**

**EPS-001**

Lung Perfusion SPEC/CT in Suspected Chronic Thromboembolic Pulmonary Hypertension: Impact on Classification of Pulmonary Hypertension and Therapeutic Decisions

N. Alvarez Mena, J. Sebastián Pascual, M. García Aragón, B. Pérez López, C. Gamarra Llera, M. Alonso Rodríguez, M. González Soto, A. Sanz Esteban, R. Risoa Pérez, Hospital Clínico Universitario de Valladolid, Valladolid, SPAIN.

**EPS-002**

Reproducibility of semi-automated hepatic perfusion measurements using 18F-water PET

M. Lubbenink, P. Runesson, E. Lindström, S. Roslin, J. Vestby, G. Hestand, F. Roiemo, Uppsala University, Uppsala, SWEDEN.

**EPS-003**

Lymphphoscintigraphy of lower limbs: A mapping technique for surgery needing lymph node transfer in DEEP reconstruction after breast cancer

E. Ivenborg, B. Jørg, P. Ahl Summa, N. Schøler, M. Niocod-Lalande, N. Torsvik, CHUV, Lausanne, SWITZERLAND.

**EPS-004**

Impact of COVID infection on brain metabolism: the revealing role of 18F-FDG PET/CT

C. Ferrand, T. Mosi, A. G. Nappi, V. Lavelli, P. Mammucci, R. Ruta, A. R. Moini, G. Rubini, Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University A. Modena, Bari, ITALY.

**EPS-005**

Assessment of neuroinflammation using [18F]DPAt14 PET in post-COVID-19 patients with and without persisting complaints

D. Wiser, S. S. V. Golgi, S. J. C. Vanhalleve, E. E. Coomans, R. M. Nikolaou, S. M. van der Giet, S. Boest, D. M. A. Kamers, M. E. den Hollander, A. Verveen, M. Yaqub, F. Barkhøff, L. A. Schwarten, D. W. Koch, R. C. Schraut, A. D. Windhorst, R. Boekkland, M. van Vugt, H. Knopp, B. N. M. van Berckel, N. Oostra, Department of Radiology & Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, Department of Medical Psychology, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, Division of Human Nutrition & Health, Wageningen University, Wageningen, NETHERLANDS, Department of ETV, University Medical Center Utrecht, Utrecht, NETHERLANDS, Institute of Neurology and Healthcare Engineering, University College London, London, UNITED KINGDOM, Department of Anesthesiology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, Department of Internal Medicine, University of Amsterdam, Amsterdam UMC, Amsterdam, NETHERLANDS, Department of Radiology & Nuclear Medicine, University Medical Center Utrecht, Utrecht, NETHERLANDS.
EANM'22 WORLD LEADING MEETING
OCTOBER 15-19, 2022
Glostrup, Copenhagen, DENMARK,
L. Guillon
Rigshospitalet, Copenhagen, DENMARK,
C. Wu
University, Cleveland, OH, UNITED STATES OF AMERICA.
Radiopharmaceuticals
A Mesh-based Model of Brain Vasculature: Improved
Longitudinal assessment of remyelination and
UNAM, Mexico City, MEXICO.
, M. Ávila-Rodríguez;
Vectorial analysis of dual-tracer PET imaging in Parkinson's
Department of Clinical Research, University of Southern
S. Madsen
EPS-008
EPS-006
EPS-007
EPS-005
EPS-014
EPS-013
EPS-012
EPS-011
EPS-010
EPS-009
EPS-008
EPS-007
EPS-005
EPS-014
EPS-013
EPS-012
EPS-011
EPS-010
E-POSTER PRESENTATION SESSIONS

EPS-039
Optimizing Dose Regimen for Ga-PSMA PET/CT Imaging While Preserving Image Quality required for Lesion Detection
P. Sheikhzadeh, A. Mostofi, A. Ghafari, E. Ahmadi;
Department of Nuclear Medicine, University Hospital of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF;
Department of Biomedical Engineering, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

EPS-040
A highly reproducible ejection fraction estimation through PACS data-driven deep learning for automatic segmentation of diastole and systole regions of interest in ECG scans
S. Seo, J. J. D. P. Park, D. Lee; S. Han, D. Moon;
Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF;
Department of Biomedical Engineering, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KOREA, REPUBLIC OF.

EPS-041
18F-FDG PET/CT in Infection Endocarditis: Impact As A Major Diagnostic Ductile Criterion And In The Evaluation Of Extracardiac Infectious Manifestations
Hospital General Universitario Gregorio Marañon, Madrid, SPAIN, University Hospital of Canarias, Tenerife, SPAIN.

EPS-042
E-POSTER PRESENTATION SESSION 3 - Inflammation & Infection Committee: Best e-Posters on Infection and Inflammation

EPS-043
Lung perfusion assessment in Long-COVID children: a pilot study
D. F. Pena, D. Buonomo, A. Faroga, F. Baldo, D. Di Gaudio;
Nuclear Medicine Unit, Department of Radiology, Rheumatology and Immunology, Fondazione Policlinico Università dei Gemelli, IRCCS, Rome, ITALY, Department of Cancer, Radiotherapy and Immunology, Fondazione Policlinico Università dei Gemelli, IRCCS, Rome, ITALY.

EPS-044
Expiratory flow sets substantially reduce exhaled small bioaerosol particles and potential COVID-19 virus load. H. Haueter, T. Baren, K. Daniechem, L. Agnese, T. Laurie, R. Herrmann;
University Hospital Essen, Department of Nuclear Medicine, Essen, GERMANY, University of Göttingen, Institute of Medical Informatics, Göttingen, GERMANY.

EPS-045
E-POSTER PRESENTATION SESSION 4 - Radiopharmaceutical Sciences + Translational Molecular Imaging & Therapy Committee: New Tracers – From Production to Translation

EPS-046
Lung ventilation and perfusion SPECT in long-COVID patients
D. Iapo, A. Marenna, P. Iapo, G. Cessa;
Centro Hospitalar e Universitária de Coimbra, Coimbra, PORTUGAL, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL, Faculdade de Medicina da Universidade de Coimbra, Coimbra, PORTUGAL.
clinical course: serial FDG-PET/CT analysis
A. N. Bakulev Scientific Center for Cardiovascular Sciences, Tomsk, RUSSIAN FEDERATION.
N. Surkova; O. K. Kon. K. Jung
Dong-A University Hospital, Busan, KOREA, REPUBLIC OF.

E-Poster Session 6 - Physics & Radiation Protection Committee: Physics & Radiation Protection

EPS-100
Phantom Validation of SPECT-CT Quantification with Varying UCU Tc Uptake
C. Turner
Swansea Bay University Health Board, Swansea, UNITED KINGDOM
Swansea University, Swansea, UNITED KINGDOM

EPS-109
Comparison of a brain-dedicated PET/MR scanner for the diagnosis of neurodegenerative disorders
Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IDISSC), Hospital Clinico San Carlos, Universidad Complutense, Madrid, SPAIN
General Equipment for Medical Imaging S.A, Valencia, SPAIN
Department of Nuclear Medicine, Instituto de Investigación Sanitaria San Carlos (IDISSC), Hospital Clinico San Carlos, Universidad Complutense, Madrid, SPAIN

EPS-110
Dose reduction of [18F]Ga-DOTA-TATE PET/MR in comparison with PET/CT
C. P. Cox, T. Brabander, P. A. Verburg, M. Segben, Erasmus MC, Rotterdam, NETHERLANDS

EPS-111
Preliminary Experience and Performance Characteristics of an Extended Bore Length Solid-State Digital SPECT/CT System
J. Kennedy; T. Palchan Hazar, O. Maronick, O. Caseley, F. Courbon, M. Levy, Z. Redark
Rambam - Health Care Campus, Haifa, ISRAEL
Rambam - Health Care Campus, Haifa, ISRAEL

EPS-105
Zero-TE MR-IR Attenuation Correction with a Deep Learning Approach: Impact of bone components on Attenuation Correction for Chest FDG PET/MR
Department of Radiology, Kobe University Graduate School of Medicine, Kobe, JAPAN
Department of Radiology, Kobe University Hospital, Kobe, JAPAN

EPS-104
Assessment of microinflammation severity with the use of Na[18F]F PET/CT in the evaluation of aortic valve calcification
HUiP La Fe, Valencia, SPAIN
IFIC (CSIC-U.Valencia), Valencia, SPAIN

EPS-103
Investigation of a portable gamma camera with pinhole collimator for Leu-177 imaging using Monte Carlo simulations
P. Papadimitrakis, G. Savvidis, E. Fysikopoulos, M. Georgiou, E. Koulourakis, K. Katsopoulou, G. Iolisadis
BIDEMTECH, Athens, GREECE

EPS-102
Imaging characteristics and prediction of therapeutic efficacy in patients with dilated cardiomyopathy treated with isotropic II receptor blocker using F-18 FDG PET and 11C MBG scan: a preliminary study
K. Jeong, K. Park, K. Kang, J. Jang
Dong-A University Hospital, Busan, KOREA, REPUBLIC OF.

EPS-101
Novel CZT-based multi detector SPECT/CT system: daily QC tests and performance evaluation at one year after installation
V. Ferri, K. Igasang, P. Casado, A. Lagani
Stanford University, Palo Alto, CA, UNITED STATES OF AMERICA

EPS-100
Phantom Validation of SPECT-CT Quantification with Varying UCU Tc Uptake
C. Turner
Swansea Bay University Health Board, Swansea, UNITED KINGDOM
Swansea University, Swansea, UNITED KINGDOM

EPS-99
Relationship between diphosphonate uptake distribution and myocardial contractility in ATTR
L. Santamaria-Chico, K. E. Velázquez-Díaz, P. M. Meneses-Saavedra, I. Obelleiro, J. B. Moliva-Polomera, A. Sánchez-Gómez, F. de Haro-del-Moral
Hospital Universitario Puerta de Hierros, Madrid, SPAIN

EPS-98
Prognostic value of coronary flow reserve estimated using dynamic SPECT with CZT camera
M. Hauh, M. Kuremborn, P. Amandos, L. Quinn, J. Metelkova, V. Kindl
1 University of Health Sciences Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE
2 University Hospital Olomouc, Olomouc, CZECH REPUBLIC

EPS-97
The role of microvascular dysfunction in heart failure with preserved left ventricle ejection fraction
K. Kowak, A. Mochula, A. Maltseva, V. Shpulien, K. Zavadovsky
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION

EPS-96
Prognostic value of cardiac scintigraphy in the prediction of responders to cardiac resynchronization therapy in patients with chronic heart failure
T. Atembekov, N. Batalova, S. Sazonova, S. Kiveliov, V. Suschkin, M. Khlynn, Y. Varlamova, K. Zavadovsky, S. Popov
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION

EPS-95
Assessment of myocardial ischemia severity with the use of Na[18F]F PET/CT in the evaluation of aortic valve calcification after TAVI: preliminary results
M. Opalinska, D. Staryk*, A. Sowas-Staszczak, A. Grochowska, A. Zawrotny, N. Manuszak, M. Bagien, M. Sunarski, S. Bartu*, D. Udziela*
1 Nuclear Medicine Unit, Department of Endocrinology, University Hospital, Krakow, POLAND
2 Department of Cardiology, Jagiellonian University Medical College, Krakow, POLAND
3 Department of Cardiology and Cardiovascular Interventions, University Hospital, Krakow, POLAND

EPS-94
Use of Na[18F]F PET/CT in the evaluation of aortic valve calcification
M. Hau, M. Kuremborn, P. Amandos, L. Quinn, J. Metelkova, V. Kindl
1 University of Health Sciences Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE
2 University Hospital Olomouc, Olomouc, CZECH REPUBLIC

EPS-93
The value of cardiac sympathetic innervation imaging and epicardial adipose tissue characteristics in predicting of atrial fibrillation catheter ablation outcomes
Y. Varlamova, S. Sazonova, E. Popov*, S. Minni, A. Ramanov, R. Batalov, S. Popov*
Cardiology Research Institute, Tomsk NRMC, Tomsk, RUSSIAN FEDERATION

EPS-92
The feasibility of dynamic SPECT/CCT measurement of myocardial blood flow and reserve in patients with dyslipidemia and non-obstructive coronary artery disease
Coronary flow reserve and extracellular matrix remodeling
EPS-089
Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc-Olomouc, Olomouc, CZECH REPUBLIC, Institute for Molecular Imaging, Brno, CZECH REPUBLIC

EPS-91
Coronary flow reserve and extracellular matrix remodeling of myocardial blood flow and reserve in patients with dyslipidemia and non-obstructive coronary artery disease
E. Grakovåe, K. Kowak, A. Maltseva, A. Mochula, K. Zavadovsky
Cardiology Research Institute, Tomsk National Research Medical Centre, Russian Academy of Sciences, Tomsk, RUSSIAN FEDERATION

EPS-90
Impaired myocardial perfusion and blood flow in patients with multivessel CAD: diagnostic solution capabilities
A. Shaikhova, I. Aslanidis, I. Shurupova, I. Ekaeva, M. Rumyantseva, I. Obedkova, V. B. Moñivas-Palomero, A. Sánchez-Gómez, F. de Haro-del-Moral
1 University of Health Sciences Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE
2 University Hospital Olomouc, Olomouc, CZECH REPUBLIC

EPS-89
Prognostic value of coronary flow reserve estimated using dynamic SPECT with CZT camera
M. Hau, M. Kuremborn, P. Amandos, L. Quinn, J. Metelkova, V. Kindl
1 University of Health Sciences Kayseri City Training and Research Hospital, Kayseri, TÜRKIYE
2 University Hospital Olomouc, Olomouc, CZECH REPUBLIC

EPS-88
Clinical course: serial FDG-PET/CT analysis
A. N. Bakulev Scientific Center for Cardiovascular Sciences, Tomsk, RUSSIAN FEDERATION
N. Surkova; O. K. Kon. K. Jung
Dong-A University Hospital, Busan, KOREA, REPUBLIC OF.
Monday, October 17, 2022, 15:00 - 16:30

### E-Poster Presentation Session 7 - Paediatrics Committee: e-Posters on Paediatrics & Neonatology

#### EPS-120
**The Optimal Use And Effectiveness Of 111mTc-labeled Dextran for High-Risk and Relapsed/Refractory Neuroblastoma**

I. Plaza de las Heras, M. Oscura Manco, I. Martín López, M. Villa Nicolás, C. Fidal Gualda, L. García Carahuama, B. López Romo, AM Hospitals, MADRID, SPAIN.

#### EPS-121
**Do age influence bone scan detection of osteoarticular findings in clinically unsuspicous locations in acute pediatric scenarios? A retrospective decade-long analysis**

M. Montero, A. R. Moreira, A. Alpunquega, G. Costa, Servicio de Medicina Nuclear del Centro Hospitalario Universitario e Insituto de Oncología, MADRID, SPAIN.

#### EPS-122
**Management of non-refluxing meagueriner in children. The role of diuretic renography with 99mTc-DTPA**

R. Delgado-Noño, S. Pérez-Quemada, D. Vega-Pérez, E. Martínez Alén, S. Ángelita, P. Zarazúa-Ballester, J. Gómez-Frías, M. J. Tábuenca Maestro, Medicina Nuclear - PET CT Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, SPAIN.

#### EPS-123
**Dose Reduction in DMSA Renal SPECT in infants: beyond the Guidelines**

F. Fahey, H. Pretorius, S. Trevor, N. Kewati, R. Vial, M. Dugan, X. Cai, W. Fu, J. Luf, Y. Yang, M. Yung, Boston Children’s Hospital, Boston, MA, UNITED STATES OF AMERICA.

#### EPS-124
**Comparison Between 75-Selenium Homocholic Acid Taurine (SeHCTA) Scintigraphy and Clinical Response To Cholestyramine in Patients Affected By Chronic Diarrhoea: A Pilot Study**

I. Bossert, A. Scheipat, M. Cincofatto, D. Dambrosio, A. Marchetti, F. Biagi, G. Trifaro, Nuclear Medicine Service, Istituti Clinici Cliniche Maugeri SPA IRCCS, Pavia, ITALY.

#### EPS-125
**Radioisotope Nephrography - Tie the Knot between Chronic Kidney Disease and Cardiovascular Disease**


#### EPS-126
**The usefulness of superficial and deep lymphoscintigraphic study in patients with suspected primary lymphedema of lower limbs: a semi-quantitative and qualitative approach**


#### EPS-127
**Use of Peritonal Scintigraphy In The Diagnosis Of Hydrothorax In Patients On Peritoneal Dialysis**

J. Corvallo, A. Marques, F. Abreu, S. Pinhão, Centro Hospitalar de Lisboa Ocidental, Carnaxide, PORTUGAL.

#### EPS-128
**Utility Of Peritoneal Scintigraphy In The Diagnosis Of Hydrothorax In Patients On Peritoneal Dialysis**

J. Corvallo, A. Marques, F. Abreu, S. Pinhão, Centro Hospitalar de Lisboa Ocidental, Carnaxide, PORTUGAL.

#### EPS-129
**Value of estimation of cortical transit time on renal 99mTc-DTPA scintigraphy in surgical management of antenatal diagnosed ureteropelvic junction obstruction in infants**


#### EPS-130
**Ga-68 Pima For The Kidney Function Evaluation: Preliminary Results: Comparison Of Ga-68 Pima Findings With Mag-3 Findings**

B. Ozdemir, U. Korkmaz, S. Saglamis, G. Durna-Aliun, Trakya University, Edirne, TURKIYE.

#### EPS-131
**99mTc-Septamib SPECT/CT for the diagnosis of indeterminate renal tumors: a pilot diagnostic accuracy study**


#### EPS-132
**SPECT/CT In The Evaluation Of Osteoporotic Lesions After Surgical Fixation Ankle Fractures**


#### EPS-133
**Gastrointestinal bleeding scintigraphy- is there still value in the 21st century?**

B. Pethok, E. Stenak, E. Phák, R. M. Agner, Medical University of Graz, Department of Radiology, Division of Nuclear Medicine, Graz, AUSTRIA.

#### EPS-134
**Lymphoscintigraphic Evaluation of Lymphatic Insufficiency After Total Knee Arthroplasty**

A. Gerner, M. Karapczik, F. Czader, University of Health Sciences, Kayseri City Hospital, Kayseri, TURKIYE.

#### EPS-135
**Comparison of lung perfusion scan and blood perfusion volume (PBV/CT) in emphysematous patients**

I. Burrone, A. Bolognesi, C. Marzolla, G. Cottolenci, M. Carrota, S. Balduzio, F. Cesar, A. Giovanelli, Nuclear Medicine Unit, Ospedale Riuniti di Torrette, Anciano, ITALY.

#### EPS-136
**Intestinal 99mTc hydroxyethylmethionine dopamine uptake in bone scans: improper radiopharmaceutical administration as a cause?**

M. Bettaieb, H. Trabelsi, A. Ezine, M. Ouachem, W. Toulal, M. Mouki, A. Chatti, Nuclear Medicine, Sahilul Hospital, Sousse, TUNISIA.

#### EPS-137
**Clinical utility of SPECT/CT imaging in bone infection**

K. Boidao, D. Gauthier, A. Dammak, J. Vilat, O. Alouini, R. Fermeill, University of the Republic, Montevideo, URUGUAY.

#### EPS-138
**Body Mass Index Assessment in PET/CT Imaging Patients**

G. Mutevelizade, Y. Pakark, C. Sezgin, E. Soyay, G. Gumuz, Department of Nuclear Medicine, School of Medicine, Cetlik Bipol Hospital, Manisa, TURKIYE.

#### EPS-139
**Incremental Value Of SPECT/CT Over Plain Images In Pre-operative Quantification Of Lobar Lung Perfusion**

N. Alvarez, M. Pina, J. Gómez Martínez, M. Alvaro, M. Hortúa Romero, B. Pérez López, C. Gamas-Lehman, M. Alonso Rodríguez, M. González Salto, A. Sainz Esteban, R. Güero Perez, Hospital Clinico Universitario de Valladolid, Valladolid, SPAIN.
EANM’22 | WORLD LEADING MEETING
OCTOBER 15-19, 2022

1109

Monday, October 17, 2022, 16:45 - 18:15

Hall 111

e-Poster Presentation Session 8 - Neuroimaging Committee: Neuro e-Posters

EPS-142
Biodistribution and pharmacokinetic evaluation of different mAb formats, targeting endothelin A receptor-positive glioblastoma stem cells using in vivo immunopET imaging.
M. Hautier1, D. Viver1, D. Peneva1, A. Herbert1, N. Costa1, C. Deny1, D. Nenashi-Kubis1, A. Malboussier1, J. Nugui1, F. Deroisy1, D. Bouquet2, C. Triller3.
1CEA/DMTS/SP4, Saclay, FRANCE, 2CEA-CNRS-Inserm, BiolMaps, Orsay, FRANCE, 3CMU/UMR CNRS 6132, Dirosse, FRANCE.

EPS-143
Imaging analysis of gliomas: comparison of T1-gd MRI and PET/CT with 18F-FTD and 68Ga-NODAGA-RGDyK.
N. Testart Dardel1,2, N. Testart1,2, A. Hottinger1, J. Prior1,3, M. A. Topcuoglu1,2,3, A. Badenas1,2,3, J. Roosen1,3.
1Department of Neurology, University Hospital LMU Munich, Munich, GERMANY, 2Department of Neurosurgery, University Hospital LMU Munich, Munich, GERMANY, 3Department of Neurosciences, Imaging and Clinical Sciences, CEA-CNRS-Inserm-CEA/CNRS-Inserm-INSERM U1191-CNRS UMR 2038, Montpellier, FRANCE.

EPS-144
Diagnostic performance of 18F-Methionine PET-CT for differential diagnosis between tumour recurrence and radiation-induced changes in patients with brain gliomas.
J. Prior1,3, M. A. Topcuoglu1,2,3, A. Badenas1,2,3, I. Moreira-Santos3, F. Poujade3, J. Roosen1,3.
1Department of Neurology, University Hospital LMU Munich, Munich, GERMANY, 2Department of Neurosurgery, University Hospital LMU Munich, Munich, GERMANY, 3Department of Neurosciences, Imaging and Clinical Sciences, CEA-CNRS-Inserm-CEA/CNRS-Inserm-INSERM U1191-CNRS UMR 2038, Montpellier, FRANCE.

EPS-145
Multimodal imaging of vascular and molecular biomarkers in glioblastoma.
E. Lyssy1,2,3, D. van der Gaar4, M. Breivik1, S. E. Svensson1, G. Agm-Wick1, B. Buggel1, O. M. Gren1, S. Stigen1, B. Blakstad1, P. Brennan1, K. E. Bremi1, J. Hovem1.
1Olso University Hospital, Oslo, NORWAY, 2Oslo University, Oslo, NORWAY, 3Universitat Politecnica de Valencia, Valencia, SPAIN.

EPS-146
PET-imaging and Protein Expression of Prostate Specific Membrane Antigen in Glioblastoma.
S. van Lith1, J. J. Pina2, N. Tolboom1, D. Henssen1, T. J. Sneijder1, M. ter Loos1, Y. C. de Witt Hamer1, B. W. Miller1, R. van Rooij1, M. L. J. Smits1, M. G. E. Gildehaus1, A. Delker2, J. Redoute2, L. O. Atay3, J. L. Humm4.
1Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY, 2Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University Aldo Moro, Bari, ITALY, 3Department Unit of Medical Physics, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, ITALY, 4Department of Nuclear Medicine, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, UNITED STATES OF AMERICA.

EPS-147
S. Shams2, S. Karimi2, P. Gupta2, S. Gomagamati2, Shital, C. Bal2, WAMS New Delhi, Delhi, INDIA.

EPS-148
Towards Microscopic Level Dosimetry for Colorimetric Hepatocellular Metastases Assessment with Trans-arterial Radioembolization using Micro-CT and Autoradiography of 192Ir PET/CT-guided Biopsy Specimens.
1Morsani Center for Clinical Research, New York, NY, UNITED STATES OF AMERICA, 2University of Kentucky, Lexington, KY, UNITED STATES OF AMERICA, 3Lock Haven University of Pennsylvania, Lock Haven, PA, UNITED STATES OF AMERICA, 4University of Arizona, Tucson, AZ, UNITED STATES OF AMERICA.

EPS-149
First clinical experiences on fractionated intraarterial radioimmunotherapy with Lu-177 labeled 64CaF2 fragments in patients with glioblastoma.
W. Rolf1, M. Muth2, L. Bong3, A. Dieker1, N. W TYPEK, P. N. S."azmaxa"4,5, M. Schrefl1,2, W. Stumment3,4, R. Zeidler1, H. J. Reuten1, L. Stegger1.
1Department of Nuclear Medicine, University Hospital Münster, Münster, GERMANY, 2Department of Neurosurgery, University Hospital Münster, Münster, GERMANY, 3Department of Nuclear Medicine, University Hospital LMU Munich, Munich, GERMANY, 4Clinical Unit for Heimbachl Centre Munich, German Research Center for Environmental Health, Munich, GERMANY, 5Department of Nuclear Medicine, University Hospital LMU Munich, Munich, GERMANY.

EPS-150
A. Nappi1, V. Lavelli1, C. Fenari1, C. D’Alo1, A. Scozaccia1, G. Santi1, V. Dabadi2, G. Rubin3.
1Section of Nuclear Medicine, interdisciplinary Department of Medicine, University Aldo Moro, Bari, ITALY, 2Department Unit of Medical Physics, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, ITALY.

EPS-151
S. Bliniez1, F. Debardouix1, B. Blanc1, E. Hindle1, B. Lapiaye1, J. Y. Lavallée1.
1University of Bordeaux, Bordeaux, FRANCE.
E-POSTER PRESENTATION SESSIONS
EANM'22 | WORLD LEADING MEETING
OCTOBER 15-19, 2022

E-POSTER PRESENTATION SESSIONS

Tuesday, October 18, 2022, 09:45 - 11:15

Technology’s e-Poster Presentations Session: Tech's e-Posters

TEPS-01
An Italian survey on the use and purpose of ct protocols and related technical parameters in pet ct
G. Rompione, A. Parmintier, G. GTM group, E. Vaccaro, S. Panov

TEPS-02
Large axial field-of-view PET/CT and the claustrophobic patient
R. Schepers, J. Albers, M. Visocone, A. Hisham Omrieh, A. Rominger
Interplic, Bern, SWITZERLAND

TEPS-03
Evaluation of the use of breath hold acquisitions in routine practice
C. Pozza, J. Prier, M. Nicolalde, N. Schafer, S. Soares Schibani, S. Boughfled
CHU, Louvain, SWITZERLAND

TEPS-04
A practical tool to evaluate the quality of myocardial perfusion images
V. Ostermann, B. Hoye Mathiesen
Department of Nuclear Medicine, Vejle, DENMARK

TEPS-05
Clinical Audits in Nuclear Medicine: A Modified Model Adapted to the Portuguese Reality

TEPS-06
Interest of the “Medrad Integro” combined automatic dispenser and injector system during 18F-FDG PET Image Fusion
A. Ben Amar, A. Ezzet, H. Boudagh, S. Menfi, M. Naukkar, M. Ben Refae, A. Chaty
Nuclear medicine department, Saint Louis, TUNISIA, University of Medicine and Faculty of Medicine, Saint Louis, TUNISIA

TEPS-07
Device Received to Hands (Fingers) While Dispensing and Administration of Radioactive Injections (F-18) to Patients
M. Khaskhali, C. Crouch, Oxford University Hospitals NHS Foundation Trust, Oxford, UNITED KINGDOM

TEPS-08
Radio dance Dose To The Patients From F18-FDG WB PETCT
P. Devi, P. A. Muthu, V. Ranganaraj
Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Mumbai, INDIA, Tata Memorial Centre, Mumbai, INDIA

TEPS-09
Radiotherapy safety assessment of 18F-DOTATATE Intra-Arterial peptide receptor therapy (PRRT)
Advanced Centre for Treatment Research & Education in Cancer, New Mumbai, INDIA, Narayna Hospital, Mumbai, INDIA, Mochlo Bhattacharya National Institute and Regional Medical Research Centre, Mumbai, INDIA

TEPS-10
Diagnostic Reference Levels in Nuclear Medicine: Development of a Simple Tool to Help Assessing the Portuguese Reality

TEPS-11
Reduction of the finger dose of technologists by the use of an automatic injection unit in myocardial perfusion PETCT studies with 18F-NaF
V. Schob, P. Vuithuys, T. R. Büschel, J. Trinkaus, T. Berthold, P. Kaufmann, M. Hofbauer, University Hospital Zurich, Zurich, SWITZERLAND

TEPS-12
Head & Neck Sentinel Node procedure - lessons from practical experience
L. Pereira, A. Lemos, K. Brooks, P. Nair, A. Conrani, B. Bisate, T. Barniden
NINS, Madisate, UNITED KINGDOM, Madisate and Tubnidge Wells NHS Trust, Madisate, UNITED KINGDOM, Canterbury Christ Church University, Canterbury, UNITED KINGDOM, Queen Victoria Hospital, East Grinstead, UNITED KINGDOM

TEPS-13
Value of continuous blood pressure monitoring in the evaluation of maximal hyperemia during myocardial perfusion imaging with Rubidium-82 PET/CT
A. Tegelaar, Kuisper, S. S. Koenders, J. V. A. van Lijp, J. O. van Lijs
Department of Nuclear Medicine, Isala Hospital, Zwolle, NETHERLANDS, Technical Medical Center, University Hospital Utrecht, Eindhoven, NETHERLANDS, Department of Medical Physics, Isala Hospital, Zwolle, NETHERLANDS

TEPS-14
Providing Water before Myocardial Perfusion Imaging with Digital Gamma Camera, Investigating Mechanics and Logistics of Inferior-Lateral Artefact Reduction with Profile Analysis
V. Ostermann, M. R. Pedersen, Department of Nuclear medicine, Vejle, DENMARK

TEPS-15
Around the Clock
V. Ostermann, B. Hoye Mathiesen, J. Tetz
Department of Nuclear Medicine, Vejle, DENMARK

TEPS-16
Improvement in Morphological Image Quality in Spect/ Ct Lung Studies in Patients With Differentiated Thyroid Carcinoma Treated With 131I

TEPS-17
A cost effectiveness comparison using two different pharmaceuticals as oral contrast media for PET/CT scans
C. Hansen, Ryghkliniken, København, DENMARK

E-POSTER PRESENTATION SESSIONS | FINAL PROGRAMME
Safety, biodistribution and internal radiation dose of the cell death tracer [1299nm]Duramicin in healthy volunteers
T. Cappenberg1, D. Scheppe1, F. Elvah1, C. Van de Werf1, S. De Leenheer1, L. Verheijen1, V. Van den Wijngaert1, J. Matthaes2, G. Gray3, F. Path4, S. Stobrosta4
1Nuclear Medicine, university hospital Antwerp, Antwerp, BELGIUM, Molecular imaging and radiology, Antwerp university, Antwerp, University and Nuclear Medicine, university hospital Antwerp, Antwerp, BELGIUM, Molecular Targeting Technologies, Inc, West Chester, PA, UNITED STATES OF AMERICA, 2Department of Nuclear Medicine, LUMIRX Hospital, Munich, GERMANY, 3Helmholtz Zentrum München Institut für Strahlenmedizin (IRM), Neurenberg, GERMANY.

EPS-208 Impact of Metronomic Radiopharmaceutical Therapy on Tumor and Organ-at-risk Absorbed Doses: A PBPK Modeling Approach
A. Golzaryan1, S. Sollom2, F. Monard3, B. Sabouyouhi4, A. Rahmim4
1Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran, IRAN, 2ISLAMIC REPUBLIC OF, 3Department of Electrical and Computer Engineering, University of Waterloo, Waterloo, ON, CANADA, 4Department of Radiophysics and Radiology, University of British Columbia, Vancouver, BC, CANADA.

Regression models for single point time dosimetry optimized across range of timepoints with application in 177Lu-DOTATATE therapy
C. Wang1, A. R. Petersson1, X. Wang2, M. J. Schipper3, Y. K. Devaasay4
1University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, 2Wayne State University, Detroit, MI, UNITED STATES OF AMERICA.

EPS-211 Impact of Dosimetry Method on Healthy Organ and Tumor Absorbed Dose Estimates for Lu-177-DOTATATE Therapy of Neuroendocrine Tumors
J. Brosch-Lenz1, A. Rahmim1, J. Sunderland1, F. Frey1, Y. K. Devaasay2
1BC Cancer Research Institute, Vancouver, BC, CANADA, 2University of Iowa, Iowa City, IA, UNITED STATES OF AMERICA, 3Rapid LLC, Baltimore, MD, UNITED STATES OF AMERICA, 4University of Michigan, Michigan, MI, UNITED STATES OF AMERICA, 5BC Cancer, Vancouver, BC, CANADA.

EPS-212 Accuracy assessment of absorbed dose rate calculation: evaluation of two treatment planning systems for molecular radiotherapy
J. Fragoso Negrin1, A. Vergara Gil2, L. Santamarta3, S. Vauchat4, J. Poussot4, P. De Herve5, 1Department of Molecular Imaging and Nuclear Medicine, University Hospital of Montpellier I (CHM), Montpellier, FRANCE, 2Department of Medicine Nucléaire, Institut Régional du Cancer de Montpellier (CHM), Montpellier, FRANCE, 3Department of Imaging, University of Montpellier I and Institut National du Cancer de Montpellier (CHM), Montpellier, FRANCE, 4CRCT, UMR 1194 INSERM, Université Montpellier I and Université Paul Sabatier, Toulouse, FRANCE.

EPS-213 Assessing the Impact of Dosimetry Method on Healthy organ and Lesion Absorbed Doses Estimates for 177Lu-DTPA Therapy of Prostate Early Experience from the Canadian Cancer Trials Group PR21 trial (NCT 04612747)
J. Brosch-Lenz1, X. Hau2, B. Niles3, C. Colhop4, W. R. Parulekar5, C. Delia6, F. Sadaa7, K. Che8, D. Wilson9, A. Rahmim1, C. United10, 1BC Cancer Research Institute, Vancouver, BC, CANADA, 2BC Cancer, Vancouver, BC, CANADA, 3Canadian Cancer Trials Group, Queen’s University, Kingston, ON, CANADA, 4Prostate cancer research, Montreal Cancer Institute, CRCHUM, Montréal, QC, CANADA.

EPS-215 Revision of the reference biokinetic models for dosimetry in diagnostic nuclear medicine
A. Jadczak1,4, A. Anderson2, A. Gausman3, M. Hasson4, K. Wang5, S. Leppä-Seppänen4, S. Mattsson5, D. Naskal6, J. C. Ocampo-Ramírez7, N. Petrush-Hens8, L. Soderberg9, 1Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, 2Department of Physics, University of British Columbia, Vancouver, BC, CANADA, 3Nuclear Medicine, University Hospital Galante, Lyon, FRANCE, 4Department of Medical Physics, University of Helsinki, Helsinki, FINLAND, 5Department of Nuclear Medicine, University Hospital of Montpellier I (CHM), Montpellier, FRANCE, 6Department of Nuclear Medicine, University Hospital of Montpellier I (CHM), Montpellier, FRANCE, 7Department of Radiology, University of Sydney, Sydney, NSW, AUSTRALIA, 8Department of Radiology, University of British Columbia, Vancouver, BC, CANADA, 9Department of Medical Physics, University of British Columbia, Vancouver, BC, CANADA.

EPS-216 A new tool for fast and accurate voxel-level dosimetry in radiopharmaceutical therapy with a grid-based bolus effect transport solver
B. Van1, J. K. Møller1, G. And2, Y. K. Devaasay2
1University of Michigan, Ann Arbor, MI, UNITED STATES OF AMERICA, 2Van Andel Institute for Cancer Research, Grand Rapids, MI, UNITED STATES OF AMERICA.

EPS-217 The Use of Machine Learning to Choose the Best Model and Evaluate Biokinetic Parameters in Molecular Radiotherapy
D. Coert1, E. Saad2,3, C. Pelt3, A. Napolitano3,3, S. Donato3, E. Sottile4,1, A. Cambo5, M. Piazzola6, M. F. Vittori7, A. Altieri8, M. C. Ganganare19, U. Cannata20, 1HCRS Bambino Gesù Children’s Hospital, Rome, ITALY, 2HCRS Regina Elena National Cancer Institute, Rome, ITALY.

EPS-218 Deep learning vs. deformable registration for image segmentation: which is better for dosimetry after multiple cycles of molecular radiotherapy?
N. Cole1, D. M. Miranda1, R. D. Deshpande1, A. S. Nelson1, 1MIIM Software, Cleveland, OH, UNITED STATES OF AMERICA.
EANM’22  WORLD LEADING MEETING
OCTOBER 15-19, 2022
WORLD LEADING MEETING  EANM’22
OCTOBER 15 - 19, 2022
FINAL PROGRAMME  |  E-POSTER PRESENTATION SESSIONS
E-POSTER PRESENTATION SESSIONS |FINAL PROGRAMME

G. Wang
University of Vienna, Vienna, AUSTRIA,
Sant’Orsola Hospital, Bologna, ITALY,
Fanti
Shariat
L. Muraglia
Department of Nuclear Medicine, European Institute of

EPS-229
PSMA-targeted prostate biopsy: a single-center retrospective analysis
A. Farolfi
1 L. Djaileb
2 L. S. Marks
1,2 D. Robesti
152
Department of Radiological Sciences, Department of Nuclear Medicine and Molecular Imaging, Singapore General Hospital, Singapore,
Nuclear Medicine, National University Cancer Institute, Singapore,
Oncology, National University Cancer Institute, Singapore,
Department of Interventional Radiology, National University Cancer Institute, Singapore,
Department of Medical Oncology, National University Cancer Institute, Singapore,
Department of Hematology and Transplant Center Division, IRCCS San Martino Hospital, Genoa, GENOA,
University Hospital Ospedale Di Circolo Fondazione Macchi, AAST, Bellagio, VARESE, ITALY,
Department of Medical Oncology, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Department of Nuclear Medicine, University Hospital Ospedale Civile S.Maria delle Croci, Azienda Universitaria Sanita Locale Rovigo, Rovigo, ITALY,
Non-Hodgkin lymphoma
lilotomab satetraxetan treatment in patients with indolent
Ahlström
Department, Champalimaud Foundation, Lisbon, PORTUGAL.

F-Fluorocholine PET/CT is a problem solving tool
P. Currado, D. Canziani, M. Colombo, R. Meneghini
University of Genova, Genova, ITALY.

FDG PET/CT in persistent/recurrent primary hyperparathyroidism
M. Aron, B. Patel, L. Perry, A. Alsaif, C. Harvey, A. Alves,
Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

Iodine-123 metaiodobenzylguanidine (MIBG) in the diagnosis of pheochromocytoma and paraganglioma
Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL.

F-Fluorodeoxyglucose (FDG) PET-CT and its correlation with biochemical markers in patients with 
endocrine neoplasms
Centro Hospitalar e Universitário de Coimbra, Coimbra, PORTUGAL.
EP-001 During Congress Opening Hours
A: Preclinical Studies -> A1 Medical Preclinical
- A1 In Vitro Studies
EP-001
Is it possible to replace the measurement of GFR with creatinine clearance based aGFR in children with posterior urethral valve?  
K. R. Balniamuthu, M. Chal, A. H. Nazer, S. Baran, A. A. Azya, P. K. Pradhan, S. Gambhir; Sangam Gandhi Post Graduate Institute of Medical sciences, Lucknow, INDIA.

EP-002
Dosimetric uncertainties associated with dose-response relationship in pre-clinical molecular radionuclide therapy  
S. R. A. Durgraham, A. B. Manchara, J. A. Prager, M. Barales; IVMER, Montpellier, FRANCE, Institut de Recherche en Cancérologie de Montpellier (IRCM), Montpellier, FRANCE.

EP-004
Ga-Ga Labelling of Tetrahydroquinoline-Based Compound as PET Tracers for C-CX-Chemokine Receptor Type 4 Imaging  
R. S. Sawatyananrun; S. Yar; C. Chatapinath; M. Karan; P. Roythait; D. Vajragupt; Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, THAILAND; National Cyclotron Laboratory, Chulabhorn Hospital, Bangkok, THAILAND; Thailand University, Thailand; Nuclear Research Network, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, THAILAND.

EP-005
Radiochemical and preliminary biological comparison of 3P-C-NETA-PSMA and a DOTA-GA-PSMA derivative E. Murcier; S. Aronen3; L. van der Brink3; S. Dalm3; C. Cerey3; Y. Sembille3; University of Maastricht, Netherlands, NETHOLL; Athabasca University, Athabasca, CANADA.

EP-006
Investigation of in vitro models to unravel salivary gland toxicity mechanisms after [15]Lu-LuPSMA-617 Therapy  
N. Heyns; C. Segert; S. Biestiaux; K. Vermeulen; Radiotherapy Unit, Interdisciplinary Biosciences; Institute for Environment, Health and Safety, Belgian Nuclear Research Centre (SCK CEN), Mol, BELGIUM; Department of Molecular Biotechnology, Ghent University, Ghent, BELGIUM.

EP-007
Development of Reconstruction Algorithm for High Resolution microPET Scanner Using Sudden-based System Matrix  
S. Harri Tabrizi; B. Tornmian; M. Farhashi; M. Aye; Research Center for Molecular and Cellular Imaging, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-008
Synthesis and in vitro evaluation of [17]Th-bombesin complexes  
K. Lanyove1, D. Klementyeva1, A. Bruskin1, A. Lunev1; 
GRC – IMBC, Moscow, RUSSIAN FEDERATION, Moscow.

EP-009
Comparing Folate Receptor β Targeting Tracers in Experimental Myocarditis Model  
E. Atenico Herrel1, X. Li1, H. Lijnenacker1, M. Vanmeert2; A. Kołodziejczyk1, P. Piwkowski1, A. Macioszek; Centre Hospitalar Universitaire de Coimbra, Coimbra, PORTUGAL; 1Turku PET Centre, Turku, Turku, FINLAND, 2Department of Nuclear Medicine, University of Turku, Turku, Turku, FINLAND.

EP-100
Quantitative determination of blood-brain barrier permeability assessed using [18F] fluoro-2-deoxy-sorbitol as a feature of neuroinflammation in a mouse model of endotoxemia  
S. Letertier; S. Goulal, W. Sabo, H. Guban, M. Gosslard, S. Sprecklin, V. Lebon, A. Winkeler, N. Toumier; CEA/CNRS, Inserm, BioMaps, Université Paris-Sud, Orsay, FRANCE.

EP-011
Cannabinoid Treatment Prevents the Expression of Cocaine Sensitization in the Hippocampus: a Diminutive [18F]FDG PET Preclinical Study  
L. Speith1; P. Car3; C. CA, C. Reap2; A. Buchelguge2; J. Marcoukorl; 1University of São Paulo, São Paulo, BRAZIL, University of Arizona, AUSTIN, USA; 2University of Arizona, AUSTIN, USA.

EP-012
Alcohol and tobacco: PET imaging using 2-[18F] fluoro-65380 unravels change in nicotinic receptor availability induced by ethanol exposure during adolescence  
W. Sabo; M. Gosslard; L. Reuf; C. Carl2; N. Toumier; INserm U1281, CNRS, Université Paris-Sud; Orsay, CEA/CNRS, INRS, France.

EP-013
Albumin based molecular imaging to evaluate the age-related deterioration of subarachnoid space macrocule clearance via lymphatics  
A. Skarsk; M. Yoo; Y. Cho; J. Park; Y. Lee; J. Lee; Sexual Natal University, South Korea, REPUBLIC OF.

EP-014
Longitudinal Assessment of Cerebral Oxygeneal Metabolism in a Rat Model of Neonatal Hypoxic- Ischemic Encephalopathy using PET with [18F] fluorodeoxy glucose and PET with [18F] fluorine as a feature of neuroinflammation in a mouse model of endotoxemia  
T. K. Terkenli1; E. Sabah2; T. Kelter3; O. Erkal4; F. Lopez-Rincón1; J. R. Aguiar1; F. Barakat5; O. Solin6; Van Pランキング6; 1Turku PET Centre, University of Turku, Turku, FINLAND, 2MediCity Research Laboratories, University of Turku, Turku, FINLAND; 3Turku PET Centre, Åbo Akademi University, Turku, FINLAND.

EP-015
Evaluation of PET imaging as a tool for detecting neonatal hypoxic-ischemic encephalopathy in a preclinical model  
T. K. Terkenli; E. Sabah; T. Kelter; O. Erkal; F. Lopez-Rincón; J. R. Aguiar; F. Barakat; O. Solin; Van Pランキング; 1Turku PET Centre, University of Turku, Turku, FINLAND, 2MediCity Research Laboratories, University of Turku, Turku, FINLAND; 3Turku PET Centre, Åbo Akademi University, Turku, FINLAND.

EP-016
A novel PET radiotracer for imaging reparative microglia L. Vivas1; R. Muñoz2; A. Wang1; M. Biderer; B. Lupi; L. Ackermann1; J. Kipps1; J. Babić; Monash University, Melbourne, AUSTRALIA; V. Geary, Institute of Mental Health, Melbourne, AUSTRALIA; Austin Hospital, Melbourne, AUSTRALIA.

EP-03 During Congress Opening Hours
A: Preclinical Studies -> A1 Medical Preclinical
- A13 Preclinical Oncology
EP-017
Preclinical Models and PET/CT Imaging to Study Malignant Pleural Mesothelioma  
O. Bejuy; J. Senoer; S. Germann; F. Torpinerez; V. Serre-Benett1; D. Ley1; K. Sato; 1CIBM Centre for BioMedical Imaging, Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND, 2Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, Geneva, SWITZERLAND, 3Small Animal Imaging Facility, Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND.

EP-018
Reactive astrogliosis imaging with [11]C-acetate PET in patients and mouse models with glioblastoma  
H. K. J.; C. Zhang; T. Kim; Y. Kim; L. Chen; M. Lee; H. Nan; J. Chang; C. Lee1; M. You2; 1Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF; 2Institute for Basic Science, Daejeon, KOREA, REPUBLIC OF; 3Peine National Institute, Incheon, KOREA, REPUBLIC OF; 4Morea Institute of Science and Technology, Seoul, KOREA, REPUBLIC OF.

EP-019
PET/SPECT/MI/MR Imaging of the CAM Model as a Theragnostic Platform for Cancer  
O. Bejuy1; J. Busungny; S. Germann1; A. Martorell1; F. Boistr1; J. Dieguez1; D. Veit1; J. Prost1; V. Gantelet2; D. J. Cohen; 1CIBM Centre for BioMedical Imaging, Faculty of Medicine, University of Geneva, Geneva, SWITZERLAND, 2Division of Thoracic and Endocrine Surgery, University Hospitals and University of Geneva, Geneva, SWITZERLAND.
of Nuclear Medicine and Molecular Imaging, University of Geneva, Geneva, SWITZERLAND.4) Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital and University of Lausanne, Lausanne, SWITZERLAND.5) Virtual Imaging Facility, Department of Research and Training, University of Lausanne, Lausanne, SWITZERLAND.

EP-020
Use of the fibroblast activation protein inhibitor 64Cu-DOTA-N1AZI-PI for PET imaging of murine orthotopic head and neck cancer
I. Ben-Salem1, I. Bouchoucha1, Y. Drouin1, J. Dufour1, L. Demers1, E. Morin1, J. Hétu2, H. Marcoux3, and D. Fortin4
1) Centre d’Imagerie Moléculaire de l’Université de Bourgogne UMR LIIC EPHE-PSL-UB, Dijon, FRANCE, 2) INSERM UMR1231 « Lipides Nutrition Cancer, Dijon, FRANCE, 3) Covalab, Bron, FRANCE, 4) CGFL, Herblain, FRANCE, 5) University of Ottawa, Ottawa, ONTARIO, CANADA.

EP-021
Development of an easily bioconjugatable water-soluble SPECT/OPTICAL biodiagnostic tool to target the cancer biomarker CD133
D. Lablond1, C. Beiran2, A. Aouad3, S. Ravina1,23, S. Rayon2, J. P. Mante2,4, J. L. Vinatier2,5, G. Desta2,4,6, and I. Verina7
1) Department of Medical Chemistry at Université d’Angers, Inserm U1307, CNRS U6075, Université d’Angers, France, 2) CRCI2NA, Université d’Angers, Inserm U1307, CNRS U6075, Nantes Université, France, 3) Unité de Neurosciences Moléculaires et Radiobiologie, Hôpitaux Universitaires de Nantes, France, 4) UMR1235 Neurosciences Moléculaires et Radiobiologie, INSERM, Nantes, France, 5) UMR1188 Institute of Molecular and Cell Biology, University of Geneva, Geneva, Switzerland, 6) UMR1231 Lipides Nutrition Cancer, Dijon, France, 7) Unité de Pharmacologie, Université d’Angers, Inserm U1307, CNRS U6075, Université d’Angers, France.

EP-022
Pre-clinical evaluation of a Ga-labeled PSMA/GPR17-targeting heterodimeric Radiotracer for PET Imaging of Prostate Cancer
F. Laurent1, S. Abouzahra1, S. Rinen1, V. Tolmachov1, A. Griva1, U. Rosenzweig1,2
1) Department of Nuclear Medicine at Université d’Angers, Inserm U1307, CNRS U6075, Nantes Université, France, 2) CRCI2NA, Université d’Angers, Inserm U1307, CNRS U6075, Nantes Université, France.

EP-023
A designed radiolabeled Poly (Lactic-Co-Glycolic Acid) nanoparticle for therapeutic applications
M. Yarai1, V. Benvenuto1, M. Serafinelli1, C. Lauren2, A. Signore2, La Sapienza University, Rome, ITALY.

EP-024
A template mediated site-selective labeling method for preclinical imaging of therapeutic antibodies
L. Marx1, V. Postupalsky1, A. Krenkel1, M. Paniz1, N. Gopner1, A. Johansson1, T. Dено1, G. Hagen1, J. Segura1, F. Levy1, P. Gamxal1, J. Priet1, M. Schott1, N. Scharf1, D. Nyangwale1,2, Department of Research and Manufacturing, SA, Marting, Switzerland, 3) Lausanne University Hospital, Nuclear Medicine and Molecular Imaging, Lausanne, Switzerland, 4) Neptis, Valais-Wallis, Switzerland, 5) IFIS-QS, Valais-Wallis, Switzerland, 6) Institute of Life Technologies, University of Geneva, Geneva, Switzerland, 7) Department of Biomedical Imaging, University of Geneva, Geneva, Switzerland.

EP-026
Immuno-PET Imaging for CD20 Expression in Non-Hodgkin’s Lymphoma
E. T. Sorcan Bozkız1, S. Payası1, M. Rustuha2, A. Y. Özler1, C. Manalpa1, N. Harman1, V. Gouverneur1, A. Bratton2,3,4,5,6, Georges François Leclerc, Dijon, FRANCE, 1) Institut de Chimie, Dijon, FRANCE, 2) Centre de Chimie Moléculaire de l’Université de Bourgogne UMR C2MIC, Dijon, FRANCE, 3) Centre de Recherche du CHU (CRCHU), Dijon, FRANCE, 4) UMR LIIC EPHE-PSL-UB, Dijon, FRANCE, 5) Covalab, Bron, FRANCE, 6) CGFL, Herblain, FRANCE.

EP-027
Development and Preclinical Evaluation of Two Biphasic PSMA/FAP-targeting Radiotracers
A. Verena1,2, Z. Zhang1, H. Mekem2, A. Pan1, N. Coulo3, R. Wilson4, J. Helbling1, K. Lai1
1) British Columbia Cancer Research Institute, Vancouver, BC, CANADA, 2) Department of Radiology, University of British Columbia, Vancouver, BC, CANADA.

EP-028
Synthesis, Radiolabelling, and In Vitro Evaluation of an Iodine-123 agent for Targeted Radiolabelling Therapy of PAEP-expressing Tumours
G. Desta1,2, Z. Chen1,3, G. Dias1, C. Fraser1, M. Mosley1, S. Dall1, H. O’Neill1, H. Goulbourn2, and B. Comley1, University of Oxford, Oxford, UNITED KINGDOM.

EP-029
Targeting mutant p53: Evaluation of novel anti-p53 monoclonal antibodies as agents for molecular imaging
D. Spiegelberger1,2, L. Hwang1, Y. Park1, S. Kapabhatik1, H. X. Kopp1, D. P. Lapenna1, M. Nestor2, 1) Department of Immunology, Genetics and Radiology, University of Oxford, Oxford, UNITED KINGDOM, 2) Department of Surgery, Université de Strasbourg, Strasbourg, FRANCE.

EP-030
The pharmacologic effect of PSMA-617 on Prostate Cancer growth
F. Zhao1, N. Nethak1, A. Heim1, A. Hibreki1, M. Manu1, L. Utzner1, M. Gaug1, 1) Department of Nuclear Medicine, Molecular Imaging, Diagnostics and Therapy, University Hospital of St. Jörg, GERMANY.

EP-031
K. Camacho1, J. Dias1,2, V. Tavano3, M. Cabre1, L. Reyol1, A. Pasciolo1, M. Ferreira1, E. Savio1, P. Duarte4, P. Cabral1, J. Gombao1,2, 1) Universidade de la Republica, Montevideo, URUGUAY, 2) Centro de Imagenologia Molecular, Montevideo, URUGUAY.
EP-044
Chelator-free Radiolabelling of Graphene Oxide Nanoparticles for in vivo Imaging
H. Grover; A. Ananthan, A. Gavrylenko, B. Ellis, R. Kostarelos, O. Jasmin
*Manchester University NHS Foundation Trust, Manchester, UNITED KINGDOM, *School of Chemistry & National Graphene Institute, University of Manchester, Manchester, UNITED KINGDOM
**Department of Medical Physics and Engineering, University of Manchester, Manchester, UNITED KINGDOM

EP-045
Therapeutic Response Monitoring with ⁸¹⁸F-DFO-Petuzumab Immunopeptide for anti-HER2 immunotherapy and HSP90 inhibitor treatment in JIMT-1 Xenograft Model
T. Lee; K. Park, J. Park, K. Kim, J. Kang
*Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, KOREA, REPUBLIC OF, *Kwangjeon, Jeonju, KOREA, REPUBLIC OF.

EP-046
Comparative study of rheumatoid arthritis treatment by ⁹⁹mTc-hydroxyapatite and ¹⁸¹Re-sulfate in rabbit knee joints
S. Mazali, M. Shamsi, A. Shokri
*Parsisotope Company, Tehran, IRAN, ISLAMIC REPUBLIC OF, **Research Center for Molecular and Cellular Imaging, Tehran, IRAN, ISLAMIC REPUBLIC OF

EP-052
Preclinical evaluation of ¹⁸F-fluorocholesterol PET for evaluating skeletal muscle atrophy in starvation induced rat model
B. Moon, S. Park, B. Kim, K. Lee
Ewha Womans University College of Medicine, Seoul, KOREA, REPUBLIC OF,

EP-053
Diagnostic performance of PET radiotracers for infection: in vitro and in vivo studies in an acute infection animal model in mice
1Department of Nuclear Medicine, University of Health Sciences, Department of Nuclear Medicine, University of Health Sciences, Korea Institute of Radiological and Medical Sciences (KIRAMS), Seoul, KOREA, REPUBLIC OF, 2Department of Medical Physics and Imaging, University of Navarra, Pamplona, SPAIN, 3Department of Microbiology and Parasitology, Pamplona, SPAIN, 4Telmus Therapeutics, Nijmegen, NETHERLANDS

EP-054
Development of intranasal microimplants with ¹¹¹In-radiolabelled rispenserin for in vivo and in vitro release studies
1Department of Nuclear Medicine, Clinical University of Navarra, Pamplona, SPAIN, 2Department of Medical Physics and Imaging, University of Navarra, Pamplona, SPAIN, 3School of Pharmacy, Universidad de Navarra, Pamplona, SPAIN

EP-055
Uptake of ¹⁸F-FDG in a mouse model of rheumatoid arthritis
1Department of Nuclear Medicine, Clinical University of Navarra, Pamplona, SPAIN, 2Department of Medical Physics and Imaging, University of Navarra, Pamplona, SPAIN, 3Department of Microbiology and Parasitology, Pamplona, SPAIN

EP-056
Cerenkov luminescence imaging (CLI) of interstitial brown adipose tissue (iBAT) using TSPO-targeting (⁹⁹mTc-F9001)
1Department of Nuclear Medicine, Seoul National University Hospital, Seoul, KOREA, REPUBLIC OF, 2Department of Biomedical Imaging, Seoul National University College of Medicine, Seoul, KOREA, REPUBLIC OF

EP-057
PET to assess the pulmonary disposition of inhalation drug
1Department of Clinical Pharmacology, Medical University of Vienna, Vienna, AUSTRIA, 2Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA

EP-058
Use of ¹⁸F-fluorodeoxyglucose (⁹⁹mTc-FDG), and ¹⁸F-fluoroparaffinbenzoic acid (⁹⁹mTc-BPA) as gram positive and negative specific PET radiotracers for diagnosis of infection in a chronic model of foreign body osteomyelitis in rats
1Department of Nuclear Medicine, Clinical University of Navarra, Pamplona, SPAIN, 2Department of Medical Physics and Imaging, University of Navarra, Pamplona, SPAIN, 3Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA, 4Kear Facility Laboratory Animal Breeding and Husbandry, Medical University of Vienna, Vienna, AUSTRIA

EP-059
Nanosized graphite encapsulating technetium-99m metal complex for lung ventilation: Seen in rats
1Department of Nuclear Medicine, Clinical University of Navarra, Pamplona, SPAIN, 2Department of Medical Physics and Imaging, University of Navarra, Pamplona, SPAIN, 3Department of Cell Biology, Clinical Universidad de Navarra, Pamplona, SPAIN

EP-060
The Scintigraphic Evaluation of The Effect of Extremely Low Frequency Magnetic Fields Exposure on Nasal Mucociliary Clearance
N. Dizdar; A. Akbualtı, G. Kocat, N. Yumusak, A. Canerven, C. Cemal, C. Cemal, H. Elif, Y. Hakan, R. Dilek
*Department of Nuclear Medicine, University of Health Sciences, Ulus Training and Research Hospital, Ankara, TURKEY, **Department of Nuclear Medicine, University of Health Sciences, Ankara Training and Research Hospital, Ankara, TURKEY

EP-061
High Resolution PET Detector Design Using SiPM Array
A. Rashid, M. Farashahi, M. Afzal
*Research Center for Molecular and Cellular Imaging, Tehran, IRAN, ISLAMIC REPUBLIC OF, **Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF

EP-062
Prognostic value of ¹⁸F-FDG brain PET in suicidal hanging: A preclinical study using a rat model of hanging-induced hypospadias brain injury
D. Kim; H. Yoon
Incheon St. Mary’s Hospital, The Catholic University of Korea, Incheon, KOREA, REPUBLIC OF, *Yeshiva University School, Seoul, KOREA, REPUBLIC OF

EP-063
Angiogenesis probe,68Ga-NODAGA-RGD: Study of pharmacokinetic behavior and quality control parameters
H. Pise; R. Shera*, M. Manz*, V. Bonyk*
Tata Memorial Hospital, Mumbai, INDIA, *Inmoe Bhadrab National Institute, Mumbai, INDIA

EP-064
The Process of Radiation Exposure Lymphocyte Damage Assessed by γH2AX Expression Level using Flow Cytometry
*Department of Nuclear Medicine, Kanazawa University Hospital, Kanazawa, JAPAN, **Department of Pediatrics, Kanazawa University Hospital, Kanazawa, JAPAN, 1Department of Radiation and Medical Physics, Research Center for Experimental Modeling of Human Disease, Kanazawa, JAPAN

EP-065
GFR determination in pigs based on late samples only
L. Jedli; J. J. Bingren*, C. L. Ledegard*, L. Lund*, T. B. Anderson
1Dept. of Nuclear Medicine, Aalborg University Hospital, Aalborg, DENMARK, 2Dept. of Urology, Aalborg University Hospital, Aalborg, DENMARK, 3Dept. of Urology, Odense University Hospital, Odense, DENMARK

EP-066
Multimodal MR/PE/TCT imaging to monitor disease progression in a reproducible lung irradiation rat model
1Lund University Bioimaging Center, Lund, SWEDEN, 2Department of Translational Medicine, Medical Radiation Physics, Malmo, SWEDEN, 3Department of Nuclear Medicine, Lund University Medical Center, Lund, NETHERLANDS, 4Vita-Lab, Medican Village, Lund, SWEDEN

EP-050
Comparative studies of ¹⁸F-labeled human serum albumin in the mouse and CAM model
1Klinik für Nuklearmedizin, Ulm, GERMANY, 2Klinik und Experimentelle Traumains-Chirurgie, Ulm, GERMANY, 3Klinik für Cerebrovascular Medicine, Ulm, GERMANY
B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B14 (including Mesothelioma)
EP-153 Optimization of prostate cancer patient lymph node staging via the integration of neutrophil lymphocyte ratios, platelet lymphocyte ratios and "Ga-PSMA-PET-" derived SUVmax values
K. Tong, X. Liu, H. Chen, W. Rao, H. Hu, Xiangya Hospital Central South University, Changsha, CHINA.

EP-154 Usefulness of semi-quantitative analysis in the differentiation of prostate cancer stage in the initial staging of prostate cancer: SPECT/CT multiFOV
A. Castro López, M. Gallego Martínez, J. Veneno Chaparro, D. Becerra García
Hospital Universitario Clinicino San Cecilio, Granada, SPAIN.

EP-155 Relationship between SUVmax and ADC values of metastatic lymph node also ADC values of metastatic and reactive lymph nodes detected by Ga-68 PSMA PET/MR in prostate cancer patients
Istanbul University-Cerrahpaşa, Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, TÜRKİYE.

EP-156 18F-Fluorothioline PET/CT radiomic analysis for newly diagnosed prostate cancer patients: a first monocular experience
D. Pizzuto, E. A. K. Trumbull, R. Bennett*, J. A. Bistrian, R. Castrogiovanni1,2, M. De Summa1, F. Perera1, M. De Cabo-Ripoll1,2, L. García Zoghby1,2, A. García Vicente1,2, C. Caldarella, M. Canclini, S. Amorena1, M. Zucchi, D. Zogala, L. García Zoghby1,2, A. Garcia Vicente1,2, A. Soriano1,2
1Institute of Nuclear Medicine and Oncology, Trieste, ITALY, 2University of Trieste, Trieste, ITALY.

EP-157 Role of volumetric parameters on [18F]PSMA-1007 PET/CT in primary staging of prostate cancer patients
1Department of Nuclear Medicine, University College of Medicine, Seoul, KOREA, REPUBLIC OF, 2Department of Nuclear Medicine, Samsung Medical Center, Seoul, KOREA, REPUBLIC OF.

EP-158 Evaluation of PROMISE criteria inspired intraprostatic PSMA-score against PRAD-Index in patients undergoing radical prostatectomy
W. Wang, K. Chen, P. Bárzilai, A. Bajorek, M. Foot, D. Damen Bolman, M. Masure
1Austin Health, Melbourne, AUSTRALIA, 2Lund University, Lund, SWEDEN, 3Gustavus-Volmer University, Gothenburg, SWEDEN.

EP-159 Intra-individual intermodal comparison of [18F] siPSMA PET/14C14 imaging and mpMRI in primary staging of prostate cancer patients: a comparative study with [18F] FDG PET/CT
1Department of Nuclear Medicine University Hospital Ulm, Ulm, GERMANY, 2Department of Radiology, University Hospital Ulm, Ulm, GERMANY, 3Department of Radiation Therapy, and Therapy, University Hospital Ulm, Ulm, GERMANY.

1Institute of Nuclear Medicine, First Medical Faculty and General University Hospital, Prague, CZECH REPUBLIC, 2Department of Radiology, First Medical Faculty of Charles University and General University Hospital, Prague, CZECH REPUBLIC.

EP-161 "Ga PSMA PET-CT and PSA Score Affecting Therapeutic Decision-Making in Treatment Naive High-risk Prostatic Carcinoma
T. Pamuk, N. Yonum, S. Adayan, A. Shashik
Institute of nuclear medicine and oncology Lahore, Lahore, PAKISTAN.

EP-162 Diagnostic and therapeutic impact of PET/CT with 18F-Fluciclovine in intermediate stage of metastatic prostate cancer
L. García Zoghby1,2, A. Palsadi Berezko1, M. Sócoa Paez1, A. García Vicente1,2, J. Jimenez Garcia1,2, F. Pena Pardo1, E. Nooré Alvarez1, A. Sanano Gastero1,2
1Nuclear Medicine Department, General University Hospital of Ciudad Real, Ciudad Real, SPAIN, 2Hospital General University of Alicante, Alicante, SPAIN, 3University General Hospital of Albacete, Albacete, SPAIN, 4University Hospital of Guadalajara, Guadalajara, SPAIN.

1University of Twente, Enschede, NETHERLANDS, 2UOZ, UZ, NETHERLANDS.

EP-164 To evaluate the diagnostic efficacy of 99mTc-mPSCIT scintigraphy for disease mapping in prostate cancer patients: A comparative study with68Ga-PSMA-PET
M. Hoads, S. Prashut, H. Singh, R. Mohan, N. Kakkar, S. K. Singh, B. Singh
1Department of Nuclear Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF, 2Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-165 Impact Of 18f-DCFpYl With Respect To 18f-Fluorocholine PET/CT In TNM Assessment In Prostate Cancer Biochemical Recurrence
L. García Zoghby1,2, A. García Vicente1,2, C. Caldarella, M. Canclini, S. Amorena1, M. Zucchi, D. Zogala, L. García Zoghby1,2, A. Garcia Vicente1,2, E. Noreña Álvarez, J. Calahorra Fernández*, P. Rial*, M. De Carlo Rปาpil, A. Salina Sánchez, F. Leal Hernández*, M. Villegas Rícula, A. Sánchez Jorda, M. De Summa1, F. Perera1, M. De Cabo-Ripoll1,2, L. García Zoghby1,2, A. Garcia Vicente1,2, C. Caldarella, M. Canclini, S. Amorena1, M. Zucchi, D. Zogala
1Department of Nuclear Medicine, University College of Life Science and Bioengineering, Incheon, KOREA, REPUBLIC OF, 2Department of Pathology in Yonsei University College of Medicine, Seoul, KOREA, REPUBLIC OF.

EP-166 Role of 18F-DCFpYl (PSMA) PET/CT in treatment changes decision in suspected biochemical recurrence of prostate cancer patients in our centre

EP-167 The most important clinical factors connected with the positive "Ga-PSMA-PET-CT scan in patients with biochemical recurrence of prostate cancer patients" in our centre
1Department of Nuclear Medicine and Radiation Protection, University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-168 "F-18 FLY PET/CT detection rate by prostate-specific antigen serum values in patients with biochemical recurrence prostate cancer treated with radical prostatectomy: Experience of the University Hospital of Salamanca

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B18 Prostate BC Recurrence

During Congress Opening Hours
- Poster Area

B: Imaging Clinical Studies
**EP-201** Head to Head Comparison of [Ga(Ga-FAPi)-04 and [Ga(Ga-DOTATATE PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma
E. Enk, C. Cyma, D. Hanssimian, M. Apakian, N. Guil, S. M. Erdük, Y. San, S. Ruyumcu, Istanbul University, Istabul Faculty of Medicine Nuclear Medicine Department, Istanbul, TURKEY.

**EP-202** Prostate-Specific Membrane Antigen (PSMA)-Expression in Poorly Differentiated and Anaplastic Thyroid Cancer - a new therapeutic option?
E. Elsaeger, P. D. Fazal, E. Meurer, J. Hanafiah, C. Kretzer, A. Rostkowski, J. Licnian, D. R. Bartl, M. Luster, S. Wächter, Philips University, Department of Nuclear Medicine, University Hospital Marburg, Marmburg, GERMANY; Philips University, Department of Visceral, Thoracic and Vascular Surgery, University Hospital Marburg, Marmburg, GERMANY; Philips University, Department of Pathology, University Hospital Marburg, Marmburg, GERMANY.

**EP-203** "I-131 accumulation in the digestive system: Results on the Differentiated Thyroid Cancer Population treated in our hospital the last 9 years
T. Karanios, K. Kouvelis, C. Albar, E. Tatsikou, M. Bélia, S. Giammoulopoulos, Y. Kouroudis, S. Saranti, "Saints Anargyroi" Cancer Hospital, Athens, GREECE.

**EP-204** Thyroid cancer recurrence risk in Grave’s disease and other causes of hyperthyroidism

**EP-205** Diagnostic Performance of FDG-PET/CT in Anaplastic Thyroid Carcinoma Staging

**EP-206** Quantification of thyroid remnant in thyroid cancer with "131I Nal" PET/CT.
W. Zeng, Q. Lu, B. Zhang, N. Su, A. R. Aghdami, The Ottawa Hospital, Ottawa, ON, CANADA.

**EP-207** Diagnostic Role Of F-FDG PET-CT Based on Thyroid Nodules:
D. Dezzo, K. Zámhó, R. Zitter, B. Zádai, S. Szemmer, E. Meitl, I. Bokor, J. Schuh, University of Pécs, Medical School, Department of Medical Imaging Diagnostic, Division of Nuclear Medicine, Pécs, HUNGARY; University of Pécs, Medical School, 1st Department of Medicine, Pécs, HUNGARY.

**EP-208** Early FDG PET-CT in staging of thyroid carcinoma of follicular origin in Balearic Islands
A. Repetto, J. Luna, F. Angel, O. Prieto, L. Nieto, C. Sampol, S. Rubi, M. Gemenet, C. Petriá, Nuclear Medicine Department, Hospital Universitario San Espiarios, Palma De Mallorca, SPAIN, Palma, Palma de Mallorca, SPAIN.

**EP-209** Comparison of biodistribution of [18F] F-PSMA-1007 and [123I] Ga-DOTATATE PET/CT in patients with differentiated Thyroid carcinoma without risk factors at surgery followed in a long-term follow-up after thyroidectomy and radioactive ablation
A. Marongiu, S. Nuvoli, P. Solinas, M. Randini, A. Papas, A. Spampin, G. Madauleu, Unit of Nuclear Medicine, University of Sassari, Sassari, ITALY.

**EP-210** Establishment of PET/MRI "Dual threshold" quantitative diagnostic criteria for identifying lymph node metastasis in patients with papillary thyroid carcinoma
T. Han, Z. Quan, H. Wei, S. Zhao, M. Wang, X. Meng, J. Wang, G. Li, J. Wang, F. Kang, Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, 6127, West Changzhong Road, Xian, CHINA.

**EP-211** Association of Neck Ultrasound and I-131 and Whole body SPECTigraphy among Adult Patients with Well-differentiated Thyroid Carcinoma and Locoregional Lymph Node Metastasis after Total Thyroidectomy and Radioactive Iodine Ablation
I. Bondong, F. P. Gaina, C. J. MaYa, St. Luke’s Medical Center-Quezon City, Queen City, QUEZON, PHILIPPINES.

**EP-212** Comparison of treatment efficacy 1 and 2 years after thyroid remnant ablation with 1110 versus 5550 MBq of iodine 131 in patients with intermediate risk differentiated thyroid cancer
A. Aghare, N. Azizi, A. Sharife, Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

A. Palomar-Murias1, P. Barrio-Budkhal, M. D. Marti-Cardona2, G. Reynés1, J. G. Ros3, C. V. Martinez-Ramallo4, S. Binda-Blanc1, J. R. Robles1, P. C. Castilla1, L. M. Grañó-Sánchez1, M. Cortés-Romero1. 1Hospital Universitario La Paz, Madrid, SPAIN, 2University Hospital La Fe, Valencia, SPAIN, 3Hospital Universitario Daniel Zorilla, Ciudad Real, SPAIN, 4Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat (Barcelona), SPAIN.

EP-220 Prognostic significance of [18F]-FDG PET/CT in Gynecological Cancers

P. Spiridon1, A. Gherrra1, C. Maziu1, D. Cucun2, C. Calin1, F. Jonela-Roldán3, M. J. Ríos-Jaén4, Central University Emergency Military Hospital. Bucharest, ROMANIA.

EP-221 Clinical impact of PET/CT in paraaortic staging in patients with locally advanced cervical cancer

Y. Abadi Sedraoui1, M. Coronado Poggio1, C. Lancha Hernández1, J. González Roncal2, Escuecas Del Pino3, S. Rodado Marina4, S. Rialdell Monlar4, D. Travgino Morales1, E. López López1, G. Gómez-González1, L. Domínguez Gadea1. Hospital Universitario La Paz, Madrid, SPAIN.

EP-222 Quantitative metabolic parameters of [18F]-FDG PET/CT as predictors of complete cytoreduction in patients with diffuse large B-cell lymphoma


EP-223 Diffuse splenic [18F]-FDG uptake and peripheral blood lymphocyte monocyte ratio for prognosis prediction in patients with large B-cell lymphoma

K. Kim1, S. Kim1, X. Yin2. 1Pusan National University, Busan, KOREA, REPUBLIC OF, 2Kyungpook National University, Busan, KOREA, REPUBLIC OF.

EP-224 The prognostic role of baseline [18F]-FDG PET/CT in peripheral T-cell lymphoma

F. Czibulka1, J. Bezak Hansen2, S. Gormsen3, D. Sandfeld-Paulsen1, N. Aagaard-Pedersen1, M. Holm Venerdal1,2,2. 1Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, 2Institute of Biomedicine, Aarhus University, Aarhus, DENMARK, 3Sprint Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, DENMARK.

EP-225 The role of [18F]-FDG PET/CT biomarkers in the prognosis of patients with diffuse large B-cell lymphoma treated with Chimeric Antigen Receptor T Cell Therapy, our experience

J. Cañadas Salasor1, A. Martín López1, D. González García1, J. García García-Sancho, Á. Peñaherrera Cepeda1, G. Villanueva Curto1, F. Gómez Camarero López2, F. Tamayo Alonsa3, Gacit, Salamanca; SPAIN.


M. Sádki1, S. Barrington1, J. Úbeda1, Ó. Ñoraudoa1, Ó. T. García1, T. Saboury1, A. Lethiep Nolan1, A. Loft Jaksbø2, A. Loaiza Gonzaga3, J. López-Urdiales1, R. Kumar1, L. Lendenbrand1. 1Medicine, Gothenburg, SWEDEN, 2Clinical PET Centre, London, UNITED KINGDOM, 3Epigeneion AB, Malmö, SWEDEN, 4Electrical Engineering, Gothenburg, SWEDEN, 5Clinical Physiology and Nuclear Medicine, Malmö, SWEDEN, 6Molecular and Imaging Sciences, Bethesda, WA, UNITED STATES OF AMERICA, 7American Nuclear Medicine, Odense, DENMARK, 8Clinical Physiology, Copenhagen, DENMARK, 9Diagnostic Imaging, Oslo, NORWAY, 10Institute of Medical Physics and Electrical Engineering, University of California, San Francisco, UNITED STATES OF AMERICA.

EP-227 Bone marrow assessment in Hodgkin and Non-Hodgkin lymphomas with [18F]-FDG PET/CT imaging, how confident can we be?

A. Lavande Málchir1, C. Vigo Díaz1, J. Maraña-González1, J. Rodríguez Díaz1, S. Narroño Sanchez1, M. Domínger Grande1, N. Martín Fernández1, J. Suárez Fernández1, M. Fernández Luna1, A. Álvarez Blanco1, M. García Lleona, N. Téllez Ramón2, M. López Carballa3, A. Alvarez Alonsa1, F. González Garcia1, HUCA, Oviedo, SPAIN.

EP-228 Diagnostic performance and therapeutic impact of [18F]FDG PET/MI in monoclonal gammopathy of uncertain significance (MGUS)

J. García1, A. Compte1, J. Romo1, E. Valls2, S. Moure2, M. Kauk2, M. Solé1, T. Blanch1, E. Reina. 1CEIBLA ASOCIES Grupo biomédico, Barcelona, SPAIN.

EP-229 Metabolic Tumour Volume Improves the Prognostic Value of Pre-existing Scoring Models in Sarcoma

M. Pedersen1,2, J. Bezak Hansen1, S. Gormsen3, D. Sandfeld-Paulsen1, N. Aagaard-Pedersen1. 1Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Aarhus, DENMARK, 2Institute of Biomedicine, Aarhus University, Aarhus, DENMARK, 3Sprint Diabetes Centre Aarhus, Aarhus University Hospital, Aarhus, DENMARK.

EP-230 Accuracy verification of Z-score calculation software for bone metastasis diagnosis in bone SPECT/CT

Y. Yakushiji1, K. Mihara2, S. Fukuda1, K. Kurusu1, A. Takeda3, N. Miyata1, K. Watarisuma1, N. Nishikawa4, T. Hasegawa5. 1Kasato University Graduate School of Medical Sciences, Kanagawa, JAPAN, 2Fukushima Medical University, Fukushima, JAPAN, 3Hahnahs Hospital, National Center for Global Health and Medicine, Chiba, JAPAN, 4Department of Nuclear Medicine, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JAPAN, 5Gun Metropolitan Institute of Genterology, Tokyo, JAPAN, 6International University of Health and Welfare, Tokachi, JAPAN.

EP-231 Diagnostic significance of myelolipomas

M. Navas de la Cruz1, P. Abu2, M. Estaban3, A. Badenes1, C. Sánchez Caballero1, J. Luster2. 1Hospital Universitaria Dr. Peset, Valencia, SPAIN.

EP-232 ***Tc-MDP SPECT/CT for the characterization of enostosis

A. Fernandez1, A. Dornan2, D. Guller2, J. Raudí1, L. Guller1, E. Lischicki1, C. Carreras1, M. Villavicencio1, A. Damian2. 1University of the Republic, Montevideo, URUGUAY, 2Centro Uruguay de Imagenología Molecular - CUDIM, Montevideo, URUGUAY.

EP-233 Feasibility and toxicity study of intra-articular 188Re Colloid injection in patients with rheumatoid arthritis with three phase positive bone scan and radiatory knee joint pain

A. Aghaei1, Z. Mirfakhri1, N. Narooobei2, S. Zakavi2. 1Nuclear medicine research center, Mashhad university of Medical Sciences, Mashhad, IRAN, 2Islamic Republic of Iran, Mashhad university of Medical Sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-234 Evaluation of vertebral destruction with SPECT/CT and MRI

D. Arguelles1, F. Lemos Ramírez1, J. Dominguez2, K. Vite Pineda3, I. Palacios4, J. Pardinas5, P. Pardo6, J. Durán7. 1Instituto Nacional de Rehabilitación, Mexico, MEXICO, 2Intituto Nacional de Cancerologia, Ciudad de Mexico, MEXICO, 3ID, Otto Rodriguez Polanco, 4San Pedro, BELLEZ, 5NC 35 Instituto Mexicano de Seguro Social, Ciudad Juarez, MEXICO.

EP-235 PET/CT versus SPECT/CT and Planar Bone Scintigraphy in Characterization of Suspicious Osseous Lesions in cancer patients

N. Bashank1, A. W. Husseen1, M. Mekawy2, H. Aksar1. 1Assut University Hospitals, Assut, EGYPT.

EP-236 Pitfalls in dual tracer uptake of [18F]-FAPi-46 and [18F]-FDG PET/CT in Ewing sarcoma

N. Dodger. Research Center, Imam Reza University, Razavi Nuclear Medicine and Molecular imaging, Mashhad, IRAN, ISLAMIC REPUBLIC OF.


N. Maneska1, D. Todorova Stefanovska1, A. Tatatovska1, A. Janukovska1, T. Maksalova2, S. Stopanska2. 1Medical Faculty, Skopje, NORTH MACEDONIA, 2University Institute for Radiation Emission: Tomography, Skopje, NORTH MACEDONIA, 3University Clinic of Pulmonology and Allergy, Skopje, NORTH MACEDONIA.

EP-20 Evaluation during Congress Opening Hours

B: Imaging Clinical Studies -> B1 Oncological Imaging Clinical Study -> B24 Melanoma
EP-247
IGG-related diseases: Utility of 18F-FDG PET/CT
S. Sagar, D. Khan, A. Mahata, A. K. More, S. X. Woknang, J. Pathak, S. A. Sharma, N. Y. Kamar, AIMS, Delhi, INDIA.

EP-248
Role of 18F-FDG PET/CT in the diagnosis of benign vs. malignant tumor thrombus: a retrospective study
S. Sagar, D. Khan, A. Mahata, A. K. More, S. X. Woknang, J. Pathak, S. A. Sharma, N. Y. Kamar, AIMS, Delhi, INDIA.

EP-249
Department of Thoracic Surgery, Istanbul, TÜRKIYE.

EP-250
Hospital Universitario La Paz, Madrid, SPAIN.

Preliminary Results: Characterization of FDG PET/CT
N. Al-Oybadi, H. D. Zacho; Non-malignant FAPI-avid PET/CT Findings: A Review University Hospital, Aalborg, DENMARK.

F. Manchon Adsuar; EP-251 Radiography and Radiation Therapy Planning

EP-252
Sentinel Lymph Node Biopsy in patients with prior ipsilateral breast cancer surgery
P. Guendou Jimena, A. Santos Bueno, A. Rebollos Auquier, A. Moena Ballestos, J. Bayo Calas, A. Jimena Heffernan; Hospital Universitarios Juan Ramón Jimenez, Huelva, SPAIN.

EP-254
Follow-up after radical prostatectomy with sentinel node biopsy and pelvic lymph node dissection: oncological outcome and results of advanced imaging in patients with biochemical recurrence
A. Berrera, R. Van Velter, E. Witt, P. J. van Leurouw, M. L. Donovick, F. W. B. van Leurouw, H. G. van der Pas\textsuperscript{1}; \textsuperscript{1}Center of Urology and Urological Research, Royal Netherlands, AMSTERDAM, NETHERLANDS; \textsuperscript{2}University of Utrecht, Utrecht, NETHERLANDS, \textsuperscript{3}Leiden University Medical Center, Leiden, NETHERLANDS, \textsuperscript{4}Amsterdam University Medical Center (VUMC), AMSTERDAM, NETHERLANDS.

EP-255
Follow-up of patients with C10 tongue cancer and negative sentinel selective sentinel lymph node biopsy
S. Bonda Bessica, J. Suli-Ramón, M. Baym-Laçaro, A. Bengí-Segura, A. Rodríguez-Gasén, J. Reyes-Sunyà, J. Sánchez-Rodriguez, N. Quiroz-López, L. Carreño-Téllez, C. González Delgado, M. Pujol, B. Hervás Solernó, I. Gil-Vicente, M. Buñak-Soró, M. Contreras-Ramón; \textsuperscript{1}Radiological-Nuclear Medicine-PEC (ED) Department, Bellvitge University Hospital, L’Hospitalet de Llobregat (Barcelona), SPAIN.

EP-256
Using 99mTc-Tulaneomoc for sentinel node detection in patients with cutaneous melanoma allows identification of sentinel lymph node despite prior-visualisation using SPECT with 99mTc-Nanocolloid
J. Pedersen, B. Zinner; \textsuperscript{1}Department of Nuclear medicine, Herlev, DENMARK.

EP-257
Results of Sentinel Lymph Node Biopsy in Endometrial Cancer: Experience in Our Centre S. Norango Sancho, J. P. Santís Fernández, M. L. Domínguez Grande, A. Laverde Mields, J. E. Marquina González, R. Rodríguez Díaz, C. Vogl Díaz, S. Paladino García, N. Martín Fernández, M. C. González García; Hospital Universitarios Central de Asturias, Oviedo, SPAIN.

EP-258
We can rationalise where we use SPECT/CT for melanoma sentinel node localisation?
P. Kinto, M. Naka, C. Fergusson, P. Khiariam, W. Svensson, N. Sonje; Imperial College Healthcare NHS Trust, London, UNITED KINGDOM.

EP-259
Unincisural sentinel in rectal cancer (SLN) biopsy in patients with locally advanced breast cancer (LABC)
J. E. Zoccola, A. Arruza Salzmann, P. Valverde Jorge, A. Arrieta Fuentes, E. Rodero Ortiz de Zasate; Hospital Universitario Cruces, Barakaldo, SPAIN.

EP-260
Sentinel Lymph Node Mapping in Vulvar Melanoma: a multicentre study
A. Flint, V. Fucco, S. M. Fugemont, T. Rasapu, J. Martinez, R. Rasapu, V. Ruhn, G. Garganese, M. Maccaurt, A. Collino; Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-261
E. Noniež-Alarcón, M. A. García Vicente, J. F. Pena Pardo, L. García Zogbi, J. Lucas Lucas, A. Abadía Bermejo, N. M. Sierra Polo, A. M. Soto Martín; Universitat General de les Corts Catalanes, Barcelona, SPAIN.

EP-263
Hospital Universitario de Bellvitge-IDIBELL, L’Hospitalet de Llobregat, SPAIN.\textsuperscript{1} \textsuperscript{1}University of Utrecht, Utrecht, NETHERLANDS, \textsuperscript{2}Amsterdam University Medical Center, Amsterdam, NETHERLANDS, \textsuperscript{3}Hospital Universitario Central de Asturias, Oviedo, N. Manevska, M. Maccaurt, A. Collino; Università Cattolica del Sacro Cuore, Rome, ITALY.

EP-264
E. Noniež-Alarcón, M. A. García Vicente, J. F. Pena Pardo, L. García Zogbi, J. Lucas Lucas, A. Abadía Bermejo, N. M. Sierra Polo, A. M. Soto Martín; Universitat General de les Corts Catalanes, Barcelona, SPAIN.
EP-24

During Congress Opening Hours

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B41 Perfusion

EP-25

During Congress Opening Hours

B: Imaging Clinical Studies -> B4 Cardiovascular Imaging Clinical Study -> B43 Heart Failure (including Sarcoidosis and Amyloidosis)

EP-265

Improvement of the detectability of perfusable tissue fraction and myocardial flow reserve after revascularization by “o-water ECG-gated PET”

A. Maruo, M. Entezarmahdi, S. Stankovic; Morkel Inc. Panorama Medical Centre, Cape Town, SOUTH AFRICA.

EP-265a

Evaluation of the Left Ventricular Segmentation Algorithm Using 8-Spline Explicit Active Surface Model in Myocardial Perfusion SPECT Images in the Presence of Perfusion Defect

M. Aniree, M. Shaaham, M. Yazd, M. Hoyaghafthatahi, T. Ghaedian, M. Entezarmahdi;

School of Electrical and Computer Engineering, Shiraz University, Shiraz, IRAN, ISLAMIC REPUBLIC OF; Department of Computer Science and Engineering, IIT, Shiraz University, Shiraz, IRAN, ISLAMIC REPUBLIC OF; Associate professor of nuclear medicine, Nuclear Medicine and Molecular Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, IRAN, ISLAMIC REPUBLIC OF.

EP-271

The Influence Of Low-Dose CT Attenuation Correction On Artefacts Of Myocardial SPECT Images For Nuclear Medicine Studies

L. Nolan, E. Séarle, M. Du Toit, C. Lackey, M. Morrell, N. Norwalk;

Tygenberg Hospital, Cape Town, SOUTH AFRICA, Cape Peninsula University of Technology, Cape Town, SOUTH AFRICA, TRH Market Inc. Panorama Medical Centre, Cape Town, SOUTH AFRICA.

EP-272

Infarct size assessed by quantitative and qualitative analyses of myocardial perfusion defect with decreased left ventricular ejection fraction measured by SPECT and 3D echocardiography

A. Lopez-Mendez, N. Espinola-Zavala, E. Aelendson-Rosas; Instituto Nacional de Cardiology, CDMX, MEXICO.

EP-273

Background of cardiac complaints after COVID-19 disease and COVID-19 cardiac involvement

R. Jóba, M. Marosvay, K. Buga;

Military Instruction Hospital In Tunis, Tunis, TUNISIA.

EP-275

The Diagnostic And Prognostic Value Of Semiquantitative Evaluation Of 99mTc-DPD And 18F-HMPAO Bone Scintigraphy With SPECT/CT For TTR-Related Cardiac Amyloidosis

E. Calviotes, R. Cavaro, R. Passera, M. Fini, A. Lessa, M. Belli, D. Deandrea, Division of Nuclear Medicine, Department of Medical Sciences, University of Turin, Turin, ITALY.

EP-276

Amyloid Lumbar Assessment In Patients With Spinal Stenosis Due To Flavum Ligament Hypertrophy: A Pilot Study


University Medicine Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN, Cardiology Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN, Pain Unit, University General Hospital of Ciudad Real, Ciudad Real, SPAIN, Rheumatology Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN, Neurorehabilitation Department, University General Hospital of Ciudad Real, Ciudad Real, SPAIN.

EP-277

***To Pyrophosphate Scintigraphy for Cardiac Amyloidosis: Concordance of Planar and SPECT/CT Imaging

N. Coskun, O. Karataş, S. İldırım, E. Ceylan;

Kartal Hospital, Ankara, TURKIYE, Medikal Vatandaşlık Ankara, Ankara, TURKIYE.

EP-278

Evaluation of cardiac amyloidosis: genetic testing and work-up between nuclear medicine physicians and cardiologists


Azienda Scaligera Verona, Legnago, ITALY.

EP-279

Features in differentiating between Positive and Negative cardiac amyloidosis findings on bone scintigraphy with 99mTc-DPD

S. Bondia-Bescos, B. Hervás-Sanz, A. McCann, M. García Vicente, S. M. García; Ankara City Hospital, Ankara, TURKIYE, Department of Nuclear Medicine, Dokuz Eylül University, İzmir, TURKIYE.

EP-280

What is an additional value of SPECT technique in scintigraphic diagnostics of TTR cardiac amyloidosis?

A. Teresinska, R. Jurczuk-Piechow, M. Ciecka, J. Wrakw, M. Czarov, J. Gzyszowski;

National Institute of Cardiology, Warsaw, POLAND.

EP-281

Usefulness of 18F-FDG PET/CT in the detection of cardiac involvement in patients with suspected sarcoidosis

I. Obiedbo, B. Rodriguez Rivero, T. Santamaria Cruz, K. E. Velacquez Díaz, P. M. Meneses Soares, M. Mijavac Carasova;

University Hospital Puerta de Hierros, Madrid, SPAIN.

EP-282

Radiological and biochemical correlation of metabolic findings on bone scintigraphy with 99mTc-DPD in the evaluation of patients with transthyretin amyloidosis (TTR)


EP-284

Semi quantitative evaluation of 99mTc-DOTANOC uptake in the normal myocardium

P. Koushan, F. Frati, K. Chudala, S. Kumar, P. Gupta, C. Bali;

All India Institute of Medical Sciences, New Delhi, INDIA.

EP-285

Towards the optimization of 99mTc-YP5 scintigraphy contribution in transthyretin-induced cardiac amyloidosis


Kartal Hospital, Ankara, TURKIYE, Medikal Vatandaşlık Ankara, Ankara, TURKIYE.

EP-286

Incidental Finding Of 99mTc-DPD Corded Cardiac Amyloidosis On Routine Bone Scintigraphy In Cancer Patients

I. Iakovou, E. Giammoudi, I. Ouassma, E. Eschaloffsky, G. Caramurowska, K. Koush, E. Spengel, E. Papapapavasileiou, O. Douras;

Nuclear Medicine dept, AHEPA hosp., Aristotle University, Thessaloniki, GREECE, 99MTCARDS, Nuclear Medicine dept, Thessaloniki, GREECE.
EP-292

EP-293
Nuclear Imaging Applied to the Cardiovascular System in the Elderly Patients S. Ferreira
School of Health Dr. Lopez Diaz, Polytechnic Institute or Castello Grao, AID-COMU, Interuniversity Research Unit - Functional Ageing Communities, Castello-Grado, PORTUGAL.

EP-294
Radionuclide Ventriculography (RVV). What Drugs are involved in “vivo” labeling or red blood cells with Tc-99m S. Perez Quirós, M. D. Martin Ferrer, S. Angiolillo Grau, A. Savasta Nazar, D. Vega Perez, V. Godgina Guilleoatea, A. Gallano Martin, E. Martinez Albera, P. Sarandones Fernandez, P. Zaragoza Ballestier, M. J. Tabuenca Mateos, Hospital University of Santander, 12 de Octubre, Madrid, SPAIN.

EP-295
Estimation of Left Ventricular Axis of the Heart using SPECT Images M. Assadi
Babahossein University of Medical Sciences (BUMS), Babahossein, ISLAMIC REPUBLIC OF, Mystical Intelligence and Medical Imaging Research Institute, K. Rey Research Center, Faculty of Intelligent Systems Engineering and Data Science, Persian Gulf University, Babahossein, ISLAMIC REPUBLIC OF.

EP-27
During Congress Opening Hours

**E-Poster Area**

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B51 Neurodegeneration

**EP-296**
Clinical implications of prompt 99mTc-labeled pharmacogenomic parkinsonism P. Volakmanakis, A. Tseoudis, A. Avramidis, E. Mavrou, V. Galokkerou, A. Zannisopoulos*

1. Nuclear Medicine Department, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE, 2. University of Eastern Macedonia and Thrace, University General, Alexandroupolis, GREECE, 3. Psychiatrie Department, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE, 4. Pharmacology Department, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE, 5. Medical Department, School of Medicine, Democritus University of Thrace, University General, Alexandroupolis, GREECE.

**EP-297**

On behalf of the AMPLE consortium, an EU-FP8 funded Project (grant agreement No 115552).

1. Moleculare Imaging GmbH, Berlin, GERMANY, 2. GE Healthcare, Amsterdam, UNITED KINGDOM, 3. Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Radiology and Nuclear Medicine, Amsterdam, UNITED NETHERLANDS, 4. Charite – Berliner Brain Research Center (BBRC), Positron Manufaktur, Barnhaven, SPAIN, 5. IMM (Hospital Medical Research Institute), Barnhaven, SPAIN, 6. Instituto de Neurology and Center for Medical Image Computing, University College London, London, UNITED KINGDOM, 7. Centro de Investigación Biomédica en Red de Biomateriales y Nanomedicina (CIBER-BM), Barnhaven, SPAIN.

**EP-298**
Cortical metabolic “F-FDG PET assessment and striatal dopaminergic transporter SPECT imaging in suspected early neurodegenerative disorders with uncertain movement and cognitive symptoms S. Nuñez, A. Lizarbe, S. Carlo, G. Gallen, A. Manzoni, L. Filipci, B. Palumbo, A. Spain, G. Madeddu

1. Nuclear Medicine Unit, University of Sassari, Sassari, ITALY, 2. Nuclear Medicine Unit, Hospital of Latina, Latina, ITALY, 3. Nuclear Medicine Department, University of Salamanca, Salamanca, SPAIN, 4. Functional Ageing Communities, Castelo Branco, PORTUGAL, 5. Functional Ageing Communities, Coimbra, PORTUGAL.

**EP-299**

1. PhAIDON, KMU, 2. Department of Health Sciences (DISSAL), University of Cantabria, Santander, SPAIN, 3. Thrance, University General, Alexandroupolis, GREECE.

**EP-300**
(‘F-FDG PET-CT study of a sample of cognitive normal older adults: Description and characteristics of AGUEDA project participants D. Rivero-Nava, C. Dell’Acqua, E. Trujilo-Rubalcoba, E. Garza-Riverena, B. Fernandez-Garza, A. Avila, D. M. Martinez-Alcaraz, J. A. González-González, F. Cortés, M. Gomá-Ruiz, J. L. Esteban-Cortés, J. K. Hirasawa, Hospital University of Zaragoza, Zaragoza, SPAIN, 2. Instituto de Investigación Biomédica de Zaragoza, Zaragoza, Spain, 3. Instituto de Psychology of Psychology, University of Pittsburgh, Pittsburgh, USA, 4. UNITED STATES OF AMERICA.

**EP-301**

1. Division of Nuclear Medicine, Faculty of Medicine, Tokohu Medical and Pharmaceutical University, Sendai, JAPAN, 2. Department of Pharmacology, Graduate School of Medical Frontier, Tohoku University, Sendai, JAPAN, 3. Division of Pharmacology, Faculty of Medicine, Tohoku University, Sendai, JAPAN.

**EP-302**

**EP-303**

1. Department of Health Sciences (DISSAL), University of Sassari, Sassari, ITALY, 2. Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DINGM), IRCCS OSPedale Policlinico San Martino, University of Genova, Genova, ITALY, 3. Nuclear Medicine Unit, IRCCS Ospedale Policlinico San Martino, Genova, ITALY.

**EP-304**

**EP-305**

**EP-28**
During Congress Opening Hours

**E-Poster Area**

B: Imaging Clinical Studies -> B5 Neurological Imaging Clinical Study -> B52 Cognitive Impairment

**EP-306**

EP-304 Association Of Severe Periodontitis With The Accumulation Of Brain Pathology

OCTOBER 15 - 19, 2022
WORLD LEADING MEETING
EANM’22

EP-308 The Role of Brain Perfusion 99mTc-SPECT-HMPAO with Automated Brodmann Areas Mapping in the Evaluation of Neurodegenerative Symptoms in Dementia


EP-310 Evaluation of Agitation Perfusion Correlates in Alzheimer’s Disease with Brain Perfusion 99mTc-SPECT-HMPAO and Automated Brodmann Areas Mapping


EP-312 Seizure timing analysis in drug-resistant focal epilepsy: a mapping study with F-FDG PET Imaging

F. Petrescu, O. Sabri, 3 M. Rullmann, 2 C. Baeken, 4 K. Peremans, 1,2 C. Baeken, 2

EP-314 FDG PET/CT in the evaluation of suspected peripancreatic pseudocysts: our experience in daily practice

F. Pena Parada, V. M. Huberdeau Garcia, A. M. Garcia Licea, E. Parraa, S. Rodrigo, F. J. Gómez de Diego, A. Sánchez-Gómez, P.

EP-315 Diagnostic role of quantified "[18F]FP-CIT (DaTscan) brain SPECT in suspected early-onset Parkinsonism


EP-307 Association Of Severe Periodontitis With The Accumulation Of Brain Pathology

J. Leonardi, H. Barthel, S. Sperberck, J. Dietzel, M. Schroeter, D.

EP-308 The Role of Brain Perfusion 99mTc-SPECT-HMPAO with Automated Brodmann Areas Mapping in the Evaluation of Neurodegenerative Symptoms in Dementia


EP-309 Evaluation of Agitation Perfusion Correlates in Alzheimer’s Disease with Brain Perfusion 99mTc-SPECT-HMPAO and Automated Brodmann Areas Mapping


EP-310 Spectral analysis and language profile in Greek speaking patients with subtypes of frontotemporal dementia


EP-311 Differential Diagnosis between Alzheimer’s Disease-Related Depression and Pseudo-Dementia in Depression - A New Indication for Amyloid b Imaging

J. Leonardi, H. Barthel, S. Sperberck, J. Dietzel, M. Schroeter, D.

EP-307 Association Of Severe Periodontitis With The Accumulation Of Brain Pathology

E. Trivino-Ituriz, 1, T. Rudolph-Salamon, M. Genc-Mehmet, S. Politi-Limni, 1 M. González-Gómez, 1

EP-308 The Role of Brain Perfusion 99mTc-SPECT-HMPAO with Automated Brodmann Areas Mapping in the Evaluation of Neurodegenerative Symptoms in Dementia


EP-309 Evaluation of Agitation Perfusion Correlates in Alzheimer’s Disease with Brain Perfusion 99mTc-SPECT-HMPAO and Automated Brodmann Areas Mapping


EP-310 Spectral analysis and language profile in Greek speaking patients with subtypes of frontotemporal dementia


EP-311 Differential Diagnosis between Alzheimer’s Disease-Related Depression and Pseudo-Dementia in Depression - A New Indication for Amyloid b Imaging

J. Leonardi, H. Barthel, S. Sperberck, J. Dietzel, M. Schroeter, D.

EP-307 Association Of Severe Periodontitis With The Accumulation Of Brain Pathology

E. Trivino-Ituriz, 1, T. Rudolph-Salamon, M. Genc-Mehmet, S. Politi-Limni, 1 M. González-Gómez, 1
EP-325 The Role of “FDG-FDG-PE/T/CT in the Diagnosis of Autoimmune Encephalitis in patients with Paraneoplastic Syndrome
Hospital General Universitario Gregorio Marañón, Madrid, SPAIN.

EP-326 Evaluation of calculated attenuation correction method in brain PET imaging
1ThVIE, Toulouse University Imaging Center, Toulouse University, Toulouse, FRANCE; 2Department of Nuclear Medicine, University Hospital of Toulouse Purpan, Toulouse, FRANCE.

EP-327 FDG PET in Autoimmune Encephalitis: Diagnostic Confidence Of The Metabolic Signature

EP-328 Increased consistency reporting of FDG PET/CT in pre-surgical assessment of medically refractory temporal lobe epilepsy
A. Hassan, S. J. Hughes.
Aston Medical School, Birmingham, UNITED KINGDOM.

EP-32 During Congress Opening Hours - ePoster Area
B: Imaging Clinical Studies -> B6 Endocrinology Imaging Clinical Study -> B61 Endocrinology (including Thyroid Benign)

EP-329 Usefulness of F-Fuorocholine PET/CT in Patients with Primary Hyperparathyroidism and Negative Presurgical Localisation Imaging Studies

EP-330 Increased glucose activity in visceral versus subcutaneous adipose tissue (VAT vs SAT) determined by [18F]-FDG PET/CT studies
M. Nieves, Gynecology and Obstetrics Departments, Granada, SPAIN.

EP-331 A. González-Jiménez
1UCV University College, Odena, DENMARK; 2Odena University College, Odena, DENMARK.

EP-332 Focal parathyroid lesions evaluated using SUV in preoperative SPECT/CT diagnosis
M. Listwerek, S. Kuhrowka, R. Tołuszewska, H. Piwowarska-Biski, J. Ivanowska, B. Biskim, Department of Nuclear Medicine, Pomeranian Medical University in Szczecin, Szczecin, POLAND.

EP-333 Evaluation of pre- and post-transplantation parathyroid scintigraphy and ultrasonography findings in patients with persistent hyperparathyroidism after renal transplantation
A. Ákats, N. Usá, A. Gençoglu, T. Colak, Basist饯 University, Ankara, TURKEY.

EP-334 Comparison of parathyroid scintigraphy findings in pediatric and adult patients with secondary hyperparathyroidism
A. Ákats, E. Baskın, A. Gençoglu, T. Colak, Basist饯 University, Ankara, TURKEY.

EP-335 The third timing for discharging DTC patients undergoing thyroid remnant ablation with 3.7 GBq 131I fixed activity
L. Traversaci,1 M. G. Grassi,2 P. Tarun,2 S. De Novo,1 A. D. Visco.
1Nuclear Medicine Unit P.O. Pescara, Pescara, ITALY; 2UCGSD Medical Physics, P.O. Pescara, ITALY.

EP-336 “The MIBI thyroid scan in amiodarone induced thyrotoxicosis: how far can we get with visual interpretation
L. Fiubra,1 M. G. Crotti,2 M. A. Wil Tomas2,3 S. Grac-ivanovski;4 T. Bogou Cimochal.2
1Department of Nuclear Medicine, Faculty of Medicine, University of Rijeka, Rijeka, CROATIA; 2Clinical Department of Nuclear Medicine, Clinical Hospital Centre Rijeka, Rijeka, CROATIA.

EP-337 Adrenal Gland - Revisiting Scintigraphic Patterns
P. Seoane, B. Pires, M. J. Rodrigues.
Centro Hospitalar Universitário de São João, Porto, PORTUGAL.

EP-338 Is there a role of Choline PET/CT in localisation of parathyroid adenoma? Review of initial experience in a teaching hospital
P. Chuah,1 V. Pant,1 F. Naen,2 R. Fernando,3 S. Vinayakum,1 N. Seethodh;2 Nuclear Medicine Department, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UNITED KINGDOM.

EP-339 Congenital Hypothyroidism: Role of Thyroid Scintigraphy with perchentide (99mTcO4) scans
M. Ben Nasr.1 W. L. Ayin,2 A. Sellén, H. Hammami;2 The Principal Military Hospital of Instruction of Tunis, Tunisie, TUNISIA.

EP-340 Usefulness of the Iogul protocol in parathyroid scintigraphy
J. Villena-Salinas, A. Montané-Fernández, B. Patu, C. Balbin-García, T. Amante-Rasouri, S. Sanz-Vieida; Hospital Universitario Virgen de la Victoria, Málaga, SPAIN.

EP-341 Thyrotoxicosis: how far can we get with visual interpretation
M. Santín-Cerezales,1 J. Suls-Ramón,2 L. Rodríguez-Bel, P. Nieto,1 M. P. Chuah,1 T. Colak,2 S. Grac-Ivanovski,4 T. Bogou,1 Cimochal.2
1Department of Nuclear Medicine, University College, Odena, DENMARK; 2Odena University College, Odena, DENMARK.

EP-342 Quantitative bone SPECT/CT for diagnosing osteomyelitis of the jaw
W. Choi,1 S. Boot, H. Yoon,2 E. Hark.
1St.Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF; 2Seoul St.Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF; 3Ewha St.Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, KOREA, REPUBLIC OF.

EP-343 Diagnostic accuracy of SPECT/CT “Th UBI 29-41 in musculoskeletal infections and its correlation with microorganisms
F. Lemus Ramírez,1 A. López Méndez,2 D. Anguita Pérez,2 K. Vite,1 Pineda,2 J. Domínguez,2 D. Hernández Oliveira,2
1Instituto Nacional De Rehabilación Luis Guillermo Ibáñez Brama, México, MEXICO; 2Postúltimo Instituto Nacional De Cardiología, México, MEXICO; 3Instituto Mexicano del Seguro Social, Ciudad Jutdez Chihuahua, MEXICO; 4Otto Rodríguez Polyclinc,2 Il San Pedro, BELIZE; 3Hospital Angeles Universidad, MEXICO.

EP-344 Correlation between clinical and imaging parameters to assess disease activity in Large Vessel Vasculitis: “FDG-FDG-PE/T/CT semi-quantitative and cut-off based scores
L. Burroni,1 P. Pettinari,1 C. Ramagnoli1, G. Ghirelli,2 A. Paltur,2 G. Iscrutico,1 F. M. Piuelli,1 C. Catrinical,1 P. Fratocchi,2
1Dept. of Nuclear Medicine, “Ospedali Riuniti di Toretto”, Ancona, ITALY; 2Dept. of Medical Clinic, Università Politecnica delle Marche, Ancona, ITALY.

EP-345 Visual Assessment of “FDG-FDG-PE/T/CT in Patients Referred To Our Department Due to Clinical Suspicion of Large Vessel Vasculitis
M. Lara Martínez1, O. Wahlokat, M. Martinet,1 J. Uhi,1 A. J. M. Van Den Beld1
1Hospital Universitario de Canarias, Santa Cruz de Tenerife, SPAIN; 2Hospital Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, SPAIN.

EP-346 B: Imaging Clinical Studies -> B7 Infection and Inflammation -> B71 Bone Infection and Inflammation

EP-347 The Role Of FDG-PET/CT In Tuberculosis
E. Llima-Tello1,2, M. Santín-Cerezales1, J. Suls-Ramón1, L. Rodríguez-Bel, P. Nieto1, M. P. Chuah,1 T. Colak2, S. Grac-Ivanovski,4 T. Bogou,1 Cimochal.2
1Department of Nuclear Medicine, University College, Odena, DENMARK; 2Odena University College, Odena, DENMARK.

EP-348 Role of “FDG-FDG-PE/T/CT in assessing patients with IgG4-related disease
M. Pudou, M. Corts-Romero, S. Bonada-Becot,3 S. Salanchich-Morato,1 B. Hervás-Sanz,1 A. Palomar-Marín,1 M. C. De Luna- Salavador3, C. Martínez-Karamán,1 E. Llima-Tello1, J. Pells-Barbé,2 R. Liébana-Sanuy,4 M. Budí-Sagot, L. Rodríguez-Bel.
1Nuclear Medicine- Ped. DIV Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN; 2Pediatrics Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN; 3Endocrinology Department, Bellvitge University Hospital - IDIBELL, L'Hospitalet de Llobregat (Barcelona), SPAIN.

A. Chirico Talà,1 C. Sampoli Basí2,3, B. Luna Molero3, C. Medina Soler,1 J. Armario Saimen,1 L. Nieto Macló, N. Ortu Tomás,1 M. Valiente Aldomà, C. Peña Vilaró3.
1Nuclear Medicine Department, Hospital Universitari Son Espases, Palma de Mallorca, SPAIN, PALAU, Palma de Mallorca, SPAIN, SPAIN, Palma de Mallorca, SPAIN; 2Radiopharmacological Department, Hospital Universitat Son Espases, Palma de Mallorca, SPAIN; 3Radiopharmacological Department, Hospital Universitat Son Espases, Palma de Mallorca, SPAIN.
EP-367 Imaging response evaluation after Yttrium-90 radioembolization treatment: our experience
EP-390
Role of 131I-Tc-pertechnetate thyroid uptake scan in predicting response to RAI therapy in Graves’ disease
K. Bishnoi, T. Emerson, A. Kumar, P. S. Patra, G. R. Paniala, K. Behera, A. Agrawal, All India Institute of Medical Sciences, Bhubaneswar, INDIA.

EP-391
The added value of mar reconstruction to bone spet ct in the evaluation of patients with arthropathy
L. Pavanella, F. Scieure, R. Eguave Mangoure, L. Locatante, M. Cucca, L. Rawll, M. Zuffante, AOUI di Verona, Verona, ITALY.

EP-392
Digital PET/CT images reconstructed Using Deep Learning Techniques have Improved Noise and Contrast Characteristics
F. Shinkawa, K. Fukuya, S. Fujita, M. Kawada, H. Ichikawa, J. Y. Shirakawa, National Center for Global Health and Medicine, Tokyo, JAPAN.

EP-393
Motion Correction software program can be used to correct head movement at a PETCT brain scan
V. Jensen, S. Svedling, Regiosticketet, Clinic for Clinical Physics, Nuclear Medicine and PET, Copenhagen, DENMARK.

EP-394
Development and validation of 2.5-dimensional super-resolution convolutional neural network for whole-body PET images
H. Endo, R. Karata, C. Kataki, K. Magota, K. Kuda, Hokkaido University, Sapporo, HOKKAIDO, JAPAN.

EP-395
Implication on the use of contrast enhanced CT for 2(51Cr) FDG PET/CT attenuation correction in state of art PET devices

EP-396
Efficacy of a ‘Contrast Correction’ Algorithm in Contrast-Enhanced Computed Tomography based Attenuation Correction of Positron Emission Tomography Imaging in the context of Lymphoma Investigations - a phantom study
V. Kilhams, K. Thompson, University Hospitals Plymouth NHS Trust, Plymouth, UNITED KINGDOM.

EP-397
Last generation digital PET: FOV overlap optimization
M. Bernardini, Hospital Européen Georges Pompidou (HEGP), Paris, FRANCE.

EP-398
Production of parametric KI images from dual time point (two 3 min clinical routine static scans)
N. Rezateb, S. Hassani, M. Zhang, P. Sheikhasladeh, Department of Engineering Science, Sharif University of Technology, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Nuclear Medicine, Mishan People Hospital, Mishan, CHINA, Department of Nuclear Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-399
Effect of time of flight and ultra HD reconstruction algorithms on standard uptake value of tumours with different sizes: a comparative study
A. Nautiyal, J. Pitkin, Crewe and Wirral Hospital, London, UNITED KINGDOM.

EP-400
Study of the Off-Axis Sensitivity in PET Scanners

EP-401
The impact of Different Reconstruction Parameters along with TQP and P5P in PET/CT Imaging: Patient with Normal and High BMI
S. Pazaz, T. F. Ghasanahi, M. Ayash, Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Center for Research of Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-402
Reconstruction Parameter Optimization for EARL Criteria on an Extended Bore Length Solid-State Digital-BGO PET/CT System
J. Kennedy, T. Paladin, I. Haas, Z. Konda, Rambam - Health Care Campus, Haifa, ISRAEL, and R. Rappaport School of Medicine, Technion - Israel Institute of Technology, Haifa, ISRAEL.

EP-403
Optimization of Time Coincidence Window and Window Width of Dedicated Brain PET: A Simulation Study
T. Zare, P. Sheikhasladeh, A. Rahmim, B. Tommason Fard, P. Ghasanahi, M. Ayash, Department of Medical Physics and Biomedical Engineering, Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Department of Radiology and Physics, University of British Columbia, Vancouver, BC, CANADA, Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; Departments of Radiology and Physics, University of British Columbia, Vancouver, BC, CANADA, Chronic Respiratory Diseases Research Centre, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF; PET/CT and Cyclotron Center, Mash Dameshk Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-404
Reproducibility of FDG PET-CT liver SUV uptake metrics as reference or normalisation factor
G. C. Rezazadeh, E. Erents, M. C. Fernandez-Fernandez, S. E. Wierges, E. B. N. Burggraaff, P. J. Lugtenburg, H. C. W. de Vet, J. M. Zijlstra, R. Boellaard, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Radiology, and Nuclear Medicine, Amsterdam, NETHERLANDS, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Radiology, and Nuclear Medicine, Amsterdam, NETHERLANDS, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Radiology, and Nuclear Medicine, Amsterdam, NETHERLANDS, Erasmus MC, Cancer Institute, University Medical Center, Hematology, Rotterdam, NETHERLANDS, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Radiology, and Nuclear Medicine, Amsterdam, NETHERLANDS, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Radiology, and Nuclear Medicine, Amsterdam, NETHERLANDS, Amsterdam UMC, Location Vrije Universiteit Amsterdam, Radiology, and Nuclear Medicine, Amsterdam, NETHERLANDS.

EP-405
A Novel Adaptive Approach to Automatic Segmentation of PSMA-positive Lesions in Positron Emission Tomography (PET) of Prostate Cancer
J. Brynjolfsson, M. Sahinoglu, J. Richter, C. Sjostrand, A. Anand, Turing Diagnostics All, Lund, SWEDEN; Challenge Medical Imaging, Bilmera, MA, UNITED STATES OF AMERICA.

EP-406
3D Printing Anthropomorphic Phantoms with Grid-Based Internal Structures as a Method to Evaluate Quantitative SPECT for Non-uniform Activity Distributions
L. Jester, M. Jurgent, J. Gustafsson, S. Liver, M. Imvau, K. Jogerun-Gronne, Medical Radiation Physics, Lund University, Lund, SWEDEN, Skane University Hospital, Lund, SWEDEN.

EP-407
Comparison of methods for post-SIRT residual activity assessment
N. Cherbuin, S. Broughard, N. Schaefer, J. Preis, R. Morcay, S. Grenier, Lausanne University Hospital, Lausanne, SWITZERLAND.

EP-408
Fanc PET Transverse Uniformity Protocol: adaptable to Spect?
A. Seret, T. Canet, University of Liege, Liege, BELGIUM, CHU Nantes, Nantes, FRANCE.

EP-409
Assessment of PET scanner SIRL and CNR factors: validation of Gate Monte Carlo code and STIR reconstruction with experimental study
M. Karimipourfard, S. Mok, S. Dadghchi, M. Shabery, R. Safar, M. Dario, Department of Ray-Medical Engineering, Shahid Beheshti University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

EP-410
Quantification with 3D-printed Source Holder Shows Geometrical Difference Between Dose Calibrators with Vtiruum 50
S. Pekkanoringen; A. Rintaita, T. Miettinen, L. Kaurat, E. Huggins; Y. Reijonen, Department of Oncology, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND, Clinical Physiology and Nuclear Medicine, HUS Medical Imaging Center, University of Helsinki and Helsinki University Hospital, Helsinki, FINLAND.

EP-411
Optimizing the Performance evaluation tests of Gemini 71564 PET/CT scanner using “Ga isotope adhering NEMA- NU-2 2007 standard”
B. Rawat, V. Savant, A. K. Jha, S. Mithun, V. Rangangan, Tata Memorial Hospital, Mumbai, INDIA, Indian Institute of Technology, Mumbai, INDIA.

EP-412
64-Copper PET/CT imaging using Bayesian Penalized Likelihood Reconstruction Algorithm
P. Sheikhasladeh, A. Monsef, A. Ghafari, Tehran University Of Medical Science, Tehran, IRAN, ISLAMIC REPUBLIC OF.
EANM'22 WORLD LEADING MEETING
OCTOBER 15-19, 2022

EP-451 A Problem and the Solution of the Algorithm for Calculating Washout Rate Using Myocardial SPECT Analysis Software

EP-414 Nobel metabolic quantification approach of dopamine activity by ‘FDOPA (PET-CT)

EP-419 Evaluation of SUL measurements in 68Ga-DOTATATE PET/CT Imaging

EP-420 Assessment of the Functional Distribution of Perfusion and Ventilation in the Lungs Lobes Using SPECT/CT

EP-422 Automatic bone scan index is feasible on pseudo planar whole body images obtained from whole body SPECT


EP-424 Optimization of parameters for PET CT image reconstruction using singular value decomposition

EP-425 Comparative study of respiratory gating techniques in last generation PET-CT

EP-428 “**TCP** MIB1 Bone Scan Image Restoration Using Blind Deconvolution Analysis

**EP-390** Development of Poisson noise reduction method using wavelet based BayesShrink technique in brain SPECT

**EP-431** Optimization of Bayesian penalized likelihood reconstruction algorithm for [(7.4methanol amylol) PET images

**EP-432** Optimization of “FDOPA Whole Body PET

**EP-433** Determining an Optimum Number of Reconstruction Iterations for SUV Quantification in Spinal Imaging using a Novel 360° CZT SPECT/CT System

**EP-434** Impact of Regularized Reconstruction on Image Quality of Metastases in PSMA PET Images

**EP-435** Long axial-field-of-view emission tomography post-radiomabilaization yttrium-90 clinical protocol optimization

**EP-436** Development and Validation of a Scatter Correction Framework for Total-Body Positron Emission Tomography using the uEXPLORER

**EP-437** SPECT acquisition and reconstruction optimisation for the pre-therapeutic step of the Selective Internal Radiation Therapy (SIRT)
D: Technical Studies -> D2 Data Analysis -> D24 Artificial Intelligence


EP-450 Explaining prediction of coronary artery disease in nuclear medical imaging using deep learning
N. Papandrianos, M. Stratakos*, A. Feleki, E. Papageorgio

During Opening Hours:

E-Poster Area

D: Technical Studies -> D2 Data Analysis -> D24 Radiomics

EP-443 Prognostic role of [18F]FDG PET imaging for Diffuse Large B-Cell Lymphoma patients: comparison of model performance with different segmentation methods and target lesions
Nuclear Medicine Division, IEO European Institute of Oncology, Milan, ITALY, Department of Radiation Oncology, IEO European Institute of Oncology, Milan, ITALY, Department of Oncology, Azienda Ospedaliera Sant'Antonio Abate, Padova, ITALY, Department of Oncology, Azienda Ospedaliera Sant'Antonio Abate, Padova, ITALY, Department of Health Sciences, University of Milan, Milan, ITALY

EP-444 Predicting prognosis of patients with recurrent Graves’ Disease: the value of additive radiomic features of planar-192 scintigraphy
Leiden University Medical Center, Leiden, NETHERLANDS, University of Twente, Enschede, NETHERLANDS

EP-445 Prognostic value of pretreatment [18F]FDG PET texture features in advanced high grade serous ovarian cancer

EP-446 Receptability prediction of Non-Small Cell Lung Carcinoma based on Computed Tomography Tomodensitometry Radiomic Features using Machine Learning algorithms
V. Jasiwar*, A. K. Jha*; R. Mittra*; U. K. B. Shankar*, M. S. Seth*; S. Rangarajan*; V. R. Rangarajan*; A. Dekker*; L. Weet
Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA, Department of Radiation Oncology, Macmillan Institute, University of Wollongong, Australia, Department of Nuclear Medicine, Tata Memorial Hospital, Mumbai, INDIA, Department of Radiation Oncology, Maaschtricht University Medical Center, Maaschtricht, NETHERLANDS, Institute of Medical Microscopy, University of Wollongong, Australia

EP-447 Can we rely on PET Segmentation for radiomic extraction for malignancy of hollow organs like the rectum?
B. Nath*, A. K. Jha*; R. Mittra*; G. S. S. Seth*, S. Rangarajan*; A. Dekker*; L. Weet
Tata Memorial Hospital, Mumbai, INDIA, Tata Memorial Hospital, Mumbai, INDIA, Maaschtricht University Medical Center, Maaschtricht, NETHERLANDS, Institute of Medical Microscopy, University of Wollongong, Australia, Department of Radiation Oncology, Maaschtricht University Medical Center, Maaschtricht, NETHERLANDS, Institute of Medical Microscopy, University of Wollongong, Australia

EP-448 Machine Learning-Based Radiomics for Multiple Primary Prostate Cancer Biological Characteristics Prediction with [PSMA]-1007 PET: Different Thresholding Segmentation Comparison
F. Yao, S. Biam, D. Zhu, Y. Yang
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, CHINA

EP-450 Explaining prediction of coronary artery disease in nuclear medical imaging using deep learning
N. Papandrianos, M. Stratakos*, A. Feleki, E. Papageorgio

During Opening Hours:

E-Poster Area

D: Technical Studies -> D2 Data Analysis -> D24 Artificial Intelligence


EP-450 Explaining prediction of coronary artery disease in nuclear medical imaging using deep learning
N. Papandrianos, M. Stratakos*, A. Feleki, E. Papageorgio
Can deep learning predict the receptors' status of breast cancer's metastases on 18F-FFDG PET/CT images ?

M. Milà López

Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA;

Slovenian University Hospital Centre Ljubljana, Ljubljana, SLOVENIA;

Department of Radiology, University Medical Centre Ljubljana, Slovenia,

Center for Security Management, PACR in Prague, Prague, CZECH REPUBLIC.

Accessing the predictability of Epidermal growth factor receptor status from Computed Tomography radiomics using machine learning

U. Sherkhande, V. Jawar, S. Mittur, A. K. Jha, V. Ranganath, L. V. Stadler, D. A. Deb, D. A. Deb, Tata Memorial Hospital, Mumbai, INDIA;

School of Chemical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN;

IRAN, ISLAMIC REPUBLIC OF.

Evaluation of a convolutional neural network for baseline total tumor metabolic volume on 18F-FFDG PET in a diffuse large B lymphoma cohort

K. Marjading, G. Dekely, D. Huglo, C. Baillier, V. Willumeit, S. Sajjadian, A. Ballauri, C. Giulivi,

CHU Lille, Lille, FRANCE;

Épargne des Hôpitaux de l’Institut Catholique de Lille, Lille, FRANCE.

Physics informed Deep Learning for PSMA-directed Pharmacokinetic Analysis

Z. Arzavey, M. Chul, D. Gripp, B. Rennefeld, J. Jiang, A. Ahzam-Daaneh, A. Ramasubbu

TU Munich, GERMANY; Max-Planck-Institut für Informatik, Saarbrücken, GERMANY;

University of Bern, Bern, SWITZERLAND;

Universitätsklinikum für Nuklearmedizin, Berlin, SWITZERLAND.

Iodine scan image denoising using deep neural network

A. Pandey, J. Choudhary, A. Herman, P.D. Sharma, C. Patel, B. R. Kumar,

All India Institute of Medical Sciences, New Delhi, INDIA;

SGTB Khalsa College, University of Delhi, New Delhi, INDIA.

Towards unsupervised segmentation of hyperfunctioning parathyroid tissue in [177]Fluorocholine PET/CT by deep PET approximation

J. Jarabek, J. Jarmisteček, A. Cudkam, F. Cvekelj, S. Roga, M. Holcapek, T. Kojan, M. Jeršeš, Z. Štefič, M. Merteljež, L. Ležaić,

University of Ljubljana, Faculty of Medicine, Ljubljana, SLOVENIA;

University of Ljubljana, School of Medicine, Ljubljana, SLOVENIA;

Masaryk Memorial Cancer Institute, Brno, CZECH REPUBLIC.

Detection of mediastinal lymph node non-small cell lung cancer metastasis based on an Artificial Intelligence reading system of 18F-FFDG PET-CT


Faculty of Medical Sciences, University of Ljubljana, Ljubljana, SLOVENIA;

Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

Estimation of CT images from PET images without non-attenuation-corrected PET images using Pix2Pix conditional Generative Adversarial Network Combined with The Bayesian Penalized Likelihood (BPL) Reconstruction Algorithm

A. Gafatra, A. Monert, P. Sheikzadeh;

Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

Accessing the predictability of Epidermal growth factor receptor status from Computed Tomography radiomics using machine learning

U. Sherkhande, V. Jawar, S. Mittur, A. K. Jha, V. Ranganath, L. V. Stadler, D. A. Deb, D. A. Deb, Tata Memorial Hospital, Mumbai, INDIA;

School of Chemical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN;

IRAN, ISLAMIC REPUBLIC OF.

Evaluation of a convolutional neural network for baseline total tumor metabolic volume on 18F-FFDG PET in a diffuse large B lymphoma cohort

K. Marjading, G. Dekely, D. Huglo, C. Baillier, V. Willumeit, S. Sajjadian, A. Ballauri, C. Giulivi,

CHU Lille, Lille, FRANCE; Épargne des Hôpitaux de l’Institut Catholique de Lille, Lille, FRANCE.

Physics informed Deep Learning for PSMA-directed Pharmacokinetic Analysis

Z. Arzavey, M. Chul, D. Gripp, B. Rennefeld, J. Jiang, A. Ahzam-Daaneh, A. Ramasubbu

TU Munich, GERMANY; Max-Planck-Institut für Informatik, Saarbrücken, GERMANY;

University of Bern, Bern, SWITZERLAND;

Universitätsklinikum für Nuklearmedizin, Berlin, SWITZERLAND.

Iodine scan image denoising using deep neural network

A. Pandey, J. Choudhary, A. Herman, P.D. Sharma, C. Patel, B. R. Kumar,

All India Institute of Medical Sciences, New Delhi, INDIA;

SGTB Khalsa College, University of Delhi, New Delhi, INDIA.

Towards unsupervised segmentation of hyperfunctioning parathyroid tissue in [177]Fluorocholine PET/CT by deep PET approximation

J. Jarabek, J. Jarmisteček, A. Cudkam, F. Cvekelj, S. Roga, M. Holcapek, T. Kojan, M. Jeršeš, Z. Štefič, M. Merteljež, L. Ležaić,

University of Ljubljana, Faculty of Medicine, Ljubljana, SLOVENIA;

University of Ljubljana, School of Medicine, Ljubljana, SLOVENIA;

Masaryk Memorial Cancer Institute, Brno, CZECH REPUBLIC.

Detection of mediastinal lymph node non-small cell lung cancer metastasis based on an Artificial Intelligence reading system of 18F-FFDG PET-CT


Faculty of Medical Sciences, University of Ljubljana, Ljubljana, SLOVENIA;

Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

Estimation of CT images from PET images without non-attenuation-corrected PET images using Pix2Pix conditional Generative Adversarial Network Combined with The Bayesian Penalized Likelihood (BPL) Reconstruction Algorithm

A. Gafatra, A. Monert, P. Sheikzadeh;

Tehran University of Medical Sciences, Tehran, IRAN, ISLAMIC REPUBLIC OF.

Accessing the predictability of Epidermal growth factor receptor status from Computed Tomography radiomics using machine learning

U. Sherkhande, V. Jawar, S. Mittur, A. K. Jha, V. Ranganath, L. V. Stadler, D. A. Deb, D. A. Deb, Tata Memorial Hospital, Mumbai, INDIA;

School of Chemical Sciences, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, SWEDEN;

IRAN, ISLAMIC REPUBLIC OF.

Evaluation of a convolutional neural network for baseline total tumor metabolic volume on 18F-FFDG PET in a diffuse large B lymphoma cohort

K. Marjading, G. Dekely, D. Huglo, C. Baillier, V. Willumeit, S. Sajjadian, A. Ballauri, C. Giulivi,

CHU Lille, Lille, FRANCE; Épargne des Hôpitaux de l’Institut Catholique de Lille, Lille, FRANCE.

Physics informed Deep Learning for PSMA-directed Pharmacokinetic Analysis

Z. Arzavey, M. Chul, D. Gripp, B. Rennefeld, J. Jiang, A. Ahzam-Daaneh, A. Ramasubbu

TU Munich, GERMANY; Max-Planck-Institut für Informatik, Saarbrücken, GERMANY;

University of Bern, Bern, SWITZERLAND;

Universitätsklinikum für Nuklearmedizin, Berlin, SWITZERLAND.
EP-516
Change in activity uptake between treatment cycles in quantitative "18F"FDG PET/CT
L. Bonney1, B. J. R. McGowan1
1University Hospitals Trust, Oxford, UNITED KINGDOM, 2University of Oxford, Oxford, UNITED KINGDOM

EP-54
During Congress Opening Hours
• Poster Area
D. Technical Studies -> DS Radiopharmacy, Radiochemistry -> DS5 New Radiopharmaceuticals - SPECT

EP-571
Design, Synthesis, and biological evaluation of quinoline based Sigma-2 receptor-specific 99mTc-(DPTA)-quinoline complex for SPECT imaging of breast tumor V. Chaudhary1, S. Chatrath1, A. Sathil2, V. Kumar1, A. K. Mohan1, N. N. D. Pawar1, A. K. J. Koyana1, N. Solan1
1SOFIE, Dulles, VA, UNITED STATES OF AMERICA, 2Homi Bhabha National Centre (HBNC), Tromsø, NORWAY, 3Center for Medical Radioisotopes, Uppsala University, Uppsala, SWEDEN

EP-55
During Congress Opening Hours
• Poster Area
D: Technical Studies -> DS Radiopharmacy, Radiochemistry -> DS5 New Radiopharmaceuticals - PET

EP-530
Optimization of Radiolabelling of 68Ga-MAA with varying incubation temperature and time
1Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Centre (HBNC), Tromsø, NORWAY, 3Center for Medical Radioisotopes, Uppsala University, Uppsala, SWEDEN

EP-56
During Congress Opening Hours
• Poster Area
D. Technical Studies -> DS Radiopharmacy, Radiochemistry -> DS5 New Radiopharmaceuticals - Therapy

EP-531
Exploring the potential of high-specific activity Samarium-153 for targeted radionuclide therapy with [188]Re-
S. Sengupta1, K. Vermeulen2, M. van der Voorden1, N. Dares3, C. Ouchterlony1, S. Pedro Rodrigues4, J. M. I. Pérez5, F. Reynes5, B. Ronsard5, A. Grenier2, J. Monneteau2, L. Lemberg2, A. Burguyon3, T. E. Cools2, T. Staud1
1School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM, 2Institute of Pharmaceutical Sciences, London, UNITED KINGDOM

EP-55
During Congress Opening Hours
• Poster Area
D: Technical Studies -> DS Radiopharmacy, Radiochemistry -> DS5 New Radiopharmaceuticals - SPECT

EP-532
Thallium-201 ("TI") - Labelled Prussian Blue Nanoparticles for Auger-Mediated Emitter Emitter Radionuclide Therapy K. Oktay1, J. Pellon2, P. Blokker1, S. Terry3, V. Askadis1, 1School of Biomedical Engineering and Imaging Sciences, London, UNITED KINGDOM, 2Institute of Pharmaceutical Sciences, London, UNITED KINGDOM

EP-533
Structure based in silico design, synthesis and preliminary assessments of Neurokinin-1 receptor (NK1R) targeted radiolabeled small molecules as potential neuroblastoma theranostic agents
P. J. H. de Brij1, W. Rosenberg1, U. Krasnem1, M. Nestor2, 1Department of Immunology, Genetics and Pathobiology, Rudbeck Laboratory, Uppsala, SWEDEN, 2Department of Radiology, University of Texas Southwestern Medical Centre, Dallas, TX, UNITED STATES OF AMERICA, 3Department of Medical Chemistry, Biomedical Centre, Uppsala University, Uppsala, SWEDEN

EP-534
Study of Radioactive Progeny Recoils Release from "Ac" Labelled TGN28 Nanoparticles
M. Sakmar1, J. Kozuymper1, L. Onaldir1, K. Fadoul2, M. VUK3, A. Morgenstern1, F. Bruchertseifer4
1Institute of Nuclear Medicine, First Medical Faculty, Charles University and General University Hospital Prague, Prague, CZECH REPUBLIC, 2Department of Nuclear Chemistry, Czech Technical University in Prague, Faculty of Nuclear Sciences and Physical Engineering, Prague, CZECH REPUBLIC, 3European Commission, Joint Research Centre, Karlsruhe, GERMANY

EP-535
Administration of [111]Lu-PSMA-617: Validation of a new method and first-experience
1Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Mumbai, INDIA, 2Homi Bhabha National Centre (HBNC), Tromsø, NORWAY, 3Center for Medical Radioisotopes, Uppsala University, Uppsala, SWEDEN

EP-517
A Comparison of image quality in myocardial perfusion scintigraphy with MIBI, Tetrofosmin Myoview and Tc
cTc-MAA Labelled TiO2 Nanoparticles
M. Aljammaz1, 1,2,3 S. Chaturvedi1, 1,2,3 S. Cournane1,2,3
1University Medical Centre, Rotterdam, NETHERLANDS, 2Institute of Technology, Delhi, INDIA, 3Department of Chemical Engineering, Indian Institute of Technology Mandi, Himachal Pradesh, INDIA

EP-518
Tc-99m Tetrofosmin ROTOP radio-pharmaceuticals - SPECT
S. Forsback1, F. Lopez-Picon1,2,3, O. Solan1
1CHRU Nancy, Vandoeuvre-lès-Nancy, FRANCE, 2Institute of Medical Radiology, Uppsala University, Uppsala, SWEDEN, 3Novo Synthesis, St. Louis, MO, UNITED STATES OF AMERICA
EANM'22  WORLD LEADING MEETING
OCTOBER 15-19, 2022
EANM'22  WORLD LEADING MEETING
OCTOBER 15 - 19, 2022
FINAL PROGRAMME  |  E-POSTERS
E-POSTERS |FINAL PROGRAMME

EP-57
During Congress Opening Hours
e-Poster Area

D: Technical Studies -> DS Radiopharmacy/ Radiochemistry -> DS5 New Biological Targets and Ligands

EP-538
**Te-FG2**: A Novel Approach for the Diagnosis of Early Prostate Cancers
M. Varani, V. Bugentjigs, D. Runenberg, M. Serenelli, C. Laun2, A. Signore

EP-541
Anti-HER2 antibody dota-pertuzumab conjugation and labelling studies with Ac-225
K. Flatow, F. Cnaoul2, M. Wij2, J. Kozempel3, M. Prazyna1, F. Bruchterrte2, A. Margreten3

EP-542
Faculty of Nuclear Sciences and Physical Chemistry, Technical University of Prague, Prague, CZECH REPUBLIC; Faculty of Clinical and Experimental Medicine, Prague, CZECH REPUBLIC; Institute of Nuclear Chemistry and Technology, Warsaw, POLAND, European Commission, Joint Research Centre, Karlsruhe, GERMANY.

EP-543
The Great Potential of Long Axial Field of View PET Systems for Imaging-based Pharmacokinetic Analysis Exemplified With the Radiolabeled Antibiotic (**Te**)
Ciprofloxacin
I. Hernandez-Lazano1, S. Manninger1, T. Fil populations, M. Lobschat1, S. Starke2, T. Wanne2, O. Lang2

1. Department of Clinical Pharmacology, Medical University of Vienna, Vienna, AUSTRIA; 2. Core Facility Laboratory Animal Breeding and Husbandry, Medical University of Vienna, Vienna, AUSTRIA; 3. Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, AUSTRIA.

EP-544
Artificial intelligence and the diagnosis of neurodegenerative diseases: making the future for radiopharmaceutical development
M. LM. Lindberg, Y. Huang1, K. Huang1, M. Chen1

1. Radiopharmaceutical Theranostic Center, Radioisotope Foundation; 2. Institute of Nuclear Medicine, Medical University of Vienna, Vienna, AUSTRIA; 3. Informatics Group R&D Department, Insilico Medicine Tuwaan, Taipei, TAIWAN; 4. Department of Hematology and Medical Oncology, Radioisotope Foundation; 5. Radioisotope Foundation Center, Taipei, TAIWAN; 6. Manager of Theranostic R&D, Advanscience Research Co, Taipei, TAIWAN.

EP-545
**Te**-FIC: Silk Fibroin Nanoparticles: A dual labeled probe for biodistribution studies
M. Asensio Ruiz1, J. Arango Garzón1, M. J. Bravo-Ferrer Morena2, M. A. Lozano-Pérez3, M. T. Martínez Martínez4, D. Peñuelas J1,4

1. Universidad de Navarra Hospital, Pamplona, SPAIN; 2. Department of Clinical and Molecular Medicine, Faculty of Medicine and Psychology, “Sapienza” University of Rome, Rome, ITALY.

EP-549
Development of a ^99m^Tc Generator (4.45 Gbq): Pars-Gallugen 70 as Largest Commercial ^99m^Tc Generator
M. Chand, C. Peña1, A. Peña2, G. Nevada2

1. University of Uppsala, Uppsala, SWEDEN; 2. All India Institute of Medical Sciences, New Delhi, INDIA.
EP-562
Fractionating cold kits for labelling with 99mTc: our experience and outcomes
E. Lemos Pereira, L. Alves, M. de Araújo, F. Ribeiro, T. Almeida, L. Pereira,
Nuclearmed - Instituto De Medicina Nuclear, Almada, PORTUGAL.

EP-563
Fast And Improved Leukocytes Labelling Procedure With
111In-DTPA-IDA
P. Bueno, R. Sánchez, M. Requena, M. Martín, F. Morena,
Hospital Universitario de Badajoz, Badajoz, SPAIN.

EP-564
Quality control of Ac-225 labelled peptides on the example of
153Ac-Ac-DOTA-Substance P - preliminary results
D. Pawlak, J. S. Dus, O. Krzysik, J. Dzwierzak, A. Duda, V. C. B. Dalk,
Fontis, Memorial Research Institute, Gurgaon, INDIA.

EP-565
Validation of In-house Manual synthesis of 68Ga-
Tricine and its Biodistribution for targeting the
‘Integrin2’ expressing tumors
P. Thakral, J. S. Dus, O. Krzysik, J. Dzwierzak, A. Duda, V. C. B. Dalk,
Fontis, Memorial Research Institute, Gurgaon, INDIA.

EP-566
Two Different Radiochemical Cold Kits And One
Molecular Target The Prostate-Specific Membrane Antigen
(PsmA)
S. Migliori, B. Janotta, M. Scariatti, G. Balboni, U. Maesoni,
Nuclear Medicine Division, Azienda Ospedaliero-Universitaria
di Parma, Parma, ITALY.

EP-567
One-year experience in preparation of Ga-68 tracers using cold kits in a single camera PET centre
J. Aerts, T. Debroecker, L. van Linden, J. Pamelet, T. Penin, O.
Draguin, G. Goudaïf,
Centre Hospitalier de Luxembourg, Luxembourg, LUXEMBOURG.

EP-568
Identification of ([111In]Lu)-PSMA IIT, ([111In]LuCl3 and ([111In]Lu-
Lu-DTPA by a single reversed-phase TLC
C. Cucchietti, A. Bogni, M. Mainente, C. Beretta, M. Kirienko, E. Seregni,
Nuclear Medicine Division, Azienda Ospedaliero-Universitaria di
Parma, Parma, ITALY, Università di Parma Radiocoscintigraphia
Centro POLATOM, Chorzow, POLAND, Università di Parma, Parma, ITALY.

EP-569
A rare case of congenital pulmonary venolobar syndrome
with diaphragmatic hernia
M. Guya, Y. Katliamov, O. Uvaronik,
Cardiology Research Institute, Tomsk MIRN, Tomsk, RUSSIAN FEDERATION.

EP-570
The effects of Henne Plant (Lawsonia inermis) on iodine
thyroid uptake and its implications on radioactive iodine
therapy : A Case-report study
M. Bettaiia, A. Ezzam, A. Garchene, W. Touila, M. Noura, K. Chatti,
Centre hospitalo-universitaire Sahloul, Sousse, TUNISIA.

EP-571
Metabolic Response to Risruitsubin Treatment in
Granulomatosis with Polyangiitis
N. Filipozzi, L. Kuzucuoglu, C. O. Engur, S. Kesen, K. Niftaliyeva, T. N.
Kissa, Z. L. Balaban Genc, S. Ozgun, F. Sen, T. Ones, H. T. Tunugul,
Marmara University Pendik Training and Research Hospital, Istanbul, TURKEY.

EP-572
An unusual presentation of Acute Myeloid Leukemia:
Neuroleukemiosis on FDG PET/CT
N. Filipozzi, L. Kuzucuoglu, S. Kesen, C. O. Engur, K. Niftaliyeva, T. N.
Kissa, Z. L. Balaban Genc, S. Ozgun, F. Sen, T. Ones, H. T. Tunugul,
Marmara University Pendik Training and Research Hospital, Istanbul, TURKEY.

EP-573
IgG4-related Myositis of Levator Palpebrae Superioris
Muscle on 18F-FDG PET/CT
Balaban Genc, K. Ozsargın, S. Özgün, F. Sen, T. Önces, H. T. Tunugül,
Marmara University Pendik Training and Research Hospital, Istanbul, TURKEY.

EP-574
Ventilation/Perfusion Scintigraphy In Pulmonary Venous
Thrombotic Occlusion
V. Rodriguez Morales, A. Castillo Simón, C. Castillo Arias, C.
Carrero, J. M. Nieto, J. Muñoz Iglesias, J. M. Iglesias-Marin,
Hospital Clínico Universitario de Valencia - Nuclear Medicine Division,
Valencia, SPAIN.

EP-575
Relevance of radioactive iodine therapy in the treatment of
mixed anaplastic-papillary thyroid carcinoma
A. Missouni, F. Harazi, A. Ben Ahmed, H. Naaman, M. Maalouf, K.
Ouassouia, F. Guermaz,
Department of Nuclear Medicine, Habib Bourguiba University Hospital, Sfax, TUNISIA.

EP-576
A common mistake in the radiolabelling of peptides
T. Al-Majed, J. Al-Obaidi, A. Al-Ahmad, M. Al-Faraj, C. Elahi,
Hospital Universitario La Paz, Madrid, SPAIN.

EP-577
A Novel Case of Bilateral Breast Metastasis from Pancreatic Neuroendocrine Tumor
H. Sariyildiz Gumusgoz, O. Omur,
Istanbul University, Istanbul, TÜRKIYE.

EP-578
Atypical Onset Of A Bronchial Carcinoid Through Ocular
Symptoms: A Case Report
A. G. Gómez, A. Bajenaru, A. Lazar, M. Mutucaru, M. Gheorghe,2
Institute of Oncology: Professor Doctor Alexandru Trestioreanu,
Bucharest, ROMANIA, 1University of Medicine and Pharmacy
Carol Davila Bucharest, Bucharest, ROMANIA.

EP-579
Incidental Liver Involvement of Multiple Myeloma on 18FDG PET/CT
M. Keskin, B. Temelli,
Mercin City Hospital, Mercin, TURKEY.

EP-580
Abnormal biological distribution related to normal saline among 99mTc-DMSA scans
T. A Bulušić,
Royal Hospital, Muscat, OMAN.

EP-581
Acute Phase of Herpes Simplex Virus-1 Encephalitis on
18F-FDG PET/CT
V. Rodríguez Morales, A. Castillo Simón, C. Martínez Ramos, G.
Ventilation/Perfusion Scintigraphy In Pulmonary Venous
Thrombotic Occlusion
V. Rodriguez Morales, A. Castillo Simón, C. Castillo Arias, C.
Carrero, J. M. Nieto, J. Muñoz Iglesias, J. M. Iglesias-Marin,
Hospital Clínico Universitario de Valencia - Nuclear Medicine Division,
Valencia, SPAIN.

EP-582
Hepatic chronic veno-occlusive disease mimicking hepatic metastasis on FDG PET/CT in a patient with distal esophageal squamous cell carcinoma
A. Abdelrahman, S. Gavone, T. Eljaboue, S. Thung,
Johns Hopkins School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA.

EP-583
"FF-FDG PET/CT identifying rare extrapleural localizations of endometriosis: a case report
A. Franchini, A. Scarampi, E. Gaj, G. Cabib, S. Cempa, K. Shly.
UBC, Department of Nuclear Medicine, Radiation Protection,
University Hospital Centre Zagreb, Zagreb, CROATIA.

EP-584
Angular distribution of radioactivity in a single camera PET
S. Asomoglou, O. Omur,
Istanbul University, Istanbul, TÜRKIYE.

EP-585
An unusual presentation of Acute Myeloid Leukemia:
Neuroleukemiosis on FDG PET/CT
N. Filipozzi, L. Kuzucuoglu, S. Kesen, C. O. Engur, K. Niftaliyeva, T. N.
Kissa, Z. L. Balaban Genc, S. Ozgun, F. Sen, T. Ones, H. T. Tunugul,
Marmara University Pendik Training and Research Hospital, Istanbul, TURKEY.

EP-586
Importance of hybrid pulmonary scintigraphy in patients with dyspnea after COVID-19 pneumonia - case report
V. Leskov, O. Lung,
Third Faculty of Medicine, Charles University, Prague, CZECH REPUBLIC.
EP-595 Radioliodine diagnosis of differentiated thyroid cancer metastases in children: a case report


National Medical Research Center of Oncology, Moscow, RUSSIAN FEDERATION.

EP-596 (68Ga)Ga-PSMA PET/CT uptake in fibrous dysplasia of the rib: a pitfall to know

M. Di Franco, C. Spino, F. Monastier, A. Meli, M. Novelli, S. Fanti, P. R. Castellucci

Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY; Department of Nuclear Medicine and Molecular Imaging, IEO, School of Medicine at Mount Sinai, New York, NY, UNITED STATES OF AMERICA; Nuclear Medicine IRCCS, Azienda Ospedaliero-Universitaria di Bologna, Bologna, ITALY.

EP-597 Why to include the brain in 18F-FDG PET/CT/PET/CT scanning protocol in cancer patient? a case report

T. Yordanova, A. Ksikasova, B. Chauvez, Z. Dancheva, T. Stoever, M. Dyankova, S. Fatima, C. Sgro,2 A. Lopez,2 H. Muller1,4

Medical University Prof. dr. P. Stoyanov, Department of nuclear medicine, Varna, BULGARIA.

EP-598 Inflammatory myofibroblastic tumor of the lung mimicking breast cancer metastasis on 18 FG PET/CT


EP-604 Evaluation by molecular imaging with PET/CT “F-FDG of therapy and follow-up of multifocal and extranodal Rosai-Dorfman Disease” EP-605 Allergic reaction after “[18F]:FDG administration

A. Castelló Simón, C. Martínez Ramos, V. Rodríguez Morales, G. Fernández-Ceniza Fernández-Herrein, J. Nogueras Alonso, J. Muñoz Iglesias, D. Ruiz Hernández, O. Tabuenca Díaz; Department of Nuclear Medicine, Medical University ’Prof. Dr. Paraskev Stoyanov’ Department of Diagnostic Imaging, Interventional Radiology and Radiotherapy Clinic of Nuclear medicine, UMHAT “St. Marina” – Varna, Varna, BULGARIA; Medical University ‘Prof. Dr. Paraskev Stoyanov’ Department of Diagnostic Imaging, Interventional Radiology and Radiotherapy Clinic of Imaging Diagnostics, UMHAT “St. Marina” – Varna, Varna, BULGARIA.

EP-611 Early diagnosis with 18F-FDG PET/CT in a case of left Ventricular Assist Device (VAD) infection

L. Burrull, G. Bisciotti, F. M. Fingreti, C. Ramagnoli, C. Cottignoli, A. Palacci; Dept. of Nuclear Medicine, Ospedali Riuniti di Taranto, Andria, ITALY.

EP-610 A rare case of McCune-Albright Syndrome and use of Tc MDP whole-body scintigraphy for the mapping of bone metastases

S. Chauvez1, J. Dancheva1, B. Chauvez1, T. Stoever1, M. Dyankova; G. Zindanova; A. Klisarova, B. Chausheva, Z. Dancheva; Medical University ‘Prof. Dr. Paraskev Stoyanov’ Department of Diagnostic Imaging, Interventional Radiology and Radiotherapy Clinic of Nuclear medicine, UMHAT “St. Marina” – Varna, Varna, BULGARIA; Medical University ‘Prof. Dr. Paraskev Stoyanov’ Department of Diagnostic Imaging, Interventional Radiology and Radiotherapy Clinic of Imaging Diagnostics, UMHAT “St. Marina” – Varna, Varna, BULGARIA.

EP-612 Challenging current knowledge of metastatic prostate cancer: isolated metastasis to an adrenal gland utilizing F-18 Fluorofolincine PET/CT

S. Peterson1, A. Patel1, G. Spilberg1, J. Bushby2; Harlond Healthcare, Hartford, CT, UNITED STATES OF AMERICA; Jefferson Radiology, Hartford, CT, UNITED STATES OF AMERICA.

EP-613 Clinical Value of 18F-FDG PET/CT in the Management of the Tuberculous Lymphadenitis

N. Filizoglu1, H. I. Tutoglu1, C. G. Engür3, S. Krim1, N. Niyislayla1, T. N. Kizil1, E. Z. Balaban1, G. Oksuza1, S. Oguzer1, F. Sen1, T. Ciner1, T. Y. Erdal1; Mamuru University Pendañ Training and Research Hospital, Istanbul, TURKEY.

EP-613a Prostate specific membrane antigen radioguided surgery for salvage pelvic lymph node dissection in a prostate cancer man

S. Erfani1, R. Sadeghi, A. Aghian, V. Roshanmav, H. Gharbani; Mashhad University of medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-613b Myositis ossificans progressive in a 13 year old boy with myelodysplastic syndrome

F. Karamian1, S. Erfani1, A. Aghian, R. Rostami; Mashhad university of medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-613c Identification of an unusual source of biliary leakage on a scintigraphy of pulmonary embolism: added value of lung perfusion scintigraphy

F. Lanfranchi1, F. Maggio1, T. Bertolasi1, C. Delucchi1, P. O’Hare3; T. D’Ramarodi1, M. D’i Vargani2, A. Massi1, M. Paronetti; G. Villa, S. Rauff2, S. Chiari1, C. Manni1, T. Aloe1, E. Basino1, S. Marbellie1, G. Lampropoulos1, M. Bauckneht1; Department of Health Sciences (DISAL), University of Genoa, Genoa, ITALY; Nuclear Medicine Unit, IRCCS Ospedale PoliChir San Martino, Genova, ITALY; OPM Institute of Molecular Biomaging and Physiology, Milan, ITALY; Interventional Pulmonology Unit, IRCCS Ospedale PoliChir San Martino, Genova, ITALY.

EP-615 Brain FDG PET/CT imaging of patients with persistent post-COVID-19 fatigue

E. Park1, L. E. Poles Ponta, A. C. Pietrus, J. R. Deters, P. E. Gander, T. Rudorff; University of Iowa Hospitals and Clinics, Iowa City, IA, UNITED STATES OF AMERICA.


F. Karamian1, S. Erfani1, A. Aghian; Mashhad university of medical sciences, Mashhad, IRAN, ISLAMIC REPUBLIC OF.

EP-617 Persistent symptoms after COVID-19 infection: place of pulmonary scintigraphy


EP-618 Persistent dyspnea in post-COVID patients in the absence of pulmonary embolism: added value of lung perfusion scintigraphy

F. Lanfranchi1, F. Maggio1, T. Bertolasi1, C. Delucchi1, P. O’Hare3; T. D’Ramarodi1, M. D’i Vargani2, A. Massi1, M. Paronetti; G. Villa, S. Rauff2, S. Chiari1, C. Manni1, T. Aloe1, E. Basino1, S. Marbellie1, G. Lampropoulos1, M. Bauckneht1; Department of Health Sciences (DISAL), University of Genoa, Genoa, ITALY; Nuclear Medicine Unit, IRCCS Ospedale PoliChir San Martino, Genova, ITALY; OPM Institute of Molecular Biomaging and Physiology, Milan, ITALY; Interventional Pulmonology Unit, IRCCS Ospedale PoliChir San Martino, Genova, ITALY.


S. Cabrò1, L. Zanussi2, E. Birnscip2, L. Simon2, Z. Zouzouci2, B. Troumbak1, V. Müller1, M. Mavromatidou2, T. Gyger2; Department of Nuclear Medicine, Medical Imaging Centre, Semmelweis University, Budapest, HUNGRARY; Faculty of Semmelweis University, Budapest, HUNGRARY; Department of Radiology, Medical Imaging Centre, Semmelweis University, Budapest, HUNGRARY; Department of Pulmonology, Medical Imaging Centre, Semmelweis University, Budapest, HUNGRARY.
EP-620
Myocardial perfusion imaging findings of patients with history of COVID-19 infection: a single-center one-year experience
I. Armentis1, N. Sideris2, P. Sotiriou3, M. Papadelis1, E. Kitziri2, S. Kitziri2, A. Kouzomou2, 1Onassis Cardiac Surgery Center, Athens, GREECE.
2Onassis Cardiac Surgery Center, Athens, GREECE.

EP-621
FDG-avid lymph nodes (LN) in response to vaccines for SARS-CoV-2
M. Dyankova1,2, Z. Dancheva1, T. Stoeva1, S. Chasheva1, T. Yordanova1, B. Chaushev1, A. Klasarova1; 1St. Marina University Hospital, Department of Nuclear Medicine, Varna, BULGARIA, 2Medical University Varna “Prof. Dr. Paraskov Stayanov”, Varna, BULGARIA.

EP-622
Characteristics of Subacute Thyroiditis during COVID-19 Pandemic
S. Gaberscek1,2, T. Medved1, N. Medle1, K. Zaletel1; 1Department of Nuclear Medicine, University Medical Centre Ljubljana, Ljubljana, SLOVENIA, 2Faculty of Medicine, University of Ljubljana, Ljubljana, SLOVENIA.

EP-623
Contribution of low dose CT to the V/Q pulmonary scintigraphy in patients after COVID-19 virus
O. Lang1,2, V. Laskov1, I. Kuníková2; 1Charles University, 3rd Med Fac, Prague 10, CZECH REPUBLIC, 2District Hospital, Dept Nucl Med, Příbram, CZECH REPUBLIC.

EP-624
Impact of the Covid-19 pandemic on the care of patients with chronic arterial disease. A nuclear medicine physician’s perspective
M. Moreno-Caballero1, E. Moratallo-Aranda, M. Sánchez Torrente, A. Castro López, M. Gallego Márquez, D. Becerra-García; Hospital Universitario San Cecilio, Granada, SPAIN.

EP-625
Prediction of BRAF gene mutation in thyroid papillary carcinoma based on 18F-FDG-PET imaging radiomics model
Z. Jiang; Affiliated Hospital of Guilin Medical College, Guilin, CHINA.

EP-627
Emotional state of patients with prostate cancer during PSMA-PET/CT
J. Boeser1, H. Faller2, M. Lukaszek1, J. Weisbrodt1, R. A. Werner3, A. Buck4; 1University Hospital Wuerzburg, Department of Nuclear Medicine, Wuerzburg, GERMANY, 2University Hospital Wuerzburg, Department of Psychology and Psychotherapy, Wuerzburg, GERMANY.

EP-628
Referrals from the Nuclear Medicine department to the Emergency department of our hospital for incidental findings in PET-CT studies in two years of the COVID-19 pandemic
G. Cuesta Domingo1, P. Dauden1, P. Nespral1, P. Bascuñán1, M. K. Meneses Navas1, R. M. Couto Caro1, M. García Esquinas2, J. L. Carreras Delgado1, M. N. Cabrera Martín1; 1Department of Nuclear Medicine, Health Research Institute of Hospital Clínico San Carlos, Madrid, SPAIN, 2Department of Radiology, Hospital Clínico San Carlos, Madrid, SPAIN.

EP-629
Digital Technology applied to Customer Satisfaction: set-up and experience in a leading-edge Nuclear Medicine Department
A. Pisani, F. Iuele, C. D’Alò, R. Ruta, P. Mammucci, A. Di Palo, A. Gaudiano, C. Altini, G. Rubini; Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University Aldo Moro, Bari, ITALY.

EP-630
Does dose reduction affect prostatic uptake in staging PSMA PET/CT scans? A single centre, retrospective analysis on 174 ISUP grade 3 and higher patients
J. Morigí, N. Kovaleva, J. Anderson, O. Alghazo, k. duToit, A. Loughman, H. Duncan; Royal Darwin Hospital, Darwin, AUSTRALIA.

EP-631
FAP expression in alpha cells of Langherhans insulae claims for safety assessment when using FAP-targeting radiopharmaceuticals
M. Kirienko, G. Centonze, G. Sabello, E. Seregni, M. Milione; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, ITALY.

EP-632
C. Sgro1, M. Moscarnino2, R. Mei1, A. Farolfi2, A. Zappacosta2, L. Romagnoli1, S. Civollani2, P. Castellucci2, S. Fanti4; 1Nuclear medicine, Alma Mater Studiorum University of Bologna, Bologna, ITALY, 2Nuclear Medicine IRCCS, Azienda Ospedaliero-Universitària di Bologna, Bologna, ITALY, 3Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitària di Bologna, Bologna, ITALY.

EP-633
Navigating the PET DMF/ ANDA Submissions Process Recently Initiated for Academic Institutions
M. Söffing, N. Bhatt, A. Mintz; Columbia University Medical Center, New York, NY, UNITED STATES OF AMERICA.
The industry exhibition will be located on the ground floor of the CCIB – Barcelona International Convention Centre. It will give you an extensive overview of the latest achievements concerning pharmaceuticals and radiopharmaceuticals, as well as state-of-the-art technical equipment. Booksellers and publishers will display the most recent publications in the field of Nuclear Medicine and related sciences.

SUNDAY, OCTOBER 16, 2022
09:00 – 17:00

MONDAY, OCTOBER 17, 2022
09:00 – 17:00

TUESDAY, OCTOBER 18, 2022
09:00 – 17:00
**SATELLITE SYMPOSIA**

**Symposium by Pfizer:** Accelerating the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM): the role of nuclear scintigraphy and other imaging tools  
*Chairperson:* Maria Nazarena Pizzi (Barcelona, Spain)

- **13:15–13:30** Cardiac amyloidosis and the role of nuclear medicine  
  Maria Nazarena Pizzi (Chair), Universitat Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain

- **13:30–13:40** Red flags: the importance of constant vigilance  
  Stefano Perlini, Amyloid Diagnosis and Treatment Center, Pavia, Italy

- **13:40–13:50** Long-term management of ATTR-CM  
  Stefano Perlini, Amyloid Diagnosis and Treatment Center, Pavia, Italy

- **13:50–14:05** Non-invasive tools for the diagnosis and monitoring of ATTR-CM  
  Maria Koutelou, Onassis Cardiac Surgery Center, Athens, Greece

- **14:05–14:15** Panel discussion and Q&A  
  All faculty

**Symposium by United Imaging Healthcare Poland**

**The Future of Molecular Imaging**
*Chairperson:* Ken Herrmann (Barcelona, Spain)  
Jusong Xia (CEO, International Business at United Imaging Healthcare), Łukasz Mizerka (Vice President of International Business, General Manager for Europe)

- **Opening speech**
- **EANM Young Authors’ Award Ceremony**
- **Special Tracers, New Technology, Best Imaging**  
  Dr. Olivari Laura and Dr. Distakou Ioanna, Department of Nuclear Medicine and Radiometabolic Therapy IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) – Hospital Negrar, Italy
- **Academic-Industrial Partnership for Translational Study of Advanced Molecular Imaging**  
  Prof Li Hongdi (CTO of UIH and CEO of UIH America)
- **Radiopharmacy & Cyclotron**  
  Giancarlo Gorgoni (Director Radiopharmacy & Cyclotron department IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella (VR) – Hospital Negrar, Italy)
Sunday, October 16  13:15 – 14:45, Hall 212

Symposium by OncoBeta GmbH
Rhenium-SCT: the future of treating Non-Melanoma skin cancer – A new liaison between Nuclear medicine and Dermatology
Chairperson: Maria Nazarena Pizzi (Barcelona, Spain)

13:15–13:30  Non-Melanoma skin cancer and the potential of using Re188 for treatment
13:30–13:40  Recent Study Results from the Rhenium-SCT Rostock Trial
13:40–13:50  Practical Demonstration
13:50–14:05  Radiation protection in case of high energy beta emitter Re188

Sunday, October 16  13:15 – 14:45, Hall 116

Symposium by Monrol Nuclear Products Co
The Current and Future of Lutetium-177 Based Therapy: Uro-oncology & Radiology Perspective
Chairperson: Prof. Dr. Richard Baum, MD – Curanosticum Wiesbaden – Frankfurt

1:15 – 1:45 pm  Uro-oncology Perspective:
- Prof. Dr. Boris Hadaschik, MD – University of Essen
1:45 – 2:15 pm  Radiology Perspective: Assoc.
- Prof. Dr. Heather Jacene, MD – Dana Farber Cancer Institute
2:15 – 2:30 pm  Closing Remarks by the Chair:
- Prof. Dr. Richard Baum, MD – Curanosticum Wiesbaden – Frankfurt
2:30 – 2:45  Q&A

Monday, October 17  13:15 – 14:45, Hall 211

Symposium by Advanced Accelerator Applications International
PSMA-targeted Theranostics: Towards Clinical Implementation in Advanced Prostate Cancer
Chairperson: Ken Herrmann

Welcome and Introduction
Ken Herrmann (Chair)

Treatment Landscape and Future Horizons
Derya Tilki

Next Generation Imaging in Treatment Decisions
Ken Herrmann

Emerging PSMA-targeted Theranostics
Joe O’Sullivan

Panel Discussion: Multidisciplinary Approaches in Clinical Practice
Valerie Lewington & Ken Herrmann

Live Q&A Session

Monday, October 17  13:15 – 14:45, Hall 117

Symposium by GE Healthcare
How to make Molecular Imaging more Personalised?
Chairperson: Ben Newton PhD, General Manager Oncology at GE Healthcare

Investing in Next Generation Radiotracers to Improve Patient Outcomes
Paul Evans PhD, Head of Global R&D at GE Healthcare

Introducing New Digital PET/CT Platform
Prof. Frédéric Courbon, IUCT Oncopole, Toulouse, France

Unlocking the Potential of Theranostics with StarGuideTM
Prof. Patrick Flamen, Jules Bordet Institute, Brussels, Belgium

Brain Motion Management with SIGNATM PET/MR
Matthew Spangler-Bickell PhD, PET/MR Systems Engineer at GE Healthcare
Monday, October 17  13:15 – 14:45, Hall 116
Symposium by Spectrum Dynamics Medical
Next Generation SPECT Imaging
Chairperson: Prof. Denis Agostini, MD, PhD, Head of Nuclear Medicine Normandy University, CHU Caen, France

What are the fundamentals of Cardiac PET, and how do we improve patient access in Europe?
Speaker: Dr. Hein Verberne MD PhD, Department of Radiology & Nuclear Medicine, University of Amsterdam, The Netherlands

How to establish your Cardiac PET service
Speaker: Jessica Williams MS CNMT, Cardiology Application Specialist, Blue Earth Diagnostics Ltd

Why perform Cardiac PET – understanding the clinical value
Speaker: Dr. Parthiban Arumugam MD, Clinical Director Nuclear Medicine, Manchester University NHS FT, Manchester, UK

Tuesday, October 18  13:15 – 14:45, Hall 117
Symposium by Eckert & Ziegler, PentixaPharm
Theranostic Innovations in Solid and Non-Solid Tumors Targeting CXCR4, HER2, FAP, avβ6 & more
Chairperson: Prof. Margret Schottelius (PhD), Associate Professor, Translational Radiopharmaceutical Sciences, CHUV, Lausanne University Hospital

A Theranostic Roadmap: The Long or the Short Way from Diagnostics to Therapeutics
Margret Schottelius (PhD), Associate Professor, Translational Radiopharmaceutical Sciences, CHUV, Lausanne University Hospital

CXCR4 Based Theranostic: Imaging and Clinical Implications in MZL and other Hematological Neoplasms
Andreas Buck (MD), Clinical Director Nuclear Medicine, University Hospital Würzburg

CXCR4 Based Theranostic: A Promising Approach for Accurate Imaging of Multiple Myeloma and Therapy of Leukemia
François Kraeber-Bodéré (PhD, MD), Head of Nuclear Medicine Department, CHU Nantes

Radiolabeled Single-Domain Antibodies as Theranostic Tools in Oncology
Matthias D’Huyvetter (PhD), Science Director, Precinx NV, Research Professor, Vrije Universiteit Brussel

Ga-68-Trivehexin for PET-Imaging of Carcinomas: The Way To Clinics
Johannes Nolni (PhD) | Co-Founder and CSCO, TRIMT GmbH, Jakub Simecek (PhD) | Co-Founder and CEO, TRIMT GmbH

Tuesday, October 18  13:15 – 14:45, Hall 115
Symposium by Terumo Europe Interventional Systems
Advancing SIRT dosimetry with The Holmium Platform
Chairperson: Prof. Dr. C. Deroose

Introducing the EANM SIRT dosimetry guidelines & products

Recent clinical evidence & dosimetry guidance of Holmium-166 SIRT

How is individualized SIRT treatment performed in routine clinical practice?

The Clinical Program of the Holmium Platform
Tuesday, October 18  13:15 – 14:45, Hall 212

Symposium by Curium
Innovations in Prostate Cancer Imaging and Therapy

Chairperson: Sakir Mutevelic, Chief Medical Officer at Curium

Results from the Python trial: A Prospective Study on [19F]DCFPyL PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
Christoph Rischpler, University Hospital Essen, Department of Nuclear Medicine, Germany, Professor of Nuclear Medicine

One year and 500 patients later: Pylarify® [18 F]DCFPyL in the daily clinical practice
Andrei Iagaru, University of Stanford, Department of Nuclear Medicine and Molecular Imaging, USA, Professor of Radiology & Nuclear Medicine

Artificial Intelligence for Enhanced Clinical Utility of Molecular Imaging
Aseem Anand, EXINI Diagnostics AB, Sweden, Vice President

PSMA-targeted Radioligand Therapy with [177 Lu]Lu-PSMA-I&T: A Decade of Experience
Harshad R. Kulkarni, Zentralklinik Bad Berka, Department of Nuclear Medicine, Germany, Consultant Nuclear Medicine, Chief Medical Advisor, BAMF Health, Grand Rapids, USA

Tuesday, October 18  13:15 – 14:45, Hall 116

Symposium by Siemens Healthineers
Answering to clinical needs in molecular imaging

First user experiences with Symbia Pro.specta SPECT/CT
Dr. Erin Ross, Yasmin Wahid, Department of Medical Physics, University Hospital Birmingham NHS, Birmingham, Great Britain

The future of PET: Total body imaging
Prof. Juhani Knuutila, Turku PET Centre, Turku University Hospital and University of Turku, Turku, Finland

We are growing to serve the needs of our community. EARL provides unparallel support for tomorrow’s research needs with today’s molecular imaging data.
# List of Exhibitors (A - Z)

<table>
<thead>
<tr>
<th>Booth No.</th>
<th>Exhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABSCINT</td>
<td>40</td>
</tr>
<tr>
<td>ABX GmbH</td>
<td>110</td>
</tr>
<tr>
<td>ABX-CRO advanced pharmaceutical services</td>
<td>71</td>
</tr>
<tr>
<td>ACOM Advanced Center Oncology Macerata S.r.l.</td>
<td>72</td>
</tr>
<tr>
<td>Advanced Accelerator Applications, a Novartis company</td>
<td>29</td>
</tr>
<tr>
<td>Advanced Accelerator Applications, a Novartis company (meeting room)</td>
<td>W04</td>
</tr>
<tr>
<td>Advanced Cyclotron Systems</td>
<td>58</td>
</tr>
<tr>
<td>AIMN – Associazione Italiana di Medicina Nucleare ed imaging molecolare</td>
<td>W10</td>
</tr>
<tr>
<td>Alliance Medical GmbH / Life Health Care</td>
<td>16</td>
</tr>
<tr>
<td>ASNC – American Society of Nuclear Cardiology</td>
<td>W08</td>
</tr>
<tr>
<td>AtomVie Global Radiopharma Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Augmenticon AG</td>
<td>108</td>
</tr>
<tr>
<td>Bayer AG</td>
<td>W17</td>
</tr>
<tr>
<td>Best Cyclotron Systems</td>
<td>50</td>
</tr>
<tr>
<td>Blue Earth Diagnostics Ltd</td>
<td>15</td>
</tr>
<tr>
<td>BNMS - British Nuclear Medicine Society</td>
<td>96</td>
</tr>
<tr>
<td>Boston Scientific International</td>
<td>27</td>
</tr>
<tr>
<td>Brightonix Imaging Inc</td>
<td>100</td>
</tr>
<tr>
<td>Bruker BioSpin</td>
<td>9</td>
</tr>
<tr>
<td>Buy Isotope (Neonest AB)</td>
<td>83</td>
</tr>
<tr>
<td>BV Cyclotron VU (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>CANM-ACNM – Canadian Association of Nuclear Medicine</td>
<td>W02</td>
</tr>
<tr>
<td>Casram SA</td>
<td>4</td>
</tr>
<tr>
<td>CHEMATECH</td>
<td>73</td>
</tr>
<tr>
<td>Clarity Pharmaceuticals</td>
<td>65</td>
</tr>
<tr>
<td>CLERAD</td>
<td>37</td>
</tr>
<tr>
<td>CMR – Center of Molecular Research</td>
<td>48</td>
</tr>
<tr>
<td>Comecer Group</td>
<td>45</td>
</tr>
<tr>
<td>Crystal Photonics</td>
<td>99</td>
</tr>
<tr>
<td>CLIP Laboratorien / TRIMT GmbH</td>
<td>33A</td>
</tr>
<tr>
<td>CURIUM</td>
<td>25</td>
</tr>
<tr>
<td>Cyclomedica Europe Ltd.</td>
<td>32</td>
</tr>
<tr>
<td>DIAsource ImmunoAssays</td>
<td>40</td>
</tr>
<tr>
<td>diXit s.r.l.</td>
<td>9</td>
</tr>
<tr>
<td>DOSIsoft SA</td>
<td>12</td>
</tr>
<tr>
<td>DSD Pharma GmbH (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>ec2 Software Solutions</td>
<td>52</td>
</tr>
<tr>
<td>Eckert &amp; Ziegler</td>
<td>19</td>
</tr>
<tr>
<td>EFRS – European Federation of Radiographer Societies</td>
<td>W18</td>
</tr>
<tr>
<td>EITA – European Isotopes Transport Association</td>
<td>W13</td>
</tr>
<tr>
<td>Eli Lilly (meeting room)</td>
<td>W06</td>
</tr>
<tr>
<td>Elysea-raytest GmbH</td>
<td>40</td>
</tr>
<tr>
<td>Epsilon Radioactive Sources - ERS (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>Eras Labo</td>
<td>87</td>
</tr>
<tr>
<td>Euromedical Instruments (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>Evergreen Theragnostics</td>
<td>79</td>
</tr>
<tr>
<td>Fedoruk Canadian Centre for Nuclear Innovation</td>
<td>95</td>
</tr>
<tr>
<td>For-Med (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>Gamma Medical Technology</td>
<td>67</td>
</tr>
<tr>
<td>GE Healthcare</td>
<td>26</td>
</tr>
<tr>
<td>GE Healthcare (meeting room)</td>
<td>1</td>
</tr>
<tr>
<td>Global Morpho Pharma</td>
<td>28</td>
</tr>
<tr>
<td>Hermes Medical Solutions AB</td>
<td>20</td>
</tr>
<tr>
<td>Company Name</td>
<td>Booth</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Hidex Oy</td>
<td>42</td>
</tr>
<tr>
<td>HOY Scandinavian ApS (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>IAEA – International Atomic Energy Agency</td>
<td>W13A</td>
</tr>
<tr>
<td>IBA (Ion Beam Application)</td>
<td>22</td>
</tr>
<tr>
<td>ICPO Foundation</td>
<td>W16</td>
</tr>
<tr>
<td>ImaginAb</td>
<td>38</td>
</tr>
<tr>
<td>Incepto Medical</td>
<td>104</td>
</tr>
<tr>
<td>Innogamma Co</td>
<td>W11</td>
</tr>
<tr>
<td>Institute of Isotopes</td>
<td>43</td>
</tr>
<tr>
<td>Inter Medical Medizintechnik GmbH</td>
<td>57</td>
</tr>
<tr>
<td>International Meetings &amp; Announcements Desk</td>
<td>W03B</td>
</tr>
<tr>
<td>INVIA Medical Imaging Solutions</td>
<td>3</td>
</tr>
<tr>
<td>Invicro</td>
<td>55</td>
</tr>
<tr>
<td>Inviscan</td>
<td>61</td>
</tr>
<tr>
<td>Ionenix Corporation</td>
<td>85</td>
</tr>
<tr>
<td>Isotron Medical Inc</td>
<td>92</td>
</tr>
<tr>
<td>IPHASE technologies Pty Ltd</td>
<td>398</td>
</tr>
<tr>
<td>IRE ELIT</td>
<td>40</td>
</tr>
<tr>
<td>Isotopia Molecular Imaging Ltd</td>
<td>80</td>
</tr>
<tr>
<td>ITEL Telecomunicazioni SRL</td>
<td>76</td>
</tr>
<tr>
<td>ITM Medical Isotopes GmbH</td>
<td>46</td>
</tr>
<tr>
<td>Jiangsu Huayi Technology Co. Ltd</td>
<td>105</td>
</tr>
<tr>
<td>Jubilant Radiopharma</td>
<td>56</td>
</tr>
<tr>
<td>LabLogic Systems Ltd</td>
<td>42</td>
</tr>
<tr>
<td>LaCalhene</td>
<td>60</td>
</tr>
<tr>
<td>Lerner Pax</td>
<td>28</td>
</tr>
<tr>
<td>M&amp;I Materials Ltd (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>Medi-Radiopharma Ltd</td>
<td>47</td>
</tr>
<tr>
<td>Mediso Medical Imaging Systems</td>
<td>43</td>
</tr>
<tr>
<td>Mediso Medical Imaging Systems</td>
<td>44</td>
</tr>
<tr>
<td>MEDaysintell</td>
<td>40</td>
</tr>
<tr>
<td>medstep.de (VIVA Software AG) - Jobboard</td>
<td>W03A</td>
</tr>
<tr>
<td>MedTrace Pharma A/S</td>
<td>11</td>
</tr>
<tr>
<td>ME medical imaging electronics GmbH</td>
<td>33C</td>
</tr>
<tr>
<td>MLLabs B.V.</td>
<td>78</td>
</tr>
<tr>
<td>MIM Software</td>
<td>8</td>
</tr>
<tr>
<td>Mirion Technologies, Inc.</td>
<td>W14</td>
</tr>
<tr>
<td>MNT Saglik Hizmetleri A.S.</td>
<td>75</td>
</tr>
<tr>
<td>MOLECUBES NV</td>
<td>6</td>
</tr>
<tr>
<td>Monrol Nuclear Products Co.</td>
<td>21</td>
</tr>
<tr>
<td>MR Solutions Ltd</td>
<td>103</td>
</tr>
<tr>
<td>NICESOF (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>NIMEU - Nuclear Medicine Europe</td>
<td>31A</td>
</tr>
<tr>
<td>NRIQPALLAS</td>
<td>34</td>
</tr>
<tr>
<td>NSNM - Norwegian Society of Nuclear Medicine and Molecular Imaging</td>
<td>W05</td>
</tr>
<tr>
<td>Nuclear Shields BV</td>
<td>69</td>
</tr>
<tr>
<td>Nucleis</td>
<td>40</td>
</tr>
<tr>
<td>NUVA (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>OGNMB – Austrian Society of Nuclear Medicine</td>
<td>W15</td>
</tr>
<tr>
<td>Oncidium Foundation</td>
<td>84</td>
</tr>
<tr>
<td>Onco Design</td>
<td>74</td>
</tr>
<tr>
<td>OncosBeta GmbH</td>
<td>88</td>
</tr>
<tr>
<td>Oncost Medical</td>
<td>70</td>
</tr>
<tr>
<td>Oncovision</td>
<td>39</td>
</tr>
<tr>
<td>Optimized Radiochemical Applications</td>
<td>81</td>
</tr>
<tr>
<td>Pars Isotope Co</td>
<td>66</td>
</tr>
<tr>
<td>PBL SRL</td>
<td>101</td>
</tr>
<tr>
<td>PentixaPharm</td>
<td>19</td>
</tr>
<tr>
<td>Pepscan</td>
<td>93</td>
</tr>
<tr>
<td>PI Medical Diagnostic Equipment B.V. (part of the pavilion)</td>
<td>35</td>
</tr>
<tr>
<td>Piur Imaging</td>
<td>94</td>
</tr>
<tr>
<td>PMB-ALCEN</td>
<td>59</td>
</tr>
<tr>
<td>Company Name</td>
<td>Page</td>
</tr>
<tr>
<td>--------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td>POLATOM, Radioisotope Centre of National Centre for Nuclear Research</td>
<td>31</td>
</tr>
<tr>
<td>Positigo AG</td>
<td>64</td>
</tr>
<tr>
<td>Precinix</td>
<td>51</td>
</tr>
<tr>
<td>Qubiotech Health Intelligence, S.L.</td>
<td>2</td>
</tr>
<tr>
<td>Radiaprot</td>
<td>86</td>
</tr>
<tr>
<td>RADIOPROTECH</td>
<td>13</td>
</tr>
<tr>
<td>RadQual - International Isotopes (RadQual Global Sources)</td>
<td>91</td>
</tr>
<tr>
<td>Rescuedose</td>
<td>91</td>
</tr>
<tr>
<td>RI-TE Radiation Imaging Technologies, Lda</td>
<td>54</td>
</tr>
<tr>
<td>Rotern GmbH</td>
<td>39A</td>
</tr>
<tr>
<td>ROTOP Pharmaka GmbH</td>
<td>33</td>
</tr>
<tr>
<td>RPO - Radiomolecular Precision Oncology</td>
<td>109</td>
</tr>
<tr>
<td>ROS Alexander Ruffani</td>
<td>102</td>
</tr>
<tr>
<td>Scannix</td>
<td>40</td>
</tr>
<tr>
<td>Scintomics GmbH</td>
<td>5</td>
</tr>
<tr>
<td>SFMN – French Society of Nuclear Medicine</td>
<td>W19</td>
</tr>
<tr>
<td>SHINE Medical Technologies, LLC</td>
<td>63</td>
</tr>
<tr>
<td>Siemens Healthineers</td>
<td>30</td>
</tr>
<tr>
<td>Siemens Healthineers (meeting room)</td>
<td>49</td>
</tr>
<tr>
<td>Sirtex Medical Europe GmbH</td>
<td>17</td>
</tr>
<tr>
<td>SNMMI – Society of Nuclear Medicine and Molecular Imaging</td>
<td>W01</td>
</tr>
<tr>
<td>Society of Nuclear Medicine, India</td>
<td>W12</td>
</tr>
<tr>
<td>Southern Scientific</td>
<td>42</td>
</tr>
<tr>
<td>Spectrum Dynamics Medical Inc.</td>
<td>23</td>
</tr>
<tr>
<td>Sumitomo Heavy Industries, Ltd.</td>
<td>77</td>
</tr>
<tr>
<td>SYNTHRA GmbH</td>
<td>97</td>
</tr>
<tr>
<td>Taiyo Nippon Sanso Corporation</td>
<td>98</td>
</tr>
<tr>
<td>Tecnicas Radiofisicas S.I.</td>
<td>106</td>
</tr>
<tr>
<td>Telix – ANMI SA, a Telix Company</td>
<td>41</td>
</tr>
<tr>
<td>Tema Sinergie S.p.A.</td>
<td>24</td>
</tr>
<tr>
<td>Terumo Interventional Systems</td>
<td>14</td>
</tr>
<tr>
<td>Theragnostics Limited</td>
<td>107</td>
</tr>
<tr>
<td>Transrad</td>
<td>40</td>
</tr>
<tr>
<td>TRASIS S.A.</td>
<td>36</td>
</tr>
<tr>
<td>Triskem International</td>
<td>68</td>
</tr>
<tr>
<td>TSNM – Turkish Society of Nuclear Medicine</td>
<td>W09</td>
</tr>
<tr>
<td>U.S. Department of Energy Isotope Program (OAK Ridge)</td>
<td>62</td>
</tr>
<tr>
<td>United Imaging Healthcare</td>
<td>53</td>
</tr>
<tr>
<td>United Imaging Healthcare</td>
<td>82</td>
</tr>
<tr>
<td>United Imaging Healthcare (meeting room)</td>
<td>W07</td>
</tr>
<tr>
<td>vent-medis GmbH</td>
<td>338</td>
</tr>
<tr>
<td>Von Gahlen Nederland B.V.</td>
<td>18</td>
</tr>
<tr>
<td>Vortal</td>
<td>40</td>
</tr>
<tr>
<td>Walischmiller Engineering</td>
<td>89</td>
</tr>
<tr>
<td>Wallonia Export &amp; Investment Agency (AWEX)</td>
<td>40</td>
</tr>
<tr>
<td>Waters Cromatografía</td>
<td>112</td>
</tr>
<tr>
<td>WIS - World Infinity Services</td>
<td>40</td>
</tr>
<tr>
<td>Xeos Medical NV</td>
<td>111</td>
</tr>
</tbody>
</table>
# List of Exhibitors (Sorted by Booth No.)

<table>
<thead>
<tr>
<th>Booth No.</th>
<th>Exhibitor</th>
<th>Booth No.</th>
<th>Exhibitor</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>GE Healthcare (meeting room)</td>
<td>22</td>
<td>IBA (Ion Beam Applications)</td>
</tr>
<tr>
<td>2</td>
<td>Qubiotech Health Intelligence, S.L</td>
<td>23</td>
<td>Spectrum Dynamics Medical Inc.</td>
</tr>
<tr>
<td>3</td>
<td>INVIA Medical Imaging Solutions</td>
<td>24</td>
<td>Tema Sinergie S.p.A.</td>
</tr>
<tr>
<td>4</td>
<td>Casram SA</td>
<td>25</td>
<td>CURIUM</td>
</tr>
<tr>
<td>5</td>
<td>Scintomics GmbH</td>
<td>26</td>
<td>GE Healthcare</td>
</tr>
<tr>
<td>6</td>
<td>MOLECUBES NV</td>
<td>27</td>
<td>Boston Scientific International</td>
</tr>
<tr>
<td>8</td>
<td>MIM Software</td>
<td>28</td>
<td>Lerner Pax</td>
</tr>
<tr>
<td>9</td>
<td>Bruker BioSpin</td>
<td>29</td>
<td>Advanced Accelerator Applications, a Novartis company</td>
</tr>
<tr>
<td>9</td>
<td>diXit s.r.l.</td>
<td>30</td>
<td>Siemens Healthineers</td>
</tr>
<tr>
<td>10</td>
<td>AtomVie Global Radiopharma Inc.</td>
<td>31</td>
<td>POLATOM, Radioisotope Centre of National Centre for Nuclear Research</td>
</tr>
<tr>
<td>11</td>
<td>MedTrace Pharma A/S</td>
<td>32</td>
<td>Cyclomedica Europe Ltd.</td>
</tr>
<tr>
<td>12</td>
<td>DOSisoft SA</td>
<td>33</td>
<td>ROTOP Pharmaka GmbH</td>
</tr>
<tr>
<td>13</td>
<td>RADIOPROTECH</td>
<td>34</td>
<td>NRG</td>
</tr>
<tr>
<td>14</td>
<td>Terumo Interventional Systems</td>
<td>35</td>
<td>BV Cyclotron VU (part of the pavilion)</td>
</tr>
<tr>
<td>15</td>
<td>Blue Earth Diagnostics Ltd.</td>
<td>36</td>
<td>TRASIS S.A.</td>
</tr>
<tr>
<td>16</td>
<td>Alliance Medical GmbH / Life Health Care</td>
<td>37</td>
<td>CLERAD</td>
</tr>
<tr>
<td>17</td>
<td>Sirit Medical Europe GmbH</td>
<td>38</td>
<td>ImaginAb</td>
</tr>
<tr>
<td>18</td>
<td>Von Gahlen Nederland B.V.</td>
<td>39</td>
<td>Oncovision</td>
</tr>
<tr>
<td>19</td>
<td>Eckert &amp; Ziegler</td>
<td>40</td>
<td>ABSCINT</td>
</tr>
<tr>
<td>19</td>
<td>PentixaPharm</td>
<td>40</td>
<td>DIAsource ImmunoAssays</td>
</tr>
<tr>
<td>20</td>
<td>Hermes Medical Solutions AB</td>
<td>40</td>
<td>Elysia-raytest GmbH</td>
</tr>
<tr>
<td>21</td>
<td>Monrol Nuclear Products Co.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>IRE ELiT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>MEDraysintell</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Nucleis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Scanix</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Transrad</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Vortal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Wallonia Export &amp; Investment Agency (AWEX)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>WIS - World Infinity Services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>Telix – ANMI SA, a Telix Company</td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>Hidex Oy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>LabLogic Systems Ltd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>Southern Scientific</td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Institute of Isotopes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td>Mediso Medical Imaging Systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td>Mediso Medical Imaging Systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>Comecer Group</td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>ITM Medical Isotopes GmbH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td>Medi-Radiopharma Ltd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>CVR – Center of Molecular Research</td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td>Siemens Healthineers (meeting room)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Best Cyclotron Systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>51</td>
<td>Precirix</td>
<td></td>
<td></td>
</tr>
<tr>
<td>52</td>
<td>ec2 Software Solutions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>53</td>
<td>United Imaging Healthcare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>54</td>
<td>RI-TE Radiation Imaging Technologies, Lda</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Invicro</td>
<td></td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>Jubilant Radiopharma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Inter Medical Mediotechnik GmbH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Advanced Cyclotron Systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>PMB-ALCEN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td>LaCalhene</td>
<td></td>
<td></td>
</tr>
<tr>
<td>61</td>
<td>Inviscan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>62</td>
<td>U.S. Department of Energy Isotope Program (DOE Ridge)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>63</td>
<td>SHINE Medical Technologies, LLC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>64</td>
<td>Positrico AG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>Clarity Pharmaceuticals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>66</td>
<td>Pars Isotope Co.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>67</td>
<td>Gamma Medical Technology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>68</td>
<td>Triskem International</td>
<td></td>
<td></td>
</tr>
<tr>
<td>69</td>
<td>Nuclear Shields BV</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70</td>
<td>Oncosil Medical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>71</td>
<td>ABX-CRO advanced pharmaceutical services</td>
<td></td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>ACOM Advanced Center Oncology Macerata S.r.l.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>CHEMATECH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>Onco Design</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>MNT Saglik Hizmetleri A.S.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>76</td>
<td>ITI Telecommunicazioni SRL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>77</td>
<td>Sumitomo Heavy Industries, Ltd.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>78</td>
<td>MILabs B.V.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>79</td>
<td>Evergreen Theragnostics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td>Isotopia Molecular Imaging Ltd</td>
<td></td>
<td></td>
</tr>
<tr>
<td>81</td>
<td>Optimized Radiochemical Applications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>82</td>
<td>United Imaging Healthcare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>83</td>
<td>Buy Isotope (Neonest AB)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>84</td>
<td>Oncidium Foundation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>85</td>
<td>IONetix Corporation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>86</td>
<td>Radiumot</td>
<td></td>
<td></td>
</tr>
<tr>
<td>87</td>
<td>Eras Labo</td>
<td></td>
<td></td>
</tr>
<tr>
<td>88</td>
<td>OncoBeta GmbH</td>
<td></td>
<td></td>
</tr>
<tr>
<td>89</td>
<td>Wallischmiller Engineering</td>
<td></td>
<td></td>
</tr>
<tr>
<td>91</td>
<td>RadQual - International Isotopes (RadQual Global Sources)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
91. Rescuedose
92. Iotron Medical Inc
93. Pepscan
94. Piur Imaging
95. Fedoruk Canadian Centre for Nuclear Innovation
96. BNMS - British Nuclear Medicine Society
97. SYNTHRA GmbH
98. Taiyo Nippon Sanso Corporation
99. Crystal Photonics
100. Brightonix Imaging Inc
101. PBL SRL
102. RQS Alexander Ruffani
103. MR Solutions Ltd.
104. Incepto Medical
105. Jiangsu Huayi Technology Co. Ltd
106. Tecnicas Radiofisicas SL
107. Theragnostics Limited
108. Augmenticon AG
109. RPO - Radiomolecular Precision Oncology
110. ABX GmbH
111. Xeos Medical NV
112. Waters Cromatografia
31A. NMEU - Nuclear Medicine Europe
33A. CUP Laboratorien / TRIMT GmbH
33B. vent-medis GmbH
33C. ME medical imaging electronics GmbH
39A. Rotem GmbH
39B. iPHASE technologies Pty Ltd
W01. SNMII – Society of Nuclear Medicine and Molecular Imaging
W02. CANM-ACNM – Canadian Association of Nuclear Medicine
W03.A. medstep.de (VIVA Software AG) - Jobboard
W03.B. International Meetings & Announcements Desk
W04. Advanced Accelerator Applications, a Novartis company (meeting room)
W05. NSNM – Norwegian Society of Nuclear Medicine and Molecular Imaging
W06. Eli Lilly (meeting room)
W07. United Imaging Healthcare (meeting room)
W08. ASNC – American Society of Nuclear Cardiology
W09. TSNM – Turkish Society of Nuclear Medicine
W10. AIMN – Associazione Italiana di Medicina Nucleare ed imaging molecolare
W11. Innogamma Co
W12. Society of Nuclear Medicine, India
W13. EITA – European Isotopes Transport Association
W13.A. IAEA – International Atomic Energy Agency
W15. OGNMB – Austrian Society of Nuclear Medicine
W16. ICPO Foundation
W17. Bayer AG
W18. EFRS – European Federation of Radiographer Societies
W19. SFMN – French Society of Nuclear Medicine
COMPANY PROFILES

ABSCINT
Avenue du Parc Industriel 89
B - 4041 Herstal, Belgium
karine.clauwaert@abscint.com
https://abscint.com/

ABSCINT is a clinical stage molecular imaging company developing in vivo diagnostics empowered by single-domain antibodies. Our name captures our essence, which is to address unmet medical needs with the development of unique antibodies (AB) providing superior performance in scintigraphy (SCINT). Our mission is to provide more precise, more specific, more convenient and safer diagnostics in the fields of oncology, cardiology and immunology.

ABX advanced biochemical compounds GmbH
Heinrich-Glaeser-Str. 10 - 14
01454 Radeberg
info@abx.de
http://www.abx.de

ABX is the leading manufacturer of high-quality radiopharmaceutical products for molecular imaging & therapy mainly used for the detection of tumors by PET and SPECT. Our company develops, produces, tests and markets precursors/active ingredients, reagent kits and hardware cassettes. Currently ABX is constructing one of the first approved and fully automated industrial-scale production facilities for radioactive theranostics with its own sterile testing. An excerpt from our portfolio:
• FDG reagent kits & cassettes for nearly all FDG modules, Mannose Triflate, Cryptand222
• F-PSMA-1007 precursor, reagents & cassettes for GE MX, GE FX, GE FastLab, Ora Nepis, IBA Synthera, Synthra & Trissi ADX modules • nuclotriphosphate F-DOPA precursors, reagents & cassettes • PET, F-Choline, F-MISO, PET & NAF precursors, reagents & cassettes • comprehensive range of "scientific" precursors for oncology
• SPECT precursors e. g. CuMIBI, MBG, ECD • PEPTIDES e.g. PSMA-11, DOTA-TOC, DOTA-TATE & DOTA-NOC for Gallium68 labelling • Gallium-68 reagents kits & cassettes • Lutetium-177 reagents kits & cassettes • O-18 WATER • Performance of stability studies • Development of radiotracers & labelling as well as purification strategies.

Advanced Accelerator Applications, A Novartis Company
Rue de la Tour de l’Ile 4
1204 Genève, Switzerland
https://www.adacap.com/

At Advanced Accelerator Applications (AAA), we are reimagining nuclear medicine and cancer care. Our mission is to transform patients’ lives by developing and delivering targeted radioligand therapies and precision imaging radioligands for oncology.

A.C.O.M. - ADVANCED CENTER ONCOLOGY MACERATA – S.R.L.
Località Cavallino, 39/A-B
62010 Montecosaro (MC), Italy
amministrazione@acomp.it

ACOM SRL is a company operating in the nuclear medicine sector founded in 1999.
Research is the driving force of the company, with 20 years of commitment and experience in the development of innovative radiopharmaceuticals to be included in the international market. The main area of interest and development is oncology, but the activities also involve neurodegenerative and cardiovascular diseases. The focus of the research is theranostic medicine, and in particular the development of Copper(64Cu) Chloride as a theranostic agent: a real integration of a diagnostic method with a specific therapeutic intervention.
ACOM SRL is the first company in Europe to have brought in the market the radionuclide Copper-64 as a radiopharmaceutical precursor. ACOM SRL has recently obtained orphan designation in Europe for the treatment of glioblastoma with Copper(64Cu)Chloride.
The professional skills of the team, the capacity to operate in critical contexts and an innovative approach demonstrated by constant investment in research and development, are just some of the distinctive features developed in these years of business. For any further information please visit our stand and our WEB page (www.acomp.it) where you can find the most updated information.
Advanced Cyclotron Systems, Inc (ACSI) is a world leader in the design and manufacturing of cyclotron systems. With over 30 years of experience and more than 60 cyclotron systems installed, ACSI can provide a wide range of equipment and services worldwide. ACSI cyclotrons are used for the commercial production of PET and SPECT nuclides by internationally recognized companies and leading universities and research facilities. ACSI cyclotrons are designed, manufactured, and assembled in Richmond, Canada. ACSI offers a full spectrum of cyclotron systems ranging from PET cyclotrons to medium and high energy accelerators. All ACSI manufactured cyclotrons have variable energy and employ external ion source technology, offering the highest beam current output available on the market. The versatility, high beam current and exceptional quality of ACSI cyclotrons are some of the reasons why many of the world’s most prestigious universities and research centres, as well as some of the most successful commercial radioisotope producers have chosen ACSI cyclotrons to meet their radioisotope production needs.

For more information, please visit www.advancedcyclotron.com.

Alliance medical / Life Healthcare Europe

Life Healthcare Europe, consisting of Life Molecular Imaging, Life Radiopharma and Life Alliance Medical, is an integrated business including research and development laboratories, a network of cyclotrons, radiopharmacies and imaging facilities. These combined services allows physicians, pharma industry and academia greater access to established and innovative imaging agents for clinical trials and clinical routine.

Advanced Cyclotron Systems, Inc (ACSI) | www.advancedcyclotron.com

Alliance medical / Life Healthcare Europe | info@alliancemedical.eu

Atomvie Global Radiopharma Inc.

Leveraging over seven years of expertise in the GMP manufacturing and global distribution of radiotherapeutics, the Centre for Probe Development and Commercialization (CPDC) is launching AtomVie Global Radiopharma Inc. (AtomVie), a global leading Contract Development and Manufacturing Organization (CDMO). AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of your radiotherapeutics from Phase 1 to the commercial marketplace. AtomVie has in-depth expertise in radiolabeling with an array of radioisotopes such as Lu-177, Ac-225, I-131 and ligands that range from small molecules, to peptides to small and large antibodies. In partnership with Isotopia, AtomVie produces Lu-177 (n.c.a) from its own facility, offering a unique value proposition to its clients with Lu-177-based programs. Capabilities offered by AtomVie include:

• Analytical and process development
• Scale-up & stability studies
• Analytical and process validation
• Logistics to global destinations (North America, EU, Asia and more)

Management of: Program development, CMC, Regulatory affairs (FDA, Health Canada and EMA)

Atomvie has routine clinical and commercial supply to meet the needs of our clients:

• Supply of GMP-grade Lu-177 (n.c.a).

We are building a state-of-the-art, multi-product facility that will be operational in 2024. AtomVie empowers the development of your radiotherapeutics.

Advanced Cyclotron Systems, Inc (ACSI) | 150-7280 River Road

V8X 1X5 Richmond, BC, Canada | info@advancedcyclotron.com

www.advancedcyclotron.com

Alliance medical / Life Healthcare Europe | Westring 168

44575 Castrop-Rauxel, Germany | niki.polat@alliancemedical.eu

Atomvie Global Radiopharma Inc. | C/o CPDC, 1280 Main Street West, N8P 3A1

ON L8S 4K1 Hamilton, Canada | info@atomvie.com

www.atomvie.com

Augmenticon AG

Augmenticon AG was founded by Dr. Matthias Friebe and Dr. Christian Schmidt in 2019 with the mission to transform and digitalize pharmaceutical manufacturing with their AR/MR, computer vision based application suite. The benefits of our application suite are optimized resource utilization, better manufacturing process control with reduced number of human errors, minimal machine down-time, and consequently reduced costs.

Our Product Portfolio:
• Augmenticon ASSYST:
  Process guidance & control via: Step-by-step instructions with feedback function, immersive AR/MR interfaces, AI and deep learning algorithms
• Augmenticon SHARE:
  Live Expert to operator communication for remote: Training, Troubleshooting, 2nd persons verifications
• Augmenticon DOCS:
  Documentation & Analysis of: R&D lab, GMP production
  etc.

Our Services:
• Pilot projects: These allow you to thoroughly test our products before you enter into a license agreement.
• Training: The initial training of your staff is included in the license package you acquire. Our experts support you in training of new employees or third-party staff.
• Validation Services: System validation and assistance of customer specific documentation.

Our mission is to become your reliable partner for cGMP compliant INDUSTRY 4.0 applications in pharmaceutical manufacturing. Reach out to us (www.augmenticon.ch) and let us show you how we can jointly shape the future.

Augmenticon AG | Europe 19a

CH-8152 Glattbrugg, Switzerland | c.schmidt@augmenticon.ch

www.augmenticon.ch
Wallonia Trade and Investment Agency (AWEX)

Place Saintelette 2
1080 Brussels, Belgium
LIFESCIENCES@awex.be
https://www.awex.be/en

The Wallonia Foreign Trade and Investment Agency, also known as AWEX, is Wallonia - Region of Belgium’s government agency in charge of foreign Trade and foreign investment. Wallonia is home to many nuclear medicine companies of various sizes, from SMEs to large companies, such as IBA and IRE, including spinoffs, suppliers and service providers.

Our regional government supports the development of existing or newly established innovative activities with regard to R&D and production in the radiopharma and radiotherapy industry. AWEX is a one-stop shop for all foreign companies interested in setting up or expanding their business in Wallonia, as well as a partner for all Walloon companies wishing to develop their activities outside Belgium. If you’re interested to know more, we will provide you with tailor-made information.

Our partner BioWIN, the Health Cluster of Wallonia since 2006, encourages innovation and international development of Walloon actors active in this sector. BioWIN connects some 250 key players: universities, research units and centers, R&D as well as manufacturing companies, incubators, capital providers, hospitals. To find out more about BioWIN’s activities, please visit https://biowin.org/.

Bayer AG

Radiology Commercial Operations EMEA
Muehlberri 178
13342 Berlin, Germany
Ronja.reuber@bayer.com
radiology.bayer.com

As a true life-science company, Bayer understands where treatment starts: With an early and precise diagnosis. Our dedication to quality in everything we do supports Radiologists to focus on patient care. For approximately 100 years, we have pioneered products and services to enhance medical imaging. Today, we continue to be a preferred partner to radiologists and other physicians as they work to provide the best care for patients.

We provide radiologists with a portfolio of products that enhance medical imaging and facilitate greater efficiency with a focus on image acquisition, from Contrast Media, Injection and Infusion Systems, Service to Software Solutions.

Best Cyclotron Systems

413 March Rd
K2K 0E4 Kanata, Canada
clemens.schroeder@theratronics.ca

Best Cyclotron Systems has been established in Springfield, Virginia, U.S.A., for the design and production of commercial cyclotrons. Our Cyclotrons are manufactured and tested at Best Theratronics in Ottawa, Ontario, Canada. BCS is currently focused on five different energy cyclotrons: the 15, 25, 30, 35 and 70 MW negative hydrogen ion accelerators.

Biosynth (formerly PEPSCAN and Vivitide)

Zuidersluisweg 2
8243RC Lelystad, The Netherlands
order@pepscan.com
www.pepscan.com

Biosynth - Peptide and Antibody division (formerly Vivitide and Pepscan) - is showcasing its new offering across the full range of peptide products and services. From custom peptide synthesis and library production, lead discovery and optimization, large scale peptide manufacture and GMP compliant NCEs, as well as our class-leading neoantigen peptide programs. Targeted nuclear medicine has experienced rapid growth, both in diagnostic imaging and therapy as well as the combination thereof: theranostics. Peptides play an important role in this field as they can specifically deliver both radioactive markers and therapies to a tumor.

Biosynth offers a unique CLIPS™ phage display platform to discover highly constrained de novo peptides with enhanced affinity against your target of interest, selectivity and proteolytic stability. We employ some of the industry’s finest chemists to further optimize and design your lead peptides to make them fit for your purpose.

We have a proven track record in synthesizing precursors for peptide radiopharmaceuticals suitable for a wide range of applications, both following our internal peptide discovery program as well as lead peptides discovered by our customers.

Come and talk to the Biosynth team if you want to know how we can assist you in progressing your peptide project through (pre-) clinical development, application and commercialization and support you in making your project a success story!
Blue Earth Diagnostics

Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is an international molecular imaging company on a growth trajectory to develop and commercialise innovative, well-differentiated diagnostic solutions that inform patient care and drive future therapies in cancer. Formed in 2014, the Company’s success is driven by its management expertise, supported by a proven track record of rapid development and commercialisation of positron emission tomography radiopharmaceuticals. With a clinical focus in cancer, Blue Earth Diagnostics’ expanding pipeline encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialisation of precision radiopharmaceuticals for potential use in diagnostic imaging and therapy. For more information, please visit: www.blueearthdiagnostics.com.

Boston Scientific International S.A.

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Boston Scientific collaborates with health care professionals to develop meaningful innovations that help more people live longer, healthier lives. We invest in bringing new products to large, high-growth markets while building our unique pipeline of technologies to expand our category leadership and address unmet patient needs. Our innovative culture has enabled us to serve approximately 30 million patients annually.

Interventional Oncology is giving medical teams powerful new options and patients new hopes. We believe this is just the beginning and are committed to working with you to change the fight against cancer. Our best-in-class portfolio enables personalised interventional strategies, supported by evidence and educational partnerships.

Brightonix Imaging Inc.

Brightonix Imaging is a innovative healthcare company established with the goal to provide society with innovative biomedical imaging devices and solutions. We are currently offering AI-powered medical imaging solutions and preclinical PET systems. SimPET is the most compact and reliable MR-compatible SiPM-PET insert for truly simultaneous PET/MRI studies in small animals, to molecular imaging scientists.

BTXBrain is AI-powered automated brain PET quantification software, and runs without the aid of 3D MR images. It is very fast and reliable, and it also provides flexible settings and user-friendly interfaces for easy interactions.

Brightonix Imaging is also developing clinical PET scanner for brain and other peripheral organs with support from Korea Medical Device Development Fund.

Bruker

Bruker offers advanced preclinical imaging solutions for a broad spectrum of application fields, such as oncology, neurology, cardiology, inflammation, infectious diseases, cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. With more than 20 years of experience in molecular imaging, we are committed to enhancing each laboratory’s ability to explore cellular and molecular processes in living animal models.

This commitment drives our innovation agenda by gathering knowledge, building networks, and exploring new technologies with the goal of enabling new theranostic methods and discovering new drugs in oncology, cardiology, neuroscience, and immunology.

From floor-standing instruments to benchtops, from software to service, from academic research to applied research, Bruker brings you the world of molecular imaging and offers advanced hybrid imaging devices such as PET/CT, PET/MR and PET/SPECT/CT to help scientists and life science industry to advance their research or business.
Buyisotope (Neonest AB)

Storgatan 70C
Solna, Sweden

info@buyisotope.com

www.BuyIsotope.com

Buyisotope (Neonest AB) offers a range of high quality enriched isotopes e.g. Zn-68, Ga-68, Ga-69, Ca-44, Ca-43, Pb-202, Sr-88, Lu-176, Yb-176, Ir-191, Ba-130, TI-203, Yb-168, Sm-152, Sr-84, Sr-88 in different chemical forms: e.g. oxide, metal, carbonate and enriched isotopic gases e.g. Xe-124, Xe-129, Xe-131. On request: we produce monoisotopic chemical compounds e.g. cisplatin, nitrates, chlorides and convert of rare-earth oxides to metals. We can produce different structured forms of the enriched isotopes e.g. targets, foil, rod, cylinder, pins, pellets.

Buyisotope offers non enriched products e.g. Iridium pellets, Iridium discs, Iridium pins, Rubidium metal (purity 99.997%) and over 1000 High Purity Inorganic Compounds including Alkali and Rare Earth metals and compounds.

Please let us know what is your requirement and we will find a solution.

BV Cyclotron VU

Van der Boechorststraat 6 A
1081 BT Amsterdam, The Netherlands

info@cyclotron.nl

www.cyclotron.nl

BV Cyclotron VU produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Strategically located in Amsterdam next to Amsterdam UMC we produce GMP-compliant medical isotopes in our state-of-the-art manufacturing facilities. Our long standing track record on supplying daily to the customers, our great expertise combined with strong collaborations makes us a reliable partner for hospitals, pharmaceutical companies and research centers all over the world.

Capintec (A Mirion Medical Company)

7 Vreeland Rd.
07932 Florham Park, New Jersey, United States

capintec@mirion.com

www.capintec.com

Recognized as a leader in the development and manufacturing of state-of-the-art radiation measuring and monitoring instrumentation, Capintec (A Mirion Medical Company) seeks to better the human condition by protecting people from exposure during potentially life-saving diagnosis and therapy. From dose preparation to patient administration, Capintec’s nuclear medicine and molecular imaging solutions enhance safety and efficiency for technologists and physicists throughout the care continuum.

CASRAM

Via Cantonale 31
6805 Mezzovico, Switzerland

info@casram.com

www.casram.com

Casram – based in Switzerland since 70 years – is a manufacturer of tungsten heavy alloys for radiation shielding, with fully integrated specialized workshops: A Powder metallurgy workshop with high end sintering technology, a state-of-the-art machining workshop to obtain most complex dimensions with most severe tolerances, surface treatment shops and a complete QC laboratory for non-destructive testing and certifications. Every manufacturing step is located in one single EN 9100 and ISO 9001 certified facility.

Our tungsten heavy metal alloys are used for transportation containers, syringe shieldings, collimators and all other kind of radiation shielding applications.
<table>
<thead>
<tr>
<th>Company</th>
<th>Address</th>
<th>Contact Information</th>
<th>Website</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarity Pharmaceuticals</td>
<td>4 Cornwallis Street, National Innovation Centre, Eveleigh 2015 NSW, Sydney, Australia</td>
<td><a href="mailto:bd@claritypharmaceutical.com">bd@claritypharmaceutical.com</a></td>
<td><a href="http://www.claritypharmaceutical.com">www.claritypharmaceutical.com</a></td>
<td>Clarity is a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer. Clarity is a global leader in Targeted Copper Theranostics (TCTs), developed with its proprietary SAR Technology platform. TCTs are the next-generation disruptive platform in radiopharmaceuticals that employ the “perfect pairing” of copper-64 (64Cu) and copper-67 (67Cu) for diagnosis and therapy. TCTs deliver a compelling combination of high accuracy and high precision in the treatment of a range of cancers, as well as provide supply, logistical and environmental advantages over the current generation of theranostics.</td>
</tr>
<tr>
<td>CHEMATECH</td>
<td>2 rue Pauline Kergomard 21000 Dijon, France</td>
<td><a href="mailto:info@chematech-mdt.com">info@chematech-mdt.com</a></td>
<td><a href="http://www.chematech-mdt.com">www.chematech-mdt.com</a></td>
<td>CheMatech is a leading company specializing in the design and synthesis of bifunctional chelating agents such as DOTA, NOTA and NODAGA derivatives. These molecules are widely used for peptides or antibodies labelling especially with 67/68Ga, 111In, 64/67Cu or 177Lu. CheMatech offers a wide range of functionalized and protected chelating agents from milligrams to kilograms scale. CheMatech also offers custom syntheses, GMP production of chelators and bioconjugation services.</td>
</tr>
<tr>
<td>CLERAD</td>
<td>184-186 Boulevard Gustave Flaubert 63000 Clermont-Ferrand, France</td>
<td><a href="mailto:clerad@clerad.fr">clerad@clerad.fr</a></td>
<td><a href="http://www.clerad.fr">www.clerad.fr</a></td>
<td>Since 2000, CLERAD has become a main leader in ionizing rays detection and more specifically in the medical field of the Sentinel Lymph Node detection and radio-labelled tissues or radioguided surgery. We are operating in Nuclear Medicine and Operating Room for the radio-isotopes detection, and we are also offering other solutions in Radiology, and Radiotherapy. Our Diverse skills permit to offer innovative treatments in Oncology, directly in Operating room and Nuclear Medicine.</td>
</tr>
<tr>
<td>CMR (Center of Molecular Research)</td>
<td>Office 518, Regico Offices, the Old Bank 153, the Parade High Street WD17 1NA, Watford, United Kingdom</td>
<td><a href="mailto:info@isotope-cmr.com">info@isotope-cmr.com</a></td>
<td><a href="mailto:cmr@isotope-cmr.com">cmr@isotope-cmr.com</a></td>
<td>CMR is one of the world’s largest manufacturers and suppliers of Oxygen-18 water (GMP certified, I.E. ≥ 98%), stable and radioactive isotopes. For more than twenty years, CMR has been a reliable supplier of isotopes in different industries, mainly in nuclear medicine, science and industry. The list of enriched stable isotopes we offer for cyclotron and reactor targets includes Xe-124, Te-124, Ni-64, TI-201 and many others. CMR is ready to accept orders for almost full range of isotope elements of Periodic Table. Industrial isotopes are also on our Product List. There are Heavy Water, Depleted Zinc Oxide and others. Furthermore, we guarantee stable supply of radioactive isotopes such as Lu-177 (n.c.a. and c.a.), I-131, I-125, etc. In addition, CMR produces peptide precursors for radiopharmaceutical preparations, for example, DOTA-TATE, DOTA-TIC, DOTA-NOC, PSMA- 867, PSMA-1007, etc. CMR’s goal is to satisfy all customers’ needs therefore besides isotopes and lyophilizates we offer a wide range of reagent kits, chemicals for PET-tomography. All CMR products are produced in clean rooms and dispensed under high-level quality control conditions.</td>
</tr>
</tbody>
</table>
Comecer designs and builds systems and equipment for the safe treatment of radioactive substances used in Nuclear Medicine, guaranteeing minimum exposure to the operator, total decontamination and inalterability in any working condition. In particular, Comecer excels in the field of radiochemistry where, on behalf of large industrial groups or research institutes, it manufactures shielding systems for special applications. Comecer follows the product at every stage, from production to use in radiopharmaceutical laboratories and nuclear medicine facilities, certifies all its products, and all systems are tested and subjected to a wide range of validation tests according to the regulatory standards in force at the national, European and international level. In the Nuclear Medicine sector, Comecer’s products are used in the most advanced and prestigious research centres, universities, hospitals and pharmaceutical companies worldwide. The ability to build customised solutions for its customers is the basis of Comecer’s success. With three production sites in Castel Bolognese, Siena (Italy) and Joure (Netherlands), and offices in Chicago (USA), Dubai (UAE), Mumbai (India) and Taipei (Taiwan), Comecer employs over 300 people and markets its products in over 100 countries through a direct sales network and some technological partnerships for the joint development of new products.

Crystal Photonics GmbH

Crystal Photonics and SurgiEye are engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and for intraoperative and transcutaneous sentinel lymph node localization (SLN) since 20 years. The product range includes our excellent mini-USB Hand-Held-Gamma-Camera “CrystalCam”, the surgical Gamma Probe System “Crystal Probe - automatic” with various kinds of cable and wireless probes, the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), the very new CrystalAnalyzer for HPLC-investigation in coincidence for any PET-drugs and the 3D-free-hand-spect imaging system declipse®SPECT in various versions. Also our CE-confirmed software DosePlan for accounting the dose rate distribution while a SIRT-treatment is now ready for using. In addition, we present the first time our very new mini-Laparoscopic gamma probe for robotic-assisted minimal-invasive surgeries (Drop-in-Probe) special designed for the Da Vinci robotic operation system. This probe was developed in the course of the new PSMA-technology for Prostate Cancer and is ready for using. Additionally, we offer exclusive services especially for manufacturers of radiopharmaceuticals. These include, for example, sterility testing of radiotherapeutics with membrane filtration, “hot” leachables & extractables studies, testing of peptides and antibodies as precursors for radiopharmaceuticals and many other.

The CUP Laboratorien Dr. Freitag GmbH is a highly specialised, GMP-certified and FDA-inspected contract laboratory. Our laboratories have also recently been audited by experts under the EANM’s Shared Audit and Supplier Assessment Initiative (SASI) and the report will be available soon. At our site in Radeberg/Germany, we have a state-of-the-art infrastructure with clean rooms, radiation protection areas and state-of-the-art analytical equipment. With our almost 60 excellent employees, we offer exclusive services especially for manufacturers of radiopharmaceuticals. Our laboratories have also been audited under the EANM’s Shared Audit and Supplier Assessment Initiative (SASI) and the report will be available soon. At our site in Radeberg/Germany, we have a state-of-the-art infrastructure with clean rooms, radiation protection areas and state-of-the-art analytical equipment. With our almost 60 excellent employees, we offer exclusive services especially for manufacturers of radiopharmaceuticals. Our laboratories have also been audited under the EANM’s Shared Audit and Supplier Assessment Initiative (SASI) and the report will be available soon. At our site in Radeberg/Germany, we have a state-of-the-art infrastructure with clean rooms, radiation protection areas and state-of-the-art analytical equipment. With our almost 60 excellent employees, we offer exclusive services especially for manufacturers of radiopharmaceuticals. Our laboratories have also been audited under the EANM’s Shared Audit and Supplier Assessment Initiative (SASI) and the report will be available soon. At our site in Radeberg/Germany, we have a state-of-the-art infrastructure with clean rooms, radiation protection areas and state-of-the-art analytical equipment. With our almost 60 excellent employees, we offer exclusive services especially for manufacturers of radiopharmaceuticals. Our laboratories have also been audited under the EANM’s Shared Audit and Supplier Assessment Initiative (SASI) and the report will be available soon. At our site in Radeberg/Germany, we have a state-of-the-art infrastructure with clean rooms, radiation protection areas and state-of-the-art analytical equipment. With our almost 60 excellent employees, we offer exclusive services especially for manufacturers of radiopharmaceuticals. Our laboratories have also been audited under the EANM’s Shared Audit and Supplier Assessment Initiative (SASI) and the report will be available soon. At our site in Radeberg/Germany, we have a state-of-the-art infrastructure with clean rooms, radiation protection areas and state-of-the-art analytical equipment. With our almost 60 excellent employees, we offer exclusive services especially for manufacturers of radiopharmaceuticals.
Cyclopharm Ltd

Unit 4 / 1 The Crescent  
2208 Kingsgrove NSW, Australia  
info@cyclopharma.com  
https://www.cyclopharma.com/

We are Cyclopharma – bringing light into Molecular Imaging since 1986. We have paved the way with Molecular Imaging solutions in Australia and around the globe. From innovation, development to clinical practice applications – we are the world leaders in functional lung ventilation imaging with our proprietary technology: Technegas®.

Created and manufactured in Australia, our flagship product Technegas® has revolutionised diagnostic lung imaging and today transform the lives of millions of patients in more than 61 countries around the world.

A new era in Nuclear Pulmonology continues to unfold as new innovations come to light. Technegas® currently has a wide cross-section of clinical applications and several potential new Beyond PE indications for functional lung imaging. The exciting thing about our solution is our ongoing commitment to research, clinical trials, development and innovation.

We are cultivating business partners globally to deliver cutting edge products in Molecular Imaging, PET and Theranostics. In Molecular Imaging, we offer solutions for your needs.

DIAsource ImmunoAssays SA

Rue du Bosquet 2  
B - 1348 Louvain-la-Nouvel, Belgium  
info@diasource.be  
www.diasource.be

DIAsource ImmunoAssays SA, a Biolendor Group company, is an international diagnostic company based in Belgium, who develops, manufactures and markets clinical diagnostic products in the field of endocrinology and infectious diseases.

DIAsource provides a complete range of RIA (radioimmunoassay) kits in the fields of Autoimmunity, Biogenic Amines, Ileal metabolism, Cancer markers, Cardiovascular and Salt Balance, Diabetes, Fertility, Growth factors, Thyroid kits, Gastrointestinal markers, Immunology and Infectious diseases is presented to our customers. For automation of RIA assays we offer automates like Conext 125 ( Pipetting automate) and refurbished IMAFET systems (fully automated RIA processor).

DIAsource aims to be a world leader on the RIA market and to become a ”one time shopping RIA company” by offering the most complete range of RIA kits. DIAsource is also involved in the refurbishing and sales of gamma counters Riamat’s, a Strateg fully automated RIA platform and the Conext 125. Moreover, we sell radioactive decontaminating products used in clinical, pharmaceutical and research labs that use I125 as an isotope, as well as to the nuclear medicine departments. With this complete service to RIA labs we want to convince our end users that our golden standard kits are the best possible choice.

ISO certificates: ISO9001 and ISO 13485

Our kits are CE marked and available worldwide, with the exception of Canada, Japan and USA. For those countries only certain kits are available since special registration is required.

Dixit S.r.l.

Via Giuseppe Gaceda 38  
10125 Torino, Italy  
contact@dixitsolutions.com  
www.dixitsolutions.com

Based in beautiful Turin, the first capital city of Italy and a technological hub, Dixit is a company focused on building efficient medical applications and services.

Its main product, WIDEN (www.dixitsolutions.com/widen), is a Web Service designed to make the management, quality assurance and review of imaging studies in clinical trials simpler, more effective and more reliable. Trials can then easily scale in size and statistical significance can be achieved in a short time.

Dixit works with leading international imaging and oncological societies and cooperative groups that use qualitative and quantitative imaging, especially PET/CT, in their cancer treatment protocols.

Since 2012, WIDEN has been used in more than 40 multi-centre clinical trials, whose coordinating bodies reside in Austria, France, Switzerland, UK, Poland, Italy and Australia. WIDEN users are located in 25 different countries and more than 250 clinical centres.

WIDEN is also suitable for retrospective imaging-based clinical trials, that could be simply configured and operated. Their data can be quickly analysed, to assess the results and design more ambitious, prospective trials to validate them.

DOSIsoft

45/47 Avenue Carnot  
94230 Cachan, France  
info@dosisoft.com  
www.dosisoft.com

Spin-off between Gustave Roussy & Institut Curie, DOSIsoft was founded in 2002. It develops patient-specific imaging and dosimetry software in Radiation Oncology & Nuclear Medicine to improve patient safety & treatment quality. 20 years of innovation and R&D investments have led to world-leading software used in over 100 hospital centers in 50 countries.

PLANET® Software Suite is a Patient-specific, multi-radiotrace (90Y/177Lu/131I/166Ho) & theranostics platform for Molecular Imaging & Molecular RadioTherapy dosimetry. It comprises:

- PLANET® Oncos: Oncology software for Molecular Imaging (MI) & Radiotherapy. It helps to optimize disease diagnosis & therapy through registration, contouring, advanced quantification & patient response from multimodal imaging. Texture analysis for diagnosis, follow-up & radionics is provided.
- PLANET® Dose: Dosimetry software for Molecular RadioTherapy (MRT) providing multiple and integrated workflow for 90Y/177Lu/131I/166Ho dosimetry. It allows to personalize patient therapy through pre/post-implementation dosimetry, automatic structure propagation, calculation of residence time & comparison between treatment planning & validation control dose maps. Consolidation of multi-treatment stages is available.
DSD Pharma GmbH

Schuhmeistersstr 24
1140 Purkersdorf, Austria

office@dsd-pharma.com

www.dsd-pharma.com

Diagnostics
In nuclear medicine diagnostics, patients are administered radioactive drugs, so-called radiopharmaceuticals. Depending on their pharmacological properties, these accumulate in varying concentrations in the organs or tissues of the person. The radiopharmaceutical then emits a weak radiation that can be detected in PET-CT, SPECT-CT or scintigraphy, depending on the type of examination. In diagnostics, DSD Pharma offers a range of radiopharmaceuticals, peptides and labelling kits for the fields of scintigraphy, positron emission tomography (PET) and single photon emission computed tomography (SPECT).

Solutions
DSD Pharma is a competent partner in all matters relating to diagnostics, therapy and theranostics in nuclear medicine. DSD Pharma’s innovative and broad product portfolio includes holistic and customized solutions for specific requirements – from the provision of radioactive substances to the handling of logistics and transport to the set-up of hot rooms.

Diversity
DSD Pharma works with national and international suppliers and manufacturers who enable us to ensure the diversity and variety of our product portfolio. In addition to diagnostics, DSD Pharma also offers therapeutic, medical devices, medical-technical equipment, synthesis modules for the production of radiopharmaceuticals, equipment for radiotherapy and hot rooms, nuclide databases, contained sources and much more.

ec² Software Solutions

3035 E. Patrick Lane, Suite 1
89120 Las Vegas, NV, USA

Sales@ec2software.com

www.ec2software.com

Diagnostics
ec² Software Solutions and our partner company, Numma LLC, are focused on developing and commercializing workflow and compatibility solutions for the molecular imaging community. Together, with over 60 years’ experience, ec² and Numma provide innovative management solutions for cyclotrons, radiopharmacies, hot lab operations, multi-vendor connectivity, archiving and reporting. Our systems are presently installed in 6000+ facilities worldwide.

We provide Enterprise Solutions that secure ePHI patient data and consolidate installations all in a scalable architecture. The HL7 / DICOM Modality Worklist interfaces enhance scheduling and eliminate redundant data entry. NumaStatus can export patient dosimetry and dose information to the cameras, RIS/ PACS or Dose Management system using DICOM secondary capture and Radiopharmaceutical Radiation Dose Structured Report (RRD SR). The HL7 export module and deliver dose information to the EMR and MAR.

Our on-line ordering (OLO) e-prescribing solutions are used by hundreds of commercial radiopharmacies around the world. OLO enhances transcription errors and enhances patient safety.

EITA - European Isotopes Transport Association

Vandenalotte (Bus & Design Center)
Esplanade 1/85
1020 Brussels, Belgium

info@eita.org

EITA is a non-profit association, which was founded in 1998 by European logistics providers trained, licensed and specialized in the handling and transport by Road, Air and Sea of radioactive isotopes, which are mainly used for medical purposes.

Mission
- Establishment of harmonized regulations and standards.
- Aiming for harmonized national and international regulations and legislations to guarantee the free market access in every state for the EITA members.
- Compliance with applicable regulations.
- To ensure all EITA member activities are carried out in full compliance with all applicable legal requirements.
- Safety, Security and traceability.
- To ensure safety and security and full traceability at all times during the complete supply chain.
- Quality.
- To ensure high quality of handling, packing and transport of radioactive isotopes in accordance with required standards.
- Competence center.
- To provide a forum to exchange information and knowledge in order to increase awareness.

ELYSIA S.A.

Rue du Sart Tillin 375
B - 4031 Angleur, Belgium

info@elysia-raytest.com

www.elysia-raytest.com

We design, manufacture, integrate and service instruments for the measurement of radioactivity and the quality control of radiopharmaceuticals and other radioactive compounds. We work in close collaboration with radiopharmaceutical and cyclotron providers to develop new products and improve existing solutions.

Elysia is a provider of hardware and software solutions for the fully integrated quality control of your radio- pharmaceutical production. Our GINA X and SARA client/server platforms offer a user-friendly and fully GMP compliant solution to your QC problems.

Radiopharmaceuticals should be easily accessible world-wide and affordable. We assist our customers accelerate their R&D and to validate QC methods for existing and new molecules. Further our Radio-detectors are also used in TLC, HPLC and GC Radio-chromatography, Gamma Spectroscopy, Dose Calibration and well counting for the pharmaceutical, agrochemical and nuclear/PET industries.

We want to make the measurement of radioactivity and the quality control of radiopharmaceuticals easier, faster and safer.

We are a customer-oriented team of radiochemists, engineers, IT and QA specialists.

Brands: Elysia produces the specific radio-detection instruments and software for your QC needs. In order to ensure a high level of quality and to provide state-of-the-art solutions, next to our own Elysia products we work with major and well-established brands and partners, such as IBA, Shimadzu, Agilent and Charles River.
<table>
<thead>
<tr>
<th>EPSILON RADIOACTIVE SOURCES (ERS)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ferhatpaşa Mahallesi 15.Sokak</td>
</tr>
<tr>
<td>No:126-128 Ataşehir, 34888 İstanbul, Türkei</td>
</tr>
<tr>
<td><a href="mailto:info@epsilonsources.com">info@epsilonsources.com</a></td>
</tr>
<tr>
<td><a href="http://www.epsilonsources.com">www.epsilonsources.com</a></td>
</tr>
</tbody>
</table>

ERS manufactures quality assurance sources that are compatible with the leading PET OEM manufacturers to provide high-quality products and customer satisfaction. For the calibration of PET, PET/CT, PET/MR & SPECT systems, 68Ge, 22Na, 57Co and 153Gd sources are used in different forms and activities depending on the system model. Customized sources in different forms and activities can be offered upon customer request by ERS. Please contact your local distributor or ERS headquarters for product availability and additional information.

<table>
<thead>
<tr>
<th>ERAS Labo</th>
</tr>
</thead>
<tbody>
<tr>
<td>222 Route départementale 90</td>
</tr>
<tr>
<td>38330 Grenoble, France</td>
</tr>
<tr>
<td><a href="mailto:eras.labo@wanadoo.fr">eras.labo@wanadoo.fr</a></td>
</tr>
</tbody>
</table>

ERAS Labo is a GMP part II certified company specialized in the manufacturing of APIs and reagent kits mainly for the radiopharmaceutical sector. It is located at the foot of the Alps near Grenoble (France). The chemical synthesis capabilities range from the mg scale to batches of few hundreds grams. The physicochemical analyses are mostly performed inhouse thanks to the wide spectrum of analytical tools available on-site (HPLC, various chromatographic techniques, atomic absorption, ICP coupled with emission spectroscopy, thermal analysis, UV-vis and FT-IR spectroscopy, …).

Class C clean rooms allow the dispensing of the produced APIs in single dose vials and the preparation of complete reagent kits. In this way, ERAS Labo controls the manufacturing of reagent kits from the synthesis of the API to the final assembly of the kit including the quality control operations.

ERAS Labo has a recognized expertise in the synthesis of complex organic molecules and in analytical chemistry. These custom services are highly appreciated by our clients.

<table>
<thead>
<tr>
<th>EuroMedical Intruments</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 rue Raymond Losserand</td>
</tr>
<tr>
<td>75014 Paris, France</td>
</tr>
<tr>
<td><a href="mailto:sales@em-instruments.com">sales@em-instruments.com</a></td>
</tr>
<tr>
<td><a href="http://www.em-instruments.com">www.em-instruments.com</a></td>
</tr>
</tbody>
</table>

EuroMedical Intruments is the exclusive worldwide sales and marketing company of the Europrobe, a state-of-the-art surgical gamma probe manufactured by Eurorad SA, Strasbourg, France. Founded in 1982, Eurorad is a high technology company specialized in R&D, Service and Production of mono and polycrystalline semiconductors for radiation detectors, and one of the main manufacturers for this type of equipment in the world.

The Europrobe is designed to meet the needs of surgeons in nuclear medicine. It enables to accurately tag Sentinel Lymph Nodes (SLN) by detecting areas of increased radionucleotide uptake. The Europrobe is unsurpassed in its ability to detect a wide range of isotopes.

With a single readout module and a whole range of gamma probes, the Europrobe fulfills all the needs of per-operative and percutaneous detection within 7 major clinical fields: Breast, Gynaecology, Dermatology, Head & Neck, Endocrinology, Urology and Nuclear medicine.

We have added a new fluorescent detection modality via an add-on module. In combination to the core gamma detection, fluorescence detection enables to reach almost 100% identification of SLNs, and thus fulfills standard of care dual detection recommendation.

The Europrobe system and probes are commercialized in 67 countries worldwide, including the USA, and over 1000 systems have been placed in major cancer treatment centres.

<table>
<thead>
<tr>
<th>Evergreen Theragnostics Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 Commerce Street</td>
</tr>
<tr>
<td>07081 Springfield, NJ, USA</td>
</tr>
<tr>
<td><a href="mailto:diana.kaskiw@evergreentgn.com">diana.kaskiw@evergreentgn.com</a></td>
</tr>
<tr>
<td><a href="http://www.evergreentgn.com">www.evergreentgn.com</a></td>
</tr>
</tbody>
</table>

Evergreen Theragnostics, founded in 2019, is a US-based radiopharmaceutical CDMO dedicated to high quality & high reliability manufacturing of radiopharmaceuticals using a variety of isotopes, from early development through commercialization all under one roof in Springfield, NJ. We offer research and commercial scale, centralized production capacity for therapeutic and long-lived diagnostic products built into our brand-new state of the art manufacturing facility. The design of the facility in Springfield also allows us to expand operations within our existing walls for project-specific needs or partnership opportunities. Our combination of top industry talent, compliance with global cGMP standards, and strategic facility location uniquely position Evergreen as a premier radiopharmaceutical development, manufacturing, and distribution organization in North America.
Eckert and Ziegler Isotope Products (EZIP) offers a full range of solutions for the needs of Nuclear Medicine departments worldwide. EZIP is dedicated to serving the marketplace with high-quality products safely constructed and delivered on time through a quality system founded on customer satisfaction, regulatory compliance and continuous improvement.

Eckert & Ziegler Medical is one of two business segments of the Eckert & Ziegler Group, with headquarters in Berlin, Germany. With more than three decades of experience in the field, Medical represents the combined expertise in nuclear medicine, molecular imaging, radiation therapy and beyond, while always focusing customer success.

We complement our wide-ranging portfolio of innovative high-quality technical solutions with the provision of versatile services such as development and contract manufacturing. With our global network of GMP suites, we offer fully licensed radioisotope labs, stable supply arrangements for almost all pharmaceutical radiotracers, a state-of-the-art infrastructure including logistics, and a highly experienced staff that can be seconded to help with your preclinical and clinical projects.

As a one-stop-shop for all your radiopharmaceutical needs, using alpha, beta or gamma emitters, our products include everything from hot cell solutions to radiochemicals (e.g., Lu-177), radiopharmaceuticals (Yttrium, Gallium68), radioisotopes, radioisotope radiopharmaceuticals (Ga67), radiopharmaceuticals (Ga68), stable supply arrangements for almost all pharmaceutical radiotracers, a state-of-the-art infrastructure including logistics, and a highly experienced staff that can be seconded to help with your preclinical and clinical projects.

As a one-stop-shop for all your radiopharmaceutical needs, using alpha, beta or gamma emitters, our products include everything from hot cell solutions to radiochemicals (e.g., Lu-177), radiopharmaceuticals (Yttrium, Gallium68), radioisotopes, radioisotope radiopharmaceuticals (Ga67), radiopharmaceuticals (Ga68), stable supply arrangements for almost all pharmaceutical radiotracers, a state-of-the-art infrastructure including logistics, and a highly experienced staff that can be seconded to help with your preclinical and clinical projects.

PentixaPharm, a subsidiary of Eckert & Ziegler AG, is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. These two small peptide-based radiotherapeutics specifically target the CXCR4 receptor expressed by many diseases, such as haematological and solid cancers as well as cardiovascular indications.

With PentixaFor it is the aim to develop a small PET/CT tracer linked to Gallium-68 for accurate localization of tumors or inflamed tissues. PentixaTher binds to the same receptor as the diagnostic agent but is linked to a stronger radiating nuclide (Yttrium-90). Therefore, PentixaTher has the potential to precisely destroy the pathological surrounding tissue only in the near proximity. Both products are currently under clinical development.

PentixaPharm, a subsidiary of Eckert & Ziegler AG, is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. These two small peptide-based radiotherapeutics specifically target the CXCR4 receptor expressed by many diseases, such as haematological and solid cancers as well as cardiovascular indications.

With PentixaFor it is the aim to develop a small PET/CT tracer linked to Gallium-68 for accurate localization of tumors or inflamed tissues. PentixaTher binds to the same receptor as the diagnostic agent but is linked to a stronger radiating nuclide (Yttrium-90). Therefore, PentixaTher has the potential to precisely destroy the pathological surrounding tissue only in the near proximity. Both products are currently under clinical development.

PentixaPharm, a subsidiary of Eckert & Ziegler AG, is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. These two small peptide-based radiotherapeutics specifically target the CXCR4 receptor expressed by many diseases, such as haematological and solid cancers as well as cardiovascular indications.

With PentixaFor it is the aim to develop a small PET/CT tracer linked to Gallium-68 for accurate localization of tumors or inflamed tissues. PentixaTher binds to the same receptor as the diagnostic agent but is linked to a stronger radiating nuclide (Yttrium-90). Therefore, PentixaTher has the potential to precisely destroy the pathological surrounding tissue only in the near proximity. Both products are currently under clinical development.
For-med.nl is a design and manufacturing company for standard and custom made accessories:
- Foot support for SPECT/CT/MRI
- Breast support prone position
- Arm and headrest combination
- Knee angle
- Baby support
- Wedges, Blocks and Mattresses

Gamma Medical Technology - Gamma Probe Systems for Nuclear Medicine
Gamma Medical Technology is a young and dynamic company. German Company, focused on the production and commercialization of high-quality Gamma Probe Systems for the Sentinel Lymph Node Biopsy (SNLB).

Our Gamma Probe Systems are part of what we have to advance our cause. They are designed to fit into the user’s everyday life and adapt to their needs, not the other way around. After years of developing our Gamma Probe Systems, our focus has always been on one aspect: supporting the user’s work to make patients’ lives easier.

The realization of our products, including hardware and software development, production as well as service, takes place in Germany. Through a close interlocking between these areas, Gamma Medical Technology offers our customers comprehensive competence for gamma probe systems.

The company’s client base is vast and includes polyclinics, medical centers, and well-known hospitals both private and government.

Our mission is to improve people’s lives and help them live healthy lives without limitations. We believe that people can reach their full potential when they are healthy and can thrive without limitations.

GE Healthcare is a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator. The company enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, GE Healthcare operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights for the latest news, or visit our website www.gehealthcare.co.uk for more information.

Global Morpho Pharma is a turnkey technology and service provider for the production and distribution of medical radioisotopes. We are developing innovative equipment and building efficient supply chains to enable our partners worldwide to manufacture nca Lu-177 and other radioisotopes of interest.

We are dedicated to improving the accessibility of medical radioisotopes for the benefit of patients by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem.

Radioisotopes of interest: Lu-177, Tb-161, Ac-225.
Hermes Medical Solutions continuously innovates to enable faster and more personalized diagnosis and therapies in molecular imaging. For 45 years we empower healthcare professionals with state-of-the-art software for all clinical scenarios in Nuclear Medicine into ONE vendor-neutral platform: HERMIA. Powerful and vendor agnostic software enables clinicians to simplify their workflow, increase consistency and quality and keep pace with the fast development of scanners, tracers and therapies. The result is improved quality and outcomes for healthcare providers and their patients worldwide. At this year’s EANM we are proud to showcase groundbreaking functionality within Hermia in the areas of quantitative SUV-SPECT, organ- and voxel-based dosimetry and automatic segmentation.

Hermes Medical Solutions
Strandbergsgatan 16
112 18 Stockholm, Sweden
info@hermesmedical.com
www.hermesmedical.com

Hermia is the software of choice for theranostics and therapies with single time point voxel dosimetry, CE-marked, FDA and Health Canada cleared for a wide range of imaging isotopes. Make personalized therapies a reality for your clinical practice. Discover more by visiting our booth #20 at the EANM and our website at www.hermesmedical.com.

Hidex Oy
Lemminkäisenkatu 62
20520 Turku, Finland
info@hidex.com
www.hidex.com

Hidex is a world leader in detection of alpha, beta and gamma emitters. Our liquid scintillation and gamma counters are used worldwide in development and quality control of radiopharmaceuticals using Actinium, Radium, Thorium, Lutetium, Strontium, Yttrium and other isotopes. Hidex gamma counters are optimized for molecular imaging isotope energies and streamlined for workflow, sample tracking and GxP compliance. At EANM Hidex is exhibiting solutions for:
- Automated gamma counting: Hidex AMG automatic NaI well detector with on board sample balance is ideal for metabolic studies, blood input function curves, Glucomerase filtration rate or general nuclear medicine applications.
- Hidex Radiowater Generator is an online system for preparation of Oxygen-15 H2O infusions. With approximately 50 installation Hidex is the pioneer in nuclear medicine applications.
- Hidex Liquid scintillation counters 300SL and 600SL are used by radiopharmaceutical production facilities for development and quality control of medical use isotopes, detection of impurities, contamination control with wipe tests as well as activity standardization.

Please book a meeting with our specialists or stop by our booth to learn more!

HOY Scandivavian ApS
Jakob Møllerupade 4
9560 Hadsund, Denmark
info@hoyscandinavian.dk
www.hoyscandinavian.dk

HOY Scandivavian was founded in 1991 as a supplier and distributor for Nuclear Medicine and radiochemistry department in Scandinavia. The “HOY Exclusive” product range was launched in 2006. The head office is located in Hadsund Denmark, and all the HOY Exclusive product range are produced in Hadsund. Today HOY Scandivavian is an international business that supplies products to nuclear medicine and oncology departments at hospitals and laboratories all over the world. We are known for supplying very high quality products and are now a market leader in many markets – particularly in Scandinavia and Europe.

Our home market is primarily Denmark and Sweden. We are represented in other markets by a distributor network. Products and activities
HOY Scandivavian is a company for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

IBA RadioPharma Solutions
Chemin du Cyclotron 3
1348 Louvain-la-Neuve, Belgium
RadioPharmaSolutions@iba-group.com
www.iba-radiopharmasolutions.com

IBA is the world leader for the supply of PET & SPECT cyclotrons for radiopharmaceuticals production. IBA also offers a wide range of radiochemistry solutions designed to be highly productive and reliable for your everyday tracer needs, as well as customizable and flexible for your research purposes. Headquartered in Belgium, IBA installed and supports over 320 cyclotrons and more than 600 Synthera family radiochemistry modules across the world. Based on more than 35 years of experience, IBA RadioPharma Solutions helps nuclear medicine department to design, build and operate PET center for the production of radiopharmaceuticals used for the detection and treatment of cancer and other critical diseases.

• At HOY we develop and manufactures “Hoy Exclusive”, an all in-house product design - offering quality products for radiation protection in nuclear medicine and PET departments.
• The "HOY Exclusive" product portfolio has a modern timeless Scandinavian design, and offers maximum ergonomic comfort aligned to European standards.
• Key products are: Val glass Shields - Syringe Shielding - Syringe handling - Syringe Carrier and transports - Waste Contains - Tongs for Vials.
The International Centers for Precision Oncology Foundation (ICPO) is a German non-profit organization established in 2019 by leading medical and industry entrepreneurs. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO is helping build momentum to scale global patient access to Molecularly Targeted Precision Oncology to accelerate this paradigm shift. To scale patient access, ICPO aims to develop a network of International Centers for Precision Oncology organized in a social model based on shared know-how, certified education, and design and process standardization enabling validated best clinical practice. Furthermore, the ICPO Foundation empowers its centers network within a growing global, inclusive community spearheading its model and living up to the Precision Oncology promise to eventually be curative and abundantly available to all patients in need, irrespectively of region, country, or social status.

ImaginAb is a clinical stage and revenue-generating biotech company, with offices in the United States and the United Kingdom. We focus on developing next generation imaging and therapeutic radiopharmaceuticals (RPT) based on our proprietary Minibody and Cys-diabody platform. 89Zr Crefmirlimab berdoxam (CD8 ImmunoPET agent) is currently in Phase II, and is used by numerous Pharmaceutical and Biotech companies in their clinical trials.

Incepto is the leading European platform for artificial intelligence solutions for all medical imaging, especially nuclear medicine. Incepto has two missions: integrate AI solutions from partner AI vendors and develop AI algorithms. On one hand, it provides the full range of technical and clinical services to integrate clinical routine AI solutions through a unified, secure and interoperable platform. On the other hand, Incepto’s scientific and medical teams are developing artificial intelligence solutions on clinical needs not currently addressed by other AI vendors. Our goal is simple: help doctors to make full use of AI technologies to save time, improve diagnosis and ultimately build together with them a more precise and human radiology for the patient.

Development and production of devices for Radiopharmaceutical industry.
Institute of Isotopes Co. Ltd.

Institute of Isotopes Co. Ltd. is on the forefront of radioisotope technology collaborating with long-term partners and customers. Over the years we have developed numerous products from diagnostic kits to radioactive sources for various radioactive applications. Our company provides varied and flexible services in this unique field.

Our Radiopharmaceutical Business Unit has been exclusively focused on supplying radiochemical products to nuclear medicine professionals serving the recovery of patients worldwide and supporting early diagnosis. Our production complies with the highest quality standards and the Quality Management System is compliant with customer standards and regulatory requirements and ensures the high-quality of our products.

Besides being key participant on the market for many years, we are also engaged in product development projects and offer contract manufacturing, OEM services for our customers. We are looking forward to new products to widen our portfolio and meet our growing customer demands.

Our main products, services:

- Thyrotop I-131 sodium iodide hard capsules
- T-131I sodium iodide sterile solution / I-131 MIBG injection for therapy and for diagnostic use
- Radiochemicals / I-125, I-131/
- Cold kits for Tc-99m-labelling: DMSA, DTPA, FYTON.
- IN121, MIBITop, MDP, TECHIDA
- Cold kits for Tc-99m-labelling: DMSA, DTPA, FYTON.
- Radiochemicals: I-125, I-131/
- Multinucleotide Fusion (v. 1.0), 3D rendering and the 3D neurological brain evaluation package, we offer what you are looking for.
- Would you like to evaluate interdisciplinary data? With the Multimodality Fusion software, you can use data from different systems such as ultrasound, PET, MR.
- We offer the possibility of merging and evaluating data from different manufacturers.
- With the MultiCam 3000 and our in-house software, we make it possible to view images from different manufacturers.
- Visit our booth to see how we can enhance your services for our customers. We are looking forward to new products to widen our portfolio and meet our growing customer demands.
- Our main products, services:
  - Thyrotop I-131 sodium iodide hard capsules
  - T-131I sodium iodide sterile solution / I-131 MIBG injection for therapy and for diagnostic use
  - Radiochemicals / I-125, I-131/
  - Cold kits for Tc-99m-labelling: DMSA, DTPA, FYTON.
  - IN121, MIBITop, MDP, TECHIDA
  - Cold kits for Tc-99m-labelling: DMSA, DTPA, FYTON.
  - Radiochemicals: I-125, I-131/
  - Multinucleotide Fusion (v. 1.0), 3D rendering and the 3D neurological brain evaluation package, we offer what you are looking for.
  - Would you like to evaluate interdisciplinary data? With the Multimodality Fusion software, you can use data from different systems such as ultrasound, PET, MR.
  - We offer the possibility of merging and evaluating data from different manufacturers.
  - With the MultiCam 3000 and our in-house software, we make it possible to view images from different manufacturers.
  - Visit our booth to see how we can enhance your services for our customers. We are looking forward to new products to widen our portfolio and meet our growing customer demands.

Inter Medical Medizintechnik GmbH

The Inter Medical Medizintechnik GmbH Company is specialized in medical software and hardware with the focal point in Nuclear Medicine technique. Long time experience in product innovations, development and production of Nuclear systems makes Inter Medical to a competent partner for all technical requirements in the Nuclear Medicine and other medical departments.

Are you looking for a special camera or software for heart and brain examinations? With the MultiCam 3000 and our in-house software such as AutoCardio 4D, 3D rendering and the 3D neurological brain evaluation package, we offer what you are looking for.

Would you like to evaluate interdisciplinary data? With the Multimodality Fusion software, you can use data from different systems such as ultrasound, PET, MR.

We offer the possibility of merging and evaluating data from different manufacturers.

Visit our booth to see how we can enhance your institute with our product portfolio of 1-2-3-n Head Gamma Cameras.

INVIA

3025 Boardwalk Drive, Suite 200
MI 48108 Ann Arbor, United States

info@inviasolutions.com

www.inviasolutions.com

INVIA is dedicated to developing advanced non-invasive cardiac imaging software for medical professionals to optimize patient care. Physicians use our software, 4DM, to accurately quantify, review, and report cardiac perfusion, function, and anatomy. 4DM is available integrated with more than 25 camera, workstation, EHR and PACS manufacturers, or as a software-only solution for Windows laptops and workstations. Originating at the University of Michigan more than twenty years ago, we developed 4DM with the patient in mind – enabling physicians around the world to make accurate interpretations.

Our software is always advancing; visit us at booth to explore 4DM’s latest features.

Invicro

1121 Budapest, Hungary

konkoly-thege miklos u. 29-33.

commerce@izotop.hu

www.izotop.hu

Headquartered in Needham, MA, Invicro was founded in 2008 with the mission of improving the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multi-disciplinary team provides solutions to pharmaceutical and biotech companies across all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology, and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are backed by Invicro’s industry-leading software informatics platforms, VivoQuant® and iPACS®, as well as their pioneering IQ-Analytics Platform, which includes AmyloidIQ, TauIQ and DaTIQ.
Inviscan Imaging Systems is a high technology company located in France. Inviscan manufactures preclinical imaging systems used in Medical Research. The products of Inviscan include PET and CT systems based on new photodetector components. Inviscan is partner in international projects with academic partners to develop MRI compatible PET imaging instrumentation for research on the human brain and neurodegenerative diseases. Inviscan has research offices and laboratory area located in Strasbourg, France.

Inviscan SAS
- 23 rue du Loens, Bat. 25
- 67200 Strasbourg, France
- info@inviscan.fr
- www.inviscan.fr

Ionetix Corporation
- 3130 Sovereign Drive
- 48911 Lansing, United States
- N-13Ammonia@ionetix.com
- www.ionetix.com

IONETIX is a US-based cyclotron and technology company providing full-service radioisotope production and end-to-end radiopharmaceutical manufacturing solutions. Utilizing its proprietary cyclotron technology platform, Ionetix has developed innovative solutions that enable access to scarce radioisotopes used for both diagnostic and therapeutic radiopharmaceuticals.

Targeted Alpha Therapy Solutions
- Ionetix offers both high-purity Actinium-225 (Ac-225) and Astatine-211 (At-211) for use in targeted alpha therapies. It’s decentralized production and distribution supply chain includes contract drug manufacturing and “cold” production, allowing global access to these alpha-emitting isotopes and targeted radiotherapeutics. Ionetix will initiate GMP production of both n.c.a Ac-225 and At-211 beginning in early 2023.

Compact Cyclotron Solutions
- Ionetix also offers a point-of-care cyclotron to produce positron-emitting radioisotopes used for diagnostic radiopharmaceuticals. The ION-125C is a compact 12 MeV cyclotron that can generate N-13, F-18 and Ga-68. The ION-125C is engineered for ease of deployment and operation for both clinical and research applications. The ION-125C is ideally suited to support theragnostic indications with local production of the radioisotopes used for the diagnostic imaging portion of the radiopharmaceutical pair.

For more information, please stop by our booth or visit www.Ionetix.com.

Iontron Medical Inc.
- 55 Madison Ave., Suite 400
- NJ 07960 Morristown, United States
- pat.donahue@iontronmedical.com
- www.copper67.com

As the first and only commercial supplier of copper-67, Iontron Medical is committed to improving the quality and accessibility of this radioisotope for the radiopharmaceutical community. Copper-67 is a proven and effective radioisotope for theranostics, particularly when paired with copper-64. This “perfect pairing” delivers key advantages over other commonly used isotopes, including:
- Identical in-vivo behavior (imaging and therapy)
- Patient dose optimization (personalized medicine)
- Optimum half-life for small molecules
- Convenient off-site central manufacturing
- No reliance on nuclear reactors for production

Through our partnership with Canadian Isotope Innovation Corp., Iontron Medical is supplying copper-67 to the US, Canada, and Europe, facilitating the development of next generation theranostics.

IRE ELIT
- Avenue de l’Espérance, 1
- B - 6220 Fleurus, Belgium
- info@ire.eu
- www.ire.eu

IRE ELIT, IRE’s innovation subsidiary, is a pharmaceutical company founded in 2010 to develop radiopharmaceutical drugs used in molecular imaging and therapy.

Our main product is a Ge-68/Ga-68 generator, Gallium Medical is supplying copper-67, Iotron Medical is committed to improving the quality and accessibility of this radioisotope for the radiopharmaceutical community.

- Copper-67 is a proven and effective radioisotope for theranostics, particularly when paired with copper-64. This “perfect pairing” delivers key advantages over other commonly used isotopes, including:
  - Identical in-vivo behavior (imaging and therapy)
  - Patient dose optimization (personalized medicine)
  - Optimum half-life for small molecules
  - Convenient off-site central manufacturing
  - No reliance on nuclear reactors for production

Through our partnership with Canadian Isotope Innovation Corp., Iontron Medical is supplying copper-67 to the US, Canada, and Europe, facilitating the development of next generation theranostics.
**Isotopia Molecular Imaging**

39 Alexander Yanna St.  
4927735 Petah Tikva, Israel

info@isotopia.co.il

https://isotopia-global.com/

Weekly global production and supply by demand of theranostic solutions.

We understand that delivering the right treatment to the patient at the right time could be the tipping point in the patient’s care. That’s where our gold standard treatment and professional service make all the difference. We supply Lu-177 tailormade to your requirements, and work closely with our customers, to devise the optimal solution and support their growth. Isotopia around the globe Patient’s care and efficacy are the most precious values of Isotopia. This is why we are working to enhance our product’s global accessibility. Next to our head quarter and N. America production facilities, we have partnered with Seibersdorf laboratories to strengthen our European presence, to build a local manufacturing site, designed to:

- Reduce complex logistics.
- Upscale production, shorten delivery time and reduce material loss.
- Ensure timely and consistent delivery to all locations.

Guidance, support, and peace of mind. We are committed to meeting your acute need for round-the-clock availability and responsiveness to solve problems in real-time. As we continue to take big strides and becoming a prominent global supplier to the radiopharmaceutical industry, while maintaining the personal touch of a local partner, we remain focused on fulfilling the promise of nuclear medicine for advanced personalized cancer care. *Marketing Authorization is coming soon.

**ITELPHARMA – ITEL HEALTHCARE GROUP**

VIA LABROLA Z1, snc  
70037 Ruvo di Puglia, Italy

marketing@itelte.it

www.iitelte.it

Itelpharma is the radiopharmaceutical division of the Italian company Itel Group. It has been established as a GMP (Good Manufacturing Practice) certified pharmaceutical facility authorized by the Italian Drug Agency (AIFA).

We produce radiopharmaceuticals for imaging diagnostics, which detect diseases in the fields of oncology, neurology and cardiology. To achieve this goal, we rely on the availability of independent production lines that can operate simultaneously. Itelpharma is recognized as one of the most trusted radiopharmaceutical manufacturers and suppliers.

In addition to marketing our own radiopharmaceuticals, we are also contractors in the production and distribution of radiopharmaceuticals owned by other big pharmaceutical companies (including GE Healthcare, AIA - Novartis, Life Molecular Imaging).

At Itelpharma we have completely managed the design and implementation of our radiopharmaceutical production facility with two cyclotrons and an in-house microbiological laboratory. In over 10 years of activity, we have perfected our specifications and competences along with growing our full operations not only in manufacturing but also in research and radiopharmaceutical development. Above all, throughout this time, we have enhanced our scientific, technical, regulatory and commercial skills.

We work in compliance with the best quality standards in microbiology and nuclear medicine, expanding and increasing the pipeline of molecular products and the services offer.

**ITM Isotope Technologies Munich SE**

Walther van Dyck Strasse 4  
85748 Garching, Germany

info@itm-radiopharma.com

www.itm-radiopharma.com

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiomolecular precision therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including two phase III studies, combining the company’s high-quality isotopes with a range of targeting molecules. By leveraging our nearly two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life.

**Jiangsu Huayi Technology Co., Ltd.**

18 Fuyu Road, Haiyu town  
215500 Changshu, Jiangsu, China

matt@huayi-isotopes.com

www.huayitec.net

Jiangsu Huayi Technology Co., Ltd. is a fully integrated provider of radiopharmaceuticals in China. We develop, manufacture, and distribute high-quality radiopharmaceutical products. CDMO services are offered to our global clients. We support projects from initial research phase to commercial production. One of the divisions, Huayi Isotopes Co. (HIC), manufactures and distributes stable isotopes, PET and SPECT precursors, reagents kits, cassettes, and sterile vials etc. Products of HIC are supplied to clients around the world.

We are client-oriented and determined to build and foster long-term partnerships with our clients. Since the company was established in 2001, we have been dedicated to serving the nuclear medicine industry. Since 2014, we have been setting up nuclear medicine manufacturing sites strategically. Our integrated radiopharmaceutical manufacturing and distribution network will enable us to reach most of the patients in China.
Jubilant Radiopharma, a Business division of Jubilant Pharma Limited
790 Township Line Road, Suite 325
PA 19067 Yardley, United States
Laura.Shaw@jubl.com
Lisa.Shearin@jubl.com
https://www.jubilantradiopharma.com/

Jubilant Radiopharma is an industry leading radiopharmaceutical company committed to driving the value of cardiac PET as a vital imaging modality, because we recognize the important role it plays in evaluating cardiac physiology and function. We strive to deliver better clinical outcomes as a result of our investment into our pipeline, infrastructure, and people—all of whom are driven by their uncompromised passion and dedication to the utility and sustainability of nuclear medicine. Partnering with Cyclomedica in the EEA, we aim to provide expanded access to the next-generation PET products to enhance the way patients with known or suspected coronary artery disease are both diagnosed and managed.

So, whether you are looking to start a program or want to enhance your current practice; we are here to help. To learn more about the latest advancements in Cardiac PET imaging, visit our booth at EANM or contact customer service at customerservice@jdi.jubl.com.

LabLogic Systems Limited
Paradigm House, 3 Melbourne Avenue
S10 2QJ Broomhill, Sheffield, United Kingdom
solutions@lablogic.com
www.lablogic.com

LabLogic are a manufacturer of instruments and software to the Life Science, PET/Nuclear Medicine and Radiation Safety sectors. We have over 40 years’ experience and expertise in providing solutions within highly regulated environments. LabLogic will be showcasing its Tracer QC system at EANM’22. Developed in conjunction with TraceAbility this instrument is already being seen as the future of PET QC.

The Tracer QC is just part of LabLogic’s range of market leading products which can be found in some of the world’s most prestigious PET and Nuclear Medicine laboratories. These include a range of QC equipment from innovative r-TLC, r-HPLC instruments to a single point of control radiochromatography software package – Laura for PET. The complete QC package is also available from LabLogic, just ask about the QC solution.

Furthermore Lablogic offer PETra, a purpose built PET LIMS system designed to improve efficiency and compliance. PETra directly captures data from all the equipment used, acting as a central repository for all information within PET production including batch record management, QMS, trending, inventory, instrument maintenance etc. We also offer SPECtra, a software package based on PETra. Being a direct descendant of PETra, SPECtra utilises many of its features and a similar framework, to provide a dedicated Radiopharmacy LIMS. Visit stand 42 at the show to see demonstrations of the Tracer QC and other products in the nuclear medicine range.

LaCalhene
1 rue du Comté de Donegal
41100 Vendôme, France
samuel.kervoern@getinge.com
www.lacalhene.com/en/

Since the 1960s, LaCalhene has been designing and supplying high-performance equipment for nuclear research centers, radiopharmacy, fuel cycle, and other nuclear activities. LaCalhene’s expertise extends from design to maintenance on a wide range of solutions for hot cells and glove boxes:
- Telemanipulation: Mechanical or robotic remote manipulators for small, medium, or large cells.
- Transfer: Transfer solutions (based on the DPTE® system) for radioactive products in a hot cell or glove box.
- Transport: Shielded containers for safe transfer and transport of highly contaminated and radioactive materials.
- Handling: Equipment for direct manipulation inside secure contaminated containment enclosures (glove boxes).

Our purpose is to preserve your operators’ safety and your activities’ efficiency.

Lemer Pax
72, rue de Lorraine
ZA Erdre Active - Malabry
44240 La Chapelle sur Erdre, France
contact@lemerpax.com
www.lemerpax.com/en/

Worldwide leader in innovation in the radiation protection sector, Lemer Pax creates, designs, and engineers efficient radiation protection solutions for medical, research, industry, and nuclear applications. With over 50 years of innovation, Lemer Pax exports all over the world, eco-aware and cutting edge of technology radiation protection products. Lemer Pax, protecting life, we strive for excellence to protect the most important thing: Life!
M&I Materials Ltd manufactures a range of specialty products under our Wolfmet, Apiezon and Metrosil brands for nuclear medicine applications. Wolfmet tungsten alloy has been the automatic choice for radiation shielding and collimators in nuclear medicine for many years. Over the last 9 years, Wolfmet has been opening up a world of possibilities with the introduction of Wolfmet 3D printed tungsten. This revolutionary process makes complex high precision tungsten collimators a reality. The Apiezon family of hydrocarbon high vacuum greases are highly regarded for their quality, consistency, and excellent performance in vacuum applications. Apiezon L and M Grease are silicone and halogen-free greases suitable for use in scientific and industrial applications – used and respected by The European Space Agency, NASA, and NATO. Apiezon N Grease is widely used in the manufacture of all types of cryogenic equipment, including Magnetic Resonance Image (MRI) magnets, cryostats, and scientific instruments (including electron microscopes). Metrosil Quench Protection Units are silicon carbide (SiC) varistors designed to clamp voltage to a required magnitude and quickly extract energy stored in superconducting magnets during a quench. The Metrosil 12000 Series has the potential to provide quench protection for proton beam therapy machines, whereas our 4K devices have the potential to protect MRI magnets. M&I Materials Ltd is part of the Pavilion consortium (Booth 35), come and visit us to learn more about our exciting new developments.

Medi-Radiopharma Ltd. has more than 25 years of experience in developing, manufacturing, and supplying radiopharmaceutical products to customers around the globe. Our purpose is to serve the healthcare and improve patient outcomes through a wide portfolio of high-quality products. MRP specializes in the production and supply of generic in vivo kits for Tc99m labelling used in nuclear medicine. By potentially enabling accurate early diagnosis and treatment of cancers, as well as heart, brain and bone diseases, our world-class products are registered in more than 70 countries worldwide - empowering our customers with effective treatment and proven patient outcomes. We are also involved in the development of therapeutic radiopharmaceuticals. MRP holds valid Manufacturer’s Authorization, Certificate of GMP Compliance of a Manufacturer, Wholesale Distribution Authorization, Certificate of GDP Compliance of a Wholesale Distributor, GLP and ISO Certificate and relevant authorization for the manufacture and wholesale distribution of radiopharmaceuticals.

Mediso Medical Imaging is a leader in nuclear medicine since 1990 with a profile of development, manufacturing, selling and servicing molecular imaging multi-modality devices. It offers complete solutions from hardware design to evaluation and quantification software for clinical patient care and preclinical research. With its 30-years expertise, 1,300+ clinical cameras, Mediso is within the leaders in clinical patient care. Besides a unique triple modality clinical SPECT-CT-PET hybrid system, Mediso launched the new AnyScan+ TRIO family which has a triple head SPECT detector design and dedicated multipinhole collimation technology. Mediso has a leader position in the preclinical nuclear imaging market with 250+ commissioned preclinical cameras around the world. Beyond the market leading nanoScan® PET/CT and SPECT/CT, Mediso launched the world’s first integrated PET/MRI and SPECT/MRI systems. Further on 3T and 17T oxygen-free magnets and PET insert have been added to the product line, resulting in the largest install base of integrated PET/MRI systems. Products are sold directly or through a network of distributors with over 1500 imaging systems for clinical and preclinical imaging operating in 100+ countries around the globe.

MEDraysintell provides reports and directories with an exhaustive description and analysis of marketed radiopharmaceuticals, radiopharmaceuticals under clinical development, and radiopharmaceuticals under preclinical development, thru a description of about 900 products, together with a comprehensive profile of 370 companies active in nuclear medicine. Plus a complete review of the Cyclotrons used in Nuclear Medicine worldwide. Our reports have been highly appreciated by clients worldwide. Their feedback praised the outstanding level of our reports and our expertise. Some comments have been published under: https://www.medraysintell.com/clients.
MedTrace Pharma A/S is a development stage pharma and device company and an innovator in PET diagnostic imaging. The company is working on a solution to help healthcare professionals diagnose patients better and faster via 15O-water PET. Leading hospitals in the US, Europe and Japan are close partners.

In March 2022, MedTrace received FDA approval of the company’s Investigational New Drug application and the approval to commence its RAPID-WATER-FLOW Phase II Clinical Trial to evaluate the use of 15O-water PET in diagnosing Coronary Artery Disease. Two months later, MedTrace announced that it had scanned the first subject. Meanwhile, the company is preparing for regulatory clearance in the EU.

Our solution consists of:

1) the P3 system, which is a point-of-care cGMP-compliant chemistry lab combining the process of manufacturing and injecting 15O-water into the patient.
2) the analytical software aQuant, which produces images combined with quantitative data of the PET scan.

At the same time, MedTrace is exploring clinical applications outside of cardiology and looking into research areas such as oncology and neurology. MedTrace, headquartered in Hørsholm, Denmark, employs +40 people and opens its US offices in September 2022.

Brands: MedTrace Pharma, P3 System 15O-water system, aQuant cardiac analytical software

MIE medical imaging electronics GmbH

Hauptstrasse 112
23845 Seth, Germany

mieg@miegermany.de

https://mie-sciontron.com/

We have produced gamma camera and PET systems since 1981 for the complete nuclear imaging medical market of the nuclear medical diagnostic. We provide for the discriminating and price sensitive market. All our systems are produced according to current medical and technical requirements. The experience and the know-how since 1974 form the development of our data and image processing unit SCIONTRON. This diagnostic prospects are also available for the veterinary market.

Accredited service, constantly care of our hard- and software and time accordant design show our capacities.

Since 1995 MIE America, Inc. has been in business to provide a better service to our america customers. MIE America, Inc. is located in Elk Grove Village, IL, USA.

The MIE GmbH is in accordance with EN ISO 13485 certified and our gamma camera systems are with Annex II of Directive 90/42/EEG approved. Also, we are registered at the FDA – our systems are 510k approved since 1995. This extensive certification is the basis for the manufacture and distribution of medical products on the world market.

MILabs

Duwboot 7a
3991 CD Houten, The Netherlands

info@milabs.com

https://www.milabs.com/

MILabs delivers top level preclinical PET, SPECT, Bioluminescence, Fluorescence & X-ray CT imaging devices in any combination, as single integrated scalable platforms, or as standalone systems. By combining up to five modalities on a single in-line platform, MILabs has introduced the first commercial system to enable ground-breaking synergistic multi-modality imaging photons from 1eV up to 1MeV! The technology also offers:

- Down to 0.6 mm PET resolution, simultaneous multi-isotope PET-PET and PET-SPECT
- Quarter-mm diagnostic and exclusive sub-mm theranostic SPECT of alpha and beta emitters
- Sub-second 4D SPECT and PET frame rates
- Quantitative CT-guided Bioluminescence and Fluorescence Tomography
- Ultra-fast and Ultra-high resolution low dose X-ray CT
- High-throughput Bioluminescence and Fluorescence imaging
- With many hundreds of global installations, MILabs collaborates with leading universities, hospitals, contract research organizations and pharmaceutical companies to contribute to the development of new diagnostic solutions and therapies as well as to basic research.

Explore how our cutting-edge preclinical imaging and clinical technologies can accelerate research discoveries at www.milabs.com.

MIM Software Inc.

25800 Science Park Dr., Suite #180
44122 Cleveland, United States

info@mimsoftware.com

www.mimsoftware.com

MIM Software Inc. offers a comprehensive suite of applications that support Radiology and Nuclear Medicine’s important role in cancer care. MIM Software products excel in Theranostics and emphasize the importance of quantitation, collaboration, and data management to provide physicians with crucial information to generate confident clinical guidance and inform effective treatments.

MIM Software drives your nuclear medicine workflow with comprehensive support for standard nuclear medicine studies, emerging radiotracers, neuro and cardiac imaging. MIM SurePlan® offers tools to support the feasibility of molecular radiotherapy dosimetry and Y90 therapy within the busy Nuclear Medicine workflow. Quantitative images are needed to calculate accurate dosimetry, and MIM SPECTRA Quant™ provides a vendor-neutral SPECT reconstruction method that pairs dynamically with existing SPECT/CT cameras.

MIM Assistant® automates traditional clinical tasks and centralizes images and related data to a single repository. Flexible deployment options allow easy access to MIM Software from anywhere. The result is greater access to critical patient information in collaborative settings like tumor boards or for use in dictated reports.
MNT Healthcare Services

19 Mayıs Mah. Dr.Şeykül Bey Sk. No:5 34360 İstanbul, Türkiye

info@mnt.com.tr
www.mnt.com.tr

MNT provides healthcare organizations with professional nuclear medicine and radiation oncology solutions since 1990. MNT currently renders services with 63 centers in Turkey and 7 centers in Europe. MNT provides specialized diagnostic and therapeutic services for all processes of nuclear medicine and radiation oncology.

With its dynamic and innovative structure, MNT is among the "most experienced healthcare service providers" in the field and serves patients in many NM and RT Centers within universities, state hospitals, private hospitals. MNT also services directly to cancer patients with its own centers called Neolife.

Neolife brand is increasing its international presence, establishing itself as a strong global brand. MNT is active in Romania with 4 centers as Neolife, one center in Moldova, and 2 centers in Bulgaria. MNT is pursuing further projects in Africa, Balkans, Middle East, and Central Asia.

In line with golden standards in medicine, MNT is also pioneering therapeutic applications through Intheranostics. MNT’s arsenal of leading-edge technology utilizes advanced imaging, molecular probes, and limited amounts of radiation for diagnosis and targeted therapies.

Smooth and timely completion of turn-key projects:
- Project Design and Installation
- Equipment Supply and Care Services
- Recruitment of Personnel
- Radiation Safety and Training
- Project Management and Operation
For more info, visit: neolife.com.tr/neolife.ro
mnt.bg
petct.bg radiotherapy.bg intheranostics.com

MOLECUBES

Ottergemsesteenweg Zuid 808 bus 325
9000 Gent, Belgium

info@molecubes.com
www.molecubes.com

State-of-the-art modular bench-top solutions from MOLECUBES make molecular imaging more accessible for a wider community of researchers in the field of preclinical drug discovery and development, fundamental and translational research. The CUBE platform enables you to retrieve integrated in vivo information that cannot be derived from other individual techniques requiring samples.

At MOLECUBES, we believe that molecular imaging should be accessible to every research lab. MOLECUBES has therefore made it its mission to lower the barrier to preclinical PET, SPECT and CT imaging by providing compact, intuitive, flexible benchtop imaging solutions with the highest performance, supported by fast and simple workflows.

The X-CUBE, CUBE and B-CUBE are the most compact micro-CT, micro-SPECT and micro-PET scanners in modular combinations. Thanks to their benchtop design and total ease of use, MOLECUBES systems pave the way to the next generation of whole-body mouse and rat scanners.

With more than 100 CUBES installed worldwide, MOLECUBES is a trusted partner by your side.

MONROL NUCLEAR PRODUCTS CO.

Rüzgarlıbahçe Mahallesi, Çam Pinar Sokak
No:3 D: 10,11 Beykoz, 34800 İstanbul, Türkiye

monrol@monrol.com
https://www.monrol.com.tr/tr

Monrol is one of the world’s largest radiopharmaceuticals companies leading innovation for the development and manufacturing of GMP grade radioisotopes and radiopharmaceuticals having headquarters in Istanbul. Monrol is distributing its world-class radiopharmaceutical products portfolio with excellence in global markets. Monrol is a CDMO, providing early development support to its customers as well as offering fully integrated services for today’s nimble, lean, virtual companies effectively taking new product concepts into clinical trials, demonstrating proof of concept, and going into first-in-human studies. Monrol is committed to transform and improve patient journey in cancer treatment with its radiopharmaceutical products portfolio distributing to more than 50 countries around the globe.

MR Solutions Ltd

Ashbourne House, The Guildway
Old Portsmouth Road
GU1 1LR Guildford, United Kingdom

sales@mrsolutions.com
www.mrsolutions.com

MR SOLUTIONS GROUP develops and manufactures innovative imaging solutions for the research industry. The company offers a large range of products for MR, CT, PET and SPECT. All scanners are interchangeable between each other for multi-modality imaging.

The company is the worldwide leader in high-field cryogen-free MR based on its proprietary dry magnet technology. The NMR*DRYMAG product line delivers MR up to 9.4T and a bore size up to 42 cm.

Advanced coils and software tools for pulse sequence programming are also available.

The magnet technology has exclusive features such as rotating the system to 90° and the ability to ramp the field of the magnet up and down within minutes. Helium lines and shielded rooms are not required which keep the installation costs extremely low.

PET/MR imaging is possible up to 9.4T simultaneously. PET and SPECT scanners are easily removable from the MR in minutes, and can be plugged straight onto the CT. This avoids the need for numerous scanners and large rooms. Four models of PET/CT’s and CT’s are available: a Benchtop, two high resolution models and a very large bore for 1.2 kg animals.

MR SOLUTIONS can refurbish and enhance all components from any MR system. MR Solutions also manufactures compatible gradients.

MR Solutions holds the prestigious Queen’s awards 2019, 2017 & 2016, the innovation award from the Institute of Physics and is the winner in the global R&D 100 awards.
Since 1998, NICEsoft develops innovative software solutions for Medical Imaging departments. We combine zero-footprint Web technology with a high specialization in Nuclear Medicine and Radiology to design applications that can be used in hospitals, private practices or even from home without any installation. Our VENUS product line provides a complete range of solutions, from online appointment booking to a full-Web Viewing & Processing Application Server. Thanks to its Web design, your images and reporting tools can be securely accessed from anywhere, making VENUS the ideal partner to develop teleradiology services.

We are the leading RIS provider for Nuclear Medicine departments in France and have also equipped sites across Europe, the US, China and the Middle East. Come and see why!

SOFTWAY MEDICAL is a leading cloud base provider of software and services for health institution in Europe. With more than 3,000 client institutions, SOFTWAY MEDICAL covers the entire range of healthcare services in the public and private hospital sectors, as well as in radiology and outpatient medicine, becoming the second largest European player in terms of market share in the EMR sector. Based on web technologies, the SOFTWAY MEDICAL group’s solutions enable the entire patient care process to be managed and data to be shared securely between healthcare professionals. Because nothing in healthcare will ever replace the dispensation of human intelligence, SOFTWAY MEDICAL considers technology and data management as a means of increasing the potential of anyone who takes it on. Its innovations have only one objective, to allow each of its users to fully exploit their capacities and make informed decisions in their daily missions, in the interest of the patient.

NUCLEAR MEDICINE EUROPE – NMEU, eeeig

Avenue Louise 65, Floor 4, Office 33
1010 Brussels, Belgium

sales@nmeu.org

www.nmeu.org

Nuclear Medicine Europe (former AIPES), “the Industrial Association”, represents many of the major pharmaceutical & Imaging equipment companies in the field of Nuclear Medicine in Europe.

Nuclear Medicine Europe provides a wide scope of services & partnerships on behalf of its members. We maintain close contacts with the European Union representations, politicians, EMA (the European Medicine Agency), academia & the media. We also have partnerships with key EU Patient Associations & other professional bodies in the healthcare field.

Our objective is to raise awareness of the role and benefit of the industry of nuclear medicine and collectively continue to further research into molecular healthcare and its benefits for the citizens of Europe.

NRG | PALLAS

Westerdijinweg 3
1755 LE Petten, The Netherlands

den.hartog@nrg.eu

www.nrg.eu

www.pallasreactor.com

The Energy & Health Campus in Petten is home to a unique combination of nuclear installations. With the knowledge developed in these nuclear research facilities and the continuous production of medical isotopes, our services and products are literally lifesaving. Numerous preparations are being made for the future and a new research laboratory is being built called FIELD-LAB, where new nuclear medicines will be developed. The production of medical isotopes is being expanded and the construction of the Nuclear Health Centre and the new PALLAS-reactor are scheduled for the near future.

We meet the need to accelerate the development of new nuclear therapies, usually hindered by high costs and the restricted availability of proper facilities and isotopes.

We take the next step by presenting the progress we have made on three innovative projects:

- Lu-177: a new isotope for targeted therapy
- Pb-212: promising alpha therapeutic isotope for targeted therapy
- Pt-195m: to increase effectivity of cisplatin chemotherapy

Physical construction of FIELD-LAB has started in 2020 with supply of R&D batches expected by the 2023. These initiatives are financially supported by the European Regional Development Fund (EU) and the Province of North Holland (NL).

Our quest for saving lives began back in the 1960 breakthroughs in scanning technology for precise diagnosis of cancer and cardiovascular diseases, led to phenomenal growth and worldwide acceptance of radopharmaceuticals. Preparations are being made for the construction of the PALLAS-reactor, the successor the HFR.

Nuclear-Shields

Akkerveertweg 29
5827AP Vortum-Mullem, The Netherlands

info@nuclear-shields.com

www.nuclear-shields.com

Nuclear Shields is a manufacturer of radiation shielding based in the Netherlands with more than 40 years of experience. The production facility is designed to meet the requirements of long term serial production and one-off custom projects. Lines of communication are short due to our small team of sales and engineering personnel. The focus on good and fast communication with the client helps us improve our services every day and makes sure the customer is satisfied.

Nuclear Shields is part of the Van Mullikom Group which was founded in The Netherlands in 1978. All factories share a common ground in engineering and radiation shielding that can be applied to many different industries, such as the healthcare, homeland security and nuclear industry. Nuclear Shields is a seller of a wide range of products regarding the shielding of radioactivity. Our products range from hot lab necessities and radiation shielding, to radiation detection and radiation cleanup solutions.

The In-House capabilities of the Van Mullikom Group range from prototyping to full assembly, which enables us to provide a wide range of solutions for a low price, high quality and with quick customer service. These in-house departments express our capability of manufacturing a wide product range, including the creation of custom-made solutions to fit your needs.

Nuclear-Shields

Akkerveertweg 29
5827AP Vortum-Mullem, The Netherlands

info@nuclear-shields.com

https://www.nuclear-shields.com/
NUCLEIS SA

Allée du Six-Août, B
B - 4000 Liège, Belgium
info@nucleis.eu
www.nucleis.eu

Nucleis is a radiopharmaceutical company which propose and manufacture Radiopharmaceutical Drugs for Diagnostic and Therapy Monitoring. Nucleis portfolio presents Brand name drug, IMP and CMO activities. This allows Nucleis to reach nuclear medicine services and (radio)pharmaceutical industry. Nucleis maintains a strong partnership with CRC (Cyclotron Research Center) for the development of new tracers and R&D activities.

Marketing Authorization Holder:
GMP Certificate number BE/GMP/2018/060 for Human Medicinal Products
GMP Certificate number BE/GMP/2018/061 for Human Investigational Medicinal Products
MA 1932H
MA 1932 IMP

NUVIA Instruments GmbH

Dornblüthstrasse 14 A
01277 Dresden, Germany
info@nuvia-instruments.de
www@nuvia-instruments.de

With 2 sites in Dresden and Dülmen, NUVIA Instruments GmbH designs and manufactures laboratory counters and radiation monitoring systems for nuclear medicine, PET centres and therapy stations:
• Dose Calibrators
• Thyroid Uptake-Counters, Incorporation Counters, Well-Counters, Waste Water Counters
• Patient and Area Monitoring Systems
• Contamination Monitors (portable and hand-foot clothing monitors) Waste and Release Monitors
• Laboratory Furniture (standard and customized)

About the NUVIA Group:
NUVIA is the nuclear branch of Sixianche Freysinet, a subsidiary of Vinci Construction Group. Even though the NUVIA name was created in 2007, its history goes back to the beginning of the French and British nuclear industry. Today, with more than 30 years of experience and approx. 3,000 employees worldwide, the NUVIA Group offers engineering, services and products at all stages of a nuclear facility’s lifecycle design, construction, operation, maintenance, decommissioning. The NUVIATECH HEALTHCARE brand was created in 2017 to offer the Group’s complete portfolio of instruments, systems and solutions for healthcare applications.

For more information about the NUVIA Group and its activities in the healthcare sector, please visit www.nuviatech-healthcare.com.

Oncidium foundation

Avenue Hermann Debroux 40
1160 Brussels, Belgium
contact@oncidium-life.org
www.oncidiumfoundation.org

The Oncidium foundation is dedicated to support and accelerate the development of radiotheranostics (RLT) for cancer care. It strives to connect patients, practitioners & experts in the nuclear medicine field by raising awareness & improving access to cancer treatments & clinical trials worldwide. The activities are based on 3 pillars: ACCESS – Through a platform that will create cohesion between all stakeholders. Notably, for patients, to find the nearest treatment center, current clinical trials & to facilitate communication with medical experts; For practitioners to register their therapy centers; For RLT experts to help promote precision medicine & its progresses. Thus, bridging the gap between people functioning & benefits of RLT, still unknown to some practitioners & the general public.

EDUCATION – Education & awareness are essential, as they help to bring a better understanding of the functioning & benefits of RLT, still unknown to some practitioners & the general public.

HOPE – When other cures are not an option. The foundation is evaluating all possibilities to support clinical developments of efficient RLT & individual cases to reduce treatment overall costs in low-income countries.

Moreover, Oncidium endeavors beyond boarders through a worldwide network of Ambassadors in each country for awareness & education campaigns, local collaborations & shared knowledge.

Together, let’s commit to enhance Access, Education & Hope!

OncoBeta GmbH

Schlesseihener Str. 91
85748 Garching n. Munich, Germany
info@oncobeta.com
www.oncobeta.com

OncoBeta® GmbH is a privately held medical device and radiopharmaceutical company specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, Oncobeta GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. Since 2019 Oncobeta GmbH also produces tungsten (wolfram)-188/rhenium-188 Generators for commercial use.

The Rhenium-SCT® is a painless, single session, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat. It utilizes the radioisotope Re188 in an epidermal application to treat NMSCs (non-melanoma skin cancers). Since then, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers.

Oncobeta GmbH is a privately held medical device and radiopharmaceutical company specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotope applications. Since its foundation, Oncobeta GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, Oncobeta GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. Since 2019 Oncobeta GmbH also produces tungsten (wolfram)-188/rhenium-188 Generators for commercial use.

The Rhenium-SCT® is a painless, single session, non-invasive therapy that provides aesthetic results, even in cases otherwise considered difficult to treat. It utilizes the radioisotope Re188 in an epidermal application to treat NMSCs (non-melanoma skin cancers). Since then, Oncobeta GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, Oncobeta GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. Since 2019 Oncobeta GmbH also produces tungsten (wolfram)-188/rhenium-188 Generators for commercial use.
**ONCODESIGN**

**18-20 Rue Jean Mazen**
21000 Dijon, France

contact@oncodesign.com

https://www.oncodesign.com/

Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 1000 clients along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, bioanalysis & pharmacology, Oncodesign offers drivers & executes the development of drug candidates from hit findings up to early clinical phases. Oncodesign has specialties in radiotherapy image, drug discovery programs & provides molecular experts in your preclinical projects.

**Oncosil Medical Limited**

**Suite SO3, Level 5, 15 Blue Street**
NSW 2060 Sydney, Australia

info@oncosil.com

www.oncosil.com

Oncosil Medical is a global medical device company focused on Interventional Oncology. Our mission is to improve the outcomes for people living with cancer by utilizing selective and targeted intratumoral placement of Phosphorous 32 (32P) Microparticles. Oncosil is a single-use brachytherapy device that has received breakthrough designation in the European Union, United Kingdom and the United States for the treatment of unresectable locally advanced pancreatic cancer in combination with chemotherapy.

Oncosil comprises of Phosphorous-32 (32P) Microparticles suspended in a specially formulated Diluent. The Microparticles are a permanent implant which contain Phosphorous-32 (32P), a pure beta-emitter radionuclide with a physical half-life of 14.27 days. In therapeutic use, 98% of the radiation is delivered within 81 days, which gives an absorbed dose equivalent to 100 Gy.

**ONCOVISION**

**C/ Jerónimo de Monsarrut, 92**
46022 Valencia, Spain

info@oncovision.com

www.oncovision.com

Oncovision is a Spanish-based molecular vision company, founded in 2002, committed to making a difference in improving major health challenges through continued, clinically relevant innovation. Its revolutionary, IP-protected medical imaging devices have been successfully used in 100,000+ patients by nuclear physicians, radiologists, surgeons and oncologists in 35+ countries.

Oncovision is combining breakthrough interventional gamma camera systems and organ specific dedicated PET scanners:

- **Sentinella®**: World’s best intra-operative integrated gamma camera system (+CAD software) for radio-guided surgery with real-time imaging to detect sentinel and deep lymph nodes and small tumors, evaluating personalized tumor extension to lymph nodes, both in and outside of expected nodal chains.

- **Mammi®**: Dedicated breast PET (in prone position) generating functional 3D breast images and lesion quantification with an unprecedented clinical resolution (up to 1.6 mm), adding major clinical value in personalized breast cancer diagnosis and therapy follow up.

- **CareMiBrain**: Dedicated Brain PET in seating / reclined position, with vastly superior specifications in sensitivity, resolution and contrast vs whole body PET with ½ to 1/3 rd tracer dose, CMB is adding revolution in imaging, Oncodesign orients, drives & executes the development of drug candidates from hit findings up to early clinical phases. Oncodesign has specialties in radiotherapy image, drug discovery programs & provides molecular experts in your preclinical projects.

**Optimized Radiochemical Applications**

**Rue de la Salette, 15**
5600 Neuville, Belgium

info@oncodesign.com

www.oncodesign.com

We connect you with radiosynthesizers. Radiochemistry is widely used in medicine as a diagnostic tool and has extraordinary benefits for humankind, especially in the treatment of cancer. Whether you are looking to double your output or have reliable and unmatchable synthesizers in your radiochemistry lab, look no further than NEPTIS!

For more than 15 years, ORA has been at the forefront of the radiopharmaceutical industry providing multi-purpose radiochemistry synthesizers to academic and commercial organizations. Our mission is to provide innovative solutions for your lab’s research and development, and production needs. The proven expertise of ORA coupled with the NEPTIS platform’s extensive regulatory documentation support make it possible for your lab to maximize the production of PET tracers and advance the development of new pharmaceuticals to market. Founded by Dr. Vincent Tadino, in 2006, ORA is headquartered in Neuville, Belgium. ORA is a certified ISO13485 manufacturer and a leading supplier of innovative radiochemistry synthesizers. We recommend NEPTIS in your hotcells.
Pars Isotope Co. is the only producer and supplier of radiopharmaceuticals and radiopharmaceutical kits in Iran and the leading one in the Middle East. Pars Isotope produces more than 50 different types of diagnostic and therapeutic products in the field of nuclear medicine. Based on the knowledge and experience of our specialists, we have succeeded in producing unique radiopharmaceuticals and introducing various solutions to international markets. Variety, extent and quality are the main features of our products. Among our valuable products, we can mention Tc-99m and Ge-68/Ga-68 generators, which are known under the brand names of PARS-TEC II and PARS-GalluGen, respectively. Also, the variety of our radiopharmaceutical kits reaches more than 20 different types. In order to improve the quality and quantity of medical products based on cGMP regulations, Pars Isotope participates in a project to implement new modern RRP, CKP and PET facilities in Iran. In addition, we focus on the following activities according to our profession and abilities:

- Production of more than 20 types of Tc-99m radiopharmaceutical kits
- Production of 4 types of radionuclide generators to be used in PET & SPECT imaging
- Production of new ready to use PET radiopharmaceuticals
- Production of more than 22 ready to use therapeutic, bone pain palliation and radio-synovectomy radiopharmaceuticals
- Development and optimization of separation methods for different types of radioisotopes used in the production of radiopharmaceuticals
- Development and optimization of advanced methodologies in the production of new radiopharmaceuticals
- Production and development of radiation protection and measurement equipment used in various industries, including the Nuclear Medicine production sites.

PIUR IMAGING GmbH

PIUR was established as an industry-leading custom solutions provider to global pharmaceutical corporations. The entrepreneurial mindset of Franco Serventi and Marco Serventi - father and son - started in 1979 when the first automation solutions for the beverage, chemical and pharmaceutical sectors were designed, built and installed. Four decades of extensive engineering knowledge gradually obtained from thousands of successful projects are now available to our clients. The Serventi’s history and passion for excellence combined with the support of highly skilled engineers, makes PBL an unique partner for innovative and efficient solutions for leading global manufactures corporations.

PIUR IMAGING, an Austrian medtech company, which is active in the field of diagnostic ultrasound imaging and is specialized in acquisition and visualization of 3D ultrasound images. PIUR IMAGING’s vision is to provide access to affordable high-quality healthcare through AI-driven tomographic ultrasound solutions everywhere. PIUR’s tomographic ultrasound solution PIUR TUS Infinity turns any standard ultrasound system into a tomographic 3D imaging device, enabling true AI in ultrasound. With any conventional 2D ultrasound transducer, high-resolution tomographic images can be generated. While standard ultrasound requires on-the-spot assessment of the images, PIUR’s 3D ultrasound volumes of entire structures or organs allow retrospective diagnosis at any time. In combination with smart analysis tools, explicitly designed for the evaluation of thyroid and nodules, thyroid analysis becomes less operator-dependent and diagnostic workflows can be optimized. PIUR TUS Infinity is the only vendor-independent tomographic 3D ultrasound solution, designed to improve thyroid diagnostics.
### PMB-Alcen

- **Route des Michels CD56**
- 13790 Peynier, France
- [imigine@pmb-alcen.com](mailto:imigine@pmb-alcen.com)
- [www.imigine.com](http://www.imigine.com)

Deeply involved in the fight against cancer, PMB is a French company specializing in medical systems, from cancer diagnosis to treatment.

We have developed a versatile and automated radiopharmaceutical production system, combining a cyclotron with a robotized radiochemistry room. A 12 MeV superconducting cyclotron produces 18F, 11C and 68Ga radioisotopes, which are used to label a targeting agent in a robotized radiochemistry room. Our microfluidic synthesizer iMiDEV designed for R&D and preclinical phases in mind. It allows the consumption and low initial investment, iMiDEV can be easily installed in pre-existing or new premises. As a versatile unit and tight environment, it allows the development of several radiopharmaceuticals for a targeting agent in a robotized radiochemistry room. POLATOM's current commercial package includes:

- A wide range of scintigraphy kits for 99mTc labelling for the examination of organs and cancer diagnosis,
- 131I- for the diagnosis and treatment as capsules, solution, MBG, Hippurate
- 89 Sr-chloride for the palliative treatment of bone metastases,
- Radioisotope Centre POLATOM is a world-famous supplier of high-quality radiopharmaceuticals and diagnostic kits for nuclear medicine and an important manufacturer of radiochemical products for customers all over the world. Our products are exported to more than 70 countries. POLATOM is Poland’s main producer of radiopharmaceuticals and other radioactive products.

### National Centre for Nuclear Research – Radioisotope Centre POLATOM

- **Andrzeja Sołtana 7**
- 05-400 Otwock, Poland
- [polatom@polatom.pl](mailto:polatom@polatom.pl)
- [www.polatom.pl](http://www.polatom.pl)

Radioisotope Centre POLATOM is a world-famous supplier of high-quality radiopharmaceuticals and diagnostic kits for nuclear medicine and an important manufacturer of radiochemical products for customers all over the world. Our products are exported to more than 70 countries. POLATOM is Poland’s main producer of radiopharmaceuticals and other radioactive products.

POLATOM’s current commercial package includes:

- A wide range of scintigraphy kits for 99mTc labelling for the examination of organs and cancer diagnosis,
- 131I- for the diagnosis and treatment as capsules, solution, MBG, Hippurate
- 89 Sr-chloride for the palliative treatment of bone metastases,
- Radioisotope Centre POLATOM is a world-famous supplier of high-quality radiopharmaceuticals and diagnostic kits for nuclear medicine and an important manufacturer of radiochemical products for customers all over the world. Our products are exported to more than 70 countries. POLATOM is Poland’s main producer of radiopharmaceuticals and other radioactive products.

### Postirigo AG

- **Technoparkstrasse 1**
- 8005 Zurich, Switzerland
- [info@postirigo.com](mailto:info@postirigo.com)
- [www.postirigo.com](http://www.postirigo.com)

Postirigo is a pioneer in nuclear medical imaging technologies. Headquartered in Switzerland, the medical device company was founded in 2018. NeuroLF® - the company’s first device - is an ultra-compact brain PET scanner which has applications in assessment of causes of dementias, such as Alzheimer’s disease and other brain related disorders.

### Precirix

- **Burgemeester Etienne Demunterlaan 1**
- 1090 Brussels, Belgium
- [info@precirix.com](mailto:info@precirix.com)
- [www.precirix.com](http://www.precirix.com)

Precirix is a private, clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments (sdAbs).

The company’s platform allows the design and development of novel radiopharmaceuticals or targeted radioligand therapies, a technology in which radionuclides are attached to ligands that direct them to their specific target on the cancer cell. The radioactive payload is delivered in a highly selective manner to the tumor, limiting radiation to the rest of the body. Our technology platform facilitates development of sdAbs for multiple targets, in combination with different isotopes and applicability in various settings. Further, the technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy. Precirix is currently advancing its lead product candidate, the HER2-targeted radioligand therapy CAM-H2, through a Phase I/II clinical trial, while further progressing and broadening its oncology pipeline. Precirix’s next product candidate to enter the clinic is targeting fibroblast activation protein (FAP) and is expected to initiate clinical trials in 2023.
At Qubiotech we develop AI-assisted software for automatic and advanced neuroimaging analysis: Neurocloud, a CE marked tool for quantifying biomarkers in neurodegenerative diseases, which quickly, accurately and effectively helps the doctor (radiologist, neurologist and nuclear medicine doctor with PET, SPECT and MRI imaging) in the diagnosis and follow-up of the patient providing a complete report of the results in a few minutes.

Neurocloud stands out for its experience of use and its clinically validated results (CE marked and FDA in progress) that help in the early diagnosis and monitoring of neurological diseases such as Multiple Sclerosis, Epilepsy, Parkinson’s, Alzheimer’s, etc. It has both cloud and on-premise versions with complete PACS integration no matter your structure. Neurocloud aims for total integration within your existing workflow.

Neurocloud quantification allows you to go from subjective evaluations, which depend on the observer, to quantitative, reproducible evaluations, and therefore members of the same team can reach the same results with confidence while saving time in doing so.

Qubiotech was born in the Neuroimaging Group of the University Hospital of Santiago de Compostela with the aim of bringing innovation in molecular image analysis to real clinical practice and also at a very low cost compared to the alternatives we had until now.

Welcome to Augmented Neuroimaging. Welcome to Qubiotech.

Radiaprot, s.l.

Miguel Yuste 16
28017 Madrid, Spain

info@radiaprot.com

www.radiaprot.com

Radiaprot is a long established company that has a wide portfolio of products for the spanish Nuclear Medicine market, ranging from protection to specialized equipment, always offering it’s customers a wide range of the most innovative products in the market. Anything you need for your Nuclear Medicine department, Radiaprot can provide, including the knowledge required to make things easy and smooth.

Radioprotech

12 Chemin des Gorges
69570 Dardilly, France

contact@radioprotech.com

www.radioprotech.com

Radiation protection equipment for nuclear medicine department.

Designed and made in France.

Our products range cover all radioprotection needs from the arrival of the radiopharmaceutical until its disposal.

RadQual Global Sources

4137 Commerce Circle
ID 83401 Idaho Falls, United States

sales@radqual.com
info@technologyimaging.com

www.radqual.com

RadQual, LLC is the premier developer of innovative quality control products for the nuclear medicine and PET imaging communities.

We are the only remaining American-owned provider of SPECT imaging radioactive sealed sources for routine quality control. Our quality products are manufactured in Idaho Falls, ID, and distributed worldwide through a select group of dealers and nuclear pharmacies.

RadQual’s goals are straightforward: Quality Products, Fair Prices, Superior Service, and Fidelity to our Clients. We at RadQual are proud of who we are and what we do.
<table>
<thead>
<tr>
<th>Company</th>
<th>Address</th>
<th>Contact Information</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>RescueDose Ltd.</td>
<td>4 HaTnufa st. 2066717 Yokneam, Israel</td>
<td><a href="mailto:adibm@light-inst.com">adibm@light-inst.com</a></td>
<td>RescueDose Ltd. is a medical device company developing compact-sized robotic devices for automated dispensing of liquid medication. Designed with patient and medical staff safety in mind, RescueDose’s mission is to automate the process of medication dispensing in order to minimize human error, dispensing risks and ensure accuracy – by making the correct dosage easily accessible. RescueDose’s automated compounding robots are a game changer in the way medication dispensing is handled and are about to revolutionize the Dispensing Process in pharmacies and hospitals around the world.</td>
</tr>
<tr>
<td>Radiation Imaging Technologies, Lda (RI-TE)</td>
<td>UA Incubator, PCI Creative Science Park Edifício central, Via do conhecimento 3830-352 Ilhavo, Portugal</td>
<td><a href="mailto:info@ri-te.pt">info@ri-te.pt</a></td>
<td>PET is a wonderful molecular imaging technology, instrumental to tackle cancer and other diseases. We believe it should be much more available and easier to use. We’re a spin-out from the University of Aveiro developing uniquely compact and affordable high-resolution PET systems. Our innovative scanning method allows high-performance imaging while reducing complexity, weight and costs by more than 5 times, enabling a more flexible and broader use of this powerful technology. Our mission is to widen access to PET imaging, reducing gaps and improving biomedical research and diagnostics worldwide, particularly of cancer and neurodegenerative diseases. Discover easyPET3D, the most compact and affordable high-resolution PET scanner, a very versatile entry-level system for preclinical research, and a unique instrument for dedicated training of medical imaging technologists. Find out about the new iPET scanners, our latest developments to scale up easyPET technology for more advanced preclinical imaging applications and into the clinical world.</td>
</tr>
<tr>
<td>Rotem GmbH</td>
<td>Franz-Flemming-Str. 39A D-04179 Leipzig, Germany</td>
<td><a href="mailto:info@rotem-eu.de">info@rotem-eu.de</a></td>
<td>Rotem GmbH, a longtime global leader in consumables for PET imaging, supplies cyclotrons around the world with complete packages for radiotracer production. Our product range focuses on Oxygen-18 enriched water, plastic cassettes, precursors and complete reagent kits for various synthesis modules. All products are manufactured in compliance with cGMP requirements according to EU &amp; PICS and are produced in our US FDA-inspected facility. Rotem’s cGMP certified Mannose Triflate holds a certificate of suitability from the EDQM. Production is supported by Rotem’s in-house certified analytical laboratory which has a wide array of equipment and QC method development capabilities. Our highly-skilled staff provides users with comprehensive technical and regulatory support as well as excellent customer service. Rotem is particularly active in the design and production of consumables for radiotracers under development. These projects benefit from our interdisciplinary expertise, which is the result of many years of close collaboration with radiopharmaceutical companies worldwide. Rotem GmbH in Leipzig serves customers in Europe, with local representatives in the U.K. and Ireland.</td>
</tr>
<tr>
<td>ROTOP Pharmaka GmbH</td>
<td>Bautzner Landstr. 400 01328 Dresden, Germany</td>
<td><a href="mailto:info@rotop-pharmaka.de">info@rotop-pharmaka.de</a></td>
<td>ROTOP Pharmaka is a leading pharmaceutical company with over 20 years of experience that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries. Apart from the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals and the ready-to-use production of active radiopharmaceuticals, ROTOP offers broad range of CDMO services.</td>
</tr>
</tbody>
</table>


RQS Alexander Ruffani

Kantstr. 15
01809 Heidenau, Germany

m.michaelis@rqs-ar.com

www.rqs-ar.com

RQS Alexander Ruffani (Ruffani Quality Solutions) was founded in 2017. With a growing team of experienced and motivated professionals with expertise in synthesis development, radiochemistry, GMP-compliant production processes and chromatography instrumentation will help you find the best possible solution for your work application with many years of experience in radiochemistry, radio pharmacy and analytical instrumentation.

In 2020, RQS expanded to the USA and established Ruffani Quality Solutions, LLC. to provide timely and flexible local service. Our colleagues are specialized in the planning of production facilities as well as their construction, for this purpose they have been involved in several projects especially on the East Coast.

The team of now 10 employees worldwide is ready to support you with all your requests and is looking forward to get in contact with you.

SCANNIX

Rue du Mont d’Orcq 3
B - 7503 Froyennes, Belgium

info@scannix.com

https://www.scannix.com/

SCANNIX is specialized in the development and sales of nuclear spectroscopy equipment and radioprotection systems. SCANNIX offers a wide range of measurement devices in order to maintain safety of staff, assess the health of nuclear facilities and safeguard the public and the environment.

Scintomics Molecular, Applied Theranostics Technologies GmbH

Lindach 4
82236 Fürstenfeldbruck, Germany

info@sci-att.com

www.sci-att.com

Scintomics Molecular, Applied Theranostics Technologies (SCI-att) is a growing player in the radiopharmaceutical business with a particular strategic emphasis on providing unrestricted supply and support of proprietary and innovative tracer technology and non-IP protected precursors, such as PSMA I&T and next generation PSMA inhibitors for radiotherapy as well as uPSMA-14.

The well-known GRP Module Series became part of SCI-att in 2020 when SCI-att took over the Module business from its parent company Scintomics, which has been selling and installing fully automated production systems for established radio-pharmaceuticals in clinical facilities around the world since 2006.

To continue our strong track record of successful Synthesis Modules and expand our portfolio of tracers we are excited to launch our smartGRP. The smartGRP is a cost-effective alternative for doing standard syntheses, such as [68Ga]- and [177Lu]-labelling peptides. In addition, it can also be used for the syntheses that the sGRP offers.

The new model is designed with the intent of offering the usual GRP feeling while also allowing for several upgrade options.

We look forward to welcoming you at our booth!

SHINE Technologies

3400 Innovation Court
53546 Janesville, Wisconsin, United States

communications@shinefusion.com

www.shinefusion.com

SHINE is a next-generation fusion company, focused on deploying state-of-the-art fusion technology to help solve global problems and create a scalable path toward practical fusion energy. SHINE deploys its safe, cost-effective and environmentally-friendly technology in a step-wise approach, beginning with our systems used for advanced industrial imaging in non-destructive testing of components used in aerospace, defense, transportation, energy and other sectors. SHINE’s proprietary medical isotope production creates Molybdenum 99 and non-carrier-added Lutetium 177 used in tens of thousands of daily procedures to diagnose and treat heart disease and late-stage cancer. For more information, follow SHINE on Facebook, LinkedIn and Twitter.
### Siemens Healthcare GmbH

- **Address:** Henkestraße 127, 91052 Erlangen, Germany
- **Contact:** contact@siemens-healthineers.com
- **Website:** http://www.siemens-healthineers.com

At Siemens Healthineers, we pioneer breakthroughs in healthcare. For everyone. Everywhere. By constantly bringing breakthrough innovations to market, we enable healthcare professionals to deliver high-quality care, leading to the best possible outcome for patients.

Our portfolio, spanning from in-vitro and in-vivo diagnostics to image-guided therapy and innovative cancer care, is crucial for clinical decision-making and treatment pathways. With our strengths in patient twinning, precision therapy, as well as digital, data, and artificial intelligence (AI), we are well positioned to take on the biggest challenges in healthcare. We will continue to build on these strengths to help fight the world’s most threatening diseases, improving the quality of outcomes, and enabling access to care.

We are a team of 66,000 highly dedicated employees across more than 70 countries passionately pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

### Sirtex Medical Europe GmbH

- **Address:** Joseph-Schumpeter-Allee 33, 53227 Bonn, Germany
- **Contact:** Karen.nuessmeier@sirtex.com
- **Website:** www.sirtex.com

Sirtex Medical is a global healthcare business with offices in the US, Australia, Germany and Singapore, working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy called SIR-Spheres® Y-90 resin microspheres. SIR-Spheres® Y-90 resin microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

SIRT is a minimally invasive treatment that delivers high doses of high-energy beta radiation directly to the tumours.

For further information please visit www.sirtex.com.

Learn more about Sirtex in our interactive virtual booth [https://www.sirtexvirtualbooth-emea.com](https://www.sirtexvirtualbooth-emea.com)

*SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd

### Southern Scientific Limited

- **Address:** Scientific House, The Henfield Business Park, Shoreham Road, BN5 9SL Henfield, United Kingdom
- **Contact:** info@southernscientific.co.uk
- **Website:** www.southernscientific.co.uk

Southern Scientific manufacture a range of contamination monitors and probes for medical applications, including the Radhound, Handhound and Care Wise C-Trak Apollo Gamma Probe System.

The Care Wise C-Trak Apollo Gamma Probe System is a wireless/wired system which provides accurate and precise detection of gamma radiation and is used during sentinel node biopsies in breast, melanoma and other types of cancer.

The Handhound is a voice-activated hand monitor. All measurements are logged against a user and are easily downloaded to a USB.

Southern Scientific is also the UK distributor for the Capintec range of products and the MiE range of general purpose gamma cameras.

We are looking for distributors in certain countries. If you are interested, please visit stand 42 and speak to one of our team.

### Spectrum Dynamics Medical

- **Address:** Rue de Lausanne 31, 1110 Morges, Switzerland
- **Contact:** info@spectrum-dynamics.com
- **Website:** www.spectrum-dynamics.com

Spectrum Dynamics is spearheading the transformation of SPECT imaging scanners from analog to digital detection technology, enabling hospitals and clinicians to provide superior healthcare services with improved image quality, efficiency, and advanced clinical applications.

Spectrum launched the world’s first digital cardiac SPECT system: the D-SPECT® in 2007. The D-SPECT employs Broadview Technology: swiveling digital detectors made of Cadmium Zinc Telluride (CZT), along with ingenious hardware design and unique 3D algorithms for state-of-the-art imaging. It features TruCorr: 1st Artificial Intelligence (IA) based software to gen-erate attenuation corrected myocardial perfusion images using emission-only data.

Spectrum’s SPECT/CT innovation is the VERITON-CT®: featuring a 360° CZT detector design with a full diagnostic, high-resolution 64-slice CT, the industry’s most advanced hybrid nuclear camera. VERITON enables routine 3D total body NM/CT imaging. Its post-processing tools allow for advanced quantitative analysis of 3D data. Plus, unique TruFlow capability: 4D SPECT/CT for dynamic flow applications.
Stockholm Material Hub

Stockholm Material Hub is a nexus for connecting the research and infrastructure for material science with the vibrant start-ups and well-established SMEs in the greater area of Stockholm. The Hub has two main goals. The first is to leverage the strong science base provided by Stockholm University, KTH and KI, to boost economic growth. The second is to provide an arena for sharing infrastructure and providing the research collaboration to establish a knowledge center for energy, health and sustainability ventures. Stockholm material Hub is funded by The EU regional development fund and Stockholm University.

Sumitomo Heavy Industries, Ltd.

Since its establishment, Sumitomo Heavy Industries, Ltd. has contributed to the society by providing advanced technologies related to industrial machinery and infrastructure equipment to customers in the world. In particular, we have accumulated over 50 years of experience in the manufacture of accelerators, which have been applied to scientific, industrial and medical fields and have earned a high reputation. In the nuclear medicine, Sumitomo PET radiotracer production system (incl. cyclotron, target, synthesizer, etc.) were delivered to more than 220 sites in the world and have been contributed for the development of clinical use and new technologies (such as Theranostics).

In EANM 2022 exhibition, a concept model of “Smart & Innovative Laboratory for Clinical & Theranostics” will be highlighted. For further expansion of PET diagnosis all over the world, we have released a compact and powerful cyclotron “CYPRESS® HM-125C®” and a next generation radiopharma platform “SmartPharm™”. Also, we have released a metal target with liquid transfer technology, which is capable to produce 68Ga, 66Ga and 89Zr in the same target.

Additionally, CYPRESS® HM-18HC which is ultra-high beam current cyclotron for large amount of 18F production and CYPRESS MP-30 which accelerates not only proton and deuteron, but also alpha particle for 211At will be exhibited. 211At has been researched in the world and attracting attention as promising therapeutic nuclides.

We are welcome to you at our booth!

SurgicEye GmbH

SurgicEye and Crystal Photonics are engaged in Nuclear Medicine for highly qualified products of Molecular Imaging and for intraoperative and transcutaneous sentinel lymph node localization (SLNE) since 20 years. The product range includes our excellent mini-USB Hand-Held-Gamma-Camera “CrystalCam”, the surgical Gamma Probe System “Crystal Probe - automatic” with various kinds of cable and wireless probes, the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), the very new CrystalAnalyzer for HPLC-investigation in coincidence for any PET-drugs and the 3D-free-hand-spect imaging system declipse®SPECT in various versions.

Also, our CE-confirmed software DosePlan for any kind of PET-therapy is now ready for using. Additionally, we present the first time our very new PSMA-technology for Prostate Cancer and has the potential for a new treatment option. This probe was developed in the course of the “Crystal Probe - automatic” with various kinds of cable and wireless probes, the very new detection system CrystalGuard for Isolated Limb Perfusion (ILP), the very new CrystalAnalyzer for HPLC-investigation in coincidence for any PET-drugs and the 3D-free-hand-spect imaging system declipse®SPECT in various versions.

For more information, please visit our websites: www.crystal-photonics.com
www.surgiceye.com

Syntha GmbH

Syntha is a worldwide leading and specialized manufacturer of branded radiosynthesizers and concentrates over 40 years of experiences in the field of radiopharmaceutical production, quality control and lab automation. We undertake automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of (18)F-position emitters, (99m)Tc-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.

Our radiosynthesizers combine high performance and efficiency with high flexibility. Besides the attractive design, our software and synthesizer are highly user-friendly and meet the latest GMP regulations. They continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of (18)F-position emitters, (99m)Tc-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.

Our radiosynthesizers combine high performance and efficiency with high flexibility. Besides the attractive design, our software and synthesizer are highly user-friendly and meet the latest GMP regulations. They continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of (18)F-position emitters, (99m)Tc-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.

Our radiosynthesizers combine high performance and efficiency with high flexibility. Besides the attractive design, our software and synthesizer are highly user-friendly and meet the latest GMP regulations. They continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of (18)F-position emitters, (99m)Tc-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.

Our radiosynthesizers combine high performance and efficiency with high flexibility. Besides the attractive design, our software and synthesizer are highly user-friendly and meet the latest GMP regulations. They continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of (18)F-position emitters, (99m)Tc-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.

Syntha GmbH is a worldwide leading and specialized manufacturer of branded radiosynthesizers and concentrates over 40 years of experiences in the field of radiopharmaceutical production, quality control and lab automation. We undertake automated production of molecular imaging tracers and continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of (18)F-position emitters, (99m)Tc-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.

Our radiosynthesizers combine high performance and efficiency with high flexibility. Besides the attractive design, our software and synthesizer are highly user-friendly and meet the latest GMP regulations. They continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of (18)F-position emitters, (99m)Tc-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.

Our radiosynthesizers combine high performance and efficiency with high flexibility. Besides the attractive design, our software and synthesizer are highly user-friendly and meet the latest GMP regulations. They continuously provide innovative solutions to facilitate and improve the production of tracers for Positron Emission Tomography (PET). Our portfolio comprises modules for the production of (18)F-position emitters, (99m)Tc-radiotracers as well as other radioisotopes. It includes radiosynthesizers (incl. customized modules), HPLC equipment for purification and quality control, spare parts and service.
Telix Pharmaceuticaless

Telix Innovations SA, Rue de Hermée, 255 4040 Herstal, Belgium
congress@telixpharma.com
https://telixpharma.com

Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic (‘theranostic’) assets using Molecularly Targeted Radiation (MTR). Nuclear medicine is finally coming of age, with commercial critical mass building and commitment to late-stage product development. Our goal is to harness this momentum for the benefit of patients, with MTR potentially offering better-informed treatment decisions and truly personalised therapy.

Telix’s product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer.

TEMA SINERGIE

Via Malpighi, 120 48018 Faenza (RA), Italy
marketing@temasinergie.com
www.temasinergie.com

OUR KNOW-HOW AT THE SERVICE OF HEALTH, WELL-BEING AND SAFETY

Since it was founded in 1985, Tema Sinergie has been working on the Design, Production and Service of shielded equipment and measuring instruments for a safe handling of radioactive materials.

Our main manufacturing activities are: PET, Nuclear Medicine, Health Physics, Radiotherapy and Industrial Radiography equipment applications.

Sinergie to us means a strict and cooperating interaction between internal production and distributed brands, to offer our customers a complete service according to their needs, through a highly qualified staff.

Tema Sinergie counts more than 1,500 customers all over the world among which are included Hospitals, Universities, Research Centres and Factories.

Come visit us at booth 24 and see what’s new!

Terumo

Researchpark Haasrode 152 Interleuvenlaan 40 3001 Leuven, Belgium
sandrine.hocquel@terumo-europe.com

Terumo is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for 100 years. Terumo Interventional Systems is working in partnership with Interventional Radiologists and Nuclear Medicine within Interventional Oncology to ensure they have access to high quality tools for their patients. This partnership is based on Terumo’s comprehensive range of access to therapeutic technology and services to support healthcare professionals with their patient needs.

QuiremSpheres™ Holmium-166 microspheres, QuiremScout™ Holmium-166 microspheres and Q-Suite™ imaging software make up The Holmium Platform: three integrated products which aims to individualize SIRT at its full potential.

QuiremSpheres™ is the first Holmium-166 microsphere on the market which brings a wide range of benefits from higher dose rate, to optimised imaging capabilities.

QuiremSpheres™ are also the first SIRT microsphere to be designed with scout dose technology, QuiremScout™, which for the first time utilizes the same particle for the work up and the therapy, which aims to optimize patient selection and advance treatment planning using our Q-Suite™ imaging software. This CE-marked and in-house designed treatment planning software is also used for dose verification following the SIRT treatment to ensure you have delivered the dose you planned and will help to drive treatment efficacy and improve the outcomes for liver cancer patients.

Theragnostics Limited

21 Gloucester Place W1U8HR London, United Kingdom
hello@theragnostics.com
www.theragnostics.com

Theragnostics is a radiopharmaceutical company focused on developing new diagnostics and therapeutics for the oncology market. Our mission is to drive innovation in the fight against cancer by enhancing patients’ lives with precision radiopharmaceuticals. Our lead drugs are radiolabeled PARP inhibitors where we can bring therapeutic radioactive decay directly to the DNA.

Our therapeutic science is entering a Phase 1 trial later this year where we are combining our PARP with iodine-123 to use the power of Auger electron emissions to treat cancers. Auger emissions have not been used as a therapeutic to date; however, with our drug binding directly to damaged DNA, we can use the power of Auger emission to kill cancer cells while also having a better safety profile compared to other leading radiopharmaceutical therapeutics that use Alpha or Beta emissions. Our diagnostics is entering a Phase II trial later this year where we plan to demonstrate the advantage of PARP PET in the management of cancers where the needs are not met with current diagnostics.

Theragnostics received FDA approval in February 2022 for NephroScan™ Kit for the Preparation of Technetium Tc 99m Succimer Injection (99mTc-DMSA). In 2021, Theragnostics out licensed its single step Ga-68 PSMA kit IP to AAA for their product LOCOMET™.

Please visit our booth if you are interested in learning more about Theragnostics, our pipeline or NephroScan™.
TAIYO NIPPON SANSO Corporation

Fujil Bldg., 3-30-9 Shiba, Minato-ku, 108-0014 Tokyo, Japan
Isotope.TNS@tn-sanso.co.jp
stableisotope.tns-sanso.co.jp/index.html

TAIYO NIPPON SANSO, established in 1910, is a leading global industrial gas manufacturer. We developed the most energy efficient Oxygen-18O separation process utilizing our cryogenic air separation and ultra-clean technology. Since 2004, we have been supplying Water-18O to the world PET market. To meet the growing demand we completed our three plants with capacity of 600kg/year in 2015 by using state of the art separation technology. The largest capacity of 600kg/year with these three independent plants and GMP capability enable us to secure the stable supply of the highest and consistent quality of Water-18O, continuing to contribute to the advancement of the PET industry.

TRANSRAD

Avenue de l’Espérance 1
Site IRE – ZI Fleurus
6220 Fleurus, Belgium
info@transrad.be

Transrad is a logistics company created in 1988, active worldwide and specialized in the field of radioactive and nuclear material. Our company works for the nuclear fuel industry among others, but our core business remains nuclear medicine. We are proud to support the whole supply chain of medical isotopes production (from research reactors to hospitals). Next to transport, its core business, Transrad also has a storage capacity of radioactive material and its own fleet of transport packages (Transrad’s own design). Transrad also offers to its customers full dismantling, decommissioning, and recycling solutions for machines such blood irradiators, linear accelerators or even cyclotrons.

Trasis

90 Rue Gilles Maligne
4430 Ans, Belgium
events_trasis@trasis.com
www.trasis.com

Trasis is specialized in the development and the manufacturing of innovative and high quality radiopharmaceutical equipment. By carefully listening to professional users and markets trends, Trasis provides practical and reliably designed systems for automated synthesis, dispensing and packaging of radio pharmaceuticals. Trasis also offers custom development services for chemistry, reagents and disposables.

AllInOne is a multiple purpose radiochemistry unit featuring synthesizer, HPLC & reformulation in a single compact box, able to efficiently produce the most complex compounds such as nucleophilic FDopa, Thyrosine, FMT as well as FDG in multiple runs. AllInOne’s versatility also helps researchers address the growing need for new tracers.

MiniAllInOne is designed for simpler processes and to cost efficiently produce compounds such as FDG, Ga68/Lu177- peptide conjugates or NaF and requires less space in the hot cell.

EasyOne is the latest of the AllinOne family. It has been simplified to the extreme for routine production of most radionuclides labelled pharmaceuticals. Compatible with all Ga68 Generators, its ultra-compact design and ease of use are its major assets. Unidose, a high speed dose dispenser dedicated to hospitals, simplifies the procedures and reduces drastically the exposure to the technologists.

Técnicas Radiofísicas SL

C/Antonio Gil de Jasa 18, Plal.
50006 Zaragoza, Spain
info@trf.es
www.trf.es

Técnicas Radiofísicas SL (TRF) was founded in 1985 in Zaragoza, Spain, by a group of Physicists that understood and shared a common view in the radiation protection and Nuclear Medicine field. “To provide innovative and better solutions to the customer” TRF provides with proven expertise:
• Medical Physics Consulting. (Nuclear Medicine, Radiotherapy & Radioisotopes)
• Manufacturing of Radiation Protection Equipment
• Development of Software for Healthcare Applications

With over 250 projects around the world, TRF outstands in the following areas:
• Radiotherapy Linear Accelerators
• Dcay Tank System Projects for Radioactive Waste Management
• Cyclotron Projects for production of Radiopharmaceuticals & Radotracers
• TRF is recognized by the IAEA as Radiation Consultants. TRF personnel are highly trained professionals in all aspects of Radiation Safety & Protection.
• Software Engineers responsible for in-house development and support of TRF software applications.
TRIMT GmbH

Carl-Eschebach-Straße 7
01454 Radeberg, Germany

info@trimt.de

www.trimt.de

TRIMT GmbH was founded near Dresden in early 2021 and is dedicated to the development and commercialization of novel radiopharmaceuticals in molecular theranostics for the benefit of cancer patients. The inventor-founded, science and data driven company, is managed and operated by experts with a strong scientific background, supported by an interdisciplinary board of advisors. Together with a consolidated network of academic and clinical collaborators and a top choice of industrial partners, TRIMT strives to exploit the full potential of a unique IP portfolio with a strategic, diversified selection of short- and long-term development goals. The company’s current focus is on a class of cellular biomarkers called integrins. There is compelling evidence that αvβ6-integrin is found in many of the most dreadful cancers, such as pancreatic carcinoma, cervical-, head-and-neck and certain lung cancers, as well as in many kinds of fibrotic tissues, like in idiopathic pulmonary fibrosis, a slowly progressing, lethal lung disease. Ga-68-Trivehexin, the current lead compound, is a strong and selective ligand for this integrin subtype enabling early detection of the aforementioned conditions by PET imaging for this integrin subtype enabling early detection of the aforementioned conditions by PET imaging further to its range of resins Triskem also provides selective chromatography paper (DGA Sheets) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68, …). Triskem’s resins are increasingly finding use in the production of radionuclides for radiopharmacy and are employed by leading radionuclide manufacturers worldwide.

Our R&D team is constantly working on the development of new resins and methods in order to help you with your separation needs. If you have a special separation need, need help with your method development, you are interested in participating in R&D projects or you are looking for a partner to commercialize a new technology you have developed, please do not hesitate to contact us!

Triskem International

3 rue des Champs Géons
35170 Bruz, France

contact@triskem.fr

https://www.triskem-international.com

Triskem International develops, manufactures and commercializes highly selective resins for the separation and quality control of radionuclides such as Lu-177, Tb-161, Ga-67/8, Zr-89, Cu-64/7, alpha emitters (e.g. Ac-225, Pb-212, …), Ge-68, Tl-203, Sc-43/45, 68/70 Ga, and many other radionuclides for use in nuclear medicine - in diagnosis as well as in therapy. Further to its range of resins Triskem also provides selective chromatography paper (DGA Sheets) for quality control of radionuclides and generator effluents (Ra-223, Ac-225, Pb-212, Ga-68, …).

United Imaging Healthcare

Poland Sp. Z o.o.

Zwirki i Wigury 14, 02-092 Warszawa
02-092 Warszawa, Poland

biuro@united-imaging.com

www.united-imaging.eu/pl

United Imaging Healthcare is dedicated to providing, developing, and producing high-performance advanced medical imaging, radiotherapy equipment, and life science instruments, and offers intelligent digital solutions to customers worldwide. UH was founded in 2011 and headquartered in Shanghai, with subsidiaries and R&D centers across China, the United States, United Arab Emirates, Australia, Poland, India and other parts of the world.

UH has a world-class talent team including more than 140 scientists with global experience and more than 500 employees with rich R&D and management experience in the medical industry. And 39% of 5,400 employees are R&D personnel.

UH has launched over 80 ground-breaking products, including Total-Body PET/CT, HD TOP PET/MR, 75cm Ultra-Wide Bore 3.0T, MR, 640-Slice CT, Scanner, and Fully Integrated CT-linac. All core technologies are developed in house and have been globally or nationally recognized for world-leading performance. Our products have been installed in more than 9,100 medical and research institutes and nearly 900 top hospitals in 53 countries, including the U.S. and Japan. UH topped China’s new market share lists in the PET/CT, PET/MR, MR, CT and Mobile DR sector in 2020.

Our mission “To Bring Equal Healthcare for All” and our vision “Leading Healthcare Innovation” we are committed to creating more value for our customers and constantly improving the global accessibility of high-end medical equipment and services through in-depth cooperation with hospitals, universities, research institutions, and industry partners.

United States Department of Energy Isotope Program

P. O. Box 2008, MS 6158
37830-6158 Oak Ridge, TN, United States

contact@isotopes.gov

Isotopes.gov

The DOE Isotope Program supports the production and the development of production techniques of radioactive and stable isotopes that are in short supply for research and applications. Isotopes are high-priority commodities of strategic importance for the nation and are essential for energy, medical, and national security applications and for basic research; a goal of the program is to make critical isotopes more readily available to meet domestic U.S. needs.

The National Isotope Development Center (NIDC) is funded by the U.S. Department of Energy Isotope Program (DOE IP). It serves as an interface with the user community and manages the coordination of isotope production across the program facilities at Argonne, Brookhaven, Idaho, Los Alamos, Oak Ridge, and Pacific Northwest National Laboratories. These facilities produce stable and radioactive isotopes in short supply using reactors, accelerators, and other methods.

United States Department of Energy Isotope Program
Von Gahlen Nederland B.V.

Kelvinstraat 9
6902 PW Zevenaar, The Netherlands
info@vongahlen.com
www.vongahlen.com

Vortal is the leader in reusable TYPE A certified transport system. We provide transport system for liquid radio pharmaceuticals and shielding material for radiopharma facilities. We work with organizations such as Advanced Acceleration Applications, Curium, IBA, IAEA, Siemens, Europe.

Certification: TYPE A approved packaging, NF S99-700 for thermosensitive products.

Walischmiller Engineering GmbH

Schießstattweg 16
88677 Markdorf, Germany
info@hwm.com
www.hwm.com

For over seventy years Walischmiller has produced world-class innovative equipment for the nuclear industry. The company is certified according ISO 9001:2015, ISO 14001:2015, DIN ISO 45001:2018, KTA 1401 and ATEX. Walischmiller has a hard earned international reputation for performance, excellence in engineering and exceptional robotic hardware. In the most difficult and challenging nuclear environments, Walischmiller has demonstrated the ability to bring solutions and success to many of the most difficult high radiation remediation challenges.

Walischmiller Engineering is a full range supplier and offers products reaching from simple tools to advanced solutions, such as universal grippers, mechanical telemanipulators for a wide range of applications (models A100 and A200), remote-controlled power manipulators from the A1000 series for handling heavy loads and the robot system TELBOT® with unique capabilities which includes unlimited rotation in all axes, no wiring inside or outside the TELBOT® arm, and unlimited fast and precise movement.

By choosing products of Walischmiller Engineering, you choose products from a single source: engineering including product design & development, high manufacturing depth including single part assembly, all required specialised staff available within the company, installation at sites and worldwide service & maintenance.

Waters Corporation

34 Maple Street
MA 01757 Milford, United States

Waters Clinical Diagnostic Solutions - Analytical Technology for Better Care As a clinical diagnostic laboratory, quickly providing the broadest range of tests with the best accuracy and selectivity is key, but many challenges can stand in the way. Current laboratory techniques can suffer from cross-reactivity that may skew results, availability of reagent kits for new tests can be slow, and sample preparation is often too manual. Waters unlocks the potential of science by helping clinical diagnostic labs provide better patient care. Waters helps our customers enhance workflow efficiencies, improve specificity of results, and implement new diagnostic tests with LC-MS/MS solutions, so you can help provide accurate diagnosis and treatment without compromising compliance, flexibility, and performance.
WORLD INFINITY SERVICES

Rue de Hermée 255
B - 4040 Herstal, Belgium

h.vandemaele@be-wis.com

www.be-wis.com

World Infinity Services is dedicated to the worldwide transport and logistics of radioactive materials and radiopharmaceutical products. We are focused on providing a safe and secure, compliant and high-quality customer experience. We perform feasibility studies in terms of regulation, transport- and packaging permits. With our dedicated partners we provide worldwide door-to-door logistics, airfreight and charter services. Transport authorizations for radioactive products and radiopharmaceuticals in Belgium, Luxembourg, Netherlands, Germany and France. Storage facility and import license for radioactive products in Belgium. ISO9001 certified with GDP-compliance.

Xeos

Ottergemsesteenweg-Zuid 808 bus 358
9000 Gent, Belgium

info@xeos.care

www.xeos.care

Is it important for you as a nuclear medicine professional to improve patients’ treatment outcomes, fastened recovery and avoid re-surgery? XEOS wants to tackle the limitations of today’s available imaging techniques applied in surgical oncology, by using the transformative power of molecular imaging intra-operatively.

AURA 10 is the first-ever PET-CT specimen imager for the operating room, offering surgeons and imaging specialists the sensitivity of PET imaging at submillimeter spatial resolution. Thanks to the AURA 10 mobile scanner, a specimen does no longer need to be transported to the radiology or pathology department during surgery. High-quality specimen images can now be obtained in the OR within 10 minutes after excision. Founded in 2019 in Ghent, Belgium, XEOS is an expert in specimen imaging, and focuses on improving outcomes in surgical oncology through innovations in intraoperative imaging. The XEOS team is passionate about expanding the use of molecular imaging to optimize clinical workflows and improve patient outcomes.
CORPORATE MEMBERS

We gratefully acknowledge the support of the following companies (in alphabetical order):

| ABX-CRO Advanced pharmaceutical services Forschungsgesellschaft  |
| Advanced Accelerator Applications International  |
| Alliance Medical GmbH / Life Healthcare Europe  |
| Blue Earth Diagnostics Ltd.  |
| Boston Scientific International  |
| Bruker BioSpin GmbH  |
| CIS bio international (IBA) - Curium  |
| Comecer Group  |
| Debiopharma International SA  |
| Eckert & Ziegl Isotope Products GmbH  |
| Eli Lilly  |
| GE Healthcare Ltd.  |
| Hermes Medical Solutions  |
| IBA SA  |
| Isotopia Molecular Imaging  |
| ITM Isotopen Technologien München AG  |
| JSC Isotope  |
| Lemer Pax  |
| Medi-Radiopharma Ltd.  |
| Mediso Medical Imaging Systems  |
CORPORATE MEMBERS

- Milabs
- MIM Software
- Mirion Technologies (Capintec) Inc
- Monrol Nuclear Products Co.
- National Centre for Nuclear Research Radioisotope Centre POLATOM
- NRG Advancing Nuclear Medicine
- PARS Isotope
- Pharmazac
- POINT Biopharma Inc.

- ROTOP Pharmaka GmbH
- SHINE Technologies LLC
- Siemens Healthineers
- Sirtex Medical Europe GmbH
- Spectrum Dynamics Medical
- Telix Pharmaceuticals
- Tema Sinergie S.p.A.
- Terumo Europe N.V.
- von Gahlen Nederland BV
At Lilly, patients and loved ones are at the center of everything we do. For over 30 years, we have been committed to the development of both diagnostics and therapeutics in the AD space. Through our innovation, we have advanced the field by helping to shape the standards for Alzheimer’s Disease research.

VISIT LILLY.COM TO LEARN MORE
TARGET STUDY

A global real-world retrospective study that confirms TheraSphere for HCC as safe and effective, demonstrating predictable clinical outcomes across a broad patient population in 8 countries.

RESULTS

70.8% ORR* for the target lesion (mRECIST)
61.7% ORR** for all lesions (mRECIST)
20.3 months median Overall Survival

TUMOR ABSORBED DOSE WAS PREDICTIVE OF RESPONSE1,2

Responders had a 17% higher mean tumor absorbed dose (225.5 Gy*) compared with non-responders (188.3 Gy**)

1. Total perfused tumor absorbed dose and best response (61.7%) according to mRECIST
2. Non-responders (defined as stable disease, progressive disease, or non-evaluable) are not represented in the graph

JOIN BOSTON SCIENTIFIC SYMPOSIUM
16th OCTOBER - 13:15 CET, Hall 117
Y-90 Glass Microspheres: Personalised Dosimetry, Guidelines and Clinical Data

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

PI-1389903-AA © 2022 Boston Scientific Corporation or its affiliates. All rights reserved.